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For decades, gluten-free dieting (GFD) has been accepted as the only therapeutic approach to
coeliac disease (CD) and, more recently, for non-coeliac gluten sensitivity (NCGS), a term to refer to
the so-called gluten-related disorders (GRD) [1].
GFD has become popular among the general population for its supposed beneficial effects on
human health [2]. GFD is also the most frequently suggested dietary regimen in irritable bowel
syndrome (IBS) [3].
In fact, there are several concerns and misconceptions regarding GFD, which deserve special
attention. For such a reason, this Special Issue on “Gluten-Free Diet” comprises 23 peer-reviewed
papers, reporting on the most recent evidence and topics about GFD. In particular, the impact of GFD
on human health and quality of life; the emerging evidence of its beneficial effects in IBS; and the
difficult problems of compliance, costs, and availability of GF food are discussed.
Several sources of evidence support the notion that, despite its remarkable effectiveness in
remitting the vast majority of GRD symptoms, GFD comes with both a social and financial burden.
Gluten-free foods are still less available and more expensive than their gluten-containing versions [4],
thus causing patients social and psychological consequences in securing good quality of life and
compliance with the advised dietary regimen.
As Joelson AM et al. have shown, the prevalence of depression among the sufferers of coeliac
disease (CD) is high and depressive symptoms may mask the relationship between symptoms and
inadvertent gluten exposure, and thus make it more difficult to detect any lack of adherence to GFD [5].
With a systematic review and meta-analysis, Busby at al. have confirmed that gluten elimination may
well represent an effective treatment strategy for mood disorders for individuals with GRD [6].
As permanent adherence to GFD is difficult, with repeated transgression and frequent
contaminations, a reliable tool to assess compliance is currently advocated [7]. In their review, Rodrigo
L. et al. establish that the determination of the immunogenic gluten peptides in isolated samples of
faeces or urine has proven useful for assessing adherence to GFD [8].
In the opinion of some authors, several factors contribute to greater adherence to GFD; that is,
good knowledge of the disease and its treatment, high level of education, high economic status, female
sex, young age, high self-esteem, good grades at school, good availability and labelling of products,
good contact with a doctor and a dietitian, and finally membership of the Coeliac Society [9–12].
Conversely, the factors responsible for not adhering to GFD are poor taste of gluten-free products, high
price and poor availability, being adolescent, the absence of immediate symptoms following the intake
of small amounts of gluten, and low awareness of the disease [9,11,12].
From a study conducted by Czaja-Bulsa et al., it has emerged that GFD adherence has improved
over the last ten years, thanks to the popularity gained by GFD and GF food becoming more
available [13].
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Further evidence, recently accepted, shows that in spite of improvements in food formulation
over the last few years, GF foods still present with a reduced nutritional profile when compared with
gluten-containing products, with higher lipid and trans-fat content; lower level of proteins; and lower
degree of fortification with micronutrients, especially Ca, Fe, Mg, and Zn [14]. Similarly, Wiech et al.
have shown that CD children adhering to GFD for a year showed a higher increase in weight and body
mass index (BMI) when compared with healthy controls, suggesting a tendency towards metabolic
syndrome [15]. However, there is growing evidence supporting the protective effect of GFD on bone
metabolism [16] and the possible prevention of diabetes through GFD [17].
In preparing this Special Issue, GFD and fermentable oligo/di/monosaccharides and
polyols (FODMAP) as dietary therapies in individuals with IBS was an issue that the Editors
found to be important [18]. In a study evaluating the intake of foods containing fermentable
oligo/di/monosaccharides and polyols (FODMAP) in CD patients, Roncoroni et al. confirmed that
the prevalence of IBS-type symptoms among CD patients is higher than in the general population.
Moreover, they demonstrated that CD patients consume a diet high on FODMAP, which is a factor that
possibly induces gastrointestinal symptoms in treated CD patients [19,20]. Moreover, in the first RCT
DB intervention controlled study, the same researchers showed that CD patients on GFD, but with
persisting functional gastrointestinal symptoms, had a positive response to a diet low on FODMAP.
Thus, GFD associated with a low-FODMAP content is beneficial, as a support therapy, for a group of
CD patients with persistent gastrointestinal symptoms [21].
A number of questions still remain unanswered; namely, the modifications by GFD of the gut
microbiota in different populations [22,23]; the effects of gluten intake on both gastric and gallbladder
motility [24]; and the persistent motor disorders in CD patients, despite GFD, which can be explained
by low-grade mucosal inflammation [25].
Several open issues regarding GFD also remain, such as, most importantly, the ingestion
threshold for the amount of gluten considered tolerable has not been defined yet. Furthermore, the
appropriateness of a lifelong indication to GFD, particularly for patients with sub-clinical and potential
CD (i.e., not confirmed by histology), is still a matter of debate [26], especially on consideration of the
impact on patients’ quality of life posed by a restrictive gluten-free diet [27]. Finally, in a study on the
immunogenic potential of α-gliadins in Triticale, Ruiz-Carnicer et al. demonstrated that by substituting
a natural amino acid to the most immunogenic fraction of gluten (DQ2.5-glia-a 1, DQ2.5-glia-a2, and
DQ2.5-glia-a3), the toxicity of three T-cell epitopes was eliminated, while the technological properties
of commercial wheat were maintained [28]. These results may offer the opportunity to generate wheat
varieties with a reduced CD immunogenicity not safe for consumption by patients, but that might help
to prevent the onset of CD in people that carry genetic risk factors.
In conclusion, we would like to acknowledge all the authors for their valuable contributions and
the reviewers for their constructive comments. Special thanks are owed to the publishing team of
Nutrients for their professional assistance in the development of this Special Issue.
Funding: This research received no external funding
Conflicts of Interest: Luca Elli is a member of special dietary foods manufacturer Dr. Schär’s Advisory Board.
References
1. Elli, L.; Villalta, D.; Roncoroni, L.; Barisani, D.; Ferrero, S.; Pellegrini, N.; Bardella, M.T.; Valiante, F.; Tomba, C.;
Carroccio, A.; et al. Nomenclature and diagnosis of gluten-related disorders: A position statement by the
Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Dig. Liver Dis. 2017, 49,
138–146. [CrossRef] [PubMed]
2. Kim, H.S.; Patel, K.G.; Orosz, E.; Kothari, N.; Demyen, M.F.; Pyrsopoulos, N.; Ahlawat, S.K. Time Trends
in the Prevalence of Celiac Disease and Gluten-Free Diet in the US Population: Results from the National
Health and Nutrition Examination Surveys 2009–2014. JAMA Intern. Med. 2016, 176, 1716–1717. [CrossRef]
2
Nutrients 2019, 11, 589
3. Catassi, C.; Alaedini, A.; Bojarski, C.; Bonaz, B.; Bouma, G.; Carroccio, A.; Castillejo, G.; De Magistris, L.;
Dieterich, W.; Di Liberto, D.; et al. The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and
Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update. Nutrients 2017, 9, 1268. [CrossRef] [PubMed]
4. Allen, B.; Orfila, C. The Availability and Nutritional Adequacy of Gluten-Free Bread and Pasta. Nutrients
2018, 10, 1370. [CrossRef] [PubMed]
5. Joelson, A.M.; Geller, M.G.; Zylberberg, H.M.; Green, P.H.R.; Lebwohl, B. The Effect of Depressive Symptoms
on the Association between Gluten-Free Diet Adherence and Symptoms in Celiac Disease: Analysis of a
Patient Powered Research Network. Nutrients 2018, 10, 538. [CrossRef] [PubMed]
6. Busby, E.; Bold, J.; Fellows, L.; Rostami, K. Mood Disorders and Gluten: It’s Not All in Your Mind!
A Systematic Review with Meta-Analysis. Nutrients 2018, 10, 1708. [CrossRef] [PubMed]
7. Syage, J.A.; Kelly, C.P.; Dickason, M.A.; Ramirez, A.C.; Leon, F.; Dominguez, R.; Sealey-Voyksner, J.A.
Determination of gluten consumption in celiac disease patients on a gluten-free diet. Am. J. Clin. Nutr. 2018,
107, 201–207. [CrossRef] [PubMed]
8. Rodrigo, L.; Perez-Martinez, I.; Lauret-Brana, E.; Suarez-Gonzalez, A. Descriptive Study of the Different
Tools Used to Evaluate the Adherence to a Gluten-Free Diet in Celiac Disease Patients. Nutrients 2018, 10,
1777. [CrossRef] [PubMed]
9. Freeman, H.J. Dietary compliance in celiac disease. World J. Gastroenterol. 2017, 23, 2635–2639. [CrossRef]
[PubMed]
10. Silvester, J.A.; Weiten, D.; Graff, L.A.; Walker, J.R.; Duerksen, D.R. Is it gluten-free? Relationship between
self-reported gluten-free diet adherence and knowledge of gluten content of foods. Nutrition 2016, 32,
777–783. [CrossRef] [PubMed]
11. Greco, L.; Mayer, M.; Ciccarelli, G.; Troncone, R.; Auricchio, S. Compliance to a gluten-free diet in adolescents,
or “what do 300 coeliac adolescents eat every day?”. Ital. J. Gastroenterol. Hepatol. 1997, 29, 305–310. [PubMed]
12. Kurppa, K.; Lauronen, O.; Collin, P.; Ukkola, A.; Laurila, K.; Huhtala, H.; Maki, M.; Kaukinen, K. Factors
associated with dietary adherence in celiac disease: A nationwide study. Digestion 2012, 86, 309–314.
[CrossRef] [PubMed]
13. Czaja-Bulsa, G.; Bulsa, M. Adherence to Gluten-Free Diet in Children with Celiac Disease. Nutrients 2018, 10,
1424. [CrossRef] [PubMed]
14. Rybicka, I. The Handbook of Minerals on a Gluten-Free Diet. Nutrients 2018, 10, 1683. [CrossRef] [PubMed]
15. Wiech, P.; Chmiel, Z.; Bazalinski, D.; Salacinska, I.; Bartosiewicz, A.; Mazur, A.; Korczowski, B.;
Binkowska-Bury, M.; Dabrowski, M. The Relationship between Body Composition and a Gluten Free
Diet in Children with Celiac Disease. Nutrients 2018, 10, 1817. [CrossRef] [PubMed]
16. Tovoli, F.; Negrini, G.; Sansone, V.; Faggiano, C.; Catenaro, T.; Bolondi, L.; Granito, A. Celiac Disease
Diagnosed through Screening Programs in At-Risk Adults Is Not Associated with Worse Adherence to the
Gluten-Free Diet and Might Protect from Osteopenia/Osteoporosis. Nutrients 2018, 10, 1940. [CrossRef]
[PubMed]
17. Haupt-Jorgensen, M.; Holm, L.J.; Josefsen, K.; Buschard, K. Possible Prevention of Diabetes with a
Gluten-Free Diet. Nutrients 2018, 10, 1746. [CrossRef] [PubMed]
18. Rej, A.; Sanders, D.S. Gluten-Free Diet and Its ‘Cousins’ in Irritable Bowel Syndrome. Nutrients 2018, 10,
1727. [CrossRef] [PubMed]
19. Sainsbury, A.; Sanders, D.S.; Ford, A.C. Prevalence of irritable bowel syndrome-type symptoms in patients
with celiac disease: A meta-analysis. Clin. Gastroenterol. Hepatol. 2013, 11, 359–365. [CrossRef] [PubMed]
20. Roncoroni, L.; Elli, L.; Doneda, L.; Bascunan, K.A.; Vecchi, M.; Morreale, F.; Scricciolo, A.; Lombardo, V.;
Pellegrini, N. A Retrospective Study on Dietary FODMAP Intake in Celiac Patients Following a Gluten-Free
Diet. Nutrients 2018, 10, 1769. [CrossRef] [PubMed]
21. Roncoroni, L.; Bascunan, K.A.; Doneda, L.; Scricciolo, A.; Lombardo, V.; Branchi, F.; Ferretti, F.; Dell’Osso, B.;
Montanari, V.; Bardella, M.T.; et al. A Low FODMAP Gluten-Free Diet Improves Functional Gastrointestinal
Disorders and Overall Mental Health of Celiac Disease Patients: A Randomized Controlled Trial. Nutrients
2018, 10, 1023. [CrossRef] [PubMed]
22. Garcia-Mazcorro, J.F.; Noratto, G.; Remes-Troche, J.M. The Effect of Gluten-Free Diet on Health and the Gut
Microbiota Cannot Be Extrapolated from One Population to Others. Nutrients 2018, 10, 1421. [CrossRef]
[PubMed]
3
Nutrients 2019, 11, 589
23. Garcia-Mazcorro, J.F.; Rivera-Gutierrez, X.; Cobos-Quevedo, O.J.; Grube-Pagola, P.; Meixueiro-Daza, A.;
Hernandez-Flores, K.; Cabrera-Jorge, F.J.; Vivanco-Cid, H.; Dowd, S.E.; Remes-Troche, J.M. First Insights into
the Gut Microbiota of Mexican Patients with Celiac Disease and Non-Celiac Gluten Sensitivity. Nutrients
2018, 10, 1641. [CrossRef] [PubMed]
24. Massironi, S.; Branchi, F.; Fraquelli, M.; Baccarin, A.; Somalvico, F.; Ferretti, F.; Conte, D.; Elli, L. Effects
of a Gluten-Containing Meal on Gastric Emptying and Gallbladder Contraction. Nutrients 2018, 10, 910.
[CrossRef] [PubMed]
25. Usai-Satta, P.; Oppia, F.; Lai, M.; Cabras, F. Motility Disorders in Celiac Disease and Non-Celiac Gluten
Sensitivity: The Impact of a Gluten-Free Diet. Nutrients 2018, 10, 1705. [CrossRef] [PubMed]
26. Norsa, L.; Branchi, F.; Bravo, M.; Ferretti, F.; Roncoroni, L.; Somalvico, F.; Conte, D.; Bardella, M.T.; Fabiano, S.;
Barigelletti, G.; et al. Celiac Disease 30 Years After Diagnosis: Struggling with Gluten-free Adherence or
Gaining Gluten Tolerance? J. Pediatr. Gastroenterol. Nutr. 2018, 67, 361–366. [CrossRef] [PubMed]
27. Itzlinger, A.; Branchi, F.; Elli, L.; Schumann, M. Gluten-Free Diet in Celiac Disease-Forever and for All?
Nutrients 2018, 10, 1796. [CrossRef] [PubMed]
28. Ruiz-Carnicer, A.; Comino, I.; Segura, V.; Ozuna, C.V.; Moreno, M.L.; Lopez-Casado, M.A.; Torres, M.I.;
Barro, F.; Sousa, C. Celiac Immunogenic Potential of alpha-Gliadin Epitope Variants from Triticum and
Aegilops Species. Nutrients 2019, 11, 220. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




The Effect of Depressive Symptoms on the
Association between Gluten-Free Diet Adherence and
Symptoms in Celiac Disease: Analysis of a Patient
Powered Research Network
Andrew M. Joelson 1, Marilyn G. Geller 2, Haley M. Zylberberg 3, Peter H. R. Green 3
and Benjamin Lebwohl 3,4,*
1 Department of Internal Medicine, New York Presbyterian Hospital, New York, NY 10032, USA;
amj9033@nyp.org
2 Celiac Disease Foundation, Woodland Hills, CA 91364, USA; marilyn.geller@celiac.org
3 Celiac Disease Center, Department of Medicine, Columbia University Medical Center,
180 Fort Washington Avenue, Suite 936, New York, NY 10032, USA; hmz2105@columbia.edu (H.M.Z.);
pg11@cumc.columbia.edu (P.H.R.G.)
4 Deartment of Epidemiology, Mailman School of Public Health, Columbia University Medical Center,
New York, NY 10032, USA
* Correspondence: BL114@columbia.edu; Tel.: +1-212-305-5590
Received: 8 March 2018; Accepted: 23 April 2018; Published: 26 April 2018
Abstract: Background: The prevalence of depression in celiac disease (CD) is high, and patients are
often burdened socially and financially by a gluten-free diet. However, the relationship between
depression, somatic symptoms and dietary adherence in CD is complex and poorly understood.
We used a patient powered research network (iCureCeliac®) to explore the effect that depression has
on patients’ symptomatic response to a gluten-free diet (GFD). Methods: We identified patients with
biopsy-diagnosed celiac disease who answered questions pertaining to symptoms (Celiac Symptom
Index (CSI)), GFD adherence (Celiac Dietary Adherence Test (CDAT)), and a 5-point, scaled question
regarding depressive symptoms relating to patients’ celiac disease. We then measured the correlation
between symptoms and adherence (CSI vs. CDAT) in patients with depression versus those without
depression. We also tested for interaction of depression with regard to the association with symptoms
using a multiple linear regression model. Results: Among 519 patients, 86% were female and the mean
age was 40.9 years. 46% of patients indicated that they felt “somewhat,” “quite a bit,” or “very much”
depressed because of their disorder. There was a moderate correlation between worsened celiac
symptoms and poorer GFD adherence (r = 0.6, p < 0.0001). In those with a positive depression screen,
there was a moderate correlation between worsening symptoms and worsening dietary adherence
(r = 0.5, p < 0.0001) whereas in those without depression, the correlation was stronger (r = 0.64,
p < 0.0001). We performed a linear regression analysis, which suggests that the relationship between
CSI and CDAT is modified by depression. Conclusions: In patients with depressive symptoms related
to their disorder, correlation between adherence and symptoms was weaker than those without
depressive symptoms. This finding was confirmed with a linear regression analysis, showing that
depressive symptoms may modify the effect of a GFD on celiac symptoms. Depressive symptoms
may therefore mask the relationship between inadvertent gluten exposure and symptoms. Additional
longitudinal and prospective studies are needed to further explore this potentially important finding.
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1. Introduction
Celiac Disease (CD) is an autoimmune disorder that, by recent estimates, affects roughly 0.7%
of the United States population [1]. The disease is caused by gut mucosal immune activation against
gluten, a protein component of wheat, rye, and barley [2]. The clinical manifestations are numerous
and often differ between adults and children. While potential new therapies are being studied, the only
current treatment is strict avoidance of gluten in the diet [3]; a treatment that for many is expensive,
socially isolating, and can result in anxiety about accidental ingestion [3].
There are many well-described neuropsychiatric manifestations of CD. Many studies have
examined the association between CD and depression [4–12], anxiety [7,10], bipolar disorder [10],
and schizophrenia [3,6]. The prevalence of depression in CD has been reported as anywhere between
6% and 57% [13], and a 2011 meta-analysis showed that depression is more common in CD than the
general population [5]. However, other studies have demonstrated that the prevalence of depression
in CD is the same as in the general population [14] and in other cohorts that suffer from chronic
illness [5,15]. Many pathophysiologic mechanisms behind the CD-depression association have
been postulated and studied including regional cerebral hypoperfusion [12], comorbid autoimmune
thyroid disease [11], and decreased levels of cerebrospinal fluid monoamines in celiac patients,
which improve with a gluten-free diet (GFD) [16,17]. The GFD can be expensive, burdensome,
and socially isolating [3]. It is therefore conceivable that adhering to such a diet may be associated with
worsening of affective symptoms. However, one cross-sectional study demonstrated an association
between less severe depression scores and being on a gluten-free diet for more than five years [8]
and another longitudinal study found improvements in quality of life after one year of treatment
of a GFD, with less improvement in those who adhered poorly [18]. Simsek et al. (2015) identified
improved depression scores in pediatric patients adherent to a GFD [19] as did Borghini et al. [20]
in adult patients, where another study suggested improvement in anxiety only, with no change in
depressive symptoms after one year of a GFD [21]. Furthermore, depressed patients who suffer
from chronic illnesses have been found to be less compliant with treatment than non-depressed
individuals [22]. A recent meta-analysis examined 8 cross-sectional studies and concluded that
an association between poorer GFD adherence and self-reported depressive symptoms is likely [23].
Another study followed 66 patients, randomized to receive or not receive psychological support and
found reduced depression scores and better adherence to their diet at six months in patients receiving
psychological support [24]. This suggests that a relationship may exist between depressive symptoms
and GFD adherence; however, the common use of self-reported depression and dietary adherence
scales challenges the study of the topic. Furthermore, many of these studies do not specifically examine
symptoms of CD. As many common CD symptoms may mimic those of depression, this remains
a challenging relationship to evaluate scientifically.
In order to involve patients in clinical research, the Patient-Centered Outcomes Research Institute
(PCORI) created the National Patient-Centered Clinical Research Network. As an outcome of this
initiative, the Celiac Disease Foundation created iCureCeliac®, a patient-governed forum for clinical
research. We implemented this tool to study the effect of self-reported depressive symptoms as relating
to CD on the association between CD symptoms and adherence to a GFD. We hypothesized that the
presence of depressive symptoms modifies the symptomatic response to a GFD.
2. Patients and Methods
We performed a cross-sectional analysis of pre-existing study data, utilizing the research
questionnaire from iCureCeliac® a patient-powered research network. Beginning in January 2016,
the questionnaire was posted on the Celiac Disease Foundation website and reminders were
periodically emailed to newsletter subscribers. Patients had the option to enter as much or as little
data as they desired on an entirely voluntary basis with no financial incentive offered.
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2.1. Inclusion Criteria
At the time of data analysis, the iCureCeliac® questionnaire included data from 1724 individuals,
with gluten-related disorders that included CD, non-celiac gluten sensitivity, dermatitis herpetiformis,
wheat allergy, and self-diagnosed gluten-related disorder. We included patients of all ages who
indicated in the questionnaire a diagnosis of CD, diagnosed at any age by endoscopy and biopsy and
who answered the questions that applied to our study between the inception of the patient-powered
research network on 30 January 2016 and 25 August 2016. A parent or legal guardian completed
responses for children. Although per ACG and AGA guidelines [25,26], a diagnosis of CD is made
using a combination of serology and a confirmatory biopsy of the small bowel to diagnose CD in
patients with typical signs and symptoms, we assumed that biopsy-proven diagnoses were made in
patients with symptoms and serology suggestive of celiac disease.
2.2. Data Collection
We collected basic demographic information including age, sex, education level, time to diagnosis
from symptom onset, and degree of adherence to a gluten-free diet. We extracted data from one
question asking patients about depression as it relates to their gluten-related disorder, phrased as
follows: “I feel depressed because of my gluten-related disorder”. Five responses were offered
ranging from “not at all” to “very much”. We considered the responses “somewhat”, “quite a bit”,
and “very much” to indicate the presence of depressive symptoms, whereas “not at all” and “a little
bit” to indicate the absence of depressive symptoms. A smaller subset of patients responded to the
PROMIS (Patient Reported Outcomes Measurement Information System) Depression instrument.
PROMIS is a set of validated, self-reported measures that evaluate various physical, psychological
and social symptoms designed for use in adult and pediatric populations for research. The PROMIS
Depression instruments include a complete 28-item assessment, as well as 4-, 6-, and 8-question short
forms. Upon completion of the questionnaire, a raw score is generated, which corresponds to a T-score
(based on a conversion table provided) with an instrument-specific range (41.0 to 79.4 for the 4-question
short form used in the iCureCeliac® questionnaire). The T score is compared to the population mean
with standard errors provided.
We also extracted data from questions administered to questionnaire respondents relating to
symptoms and dietary adherence, which comprised most of the Celiac Symptom Index (CSI) and
Celiac Dietary Adherence Test (CDAT) questions outlined by Leffler et al. [27,28]. The CSI and CDAT
are clinically oriented, easily administered, questionnaires with 16 and 7-items, respectively. The CSI
performed well as a surrogate measure of disease activity [27] and the CDAT was shown to perform
better than tissue transglutaminase titers for evaluating dietary adherence [28].
2.3. Data Analysis
The iCureCeliac® questionnaire asked fifteen of the sixteen questions included in the CSI (missing
question: “How much physical pain have you had during the last 4 weeks”?) and five out of the
seven questions included in the CDAT (missing scaled questions: “I do not consider myself a failure”
and “Before I do something, I carefully consider the consequences”). As not all of the CSI and CDAT
questions were included in the initial iCureCeliac® questionnaire, the instruments are incomplete.
We therefore analyzed these responses out of a total of 75 and 25 possible points, respectively (compared
with 80 and 35, respectively). Higher CSI scores correlate with more severe symptoms and higher
CDAT scores correlate with poorer dietary adherence, as described by Leffler et al. [27,28].
We calculated correlation coefficients with 95% confidence intervals between: (1) adherence to
a GFD (CDAT) and CD symptoms (CSI); (2) depression and CD symptoms (CSI); and (3) depression
and adherence to a GFD (CDAT). We then stratified patients based on the presence of depressive
symptoms so as to determine whether these symptoms modify the association between adherence to
a GFD and CD symptoms. To formally test for interaction, we constructed a multiple linear regression
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model with CSI score as the outcome, and CDAT score, the presence of depression, and the interaction
term (depression*CDAT) as the dependent variables.
As a means of validating our chosen screening question for depressive symptoms, we calculated
a correlation coefficient to compare our question to the 4-item PROMIS depression score in the smaller
subset of respondents who completed both sets of questions regarding depression. For all PROMIS
Depression instruments, a T-score of 50 is equivalent to the mean of the general population with
a standard deviation of 10. The 4-item depression short form has been validated against the Center for
Epidemiologic Studies Depression Scale [29]. For the purpose of this study, patients with a raw score
greater than or equal to 11 (corresponding to a T score of, ≥60.5 or 1 SD above the mean of the general
population) were considered to have a positive depression screen.
We used the guidelines set forth by Evans [30] for interpretation of correlation coefficient values.
We used SAS version 9.4 (SAS Institute Inc. 2013, Cary, NC, USA) to calculate Pearson correlation
coefficients for the variables listed above. Although the study was designed after data collection,
our hypothesis was developed prior to data analysis. Informed consent was obtained from each patient
prior to completion of the survey. This study conforms to the ethical guidelines set forth by the 1975
declaration of Helsinki and was approved by the Institutional Review Board of Columbia University
Medical Center on 22 September 2016.
3. Results
We identified 519 patients with biopsy-diagnosed CD who met criteria for inclusion in our
study. The characteristics of our study population are displayed in Table 1. The participants were
predominantly female (86%). The mean age was 40.9 years (standard deviation (SD) ± 16.7), 26 patients
were aged 16 years or less, 92% of our study population self-reported their race as white and 65%
had completed at least one year of college-level education. Feeling depressed was reported by 46%
of respondents (“very much” by 6.7%, “quite a bit” by 12.5%, and “somewhat” by 26.8%). The mean
(±SD) CDAT score was 12.81 (±2.53, out of a 25-point scale, IQR = 16) and the mean (±SD) CSI score
was 36.1 (±11.2 out of a 75-point scale, IQR = 11).
Depression had a weak correlation with worse symptoms (r = 0.35, 95% CI 0.26–0.43, p < 0.0001)
and a weaker correlation with GFD adherence (r = 0.25, 95% CI 0.16–032, p < 0.0001). There was
a moderate correlation between worse symptoms and poorer GFD adherence (r = 0.60, 95% CI
0.53–0.66, p < 0.0001).
In patients with a positive depression screen, there was a moderate correlation between worsening
symptoms and worsening dietary adherence (r = 0.50, 95% CI 0.37–0.60, p < 0.0001) whereas in those
without depression, the correlation was still moderate, although stronger (r = 0.64, 95% CI 0.55–0.71,
p < 0.0001). When patients <16 years of age were removed from the analysis (n = 370), the results were
unchanged. The difference in CSI vs. CDAT scores in depressed vs. non-depressed patients is shown
in Figure 1. When formally testing for interaction (n = 392), the beta coefficient for CDAT*depression
was −0.935 (95% CI −1.65–−0.22, p = 0.0109), suggesting that the relationship between CSI and CDAT
is modified by depression.
137 patients answered the 4-item PROMIS Depression instrument. Using a cutoff of one standard
deviation above the mean, 24 patients (17.5%) met criteria for depression (T score ≥ 11) and 113 (82.5%)
were not depressed (T score ≤ 10). The mean PROMIS raw score was 6.9 (SD ± 3.6) corresponding to
a T score of 53.9 (SE 2.4). 91 patients (66.4%) scored below the mean and 46 (33.6%) patients scored
above the mean. Our chosen depression screening question correlated moderately (r = 0.48, p < 0.0001)
with the PROMIS score. Furthermore, in the same subset of patients, we found a similarly moderate
correlation between symptoms and adherence in depressed patients (r = 0.46, p = 0.03) and moderate,
although stronger correlation in patients who were not depressed (r = 0.57, p < 0.0001).
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Table 1. Patient characteristics of our study population. As the questionnaire was voluntary,
some questions are missing responses from all 519 participants.




Age (mean ± SD) 40.9 (±16.7)
Race/Ethnicity (n = 509)
Black/African American 3 (0.6%)
Latino/Hispanic 8 (1.6%)
White 469 (92.1%)
Other (including more than 1) 29 (5.7%)
Highest education level (n = 207)
Less than a college degree 60 (29%)
College degree or equivalent 85 (41.1%)
Master’s degree or degree beyond Bachelor’s degree 49 (23.7%)
Doctorate degree 13 (6.3%)
Currently working (n = 209)
Yes 149 (71.3%)
No—on disability 5 (2.4%)
No—retired 24 (11.5%)
No—other 24 (11.5%)







Length of time from symptom onset to Celiac Disease diagnosis
<5 years 356 (68.6%)
5–15 years 67 (12.9%)
>15 years 38 (7.3%)
Don’t Know/missing 58 (11.2%)
Depressed (n = 519)
Yes
Very Much 35 (6.7%)
Quite A bit 65 (12.5%)
Somewhat 139 (26.8%)
No
A little bit 157 (30.3%)
Not at all 125 (23.7%)
Celiac Dietary Adherence Test (n = 519)





Celiac Symptom Index (n = 392)
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Figure 1. Celiac Dietary Adherence Test vs. Celiac Symptom Index Scores in patients with depressive
symptoms versus those without depressive symptoms.
4. Discussion
In this cross-sectional study of 519 patients with biopsy-diagnosed CD, we found that self-reported
depressive symptoms were common, occurring in 46% of the respondents. We also found that the
relationship between CD symptoms and adherence to a GFD may be attenuated based on the presence
of depressive symptoms related to having celiac disease. In those without depressive symptoms,
the correlation between symptoms and dietary adherence was moderate, although stronger than
in those with a positive depression screen. This was further supported by our regression analysis
demonstrating significant interaction of depression on the relationship between GFD adherence and
CD symptoms. These results suggest that the presence of depressive symptoms may attenuate the
relationship between adherence to a GFD and symptoms of CD as those with depression may have
less symptomatic relief from better adherence to a GFD than those without depressive symptoms.
We also found a weak correlation between higher levels of depression (based on our screening
question) and poor dietary adherence. The association between adherence to a GFD and depression
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was further evaluated in a recent meta-analysis, which found a likely association between poor
GFD adherence and worsened depressive symptoms. Furthermore, Addolorato et al. demonstrated
that CD patients who received six months of psychological counseling had better adherence to
their diets and lower rates of depression [24]. The weak correlation found in our study does not
support the relationship between poor dietary adherence and depression described by others [23].
Rather, our results suggest that depression affects the relationship between adherence to a GFD and
CD symptoms. One possible, reason for this effect modification is that patients with depression may
have their symptoms driven or exacerbated by factors other than gluten exposure, which may manifest
physically. However, there are many other potential causes of symptoms in CD including functional
bowel disorders, inadvertent gluten exposure, and concomitant food intolerances. The relationship
between celiac symptoms and depressive symptoms is complex and identifying which symptoms are
attributable to each process can be challenging for clinicians.
This study has a number of limitations, some of which are inherent to its retrospective,
self-reported and observational nature. The study was compiled from a voluntary questionnaire
in a patient-powered research network. Although there was no financial incentive to complete the
questionnaire, the study population represents a self-selected cohort of patients, who may be more
aware of their illnesses and therefore may be more adherent to a GFD than the general CD population.
This is supported by the high percentage (87%) of patients reporting they “always” adhere to a GFD.
Furthermore, the majority of our research cohort was comprised of white, highly educated females.
Unfortunately, the initial questionnaire did not contain all of the questions that make up the CSI and
the CDAT, so each of these instruments is incomplete. However, for the purpose of our study, the trend
(higher CDAT scores representing worse dietary adherence and higher CSI scores representing more
symptomatic patients) was sufficient to evaluate our research question. Moreover, we feel that the
correlation of higher CD symptom scores (worse symptoms) with poorer dietary adherence suggests
validity, despite the abbreviated indices available.
Another limitation was in our utilization of a single question to screen patients for depression.
Our screening question demonstrated moderate correlation with the validated 4-item PROMIS
Depression instrument. However the PROMIS questions were completed by only a small subset
of participants, which may lead to selection for more depressed patients. By PROMIS criteria,
the prevalence of depression in our study was 17.5%. In contrast, using our 1-item screening question,
depressive symptoms in our study were more common, with nearly half of respondents (46%) reporting
that they felt at least “somewhat” depressed with regards to their disease. This difference may
be due to the use of the chosen depression screening question which may signify the emotional
reaction to having CD as opposed to clinical depression. Addolorato et al. [21] demonstrated a 57%
prevalence of depression in their study, but others have shown the prevalence of active depressive
symptoms in CD patients to be lower [4]. The prevalence of depression found in our study should
therefore be interpreted with caution, as it may represent a self-selecting, more symptomatic population.
Furthermore, these results represent self-reported data at a point in time, and not diagnoses made by
health care professionals.
5. Conclusions
In conclusion, our analysis of data provided through a CD patient-powered research network,
suggests that depression may modify the relationship between adherence to a GFD and the presence
of symptoms in CD. In patients who screened positive for depressive symptoms, the correlation
between CD symptoms and response to a GFD was attenuated. These findings support that screening
for depression should be considered in patients with CD, as those with depression may have less
improvement in symptoms despite better adherence to the diet than those without depression.
The study of this topic remains a challenge due to a lack of longitudinal and prospective studies.
The relationship between dietary adherence and depression remains complex and the direction of the
association remains unclear [23]. As suggested previously, patients receiving psychological counseling
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may show better adherence to a GFD [24], but further prospective and randomized studies are needed
to explore whether or not treatment for depression improves how patients respond symptomatically
to a GFD. Ideally, future studies will encompass more diverse groups that represent the true CD
population in the United States with validated measures of depression to further substantiate these
findings. Our study also provides demonstrable evidence of the value of patient-powered research
networks in the ongoing study of celiac disease.
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Abstract: The ingestion of gluten has been associated with gastrointestinal symptoms even in the
absence of detectable immune responses. Little is known about the pathophysiological effects of
gluten on the upper gastrointestinal tract. We aimed to assess whether the ingestion of gluten leads
to an impairment of the physiological mechanisms of gastric emptying, gallbladder contraction
and relaxation. A total of 17 healthy subjects underwent ultrasound evaluation of gastric emptying
dynamics and gallbladder contractions at baseline and every 30 min after a standard gluten-containing
and gluten-free meal (250 kcal, 70% carbohydrates). The pattern of gastric emptying was similar
after a standard meal with or without gluten, but differed in terms of the peak of the antral filling
curve, which was wider (mean area 5.69, median 4.70, range 3.71-9.27 cm2 vs. mean 4.89, median 4.57,
2.27-10.22 cm2, p = 0.023) after the gluten-containing meal. The pattern of gallbladder contractions
was different after the gluten-free meal (p < 0.05), with higher gallbladder volumes in the late refilling
phases. The results of this study show that gluten ingestion exerts objective effects on gastric and
gallbladder motility. Although the underlying pathophysiological mechanism remains unknown,
these results could account for some of the gluten-related symptoms reported by patients with celiac
disease and non-celiac gluten sensitivity.
Keywords: gluten; gastric emptying; cholecyst; celiac disease; non celiac gluten sensitivity
1. Introduction
The ingestion of gluten-containing food has reportedly been involved in the development of a
broad range of symptoms. Gluten is a structural protein found in wheat, barley and rye, composed
of two main fractions, gliadins and glutenins [1]. In celiac disease (CD), the dietary intake of gluten
leads to the intestinal exposure to gluten-derived peptides. This exposure triggers a T-cell mediated
autoimmune reaction eventually leading to villous atrophy and malabsorption [2]. In wheat allergy
(WA), an adverse IgE-mediated immune reaction develops against proteins contained in wheat (i.e.,
alpha-amylase/trypsin inhibitor, lipid transfer protein, gliadins, glutenins) with different clinical
presentations [3]. However, recent data have suggested that the consumption of gluten-containing
food can cause gastrointestinal symptoms even in the absence of detectable immune responses or
signs of inflammation [4–6], which prompted the definition of a new class of gluten-related disorders,
the non-celiac sensitivity (NCGS) or non-celiac wheat sensitivity. NCGS describes a spectrum of
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gastrointestinal and extra-intestinal symptoms occurring shortly after the dietary exposure to gluten
and resolving when a gluten-free diet (GFD) has started [7–9]. Interestingly, GFD has shown benefits
in terms of reduction of gastrointestinal symptoms when tested in a population with already known
gastrointestinal disorders, such as inflammatory bowel disease or irritable bowel syndrome [10,11].
In spite of the growing evidence on the potential direct effects of gluten or related wheat-derived
proteins on the gastrointestinal and immune system [12–15], there is still little data concerning the
pathophysiological effects of gluten on the upper gastrointestinal tract. It is known that patients with
CD tend to have higher fasting gallbladder volumes and slower gastric emptying before starting
on GFD, possibly because of impaired levels of somatostatin and cholecystokinin [16,17]. However,
these alterations of the upper gastrointestinal dynamics were considered more as a consequence of
small bowel mucosal damage than a direct effect of gluten on the gastrointestinal system mediated by
innate or adaptive immune response.
One can conjecture that, in subjects with disorders belonging to the spectrum of functional
gastrointestinal disorders, as well as in those with a diagnosis of NCGS, the ingestion of gluten exerts
a direct effect on gastrointestinal dynamics: this would explain the onset of symptoms following
gluten-containing meals. Recent data have suggested that gluten may trigger a rapid innate immune
response after ingestion also in subjects not affected by CD [15]. Magnetic resonance studies have
showed that the ingestion of wholemeal bread results in delayed gastric emptying and reduced
postprandial small bowel waters compared to a rice meal [18]. However, no significant effect on
gastric emptying and small bowel and colonic distension was observed in a subsequent study
investigating the effect of bread with different ingredients, including different gluten contents [19].
Ultrasound is a non-invasive, readily available technique that can be successfully applied in the setting
of gastrointestinal dynamics [17,20]. To date, only a small-scale study has investigated, with the aid of
ultrasound, the effect of gluten intake on healthy volunteers: it has shown no differences in gastric
and gallbladder emptying in healthy volunteers after a gluten-containing vs. gluten-free meal [21].
With these premises, the aim of this study was to evaluate the effect of a gluten-containing meal
on gastric emptying and gallbladder (GB) contraction and relaxation, as compared to a gluten-free
isocaloric meal, in order to collect more data on the relationship between dietary intake of gluten and
gastrointestinal dynamics.
2. Materials and Methods
2.1. Study Population
Between June 2014 and June 2015, 17 healthy volunteers were enrolled at the academic
Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico,
Milan (Italy). The criteria for excluding the enrolment as healthy volunteers were: the presence
of clinically relevant diseases (especially as concerns CD, food allergies and gastrointestinal
diseases including functional gastrointestinal disorders), on-going pregnancy, active smoking habits.
The absence of CD was proven by means of serological testing of tissue transglutaminase antibodies
(TTG). All the subjects gave their written informed consent to the study, which was approved by
the local ethics committee (n. 1491/2014). Basal clinical history data were collected and a physical
examination was carried out for every subject. Anthropometric parameters (weight, height) were
collected and the body mass index (BMI) was computed for each individual, using the standard
formula: weight (kg)/height2 (m2).
2.2. Ultrasound Study of Gastric and Gallbladder Dynamics
The primary outcomes of the study were the assessment of changes in the gastric antrum size,
in the dynamics of gastric emptying and of gallbladder contraction. All the subjects underwent
the ultrasound evaluation of gastric and gallbladder dynamics twice: after a standard normocaloric
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balanced gluten-free meal and an isocaloric gluten-containing meal. Each subject received each meal
in fasting conditions and after at least 72 h on a normocaloric balanced gluten-free diet.
2.3. Meal Administration
The composition of the administered meals was as follows:
a. gluten-free meal—a standard fatty meal consisting of cooked egg albumen (110 g), two slices
of toasted gluten-free bread (rice, millet and quinoa flour basis) (50 g), strawberry jam (20 g),
water (120 mL). The meal contained 250 kcal, of which 70% from carbohydrates.
b. gluten-containing meal—an isocaloric meal differing only as regards the type of bread, which was
gluten-containing (wheat flour basis).
2.4. Ultrasonographic Evaluation
Gastric emptying and gallbladder motility were evaluated by real-time ultrasound examination
with a Philips iU22 system (Philips Ultrasound, Bothell, WA, USA), equipped with a multi-frequency
convex transducer (C5-2, 5-2MHz). The gastric antral area was measured three times and the mean
values of the two diameters were used to calculate the area, assuming an elliptical shape, by means
of the formula: πAB/4, where A is the longitudinal diameter and B the anteroposterior diameter
as measured at the cross-section of the gastric antrum, corresponding to the sagittal plane passing
through the superior mesenteric vein, according to Bolondi et al. [20]. The basal antral measurements
were taken after overnight fasting (basal time, 0 min). After having the standard meal, all the subjects
underwent US measurements every 30 min until complete gastric emptying. Gastric emptying was
considered ended when the antral area returned to basal values and remained then unchanged for
at least 30 min. The gallbladder volume was calculated by the ellipsoid formula: πAxBxC/6 as
previously described by Dodds et al. [22], where A is the longitudinal, B the transverse and C the
antero-posterior diameter. Gallbladder measurements were taken at time 0 and every 30 min after the
standard meal, until the refilling occurred after an initial contraction. Also for the gallbladder three
different measurements were taken in rapid sequence and the mean values were used. The gallbladder
residual volume (mL) was the smallest volume measured at the completion of the meal-induced
emptying. The in-percent difference between the basal volume and the residual volume represented
the gallbladder ejection volume (mL) (GB EF%). All the examinations were obtained and evaluated
in real time by two expert operators (SM and AB) blinded as regards the type of meal received by
the participants. At the end of the observation time, all subjects were asked to fill in a questionnaire
regarding the onset of common dyspeptic symptoms after each meal, i.e., upper abdominal pain or
discomfort, nausea, vomiting, fullness, bloating, early satiety and belching, as well as their intensity
measured by means of visual analogic scales ranging from 0 to 10.
2.5. Statistical Analysis
This study was designed as a pilot study and a sample size estimation was not considered possible
as this preliminary stage. Demographic and clinical data were expressed as medians and ranges or
means and SD, unless stated otherwise. The difference in mean gastric antral area variations after the
two meals was evaluated by means of ANOVA or Friedman’s model. The areas under the curve were
calculated for both the gastric emptying and gallbladder contraction dynamics and the differences
were analyzed with the paired t-test or the Wilcoxon matched-pairs signed rank test. The presence
of any association between the onset of symptoms and variation in the gastric antral area or other
US parameters was evaluated by means of Pearson’s correlation test. All the data were tested for a
normal distribution using the Kolmogoroff–Smirnoff test. Statistical analysis was performed with the
software package SPSS v. 19 (IBM SPSS Statistics, rel. 2010, Armonk, NY, USA: IBM Corp). A two-tailed
p value < 0.05 was considered statistically significant.
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3. Results
The study population consisted of 17 subjects, 11 females and six males, with a median age of
30.5 years (range 25–41) and a median BMI of 20.8 Kg/m2 (range 17.7–29.9). No participant had
relevant concomitant conditions nor drug intake, nor alcohol consumption (defined as more than
1 alcoholic unit per day). Only one participant was a smoker (five cigarettes a day).
After the gluten-containing meal, the postprandial filling peak was significantly wider than after
the gluten-free meal (median antral area 4.70 cm2, range 3.71–9.27 vs. 4.57 cm2, range 2.27–10.22,
p = 0.025, Figure 1). Also the mean difference between the basal antral area and the antral filling curve
peak was significantly higher after the gluten-containing meal (3.02 ± 1.74 cm2 vs. 1.89 ± 1.68 cm2,
p = 0.01). Overall, gastric emptying dynamics were similar for both types of meals (Figure 2) and the
time-to-peak of the antral filling curve was not significantly different between the two meals (mean
45.9 ± 30.2 min after the gluten-containing meal vs. 52.9 ± 34.4 min after the gluten-free meal, p = 0.47).
Regarding gastric emptying, the emptying time was slightly longer after the gluten-containing
meal than after the gluten-free meal, although this finding was not statistically significant (mean
222.35 ± 81.5 min vs. 202 ± 64.97 min, p = 0.37). The results are summarized in Table 1. Age, sex and
BMI did not correlate with the gastric filling curve nor did they with the time-to-peak and the gastric
emptying time.
  
(a)                                       (b) 
Figure 1. Changes in the gastric antral area at peak of the 17 healthy volunteers after gluten-containing
(a) and gluten-free meals (b); p = 0.01. y-curve: area, cm2.
(a)                                   (b) 
Figure 2. Detailed gastric filling and emptying patterns (a) and gallbladder contraction (b) after the
two meals. Data are shown as mean (standard deviation).
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Table 1. Parameters of the gastric dynamics after gluten-containing and gluten-free meals.
Parameters Gluten-Containing Meal Gluten-Free Meal p
Gastric filling peak
area in cm2, median (range) 4.70 (3.71–9.27) 4.57 (2.27–10.22) 0.023
Difference peak-basal
area in cm2, median (range) 3.02 ± 1.74 1.89 ± 1.68 0.01
Time to peak
mins, mean (SD) 45.9 ± 30.2 52.9 ± 34.4 0.47
Gastric emptying time
mins, mean (SD) 222.4 (81.5) 202 (65.0) 0.37
SD: standard deviation.
The gallbladder contraction patterns were different between the gluten-containing and the
gluten-free meal aftermaths (area under the curve, AUC: 3.711 vs. 3.630, p = 0.001), with higher
gallbladder volumes being observed especially in the late refilling phases (p = 0.039 at 240 min, <0.01
at 300 min). The gallbladder ejection fraction did not differ between the two meals. The fasting
gallbladder volume did not correlate with age, sex, BMI nor with the basal antral area (Table 2).
Interestingly, no subject reported the onset of gastrointestinal symptoms after either meal.
Table 2. Parameters of the gallbladder dynamics after gluten-containing and gluten-free meals.
Parameters Gluten-Containing Meal Gluten-Free Meal p
GB basal volume
mL, mean (SD) 14.7 (6.5) 15.4 (6.8) 0.76
Gallbladder ejection fraction
%, mean (SD) 44.4 (28.1) 44.2 (28.1) 0.9
GB volume at 240 min
mL, median (range) 10.8 (5.2–13.4) 14.3 (12.1–21.2) 0.039
Pattern of GB contraction
mL*min, AUC 3711 3630 0.001
GB: gallbladder; AUC: area under the curve.
4. Discussion
The results of our study show that the ingestion of a gluten-containing meal may cause specific
effects on the upper gastrointestinal dynamics irrespective of the presence of a gluten-related disorder.
In the group of healthy volunteers we examined, small but significant differences were observed in
both the gastric filling and gallbladder contraction dynamics. Regarding gastric filling and emptying
dynamics, a significantly wider antral area was observed after a gluten-containing meal than after the
isocaloric gluten-free meal, although the filling and emptying times and the general dynamic pattern
were not altered by the different composition of meals. The gallbladder contraction after the two meals
did not vary significantly as regards the entity of the contraction, but after the gluten-containing meal
a longer contraction time was observed, with a significantly longer time required to return to the basal
fasting volume.
In patients with known gastrointestinal disorders, the ingestion of gluten-containing food exerts
upper gastrointestinal symptoms which are to date not commonly explained from a pathophysiological
point of view (in the case of NCGS) or only partially explained by the immune response to gluten
(in the case of celiac disease). Thus, this study was performed in order to objectively analyze the
presence of differences in gastric and/or gallbladder motility according to the content of gluten in a
meal, irrespective of the onset of symptoms on healthy subjects. The differences we observed, though
not dramatic, appear to confirm the hypothesis that the ingestion of gluten may exert a direct effect
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on the gastrointestinal tract and thus cause symptoms through a pathogenetic mechanism other than
those associated with the development of celiac disease.
In fact, gluten, or gluten-related peptides, can reportedly elicit several reactions when they are in
contact with the gut and in particular with immune cells [15,23,24]. The alteration of gut permeability,
as a consequence of a direct effect of gluten-derived peptides or through the triggering of an immediate
innate immune response, has been studied in both animal models and human subjects with the
aim of explaining the pathogenesis of both celiac disease and NCGS [23,24]. Moreover, the increase
in the secretion of hormones, such as insulin, links to the exposure to gliadin peptides in animal
models and in vitro [25]. A direct link between gluten and the secretion of gastrointestinal hormones
has not been demonstrated at a molecular level; however, one can suppose that the interaction
between gluten-derived peptides and immune cells in the intestinal mucosa and submucosa might
also directly influence the secretion of these hormones and thus the dynamics of gastric emptying
and gallbladder contractions [17,26]. This is in line with the observation of an impaired gallbladder
motility in patients with celiac disease in relation to a reduced secretion of enteric hormones and/or
decreased gallbladder sensitivity to them. In particular, untreated celiac patients, when compared to
controls, have showed low levels of postprandial cholecystokinin and increased fasting somatostatin
levels [17]. Moreover, a gastric emptying time longer than in controls has been observed in untreated
celiac patients, along with the concomitant increase in plasma neurotensin levels [26].
Other mechanisms that possibly explain our observations, particularly the potential role of
proteins other than gluten on the gastric and gallbladder motility are: the increased gastric filling
observed at ultrasound after the gluten-containing meal which is possibly a consequence of other
wheat components, such as amylase-tripsin inhibitors (ATI) [13] or fructans, which have been linked
to the development of gastrointestinal symptoms in both patients with NCGS and irritable bowel
syndrome [27–29]. However, this study is limited since the exact content of ATI and fructans in our
meals was not calculated. Further data would be useful to directly compare the effect of ATI, fructans
and gluten on the upper gastrointestinal dynamics.
As for the limitations of our study, first of all the small sample size may have led to less precision
of the estimates; further studies will have to be designed in order to overcome this limit. Moreover,
the group of participants was not entirely balanced as it included more women (11/17, 65%). However,
considering the cross-over design of the study, every patient acted as their own control, which helps
reduce biases. Finally, the investigation of gastric and gallbladder dynamics by means of ultrasound is
not the standard methodology for the diagnosis of altered gastric emptying, although it is easy and
non-invasive and has already been evaluated in previous studies [17,20–22].
It is worth noting that none of our healthy subjects reported the onset of gastrointestinal symptoms
after the meals, irrespective of the actual changes on gastric volume or gallbladder dynamics observed.
It is known that in subjects with functional gastrointestinal disorders, alterations in visceral motility or
distension considered within “normal” range are associated with the onset of symptom [30]. One can
hypothesize that in patients reporting symptoms after having a gluten-containing meal, the alterations
caused by the meal would be perceived differently, thus corroborating the hypothesis of an enhanced
visceral sensitivity in patients with the irritable bowel syndrome spectrum [30]. Of course, numerous
other factors could impact symptoms and responses in patients, including innate immune reactions,
size of the meals, so that the specific role of gluten still has to be clarified. In order to prove this
speculative hypothesis, further studies should investigate the effects of meals with different gluten
content on patients with IBS or NCGS.
5. Conclusions
In conclusion, the results of our study support the hypothesis of a direct effect of gluten intake
on both gastric and gallbladder motility, especially regarding the dynamics of gastric filling and
the gallbladder contraction pattern. Although the underlying pathophysiological mechanism is still
unknown, these observations could, if substantiated by further studies on patients, explain some of
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the gluten-related symptoms reported by patients with NCGS and other gastrointestinal disorders,
who are improving through GFD.
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Abstract: A subset of patients with celiac disease (CD) on a gluten-free diet (GFD) reported the
persistence of functional gastrointestinal disorders. Foods containing fermentable, oligosaccharides,
disaccharides, monosaccharides, and polyols (FODMAP) can trigger a broad range of gastrointestinal
symptoms in sensitive individuals. We evaluated the effects of a low FODMAP diet (LFD) on
gastrointestinal and psychological symptomatology in CD patients. A total of 50 celiac patients on
GFDs and with persistence of gastrointestinal symptoms were included. The patients were randomly
allocated to one of two dietary groups—one on a low FODMAP GFD (LF-GFD, n = 25) and the other
on a regular GFD (R-GFD, n = 25)—for 21 days. Psychological symptomatology and quality of life
were evaluated by the Symptom Checklist-90-R (SCL-90) and the Short Form (36) Health Survey
(SF-36) questionnaires, respectively. Gastrointestinal symptomatology and general well-being were
evaluated by visual analogue scale (VAS) scores. After 21 days, 21 and 23 patients completed the
dietary treatment on LF-GFD and R-GFD, respectively. A reduced global SCL-90 index (p < 0.0003)
was found in the LF-GFD group but not in the R-GFD one. However, the SF-36 scores did not differ
between groups after treatment. The VAS for abdominal pain was much lower, and the VAS for fecal
consistency enhanced after treatment in the LF-GFD group. General well-being increased in both
groups but with a much higher improvement in the LF-GFD (p = 0.03). A short-term LFD regimen
helps to improve the psychological health and gastrointestinal symptomatology with enhanced
well-being of CD patients with persisting functional gastrointestinal symptomatology. The long-term
clinical effects of LFD in particular subgroups of CD patients need further evaluation.
Keywords: gluten-free diet; gastrointestinal symptoms; quality of life
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1. Introduction
Celiac disease (CD) is an autoimmune multisystem disorder triggered by gluten ingestion [1,2].
CD affects genetically susceptible individuals who are known to possess the Human Leukocyte
Antigen HLA DQ2 (90%–95%) or the HLA DQ8 (5%–10%) haplotypes [3]. CD symptomatology is
mainly gastrointestinal with patients usually reporting diarrhea, bloating, abdominal pain, and weight
loss [2]. Extra-intestinal symptoms can be also frequent [4].
A gluten-free diet (GFD) is the current treatment for CD [5]. In this dietary treatment, foods
containing gluten, which is a protein found in grains, such as wheat, barley, rye, and triticale,
are excluded. Gluten induces small intestine inflammation, and a GFD helps to counteract the clinical
signs/symptoms and to prevent complications [6]. Although this treatment is highly successful,
following a strict GFD poses great difficulty to patients in their family, social, and working contexts,
thus deteriorating their quality of life [7] and causing psychological distress [8].
It is not uncommon that patients on GFDs report symptoms resembling those of irritable bowel
syndrome (IBS), which is a frequent condition in clinical practice. Reportedly, around 20–23% of treated
CD patients fulfill the Rome III criteria for IBS and also suffer from various functional gastrointestinal
symptoms, further affecting their quality of life [9]. In fact, a meta-analysis has shown that IBS-like
symptoms are common in CD patients (the pooled prevalence of IBS symptoms in treated CD patients
was 38%), concluding that higher levels of adherence to a GFD are possibly associated with some
reduction in symptomatology [10]; however, the authors also highlighted that in some patients, IBS-like
symptoms persist even after following a strict GFD.
Functional gastrointestinal disorders are characterized by recurrent or current gastrointestinal
symptoms that have no identifiable structural or biochemical basis. The most common functional
gastrointestinal disorder is IBS [11]. The variety of clinical manifestations has limited the effective
treatment of these syndromes, and most treatments to date only alleviate the primary manifestation.
A novel option for IBS treatment, which is currently generating great excitement, is the dietary regimen
with reduced amounts of fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols
(FODMAP) [12]. FODMAP are short-chain carbohydrates that are poorly absorbed in the small
intestine and increase gas production and intestinal osmolarity because of their rapid fermentation and
osmotic action [13–15]. Foods containing FODMAP can trigger gastrointestinal symptoms in sensitive
individuals [13,16].
A low FODMAP diet (LFD) appears to be associated with the reduction of IBS symptoms [17].
A very recent meta-analysis found evidence for the short-term efficacy and safety of LFD for
patients with IBS, but the long-term effects are still under investigation [18]. Recently, LFD has
been evaluated in patients with inflammatory bowel disease, showing improved symptomatology
after treatment [19]. From a clinical point of view, CD and IBS may coexist [20]. However, it is more
likely that the inflammatory process occurring in CD does not revert completely in some patients on
GFD, and similar low-grade inflammation can be present both in patients with CD and IBS [9,21].
To date there are no reports showing the potential effect of LFD on gastrointestinal symptomatology
for patients with CD; thus, we have evaluated the role of LFD on treated CD patients with the
persistence of functional gastrointestinal disorders. In addition, given the frequent manifestation of
psychopathological and behavioral abnormalities in CD patients undergoing dietary changes, their
overall psychological distress and disability were also assessed. In particular, we hypothesized that
patients being administered LFD would show improved conditions in terms of gastrointestinal and
psychopathological symptoms compared with patients on regular-GFD (R-GFD).
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2. Materials and Methods
This was a randomized double-blind intervention-controlled study, previously registered at
ClinicalTrials.gov (ref. no. IDNCT02946827). All the authors had access to the study data and reviewed
and approved the final version of the manuscript. The patients were recruited at the Center for
Prevention and Diagnosis of Celiac Disease of Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico in Milan (Italy). The University of Milan’s Institutional Review Board reviewed and
approved the study protocol according to the Helsinki Declaration, the Project Identification Code of
the Ethics Committee Approval of our study: 744_2015bis, the protocol was approved by the Ethics
Committee of Milano Area B (date 10.11.2015). All the patients gave and signed their informed consent
prior to participation in this study.
Between December 2015 and December 2017, we studied patients with CD fulfilling the
following inclusion criteria: adult age (between 18 and 60 years), treated with a GFD for at least
one year, with negative plasma tissue transglutaminase values, with IBS-like symptoms and functional
gastrointestinal disorders according to the Rome III criteria [22], and with a global well-being score
assessed by a visual analogue scale (VAS) of <4. As exclusion criteria, we considered the following:
low adherence to the GFD (as evaluated by the Celiac Dietary Adherence Test [23]), refractory CD
(as evaluated through biopsy to assess the persistence of intestinal atrophy while on a GFD and by
means of interview carried out by a trained nutritionist, who assessed patients’ adherence to the diet),
individual intolerance to disaccharides (as evaluated by hydrogen test (lactose and fructose), history
of previous nutritionist evaluation or nutritional treatment for the dietary management of IBS, taking
IBS pharmacological therapy, abdominal surgery, and type 2-diabetes.
CD was diagnosed according to positivity to the serological tests of endomysial antibodies
and tissue transglutaminase antibodies and on the basis of histological abnormalities at duodenal
biopsy according to the modified Marsh classification (following the European Society for Pediatric
Gastroenterology and Nutrition criteria) [24]. The allocation ratio was 1:1, and the recruited patients
(n = 50) were randomly allocated to either of two dietary treatments—a low FODMAP GFD (LF-GFD,
n = 25) or a R-GFD (R-GFD, n = 25)—for a time length of 21 days. Before randomization (baseline) and
at day 21, the patients underwent a physical examination, and biochemical and nutritional parameters
were assessed. After the intervention period, 21 patients in the LF-GFD and 23 in the R-GFD group
completed the protocol and were included for the analyses reported in this study. The primary outcome
was change in the VAS score for general well-being after 21 days of intervention. Secondary outcomes
were changes in the VAS score for gastrointestinal symptomatology and the Short Form (36) Health
Survey (SF-36) and the Symptom Checklist-90-R (SCL-90) scores for quality of life and psychological
symptomatology, respectively.
The sample size was calculated using G*Power v. 3.1.9.2 for Windows (Düsseldorf, Germany [25])
based on the difference in the reduction of overall IBS-like symptomatology of at least 50% after
21 days following a LFD or high-FODMAP diet in IBS patients, as reported by McIntosh et al. [26].
Considering an α-error 1% (two-tailed test) and a power of 90%, with a response of 72% after the LFD
and 21% after the high-FODMAP diet, the estimated sample size was estimated in 22 patients per
group, including an additional 20% of patients for potential losses during the follow-up. The random
allocation sequence was planned by one of the researchers (L.R.), and the participants’ enrollments
were carried out by F.B., F.F., and L.E. Both the researchers (gastroenterologists and trained nutritionists)
and the patients were blind after the assignment to each intervention group.
2.1. Clinical Evaluation
At the baseline and at the end of the intervention period, each patient underwent a clinical
and nutritional evaluation (by two gastroenterologists and two trained nutritionists). Overall health
and gastrointestinal and extra-gastrointestinal symptoms were assessed, and the gastrointestinal
symptomatology was further classified.
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2.2. Diets
The nutritional evaluation aimed at assessing anthropometrical parameters, nutritional status,
and usual dietary patterns. After clinical evaluation, a personalized GFD adjusted to match energy
and macronutrients and micronutrients daily requirements was indicated to each patient. This task
was carried out by a trained nutritionist who was only in charge of performing this task, without
involvement in patient management. In each dietary treatment, a structured 21-day dietary plan
excluding all food gluten sources was indicated. The dietary plan included structured daily meals and
specific foods/beverages and was explained in detail to each patient at the beginning of the study.
After the initial explanation, the nutritionist was available to answer any doubts or issues strictly
related to the dietary plan via e-mail or telephone. As all the patients received a structured dietary plan,
both the R-GFD, as well as the LF-GFD, received a review of their current dietary habits, in addition
to the change in FODMAP content in the LF-GFD group. The FODMAP content of the R-GFD and
LF-GFD was a median (interquartile range) of 21.8 (18.5–22.5) and 3.7 (3.0–4.12) g/day, respectively,
as previously described [27,28]. An example of the meals and foods used in both types of diets is
shown in Table 1. The group with the LF-GFD received an in-depth GFD review, food education
regarding GFD and LFD, and dietary counseling to initiate the modification of the FODMAP content
towards the LFD. The patients in the R-GFD group received an in-depth GFD review together with
food education regarding their diet. Compliance and doubts about the diet were checked 10 days later
by means of a telephone call by the same nutritionist.






Breakfast 1 cup of tea80 g of gluten free biscuits
1 glass of fresh orange juice
3 slices of gluten-free bread
3 teaspoons of honey
Morning snack 1 banana 1 apple
Lunch
130 g of gluten free pasta with zucchini
60 g of chicken
150 g of carrots
120 g of turkey thighs
200 g of cauliflowers
Afternoon snack 1 cup of blueberries 1 pear
Dinner 180 g of seafood150 g of tomatoes
200 g of asparagus soup
70 g of fresh cheese
150 g of carrots
During the day 130 g of gluten free bread6 tea spoons and half of virgin olive oil
160 g of gluten free bread
2 tea spoons of virgin olive oil
1 Dietary data represent the typical diet for a patient with an approximate energy expenditure of 1800 kcal/day.
FODMAP: Fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols; R-GFD: regular gluten-free
diet; and LF-GFD: low-FODMAP diet.
2.3. Psychological Symptoms and Quality of Life
The Symptom Checklist-90-R (SCL-90) questionnaire was used to evaluate a broad range of
psychological problems and symptomatology [29]. The scale is composed of 90 questions and assesses
the presence and severity of symptoms of mental distress regarding different symptomatic domains
(somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic
anxiety, paranoid ideation, and psychotic). Each question is awarded a score on a five-point Likert scale
with extremes from “not at all” (0 points) to “extremely” (4 points). In addition to the scores rating
specific symptoms’ intensities, a global severity index was calculated to estimate the assessment of the
patient’s psychopathological state and as an indicator of symptomatic severity and psychic distress.
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The Short Form (36) Health Survey (SF-36) questionnaire evaluated the patients’ quality of
life. This is a 36-question-long instrument conceptually referring to eight health domains: physical
activity (10 questions), role limitations due to physical health (4 questions), role limitations due to
emotional state (3 questions), physical pain (2 questions), general health perception (5 questions),
vitality (4 questions), social activities (2 questions), mental health (5 questions), and a single question
on changes in the state of health [30]. The scores for each domain ranged between 0 and 100, where
100 represents the best possible perception of quality of life.
2.4. Gastrointestinal Symptoms
We used a series of 10-cm long visual analogue scales (VASs) referring to the level of satisfaction
with their health status and the severity of specific symptoms (abdominal pain, satisfaction with
stool consistency, bloating, postprandial fullness, early satiety, epigastric pain, and other symptoms).
A further VAS evaluated satisfaction with general well-being (0 being extremely poor satisfaction
and 10 very high satisfaction). These VASs were previously used by our group in a population with
Non Celiac Gluten Sensitivity to evaluate gastrointestinal manifestations and general well-being [31].
The magnitude of change in gastrointestinal symptoms between the baseline and at the end of the
21-day-long intervention was assessed as follows: (a) comparing each VAS score at both time points,
and (b) estimating the number of patients achieving a change in VAS score for general well-being
higher than or equal to 50% from the baseline.
2.5. Statistical Analysis
The data were described as median ± Standard Deviation (SD) or median (inter-quartile range),
depending on the parametric or non-parametric distribution of variables as assessed by graphical
inspection and the Shapiro–Wilk test. All the patients who had fully completed the intervention period,
were included in the analysis (per-protocol analysis). For SCL-90 and SF-36 scores, a within-group
comparison at both time points (the baseline and day 21) and a between-group comparison at day
21 was conducted using an independent Student’s t-test or the non-parametric Wilcoxon rank sum
test, depending on the distribution of variables. For the main outcome, the VAS score for general
well-being, with two-way Analysis of Variance (ANOVA) (factors ‘treatment’ and ‘time’) with one
repeated measure (‘time’), was used. The magnitude of change in the VAS score for the general
well-being comparison between groups at day 21 was evaluated by Fisher’s exact two-tailed test.
A 5% significance level was used, and the software packages STATA® v. 13.1 (StataCorp LLC, College
Station, TX, USA) and GraphPad Prism v. 6 (GraphPad Software, La Jolla, CA, USA) were used for
analysis and figures processing.
3. Results
3.1. Patients
The participant flow is shown in Figure A1. The patients were middle-aged, mainly women,
and within the normal weight range, according to mean body-mass index (Table 2). Regarding their
clinical symptomatology at the baseline, 64% reported the presence of IBS-like symptoms, whereas
34% reported functional symptomatology (Table 2). Among the specific symptoms, diarrhea and
constipation were the most frequently reported (34% and 32%, respectively) with lower frequencies of
mixed and non-specified gastrointestinal symptoms (12% and 8%, respectively). At the baseline the
LF-GFD and R-GFD groups were similar in relation to the presence of evaluated symptoms.
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(n = 25) p value
†
Age, years 41.1 ± 10.1 40.4 ± 10.1 41.9 ± 10.2 0.73
Gender, female (%) 44 (88) 25 (100) 22 (3 no data) 0.09
BMI, kg/m2 22.5 ± 4.1 22.3 ± 3.6 22.1 ± 5.4 0.87
Diarrhea, n (%) 17 (34) 6 (6 no data) 11 (4 no data) 0.18
Constipation, n (%) 16 (32) 9 (7 no data) 7 (2 no data) 0.2
Mixed symptoms, n (%) 6 (12) 4 (10 no data) 2 (5 no data) 0.36
Non-specified, n (%) 4 (8) 3 (12 no data) 1 (9 no data) 0.29
Dyspepsia, n (%) 17 (34) 8 (5 no data) 9 (3 no data) 0.95
1 Data shown as mean ± Standard Deviation (SD) for continuous variables and frequency and percentage for
nominal variables. † p-value for comparison between groups using an independent t-test for continuous variables
or Chi-square or Fisher’s exact tests for nominal variables. BMI: body-mass index; R-GFD: regular gluten-free diet;
and LF-GFD: low-FODMAP gluten-free diet.
3.2. Psychological Symptoms and Quality of Life
A consistent reduction in most SCL-90 scores was found in the LF-GFD group but not in the
R-GFD group, with the global SCL-90 score being significantly reduced (p < 0.0003) compared with the
R-GFD group at day 21 (p < 0.04, Table 3, and Figure S1 in the Supplementary Materials). With respect
to specific sub-items of the SCL-90, there were no differences in the R-GFD group. However, in the
LF-GFD group some significant changes were observed between the baseline and day 21 in relation to
the majority (7 out of 9) of the psychopathological dimensions (Table 3).



















Global index 1.61 ± 0.39 1.44 ± 0.29 0.13 ‡ 1.49 ± 0.17 1.26 ± 0.18 0.0003 0.04
Somatization 1.87 (0.71) 1.50 (0.58) 0.13 1.83 (0.62) 1.45 (0.40) 0.01 0.43
Obsessive-compulsive 1.70 (1.0) 1.60 (0.70) 0.41 1.60 (0.50) 1.30 (0.60) 0.01 0.15
Interpersonal sensitivity 1.55 (0.66) 1.38 (0.65) 0.09 1.22 (0.44) 1.11 (0.44) 0.09 0.58
Depression 1.57 (0.73) 1.50 (0.73) 0.33 1.54 (0.46) 1.38 (0.46) 0.01 0.26
Anxiety 1.30 (0.65) 1.10 (0.51) 0.17 1.30 (0.40) 1.10 (0.15) 0.02 0.60
Hostility 1.42 (0.50) 1.42 (0.58) 0.75 1.33 (0.50) 1.16 (0.08) 0.01 0.11
Phobic anxiety 1.0 (0.14) 1.0 (0.14) 0.81 1.0 (0.14) 1.0 (0.0) 0.10 0.12
Paranoid ideation 1.66 (0.83) 1.16 (0.66) 0.22 1.33 (0.50) 1.0 (0.33) 0.01 0.20
Psychotic 1.20 (0.50) 1.10 (0.25) 0.13 1.20 (0.10) 1.0 (0.10) 0.03 0.26
1 Data shown as mean ± SD or median (interquartile range) for non-parametrical variables. † p-value for comparison
within groups using a non-parametric Wilcoxon rank sum test unless otherwise is indicated; ‡ independent t-test.
R-GFD: regular gluten-free diet; LF-GFD: low-FODMAP gluten-free diet.
The results of the SF-36 scores are shown in Table 4. Overall, there were no differences in the SF-36
sub-scores both within and between groups through the intervention (Table 4 and Figure S2 in the
Supplementary Materials). However, when evaluating the change percentage at day 21, a statistically
significant improvement in health perception, as well as in the physical functioning scores was found
in the LF-GFD compared with the R-GFD group (Figure 1).
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Figure 1. Change in the SF-36 questionnaire scores between the baseline and day 21 from intervention.
Data shown as mean (symbol) ± SEM (upper and lower whiskers). For each sub-item, the difference
between the values after intervention and the baseline was calculated and divided by the respective
baseline value, expressed as a percentage, * p < 0.05; ‡ p = 0.06, for comparison between groups for
each sub-item. R-GFD: regular gluten-free diet; and LF-GFD: low-FODMAP gluten-free diet.
3.3. Gastrointestinal Symptoms
A significant interaction was found with regard to the VAS score of abdominal pain with a
significant decrease in the LF-GFD group versus the R-GFD group at day 21 (p < 0.01, Figure 2,
and Figure S3 in the Supplementary Materials). The VAS score for satisfaction about fecal consistency
showed a tendency for a higher increase in the LF-GFD group at day 21 (p < 0.09). Post-prandial
fullness severity was lower in the LF-GFD group and decreased in both groups at day 21 (p < 0.006)
but without significant interaction (Figure 2 and Figures S4 and S5 in the Supplementary Materials).
No differences were found for non-specific functional gastrointestinal symptoms.
Figure 2. Cont.
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Figure 2. Visual analogue scale (VAS) score for gastrointestinal symptoms. VAS for abdominal pain (A),
fecal consistency (B), and post-prandial fullness severity (C). In each plot, data is shown as median (line),
inter-quartile range (box limits), and min/max (whiskers); Black dot in B) indicates an extreme value.
R-GFD: regular gluten-free diet; LF-GFD: low-FODMAP gluten-free diet; and n.s.: non-significant.
The VAS score for satisfaction about general well-being was significantly enhanced in both
groups. However, the improvement in well-being was greater in the LF-GFD group (p < 0.01, Figure 3).
Consistently, the evaluation of the change in this VAS score of general well-being from the baseline
revealed a greater change at day 21 in the LF-GFD group as compared with the R-GFD group (Figure 3).
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Figure 3. Change in the VAS of well-being between the baseline and day 21 from intervention.
VAS score for overall well-being was evaluated at the baseline and at the end of the intervention period
(day 21) for the R-GFD (A) and LF-GFD (B) groups; the magnitude of change in well-being perception
(C) was calculated by estimating the number of patients (shown in percentage for each group) with a
change in VAS score greater than or equal to 50% of the baseline value. Data are individual values at
both time points. R-GFD: regular gluten-free diet; LF-GFD: low-FODMAP gluten-free diet; VAS: visual
analogue scale. * p = 0.03 Fisher´s exact test.
4. Discussion
To our knowledge this is the first randomized double-blind intervention-controlled study that
has investigated the effects of a LFD on patients with CD following GFDs but with persisting
functional gastrointestinal symptoms. Our results showed a positive response to LFD, an improvement
in psychological health scores—but only a limited change in quality of life—and a significant
improvement in gastrointestinal symptoms with improved perception of well-being by the patients on
the LFD.
Foods containing FODMAP can trigger IBS-like symptoms. These dietary compounds can trigger
an increase in flatulence, diarrhea, and bloating that may lead to abdominal pain [13]. Our results
suggest that LFD may improve persistent gastrointestinal symptomatology in those patients who
undergo GFD and also successfully improve the psychological aspects already described in this group
of patients [32]. After our intervention, the severity of gastrointestinal symptoms, such as abdominal
pain and stool consistency, decreased when compared with the situation at the baseline and with the
R-GFD group, along with improvement in the general well-being VAS. These results are in agreement
with those reported by Halmos and colleagues, who showed that a low-FODMAP diet effectively
reduced functional gastrointestinal symptoms in patients with IBS [17]. On the other hand, a study
conducted on patients with inflammatory bowel disease has showed a positive response to LFD, thus
suggesting that a reduction in FODMAP intake offers an efficacious strategy for those patients who
present with concurrent functional gastrointestinal symptoms [33]. Although we were able to show an
effect on symptomatology as measured by VAS in the LF-GFD group, we also observed that the patients
receiving GFD reinforcement (our comparison group) did also show a decrease in symptomatology.
This issue has already been addressed in Sainsbury and co-workers, [10], who emphasized that in-depth
dietary revision as carried out by a trained nutritionist can improve any persistent symptomatology in
CD patients. Nevertheless, our results have showed that such improvement was to a greater extent in
the LF-GFD group.
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Together with the improvements in IBS-like symptoms, we have also found that LF-GFD
can overall improve the psychopathological symptoms as measured by a well-validated
instrument. The relationship between psychological and psychiatric disturbances and CD is already
well-established, significantly influencing the reduction of the quality of life and worsening the
symptoms of affected patients [34]. The results related to the SCL-90 questionnaire have shown
post-intervention differences in the LF-GFD group but none for the patients on the R-GFD. In the
former group, in fact, we have observed a change in the vast majority of the dimensions as compared
with the baseline, suggesting that the decrease in gastrointestinal symptoms may positively influence
the improvement of a patient’s overall psychopathological burden. These results are consistent with
those reported by a previous study, in which patients with CD undertook GFDs and for whom a
post-intervention change was observed, which determined a decrease in the score for anxiety but not
for depression [32].
In another report some patients newly diagnosed with CD were evaluated in relation to the
dimensions of SCL-90 and compared with a healthy control group: the scores for somatization,
obsessive-compulsive, interpersonal sensitivity, depression, anxiety, and sleep were found to be higher
in CD patients [8]. The use of SCL-90 in a population that suffers from gastrointestinal symptoms
has been already evaluated in IBS patients, who exhibited significantly more distress compared with
other groups. In addition, the patients with gastrointestinal symptoms as a group, compared with
the healthy controls, were characterized by high levels of irritable depression and somatization [35].
From this perspective, the results from the present study, which shows a significant psychopathological
improvement in CD patients on the LF-GFD versus the R-GFD, provide an important confirmation
about the relationship between gastrointestinal and mental health in CD patients who undergo different
types of diet. In particular, to our knowledge this present study offers the first report demonstrating a
significant amelioration for CD patients of most SCL-90 items in the short-term (i.e., after 21 days) as a
result of following a LF-GFD.
The quality-of-life perception, as assessed by means of the SF-36 questionnaire, has shown only
minor differences between the studied groups: we could not establish for this group of celiac patients
any significant improvement in this regard after the LFD. This finding is in discordance with what
was previously reported. Previous data about our group of patients with non-celiac gluten sensitivity
treated with GFDs, showed an improvement in the majority of the SF-36 scores after 7 days of treatment
in a cross-over study, with both mental and physical components of the SF-36 questionnaire being
significantly lower for patients positive to a gluten challenge [31]. Other authors have shown a
quality-of-life improvement in patients with atypical and typical CD, compared with healthy controls
after a one-year-long treatment, but only with differences in two items (general health and vitality) for
subjects with typical CD [36].
Of note, even though we were not able to demonstrate any improvement in quality of life when
comparing our study groups, when the percent change was evaluated for each of the items consulted,
both health perception and physical functioning turned out higher in the LF-GFD group compared
with the R-GFD group. Therefore, we could not rule out that the aforementioned mixed results possibly
depended on the limited period of observation, with a longer follow-up period to be required in order
to better assess the changes in quality of life for CD patients following the LF-GFD.
Among the strengths of our report there is the fact that it comes from the first randomized
double-blind study performed on patients with CD and to evaluate the potential effects of a reduction
in dietary FODMAP on overall health and gastrointestinal symptomatology. As a limitation, even if
we could show significant improvement in clinical symptoms, our results were obtained only after a
short period of time (i.e., limited to three weeks) and only on patients who had fully completed the
intervention (92% and 84% in the R-GFD and LF-GFD groups, respectively).
In conclusion, our results show that nutritional intervention by a LFD can have beneficial effects
for CD patients who are on a GFD but present with persisting functional gastrointestinal disorders,
even without major changes in their quality-of-life perception. The same results also suggest that, for
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those patients with CD being treated with a GFD and experiencing IBS-like symptoms, a LFD can be
indicated by a trained nutritionist, but its beneficial effects and long-term clinical effects for this group
of selected CD patients need further investigation.
ClinicalTrials.gov, ref. no. DNCT02946827.
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Figure A1. CONSORT Flow diagram.
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The authors have requested that the following changes be made to their paper [1].
In Table 2, page 6, the frequency (and percentage) of gastrointestinal symptoms are shown for
each group (regular gluten-free diet (R-GFD) and low fermentable, oligosaccharides, disaccharides,
monosaccharides, and polyols (FODMAP)—gluten free diet (LF-GFD)). Instead of showing the
percentages for each group, "No data" was included in parentheses instead of the percentages
corresponding to the frequency of symptoms in each group. The table should read as follows.
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(n = 25) p Value
†
Age, years 41.1 ± 10.1 40.4 ± 10.1 41.9 ± 10.2 0.73
Gender, female (%) 44 (88) 25 (100) 22 (88) 0.09
BMI, kg/m2 22.5 ± 4.1 22.3 ± 3.6 22.1 ± 5.4 0.87
Diarrhea, n (%) 17 (34) 6 (24) 11 (44) 0.18
Constipation, n (%) 16 (32) 9 (36) 7 (28) 0.2
Mixed symptoms, n (%) 6 (12) 4 (16) 2 (8) 0.36
Non-specified, n (%) 4 (8) 3 (12) 1 (4) 0.29
Dyspepsia, n (%) 17 (34) 8 (32) 9 (36) 0.95
1 Data shown as mean ± standard deviation (SD) for continuous variables and frequency and percentage for
nominal variables. † p-value for comparison between groups using an independent t-test for continuous variables
or Chi-square or Fisher’s exact tests for nominal variables. BMI: body mass index; R-GFD: regular gluten-free diet;
LF-GFD: low fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)—gluten free
diet (LF-GFD).
In Figure 2, page 8, visual analogue scale scores for abdominal pain, fecal consistency, and
post-prandial fullness severity are shown. Instead of stating only both times of assessment (at “baseline”
and “day 21”), a duplicate in the writing of the x-axis legend was found. The figure should read
as follows.
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Figure 2. Visual analogue scale (VAS) score for gastrointestinal symptoms. VAS for abdominal pain
(A), fecal consistency (B), and post-prandial fullness severity (C). In each plot, data is shown as median
(line), inter-quartile range (box limits), and min/max (whiskers); R-GFD: regular gluten-free diet;
LF-GFD: low-FODMAP gluten-free diet; n.s.: non-significant.
The authors apologize to the readers for any inconvenience caused by these changes. It is
important to state that both corrections do not affect our study’s results and involve no changes or
modifications in the original data supporting our results. The original manuscript will remain online
on the article webpage, with reference to this Correction.
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Abstract: (1) Background: Celiac disease (CD) is a common autoimmune disorder. The manifestations
of the disease and the obligatory life-long gluten-free diet (GFD) are associated with the impairment
of patients’ quality of life. Therefore, the present study aimed to translate, culturally adapt and
validate a celiac disease quality of life (CD-QoL) questionnaire and apply it to a representative
number of Brazilian CD patients. (2) Methods: A cross-cultural Brazilian-Portuguese version
of the CD-QoL was developed according to revised international guidelines. The questionnaire
was administered to 450 celiac patients. The reliability, reproducibility and validity were studied.
(3) Results: The Brazilian CD-QoL questionnaire presents valid measures of reproducibility and
internal consistency. Early diagnosis is related to higher scores of Brazilian CD-QoL social, sub- and
total scale. There was a positive correlation between higher education level and higher QoL.
Individuals with partners tend to have a better emotional subscale of QoL. CD-patients who follow a
strict GFD have highest QoL scale values. Men scored higher than women on the CD-QoL. All results
were statistically significant except for the gastrointestinal subscale. (4) Conclusions: Brazilian
CD-QoL allows comparative research between different celiac populations in the world. QoL research
will help in the development of effective strategies to improve Brazilian celiac patients’ quality of life.
Keywords: Brazilian CD-QoL; quality of life; celiac disease; questionnaire
1. Introduction
Celiac disease (CD) is an autoimmune enteropathy that occurs in genetically susceptible
individuals through the consumption of gluten and affects approximately 1% of the population
worldwide [1,2]. Although there are asymptomatic patients, the disorder is generally characterized
by the combination of gluten-dependent symptoms such as diarrhea, malabsorption, abdominal pain
and weight loss. Extra-intestinal manifestations may also occur, such as arthralgia, osteoporosis,
chronic fatigue, iron-deficiency anemia, depression and in some cases infertility and miscarriage [3,4].
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Despite significant advances in understanding the physiopathology and treatment of celiac disease,
the only available treatment continues to be a strict lifelong gluten-free diet (GFD) [5]. The dietary
restrictions and the symptoms can significantly impact the patient’s quality of life (QoL) [6–9].
The knowledge of the QoL is essential for the evaluation and implementation of measures that
can reduce the physical, emotional and social burden on patients affected. In this context, the celiac
disease quality of life (CD-QoL) questionnaire is a valuable tool to evaluate the difficulties faced by the
celiac patient, regarding symptoms, GFD and social exclusion [6,7]. It is also essential to provide data
to promote the improvement of public health policies and consequently, the wellbeing of CD patients.
Quality of life questionnaires specific for celiac patients have been validated and applied in
Germany (original), Italy, Turkey and France [7–10]. However, none have been adapted, validated and
performed to assess the QoL of Brazilian CD patients.
It is important to highlight that the prospect for celiac patients in Brazil is not optimal and therefore
their QoL is impacted [11]. Although there has been an increase in the number of gluten-free products
in Brazil, the market is still much smaller than that of conventional products. Finding gluten-free
products with adequate taste and nutritional value at an affordable price is a challenge for celiac
patients. Additionally, eating out becomes an even bigger challenge for celiac patients, due to lack of
information about ingredients used and the risk of cross-contamination [12,13].
Therefore, the present study aimed to translate, culturally adapt, validate and apply a CD-QoL
questionnaire to a representative sample of the Brazilian celiac population. We expect that the
present study will allow future comparative research between different celiac populations. Potentially,
this could also help health professionals and governmental institutions develop effective strategies to
improve the quality of life of Brazilian celiac patients.
2. Materials and Methods
The study was developed in six steps: (i) translation, (ii) cultural adaptation, (iii) validation of the
questionnaire, (iv) evaluation of the internal consistency and reproducibility of the QoL, (v) application
of the questionnaire to Brazilian celiac patients and (vi) statistical analysis. The study was approved by
the Health Sciences Ethics Committee, University of Brasilia, No. 69119317.3.0000.0030 and followed
the guidelines established by the Declaration of Helsinki.
2.1. Questionnaire
This study followed the original version of the CD-QoL by Häuser et al. [7], which consists
of 28 items divided into four areas (with seven items in each): (i) emotions (depressed, restless,
relaxed, happy, physically fatigued, tearful); (ii) gastrointestinal symptoms (loose bowels, sudden
urge for bowel movement, abdominal cramps, bloating, incomplete bowel evacuation, belching,
nausea); (iii) concerns (being diagnosed too late, fear of medical examinations, afraid of cancer, lack of
medical expertise, problems with health providers, inheritance of the disease to children); (iv) social
(lack of understanding by colleagues, difficulties in recreation/sports, professional limitations, lack of
understanding by family/friends, invitation/dinner, feeling of exclusion from others, sexual activities).
In the original questionnaire, responses were scored on a seven-point Likert scale in which “7”
corresponds to the best function and “1” to the worst. The total CD-QoL score ranges from 49 to
196. The scores of each area range from 7 to 49, where a higher score indicates a better quality of
life. All questions asked were based on the respondent’s experience in the past two weeks to reduce
memory bias. We chose the questionnaire designed by Häuser et al. [7] due to its capacity to evaluate
attitudes and perceptions of celiac patients, covering physical, social and emotional aspects.
2.2. Translation, Cultural Adaptation and Validation
The translation and cultural adaptation of the instrument was done in three phases following an
adaptation of the parameters established by the International Quality of Life Assessment (IQOLA)
project methodology [14] and the Delphi method [15].
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2.2.1. Translation and Retranslation
For the translation phase, two bilingual health professionals independently translated the CD-QoL
questionnaire from English to Portuguese, emphasizing conceptual rather than literal translation.
The English questionnaire was translated to a Brazilian Portuguese 7th-grade reading level to obtain
a better understanding of the questions by the general population. After the first translation,
both translators, along with two health professionals with extensive experience with CD, met to
resolve any discrepancies and integrate both translations into a single version. A single version was
retranslated from Brazilian Portuguese to English, by two different bilingual translators working
independently from each other, to confirm its accuracy to the original questionnaire. Lastly, the four
translators jointly checked the final questionnaire version for accuracy. An adapted and modified
version of the Delphi method [15] was used for the validation process.
2.2.2. Cultural Adaptation, Semantic Evaluation and Validation (First Step)
The validation of an instrument consists of a methodological procedure to evaluate its quality,
which is related to the capacity of the instrument to accurately measure what it is intended to
measure [16]. Therefore, the validation of the questionnaire occurred in two different steps. In the first
step, the cultural adaptation, semantic evaluation and content validation were analyzed by a panel
composed of professionals and researchers recognized in their areas. The expert panel consensus helps
to define the instrument items which should be maintained, revised, or excluded [17,18].
Twelve health professionals were contacted by email. They were invited to participate and assist
with cultural adaptation and semantic evaluation of the questionnaire; ten agreed to participate.
Following their consent, participants received an email with a link to the questionnaire in Brazilian
Portuguese that was placed on SurveyMonkey® (San Mateo, CA, USA), an online survey platform.
The online survey contained all 28 questions translated to Portuguese. The judges rated the questions
on a five-point Likert Scale for clarity and, when applicable, made suggestions to improve the
questionnaire regarding cultural adaptation, comprehension and clarity.
The mean grade for the evaluation of clarity and content validation of each item and semantic
evaluation was calculated considering the answers provided by the experts. The degree of agreement
among the experts for the assessment of importance and clarity of the items was evaluated through
the Kendall (W) coefficient of concordance, which ranges from 0 to 1. High W-values (W ≥ 0.66)
indicate that the experts applied the same standards of evaluation as opposed to Low W-values, which
suggest disagreement among the experts [16]. The criteria established for the approval of the item was
a minimal of 80% of agreement between the experts (W-values ≥ 0.8) [12]. Items considered unclear
were rewritten in a different manner and subject to further evaluation by the experts. Once the ten
participants approved all questions, two bilingual translators met and compared the new Brazilian
Portuguese version of the questionnaire to the original version in English. This phase ensured that
the Brazilian Portuguese version of the questionnaire was of appropriate cultural relevance while
maintaining its fidelity to the original version.
2.2.3. Pilot Test (Second Step)
In the pilot study, the new version of CD-QoL was applied to four celiac subjects that had
been patients at the University of Brasilia Hospital (HUB) out-patient celiac clinic for over ten years.
These patients rated the questions for reliability, clarity and ease of comprehension. Subsequently,
a second evaluation was carried out a week later with four other longstanding celiac patients from the
clinic. When the reliability, clarity and ease and of comprehension of each question achieved the score
(80% of agreement) the step of internal consistency and reproducibility of the QoL was achieved.
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2.2.4. Internal Consistency and Reproducibility of the Brazilian CD-QoL
The internal consistency and reproducibility of the Brazilian CD-QoL were evaluated using
18 celiac patients’ (who did not participate in previous phases) responses. The celiac patients answered
the Brazilian CD-QoL and after one week they were invited to answer the same questionnaire again.
The Cronbach alpha measure evaluated the internal consistency of the QoL subscales. The test-retest
reliability (reproducibility) of the questionnaire was verified using the Pearson correlation coefficient
and the intra-class correlation coefficient (ICC).
2.3. Brazilian CD-QoL Application
The final step was to place the Brazilian Portuguese CD-QoL questionnaire on the SurveyMonkey®
platform and apply it to a representative number of Brazilian celiac patients. The first page of the
survey contained the consent form that included the established exclusion/inclusion criteria; where
participants had to be 18 years of age or older and have been positively diagnosed by a physician for
over a year. At that point, participants gave their consent to participate. Those that did not agree to
participate were directed to a page thanking them for their time; while those that agreed, were directed
to the first page of the survey containing ten social demographic questions. The third part of the survey
consisted of applying the 28 translated and culturally adapted questions to Brazilian celiac patients.
2.4. Psychometric Evaluation, Validation and Statistics
The statistical analysis was carried out following the score proposed by the original study by
Häuser et al. research [7] where a higher score indicates a higher quality of life. Questions left blank
where substituted by a median value of the corresponding dimensions. The total score was calculated
for each demographic and clinical dimension. If more than 25% of the questions were left blank the
questionnaire was eliminated from the analysis.
The descriptive statistics (mean, median, standard deviation, floor effect and ceiling effect) of the
subscales of the Celiac Disease Questionnaire (CDQ) were presented. Student’s t-test and Variance
Analysis (ANOVA) followed by Tukey post-hoc analysis was used to compare the values of the CDQ
subscales with the variables of interest. All tests considered two-tailed hypotheses with a significance
level of 5%. Confirmatory factor analysis was used to assess the factor validity. The Root Mean Square
Error of Approximation (RMSEA) and the Chi-squared test of minimum discrepancy [19] evaluated the
factor validity. The RMSEA ranges from 0 to 1, with smaller values indicating better model fit. A value
of 0.06 or less is indicative of an acceptable model fit [20]. The statistical analyses were performed
using IBM SPSS (Statistical Package for Social Sciences) version 22 (IBM SPSS Statistics for Windows,
Version 22.0. IBM Corp, Armonk, NY, USA) and IBM SPSS AMOS (Analysis of Moment Structures)
version 22 ( Amos (Version 22.0), IBM SPSS, Chicago, IL, USA).
3. Results
3.1. Translation, Cultural Adaptation, Semantic Evaluation and Content Validation
The summary of stages of the Brazilian questionnaire process is displayed in Figure 1.
The Brazilian CD-QoL (Supplementary Material S1) was constructed considering the translation/
retranslation and suggestions made by the experts and celiac patients in the pilot test. After the
translation/retranslation steps, the first stage of the content validation and the semantic evaluation was
performed by judges and they decided to maintain all of the 28 questions with cultural and semantic
adaptations since we opted to follow an existing CD-QoL questionnaire [7]. In total, three rounds of
evaluations were necessary to obtain agreement among the experts for the content validation and
semantic evaluation. After that, a pilot study with eight celiac patients was conducted. In the first
round of the questionnaire, questions were considered adequate regarding reliability, clarity and
easy comprehension.
43
Nutrients 2018, 10, 1167
English original version
CD-QoL (Häuser et al, 2006)
Brazilian-portuguese translation (2 bilingual 
English-Portuguese translators
Consensual Brazilian Portuguese version by 
translators
Reviewed version by expert commitee: 
Consensual Brazilian portuguese version by 
experts
Cultural adaptation, semantic evaluation and 
validation (10 health professionals judges 
used Likert-sclae)
• 1st round: 26 of 28 questions presented 
80% of agreement by judges.
• 2nd round: judges received the 
modifications suggested for the questions 
number 6 and 25. The questions were not 
approved regarding the clarity and 
comprehension.
• 3rd round: a new version of 6 and 25 
questions were presented again to the 
judges and aproved.
Two bilingual translators compared the new 
Brazilian Portuguese version of the 
questionnaire (aproved by judges) to the 
original version in English
• The questionnaire was in agreement of the 
original version according to the translators
Pilot study with patients:
• 8 adult celiac patients (4 out-patient celiac 
clinic for over 10 years and 4 longstanding 
celiac patients from the clinic)
• All of the 28 question were adequate 
regarding reliability, clarity and easy 
comprehension.
• It was not necessary the second round.
Internal consistency and reproducibility of 
the QoL
• 18 of 20 celiac patients answered the 
Brazilian CD-QoL two times
• The internal consistency and 
reproducibility of Brazilian CD-QoL was 
confirmed
Brazilian CD-QoL application:
• It was nationwide online distributed. 
• 462 celiac patiet accepted to answer the 
CD-QoL
• 449 complete answered the questtionaire.
Figure 1. Process stages of the Brazilian celiac disease questionnaire of quality life (CD-QoL).
Internal Consistency, Construct Validity and Reproducibility of the Brazilian CD-QoL
The concordances of the answers (internal consistency) were verified by the Cronbach’s alpha
measure (Table 1). All four domains of the CD-QoL indicated good internal consistency (Cronbach’s
alpha > 0.7).











Emotion 26.70 (9.55) 27 (20–34) 7–49 1.3% 0.2% 0.927
Social 31.15 (8.18) 32 (25–38) 10–48 0% 0% 0.703
Worries 27.25 (9.85) 27 (20–34) 7–49 0.4% 0.9% 0.832
Gastrointestinal 34.87 (8.61) 36 (29–41) 10–49 0% 2.4% 0.793
Total Score 119.79 (30.16) 120 (99–142) 51–181 0% 0% 0.925
SD—Standard deviation; IQR—Interquartile range. The factor/construct validity was examined by confirmatory
factor analysis. The four domains (emotion, social, worries and gastrointestinal) presented a good fit in the
confirmatory factor analysis (Root Mean Square Error of Approximation (RMSEA) = 0.016 and χ2 = 309.04, df = 278,
p = 0.097).
The test-retest reliability (reproducibility) of the questionnaire was verified using the paired
t test, Pearson correlation coefficient and the intraclass correlation coefficient (Table 2). None of the
four domains composing the final questionnaire showed significant divergence among the evaluators
(p > 0.05 in the paired t test). The Pearson coefficient and Interclass correlation coefficient (ICC)
are ideally more substantial and significant (p < 0.05). Therefore, the questionnaire presents proper
measures of reproducibility.
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Table 2. CD-QoL scale reproducibility (n = 18 participants).





p * Correlation p ICC p
Emotion 25.50 (10.16) 27.06 (10.08) 0.153 0.905 <0.001 0.947 <0.001
Social 33.00 (9.17) 34.67 (7.08) 0.224 0.769 <0.001 0.850 <0.001
Worries 30.06 (7.68) 31.17 (8.54) 0.291 0.863 <0.001 0.923 <0.001
Gastrointestinal 37.06 (6.91) 35.17 (6.23) 0.247 0.486 0.041 0.647 0.018
Total 125.61 (27.11) 128.06 (27.08) 0.531 0.821 <0.001 0.905 <0.001
* paired t-test. ICC: Interclass correlation coefficient. p < 0.05 is statistically significant.
3.2. CD-QoL Application
During the period from July to October of 2017, a link to the Brazilian CD-QoL was distributed
nationwide by email to multiple Brazilian Celiac Associations (Associação dos Celíacos do Brasil—Acelbra;
and Federação Nacional das Associações de Celíacos do Brasil Fenacelbra). Those associations either emailed
the link to CD patients registered with them or published the link to the survey through social media
that was subsequently shared by members. In addition to Brazilian Celiac Associations, dietitians and
gastroenterologists were also asked to distribute the link to their CD patients. Therefore, we used a
convenience sample to perform the present study.
A total of 462 participants from 18 out of 26 Brazilian States agreed to answer the
questionnaire. The eight Brazilian States not represented were those with no Celiac Associations.
Of the 462 questionnaires, 12 were excluded because they were not filled out. The remaining
450 questionnaires responses were analyzed. The questionnaire took an average of six minutes to be
completed. Characteristics of the responders and their association with the CD-QoL subcategories are
presented in Table 3.
We divided the marital status category into either in a stable relationship (married or with a live-in
partner) or not in a stable relationship (those that are single, divorced, or widowed). We also divided
the Gluten-Free Diet category into two. Only participants that answered “always” were considered
to be on a GFD, those that responded, “almost always”, “almost never”; “never” and “sometimes”,
were considered not to be on a GFD.
Participants over the age of 40 presented higher values on the scale (statistically significant only
for the total scale and the social subscale). Early diagnosis is related to higher scores on the social,
sub- and total scale. There was a positive correlation between higher education level and higher QoL.
Individuals with partners tend to have a better QoL emotional subscale score (represent higher
values on the scale). Regarding other subscales, the marital aspect did not influence the QoL.
Individuals that follow a strict GFD have higher QoL scale values (except for the worries subscale)
and those who do not take antidepressants have a higher quality of life.
The men’s scores for the CD-QoL were higher than the women’s. All results were statistically
significant except for the gastrointestinal subscale, where there is no significant difference between
women and men (p > 0.05).
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Table 3. Sub-scores of the CD-QoL scale subcategorized by sex, age, time of diagnosis, schooling,
marital status and diet.
Emotion Social Worries Gastrointestinal Total
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Gender *
Women (n = 425) 26.42 (9.51) 30.08 (8.14) 26.80 (9.69) 34.75 (8.63) 118.55 (29.98)
Men (n = 25) 30.88 (9.03) 36.40 (6.57) 34.71 (9.96) 36.84 (8.33) 139.33 (25.95)
p 0.023 0.000 0.000 0.238 0.001
Age *
39 and under (n = 271) 26.01 (9.13) 30.28 (7.93) 26.87 (9.64) 34.28 (8.45) 117.34 (28.98)
40 and over (n = 179) 27.74 (10.08) 32.48 (8.40) 27.82 (10.17) 35.77 (8.79) 123.52 (31.59)
p 0.065 0.006 0.032 0.074 0.036
Time of diagnosis *
29 and under (n = 170) 25.27 (8.76) 29.97 (8.14) 26.75 (9.61) 33.99 (8.51) 115.72 (29.16)
30 and over (n = 273) 27.48 (9.92) 31.80 (8.20) 27.27 (9.93) 35.34 (8.67) 121.75 (30.58)
p 0.015 0.024 0.588 0.109 0.043
Educational level **
Elementary (n = 26) 23.00 (10.92) a 28.44 (6.68) a 24.23 (10.78) a 29.42 (8.68) a 106.12 (30.32) a
High School (n = 116) 24.10 (9.60) a,b 29.29 (8.20) a,b 25.69 (9.69) a,b 32.69 (9.36) a,b 111.57 (30.21) a,b
College (n = 152) 27.32 (9.13) b,c 31.34 (8.06) a,b 27.29 (9.54) a,b 35.43 (8.22) b,c 121.01 (29.36) b,c
Graduate & Post-grad (n = 156) 28.65 (9.14) c 32.79 (8.16) b 28.88 (9.90) b 36.86 (7.67) c 127.01 (28.86) c
p 0.000 0.002 0.022 0.000 0.000
Marital status *
With partners (n = 275) 27.51 (9.68) 31.69 (8.25) 27.30 (9.68) 35.36 (8.39) 121.78 (29.85)
Without partners (n = 175) 25.43 (9.22) 30.31 (8.02) 27.18 (10.14) 34.11 (8.91) 116.68 (30.47)
p 0.025 0.085 0.908 0.136 0.084
Gluten-free diet compliance *
No (n = 51) 20.61 (9.37) 28.10 (7.43) 25.16 (10.97) 29.73 (8.71) 104.20 (30.00)
Yes (n = 399) 27.48 (9.30) 31.53 (8.20) 27.52 (9.68) 35.53 (8.38) 121.76 (29.64)
p 0.000 0.005 0.108 0.838 0.000
Antidepressant medicines *
No (n = 371) 27.67 (9.37) 31.67 (7.98) 27.76 (9.78) 35.50 (8.49) 122.45 (29.63)
Yes (n = 79) 22.15 (9.09) 28.79 (8.72) 24.85 (9.90) 31.95 (8.63) 107.73 (29.81)
p 0.000 0.004 0.017 0.001 0.000
* Student t-test. ** Anova with Tukey post-hoc test. Groups with the same letters do not differ significantly.
Different letters on the same column represent statistical differences.
4. Discussion
Health is defined as “a state of complete physical, mental and social well-being” [21]. According
to the World Health Organization, to achieve optimal health, it is essential to comprehend the patient’s
perception of quality of life [22]. The Celiac Disease-specific Quality of Life Scale is an important
and cost-effective tool to understand aspects related to the QoL of celiac patients. The scale helps
us understand elements present in daily choices, management of mental and physical well-being
as well as the social limitations imposed by this chronic disease due to the necessity for lifelong
commitment [7,9].
When the quality of life assessment instrument is used in a variety of cultural settings, it is
imperative to establish whether the same aspects of life are equally important to the group studied.
Groups of people, particularly in different cultures, are likely to assign different levels of importance to
various aspects of their life; therefore, cultural and semantic validation is crucial [23]. To the best of our
knowledge, our study is the first characterization of the emotional, worries, gastrointestinal and social
features related to the quality of life in CD Brazilian adults. In this context, we validated the first specific
QoL instrument for CD patients in Brazilian Portuguese, based on the Hauser et al. [7] instrument.
The linguistic validation process (translation and retranslation) is recommended when the original
instrument is developed in a language other than the target language and there is no translated
and validated version in the target language [22]. Therefore, the first step of this study was to
translate/retranslate the original version of CD-QoL to English/Portuguese/English. The translation
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was followed by the cross-cultural adaptation process that followed the guidelines predominant in
the literature [24,25]. To acquire a reliable instrument, it is also vital to perform a semantic evaluation,
which measures the comprehension of the instrument. This step ensures the instrument is clear and
easy to understand [17]. The Brazilian Portuguese versions of the instrument demonstrate cultural
and semantic adequacy and therefore represent the first Brazilian Portuguese version developed.
A pilot study was conducted to evaluate the reliability and internal consistency of the instrument with
celiac patients.
Reliability is an estimate of the instrument’s ability to reproduce results provided that no change in
the outcome has taken place [22]. In this study, it was measured with internal consistency and test-retest
stability. The internal instrument consistency is an estimate of the extent to which the included items
of a score correlate with each other. Cronbach’s alpha coefficient was used for this estimate for all
patients, in all domains of the CD-QoL at baseline [26]. Internal consistency was considered acceptable
when Cronbach’s alpha was 0.70 or higher [27]. None of the 28 items composing the final questionnaire
showed significant divergence among the evaluators (>0.05 in the Cronbach alpha test) (Table 1).
The 28-items of the CD-QoL show reliable internal consistency; therefore, the questionnaire presents
good measures of reproducibility, which indicates that similar results under consistent conditions
are reproducible.
Once validated, the instrument was sent nationwide to Brazilian celiac patients to evaluate
their quality of life. Similar to the other studies of CD-QoL in different countries [7–9], most of the
respondents in this study were female (95%). It was expected, since the CD prevalence is higher in
female patients than male patients [1,3,28] and women tend to be more concerned about health and
participate more often in health studies [29–32]. The study conducted by Ramirez-Cervantes et al. [33]
also had more responses from female participants (75%) compared to male participants in Mexico.
In Brazil, Castilhos et al. [32] conducted a study with celiac patients that were registered in the Southern
Brazilian Celiac Association (ACELPAR), which also showed a low rate of male participation (6.8%).
They attribute these findings to the low participation rate of men in the ACELPAR meetings where the
questionnaires were administered and more broadly, to the low interest in their health when compared
to women [32].
In the present study, women’s scores for the CD-QoL were lower than men’s scores, except for the
gastrointestinal subscale. Studies have shown that CD women experience a lower level of quality of
life than men [13,34–36]. Women also report more distress caused by daily life restrictions and perceive
a higher burden with CD than men [35].
Individuals that follow a strict GFD have higher QoL scale values (except for subscale worries).
The strict adherence to the GFD tends to enhance physical and physiological aspects. Despite the
food restriction, social wellbeing aspects can also be achieved, since symptoms and other conditions
related to CD tend to be improved with the treatment adherence [37]. In line with previous studies, we
found that diet-compliant CD patients (with an internal LoC (locus of control)) had a better QoL than
noncompliant patients [7,9,32,38–40]. According to Wagner et al. [38], the GFD compliance is essential
for celiac patients to obtain optimal QoL. Psychological and educational support is also essential for
patients that are having difficulty adhering to a GFD [32,38]. According to Castilhos et al. [32], most of
the CD patients felt well informed, showed no declining trend and showed no constant worry about
their food. They believed that these results are related to the information and support received by the
celiac association (ACELPAR). These results reinforce the importance of information and support to
improve the QoL of CD patients.
Other studies showed similar results to ours; Wagner et al. (Wagner et al., 2008 [38]) showed
that better physical health, lower CD-associated burden and fewer social problems, were found
in participants who had a longer period since being diagnosed, indicating the importance of the
earliest possible diagnosis. Ramírez-Cervantes et al. [33] also concluded that, at the time of diagnosis,
CD patients had a reduced quality of life, compared to those with a longer diagnosis period—likely
due to better knowledge about the disease and acceptance of the lifestyle. In the study conducted
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by Castilhos et al. [32], patients newly diagnosed were compared with those who had the longer
diagnosis. The study showed that patients that were longer diagnosed had better QoL, suggesting that
the limitations imposed by disease and GFD influence the patients QoL. They also indicate that over
the years, there is a better adaptation to the restrictions imposed by the treatment [32]. Another study
of Brazilian CD patients showed that the longer the time since diagnosis, the lower the chances that
these patients had positive serological tests, indicating a better comprehension and adherence to the
treatment [11].
Several studies highlight the positive role families can play in providing support to patients when
adopting a GFD, as well as the support in coping with CD [13,41,42]. This active support provided
is likely the reason why those “with partner” under marital status scored higher in the emotional
subscale CD-QoL.
Past research has demonstrated that a higher educational level significantly contributes to the
patient’s physical and social function, health perception and mental health. Low education amplifies
the adverse effects of many chronic medical conditions due to lack of knowledge [43–46]. Our results,
which corroborate the above findings, showed a positive correlation between higher education level
and higher QoL. The education level tends to be associated with higher socioeconomic status [44].
A study suggests that income modulates both health-seeking behavior and access to health care [47],
which is related to higher QoL.
A potential limitation to our study was selection bias created by the manner in which the survey
was disseminated, that is, over the internet and with the use of email and social media. According to a
census by the Brazilian Institute of Geography and Statistics (IBGE), approximately half of the Brazilian
population 25 years of age and younger have less than eighth-grade education [48]. However, 56% of
our respondents had a college degree or above, which is not representative of the Brazilian population.
Consequently, there was also a selection bias regarding the socioeconomic level of the respondents,
which is much higher than the national average.
5. Conclusions
There is growing interest in assessing the outcome of CD, given the chronic nature of the disease.
The development of a self-administered Brazilian-Portuguese CD-QoL instrument that captures the
perceptions and concerns of CD individuals is an important step forward in the care of these patients.
The Brazilian-Portuguese CD-QoL questionnaire version presents good measures of reproducibility
and internal consistency. In Brazil, the time since diagnosis, higher education level, strict adherence to
GFD and male gender are related to the highest scores of CD-QoL. Knowledge of the quality of life is
important to help implement effective strategies to improve Brazilian celiac patients’ quality of life
and for reducing the physical, emotional and social burden on them. Besides the Brazilian CD-QoL,
an Italian, German, French and Turkish version of the CD-QoL have been published, which allows for
comparative research between different celiac populations in the world.
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Abstract: Management of coeliac disease (CD) requires the removal of gluten from the diet. Evidence
of the availability, cost, and nutritional adequacy of gluten-free (GF) bread and pasta products is
limited. GF flours are exempt from UK legislation that requires micronutrient fortification of white
wheat flour. This study surveyed the number and cost of bread and pasta products available and
evaluated the back-of-pack nutritional information, the ingredient content, and the presence of
fortification nutrients of GF bread and pasta, compared to standard gluten-containing equivalent
products. Product information was collected from four supermarket websites. Standard products
were significantly cheaper, with more products available than GF (p < 0.05). GF bread products
were significantly higher in fat and fiber (p < 0.05). All GF products were lower in protein than
standard products (p < 0.01). Only 5% of GF breads were fortified with all four mandatory fortification
nutrients (calcium, iron, niacin, and nicotinic acid or nicotinamide), 28% of GF breads were fortified
with calcium and iron only. This lack of fortification may increase the risk of micronutrient deficiency
in coeliac sufferers. It is recommended that fortification legislation is extended to include all GF
products, in addition to increased regulation of the nutritional content of GF foods.
Keywords: coeliac disease; celiac disease; gluten; gluten-free diet; fortification; micronutrient; cost
1. Introduction
Coeliac disease (CD) affects 1% of the population in Europe [1,2]. Gluten is a collection of
storage proteins present in major cereals such as wheat, barley, and rye, which compromise the main
components of common UK foods, bread and pasta [3]. When consumed, gluten proteins trigger an
immune-mediated enteropathy, leading to intestinal damage in genetically pre-disposed individuals.
Management of CD requires exclusion of dietary gluten, which proves a challenge for CD sufferers due
to the presence of gluten in many food products [4]. Cereals and their products contribute important
dietary nutrients, including high levels of protein, fiber and B vitamins such as niacin and thiamin.
In addition, white wheat flour is fortified by law in the UK with calcium, iron, niacin, and thiamin.
Thus, removal of wheat products from the diet may result in nutrient insufficiency in coeliac diets.
The manufacturing of gluten-free (GF) products is challenging, as gluten contributes vital
structural, rheological, and organoleptic properties to bread and pasta [3]. Currently, no direct
substitute for gluten is available and a combination of refined unfortified cereal flours (e.g., maize
and rice), hydrocolloids (e.g., hydroxypropyl methylcellulose) and proteins (e.g., egg white) are used
to make GF products, which are often unpalatable [5]. There is inadequate evidence on the impact
these foods have on the health of consumers; however, studies have demonstrated a strong impact of a
GF diet on diet-related quality of life, affecting in particular their ability to eat socially and outside the
home [6].
In addition to a reduced nutritional profile of GF foods, consuming a GF diet (GFD) has financial
and psychological effects on CD patients. The inability to purchase affordable food easily may result
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in CD patients experiencing higher levels of depression and increased psychological stress regarding
food consumption, especially in social situations [7].
The UK National Diet and Nutrition Survey (NDNS) reported white bread was the most
commonly consumed carbohydrate source, and pasta consumption is increasing [8]. If CD patients
are directly exchanging standard products for GF equivalents, GF products need to be of a similar
nutritional standard. Due to the high intakes of bread, UK manufacturers are required by the Bread
and Flour Regulations (1998) to fortify bread flours with calcium, iron, niacin, and thiamin [9] to
prevent micronutrient deficiencies in the population. The Science Advisory Committee on Nutrition
advised in 2017 mandatory folic acid fortification of standard flour to prevent anencephaly and spina
bifida in developing fetus [10], although currently no changes to legislation have been made. GF flours
and bread are exempt from these regulations, the reasons for which are unclear.
It is generally considered that GF foods are less nutritionally adequate than standard products,
although evidence is limited. Fry et al. (2018) observed higher levels of fat, sugar and salt in UK GF
foods compared to standard foods, although the study focusses solely on front-of-pack macronutrient
levels [11]. Thompson (1999) found only 9% of US GF bread products were fortified with thiamin,
riboflavin, and niacin [12]. Thompson (2000) reported iron fortification in 23% of GF breads and
no fortification in US GF pasta products [13]. Recent studies have demonstrated low intakes of
micronutrients in coeliac diets [14–17], this may be of particular concern in children [17].
The Department for Environment Food & Rural Affairs (2013), supported by manufacturing
industry representatives and public health officials, confirmed its retention of the existing fortification
legislation. According to the review, fortification of foods is cheap, convenient for manufacturers
and nutritionally beneficial for the general population. There is no apparent reason GF products are
not included in fortification legislation. This lack of fortification of GF foods may increase the risk of
micronutrient deficiency and have severe health consequences for CD patients and consumers who
choose to avoid gluten. However, recent studies have shown that CD patients may accumulate heavy
metals, due to higher metaloprotein expression in enterocytes [18] so any fortification strategy must be
carefully considered.
This study aims to examine the availability, cost and nutritional composition of GF bread and
pasta, specifically addressing the macronutrient content and micronutrient fortification of these foods.
2. Materials and Methods
This study was a cross-sectional survey of the availability, cost, ingredient labels and nutritional
values of standard and GF products available to buy in the four major UK supermarkets through
online retailer websites. Products selected for the GF data had a clear GF declaration or description
on the packaging. For each available GF product, a standard gluten-containing product of similar
characteristics was selected e.g., a GF white roll matched with a standard white roll. The four product
categories selected were white bread, brown bread, seeded bread and white pasta, to reflect common
UK consumption habits. A list of products identified through the survey is available as supplementary
material, and includes information on brand, cost, back-of-pack energy, macronutrient and salt content,
and presence of fortification nutrients.
2.1. Data Collection
2.1.1. Search Strategy
To represent the majority of purchasing options available to UK consumers, the four biggest
supermarkets were chosen; Tesco, Sainsbury’s, ASDA and Morrisons. Collectively, these supermarkets
had a 73.2% market penetration in the UK grocery market in 2015. High end supermarkets and
specialist health shops, such as Waitrose and Holland & Barrett, were excluded from the study because
of the higher price range of products and smaller numbers of stores, which may not be accessible to
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all coeliac consumers. Discount retailers such as Aldi and Lidl that display no product or nutritional
information online were excluded from the study.
The data was collected between September 2017 and December 2017. The product name, the cost
(£/100 g), the ingredient label and the nutritional information (per 100 g) were recorded. Values relating
to micronutrient levels were recorded where available, although this was limited in many products.
Branded products found in multiple supermarkets were recorded once in the study. Where the same
products were available in multiple formats (e.g., branded bread at 400 g and 800 g), only one format
was selected for the study.
Two search methods were used; typing in general product names (e.g., white bread) into the search
bar function on the supermarket websites and secondly by selecting product categories, as defined
by the supermarkets e.g., category: bread, sub-category: white bread. Both search methods returned
relevant products; however, both relied on the efficiency of the website and the correct labelling of the
products and food categories by the supermarkets. Using both methods of searching for products and
cross-referencing the resulting products in each category allowed the relevant products to be made
available to the study. This was necessary, as using the search bar often returned irrelevant products,
or the category selection did not include all available GF products. Search terms for GF products
included GF, coeliac and free-from, and was used in addition to selecting the GF product category on
the supermarket websites.
2.1.2. Food Categories
Products included in the evaluation for bread included whole loaves, sliced loaves, rolls (and
their regional names e.g., baps). Bread products not included in the evaluation were part-baked breads,
bread flours, crackers, wraps, pittas, bagels, crumpets, English muffins, 50/50 bread (half white/half
brown), and naan breads as these often did not have GF equivalents. Brown bread and seeded
bread products were recorded separately owing to the impact that seeds may have on the nutritional
content. The brown bread category included any bread that was labelled as wholemeal or brown.
Any bread product with labelling such as grains, granary, malted or any labelling referring to a seed
were categorized as “seeded” and included in the “seeded bread” data set.
Pasta products used for the standard products evaluation included dry white pasta.
Nutrient values were recorded as to the dry weight to ensure that products were comparable.
Standard pasta products not recorded in the review included wholemeal pasta, canned pasta,
pasta ready meals, gnocchi, 50/50 pasta, and fresh pasta. GF pasta products selected were direct
substitutes of white pasta, therefore products such as pea pasta or red lentil pasta were not included
in the study, as they do not directly mimic standard white pasta characteristics. The list of all the
products included in the survey can be found Table S1.
2.1.3. Nutritional Content
The back-of-pack nutritional information was recorded for each product, including energy (kJ)
per 100 g, energy (kcal) per 100 g and the following nutrients recorded in g per 100 g; fat, saturated fat,
carbohydrates, sugars, fiber, protein, salt. Other nutrients were recorded where the information
was provided, including calcium (mg), folic acid (μg), iron (mg), niacin (mg), omega-3 fatty acids (g),
riboflavin (mg) and thiamin (g). The mean value and standard deviation was calculated and a graphical
representation was created. The percentage of the contribution to the Reference Nutrient Intake (RNI)
per portion was calculated using the mean value for 100 g of bread and 75 g of pasta for standard and
GF products. The nutrient content of all the products included is listed in Table S1.
2.1.4. Ingredient Labels
The ingredient label was recorded for each product and a detailed list of the individual ingredients
was compiled. Ingredients that had the same origins, for example, rice flour, rice starch, rice flakes etc.
were grouped together under an appropriate collective term, e.g., rice. The functions of the ingredient
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(e.g., preservative) and the general nutritional contribution (e.g., protein) were recorded. The total
number of ingredients that occurred in each product was calculated, in addition to the mean number
of ingredients for each product category. The percentage of standard and GF foods containing each
ingredient was calculated. Word it Out (2018) online software was used to analyze the frequency in
which ingredients were found on labels. The list of ingredients for all the products included in this
survey can be found in Table S2 (standard products) and Table S3 (GF products).
2.1.5. Fortification of Products
The fortification count of GF products was established by examining each ingredient label for
the following nutrients; calcium carbonate, iron, niacin, and thiamin. The mean nutrient content was
calculated for products where values were given, and the resulting information used to calculate the
contribution to the RNI. The estimated contribution to the RNI for the standard breads was calculated
using the minimum fortification values for each micronutrient per 100 g of wheat flour (the Bread and
Flour Regulations, 1998). The presence of fortification for each product in the survey was recorded in
Table S1.
2.2. Calculations and Statistical Analysis
Microsoft Excel was used to calculate the mean values, standard deviation for this study and
perform all statistical tests for this study. Mean and standard deviation for each product category were
calculated, and their differences assessed using an f-test, followed by a t-test (two-tailed distribution
and two-sample unequal variance (heteroscedastic) settings). Statistically significant differences
between means were considered when p < 0.05.
3. Results
3.1. Availability of GF Bread and Pasta
GF breads and pasta were available from all four websites and each supermarket sold an
own-brand GF range. Often the same brands e.g., Genius and Schar were available from all websites,
thus the products available may be repetitive and indicate a low level of consumer choice.
As shown in Figure 1, there were significantly more standard products available than GF products
across all categories. The mean number of standard products available ranged between 23 and 62,
while the mean available GF products ranged between 4 and 11. There was a significant difference
between the number of GF white breads available, compared to the standard (p = 0.003). The lower
number of GF brown breads compared to the standard was significant (p ≤ 0.001). This is indicative of
the limited choice available for GF consumers. GF pasta had significantly lower numbers of products
available than standard products (p = 0.012). There were 83%–88% fewer GF white and brown breads
and pasta products available compared to standard products. There were 69% fewer GF seeded breads
than the standard equivalent.
A total of 110 products was used in the cost and nutritional analysis section of this study. All the
available GF products (n = 49) on the websites were used and compared to equivalent standard
products (n = 61).
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Figure 1. The average number of standard and gluten-free products available in four major UK
supermarket websites. Key: * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
3.2. Product Cost
The average cost of standard and GF products is shown in Figure 2. GF products were
significantly more expensive across all four product categories than the standard equivalents. A highly
significant difference was observed between the higher cost of GF pasta and standard pasta (p = 0.004).
An extremely significant difference was observed in the cost of GF white and seeded breads compared
to the standard equivalents (p < 0.001). When compared to standard products, an increase in the
average cost of GF products was observed in white (+307%), brown (+314%) and seeded (+220%)
breads. The cost of GF pasta increased by 70% compared to standard pasta.
 
Figure 2. The average cost (£/100 g) of standard and gluten-free products available in four major UK
supermarket websites. Key: * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
3.3. Ingredient Labels and Nutritional Adequacy of Products
The total number of different ingredients used for GF bread was 98 and 44 for standard breads.
A list of ingredients for all products in this survey can be found in Table S2 (standard products) and
Table S3 (GF products). On average, eight different ingredients were used for GF pasta and one for
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standard pasta. The average number of ingredients used in standard bread products was 14 compared
to 20 for GF bread. The higher number of ingredients was not associated with higher cost. The most
common GF ingredients used are shown in Figure 3, with common ingredients being cereal flours,
plant fibers and emulsifiers.
The nutrient content per portion of standard and GF products and their contribution to RNI is
shown in Figure 4. The average total energy, saturated fat, and salt values (Figure 4A,C,H) were similar
between standard and GF products. Carbohydrate values were significantly lower in GF white bread
(p = 0.004); however, the carbohydrate values were similar and not statistically different for other
product types (Figure 4D).
Standard products contained higher levels of sugar (Figure 4E) than GF products, significantly so
in brown bread (p = 0.041) and pasta (p = <0.001). The RNI is the daily intake needed to satisfy the
nutritional requirements of the majority (97.5%) of the population, as shown in Table 1. The sugar
content in one portion of standard brown bread and pasta as a contribution to the RNI is 4% and 2%
respectively (Table 1).
Table 1. Macronutrient and salt content of standard and gluten-free (GF) products per portion (100 g)
















White bread 1043 12 1016 12
Brown bread 984 12 1035 12
Seeded bread 1168 14 1113 13
Pasta 1134 14 1117 13
Fat (g) <70
White bread 3 4 5 7
Brown bread 3 4 6 9
Seeded bread 7 10 9 13
Pasta 1 2 1 2
Saturates (g) <20
White bread 1 3 0 2
Brown bread 1 3 1 3
Seeded bread 1 5 1 4
Pasta 0 1 0 2
Carbohydrate (g) 260
White bread 46 18 42 16
Brown bread 39 15 39 15
Seeded bread 39 15 37 14
Pasta 54 21 51 20
Sugars (g) 90
White bread 3 4 3 3
Brown bread 3 4 2 2
Seeded bread 4 4 2 3
Pasta 2 2 0 0
Protein (g) 50
White bread 9 17 4 9
Brown bread 10 21 8 16
Seeded bread 11 22 6 12
Pasta 9 18 5 9
Salt (g) 6
White bread 1 16 1 16
Brown bread 1 15 1 15
Seeded bread 1 15 1 15
Pasta 0 1 0 1
Fiber (g) 30
White bread 3 9 7 22
Brown bread 6 21 8 26
Seeded bread 6 22 8 26
Pasta 2 8 1 4
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Figure 3. Key ingredients used in gluten-free (A) bread products and (B) pasta products. Ingredients
frequently used in multiple products are indicated by larger font sizes. For a full list of ingredients,
please refer to supplementary material.
 
Figure 4. The average nutritional values of standard and gluten-free products for (A) total energy;
(B) fat; (C) saturated fat; (D) carbohydrate; (E) sugars; (F) fiber; (G) protein; (H) salt. Key: * = p < 0.05,
** = p < 0.01, *** = p < 0.001.
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Fiber was higher in all GF bread products (Figure 4F), significantly in white bread (p ≤ 0.001)
and seeded bread (p = 0.008). A portion of GF bread contributes 22%–26% of the fiber RNI, compared
to standard breads providing 9%–21%. Standard white bread contained the lowest levels of fiber at
3 g per 100 g. The fiber content of GF pasta is significantly lower than standard pasta (p = 0.039),
contributing 50% less fiber to the RNI than the standard, at 4% and 8% respectively.
As shown in Figure 4B, GF products contain significantly higher fat levels in white (p ≤ 0.001),
brown (p = 0.006) and seeded (p = 0.038) breads, with a minimal difference noted in pasta products.
A portion of GF bread could contribute 7%–13% of the fat RNI, compared to standard products ranging
between 4% and 10%.
Protein (Figure 4G) was significantly lower in all GF products, especially in white and brown
breads (p ≤ 0.001) and pasta (p ≤ 0.001) when compared to standard products. All GF products
contribute between 9%–16% of the RNI per portion, compared to standard products which contribute
17%–22% of the RNI.
3.4. Fortification of Bread and Pasta
All white bread is fortified with calcium carbonate, iron, niacin, and thiamin in accordance with
UK law [19]. Standard brown (30%) and seeded (94.7%) breads contained fortified wheat flour although
it is assumed that the use of wholemeal flour and seeds may increase the micronutrient content of
these products. In total, 10% of standard bread products contained added folic acid.
Our analysis showed that only 28% of GF breads were fortified with calcium carbonate and iron,
and only 5% of the total GF breads were fortified with all four fortification minerals, in addition to
folic acid and riboflavin. Only two of the 14 GF manufacturers, Genius and Warburtons, fortified their
products. None of the standard and GF pasta products surveyed was fortified.
Fortification of bread with nutrients contributes substantially to the RNI, especially that of calcium
(23.5%) and thiamin (24%–30%) (Table 2). These results demonstrate that where fortification is present,
a considerable percentage of the RNI can be achieved in one portion of bread. Most GF products on
the market are not contributing to this intake.
Table 2. Reference nutrient intake (RNI) for calcium, iron, niacin and thiamin and the contribution of
100 g of standard bread.
Micronutrient
RNI (mg/day) Contribution to RNI (%)
Male Female Male Female
Calcium 1000 1000 23.5 23.5
Iron 8.7 14.8 19 11
Niacin 18 14 9 11
Thiamin 1 0.8 24 30
4. Discussion
The results of this study clearly show that CD sufferers are at risk of nutritional inadequacy
owing to three main factors: (1) the low availability and high cost of commercial GF alternatives to
bread and pasta; (2) the reduced nutritional quality of GF products compared to their equivalent
gluten-containing staples; (3) the widespread lack of fortification.
4.1. Availability and Cost
These results demonstrate significantly lower numbers of GF products were available,
compared to standard products. However, the true number of available products may be considerably
lower, as the websites list GF products as sold throughout the country. It is likely that the actual
number of in-store products will relate to the size of the supermarket and thus, in smaller supermarkets
the number of GF products may be further restricted. This may considerably impact CD patients living
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in rural areas or those with access to only one supermarket. The limited number of products and
potentially limited access to food may contribute to increased anxiety and depression surrounding
food choice reported in CD patients [7]. However, global sales of GF food grew by 12.6% in 2016,
with the market expected to increase [20]. This could be due to increased awareness of CD and a
consumer perception that GF products are healthier. Despite the limited number of GF products
currently available, the expansion of the GF product market can only contribute positively to coeliac
food choice.
The results also showed that GF products are more expensive, in line with previous findings
by Fry, Madden [11] which found GF products were on average 159% more expensive than the standard
equivalents. Generally, standard bread loaves in the UK weigh 800 g, thus the average price of a
standard white bread loaf is £1.35, compared to the higher GF cost of £5.52 of comparable weight.
The results of this study demonstrate that in addition to the limited number of products available
to the consumer, the cost of GF products is significantly more expensive than standard products.
The increased economic burden of CD and the reduced availability of products may increase the
likelihood of some CD patients being unable to comply with a GFD.
4.2. Nutritional Profile According to Back-of-Pack Labelling
The results indicated that GF products tend to contain more fiber and fat, but less sugar and
protein. The higher fiber content of GF breads may be attributed to the frequent use of plant fibers
in GF products (Figure 3). Ingredients such as psyllium husk powder, cellulose polymers such
as hydroxypropyl methylcellulose and apple fibers are commonly used to in GF manufacturing,
as confirmed by the findings of Capriles and Areas [5]. The NDNS [21] reported that cereals and
cereal products provide the largest source of dietary fiber, with only 9% of adults aged 19 to 64 years
achieving the RNI of 30 g per day. CD patients following a GFD consume inadequate fiber levels,
especially women, with intakes of 13.7 g per day [15] and 12 g per day [14] observed in UK dietary
studies (fiber expressed as non-starch polysaccharides). There is limited scientific evidence of the
effects these products have on the digestive system, but recently a study has shown that a subset of CD
patients is sensitive to fermentable fibers [22]. Understanding these effects is important, especially as
the digestive mechanism of CD patients may differ to that of the general population, as CD is an
abnormal immune response to a food component.
Wild et al. found that CD patients following a GFD consumed significantly higher intakes of fat at
68.4 g per day and 93.2 g per day for women and men respectively, the latter exceeding the RNI of fat of
<70 g per day [15]. These levels are higher than those observed by Kinsey et al. [14] who reported mean
fat intakes of 59 g per day, which equates to 85% of the RNI for fat. Cereals account for a substantial 23%
of UK protein intake [23]. Both studies found that coeliac protein consumption exceeded the RNI of
70 g per day with mean values of 74.1 g and 75 g of protein consumed per day, respectively. Therefore,
while GF products are significantly lower in protein, this is unlikely to put CD sufferers at risk of
protein deficiency. These results are supported by those of Fry et al. who compared the front-of-pack
nutritional content of GF and standard products for example breads, cereals, pizza, and crackers [11].
Their study found that GF breads contained higher fat and fiber, and lower protein values than
standard breads. Their study has several limitations, including the unexplained exclusion of GF
products containing xanthan gum and egg white replacer, which are common in GF foods (Figure 3A).
Although there is a statistically significant difference in the sugar content of GF and standard products,
the small amount of sugar consumed per portion is unlikely to impact on consumer health.
Wild et al. reported lower intakes of micronutrients in CD patients when compared to the standard
population, particularly iron, folate, and magnesium [15], although Kinsey et al. concluded adequate
intakes of iron in the coeliac diet [14]. The study found that 47% of patients had been prescribed
a calcium and vitamin D supplement. On average, patients who had not been prescribed with a
calcium supplement consumed less than the RNI. Low calcium intakes are supported by the findings
of Kinsey et al. who observed intakes of 866 mg per day [14]. This is below the specific coeliac RNI of
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1000 mg per day, which is advised as an osteoporosis prevention measure. Further research into the
micronutrient intake of CD patients is needed.
While bread and pasta are staples and major contributors to nutrient intake, other sources of
nutrients need to be considered to assess nutrient intake in the CD population.
4.3. Fortification
GF products are currently excluded from fortification legislation, possibly because when the
fortification legislation came into place, CD was relatively unknown. The Department for Environment
Food & Rural Affairs [9] concluded in their review of the regulations that fortification is cheap,
nutritionally beneficial for the population and convenient for manufacturers. The present study
showed that fortification of bread contributes to nutrient intake, particularly of calcium (23.5% of RNI)
and thiamin (24%–30% of RNI). We propose that the mandatory fortification of GF foods is necessary
to provide equivalent nutrition to the healthy population. Fortification levels for GF foods must be
carefully considered, taking into account CD pathophysiology, including potential accumulation of
metals [18].
4.4. Limitations
This study represents a survey of GF bread and pasta products available in the four major British
supermarkets, through online retailing. While this represents over 70% of the market penetration in
the UK, we did not survey the remaining 30% of retailing places, including specialist shops selling
GF foods. The survey only revealed 49 GF products (bread and pasta) available. While this is a small
sample which limits the generalizability of the results, it does reflect the limited availability of GF
products. We had to exclude some bread categories (such as crumpets, muffins, naan bread) because
the GF version of these products could not be found in these supermarkets. The nutrient analysis
was based on back-of-pack information. While this is an improvement compared to studies using
front-of-pack information, chemical analysis of food should be applied to verify nutrient content,
especially micronutrient content.
5. Conclusions
Despite improvements in the formulation and availability of GF in the last decade, GF foods are
still less available and more expensive than gluten-containing versions. The macronutrient profile
suggests that GF foods generally have adequate levels of fiber and sugar, but lower levels of protein
and higher levels of fat, compared to their equivalent gluten-containing products. Very few GF foods
were found to be fortified with micronutrients. As mandatory fortification of wheat flour is considered
a successful health initiative for the general population, fortification should be extended to include GF
products. Fortification of these products may reduce the risk of micronutrient deficiency and therefore
deficiency-related diseases in CD patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/10/1370/
s1. Table S1: List of products identified in the survey with their back-of-pack nutrient information (energy,
macronutrients, and salt values in g per 100 g) and fortification; Table S2: Ingredient list for standard bread and
pasta products identified in the supermarket survey; Table S3: Ingredient list for gluten-free (GF) bread and pasta
products identified in the supermarket survey.
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adult patients with celiac disease. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 4285–4292.
17. Ohlund, K.; Olsson, C.; Hernell, O.; Ohlund, I. Dietary shortcomings in children on a gluten-free diet. J. Hum.
Nutr. Diet. 2010, 23, 294–300. [CrossRef] [PubMed]
18. Elli, L.; Pigatto, P.D.; Guzzi, G. Evaluation of Metals Exposure in Adults on a Gluten-Free Diet.
Clin. Gastroenterol. Hepatol. 2018, 16, 152. [CrossRef] [PubMed]
19. The Bread and Flour Regulations. Schedule 1: Essential Ingredients in Flour in No. 141. 1998.
Available online: http://www.legislation.gov.uk/uksi/1998/141/made (accessed on 23 September 2018).
20. Terazono, E. Healthy Appetites Drive Jump in Sales of Gluten-free Foods, in Financial Times. 2017.
Available online: https://www.ft.com/content/4ec0f2f2-2c0a-11e7-9ec8-168383da43b7 (accessed on
23 September 2018).
21. National Diet and Nutrition Survey. Results of the National Diet and Nutrition Survey





Nutrients 2018, 10, 1370
22. Roncoroni, L.; Bascuñán, K.; Doneda, L.; Scricciolo, A.; Lombardo, A.; Branchi, F.; Ferretti, F.; Dell’Osso, B.;
Montanari, V.; Bardella, M.T. A low FODMAP gluten-free diet improves functional gastrointestinal disorders
and overall mental health of celiac disease patients: A randomized controlled trial. Nutrients 2018, 10, 1023.
[CrossRef] [PubMed]
23. Nutrients, Food and Ingredients: Protein. 2018. Available online: https://www.nutrition.org.
uk/nutritionscience/nutrients-food-and-ingredients/protein.html?limit=1&start=1 (accessed on
23 September 2018).
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Preparation of a Defined Gluten Hydrolysate for
Diagnosis and Clinical Investigations of
Wheat Hypersensitivities
Herbert Wieser † and Katharina A. Scherf *
Leibniz-Institute for Food Systems Biology at the Technical University of Munich, 85354 Freising, Germany;
h.wieser2@gmx.de
* Correspondence: k.scherf.leibniz-lsb@tum.de; Tel.: +49-8161-712927
† Retired.
Received: 10 September 2018; Accepted: 25 September 2018; Published: 2 October 2018
Abstract: Gluten is the trigger for celiac disease (CD), non-celiac gluten/wheat sensitivity (NCGS),
and wheat allergy. An oral food challenge is often needed for diagnosis, but there are no standardized
gluten challenge materials with known composition available. To fill this gap, two materials,
commercially available gluten and a food-grade gluten hydrolysate (pepgluten), were extensively
characterized. Pepgluten was prepared from gluten by incubation with a pepsin dietary supplement
and acetic acid at 37 ◦C for 120 min. The components of pepgluten were crude protein (707 mg/g),
starch (104 mg/g), water (59 mg/g), fat (47 mg/g), dietary fiber (41 mg/g) and ash (11 mg/g).
The protein/peptide fraction of pepgluten (1 g) contained equivalents derived from 369 mg gliadins
and 196 mg glutenins, resulting in 565 mg total gluten equivalents, 25 mg albumins/globulins, 22 mg
α-amylase/trypsin inhibitors and 48 mg pepsin capsule proteins. The slightly acidic, dough-like
smell and bitter taste of pepgluten could be completely camouflaged in multivitamin juice with
bitter lemon, grapefruit juice, or vegetable and fruit smoothies. Thus, pepgluten met the criteria
for placebo-controlled challenges (active and placebo materials are identical regarding appearance,
taste, smell, and texture) and is appropriate as a standard preparation for the oral food challenge and
clinical investigations to study wheat hypersensitivities.
Keywords: celiac disease; diagnosis; gliadin; gluten; glutenin; non-celiac gluten sensitivity; oral food
challenge; pepsin; wheat allergy
1. Introduction
Wheat hypersensitivities can be classified into celiac disease (CD) and related disorders
(dermatitis herpetiformis Duhring and gluten ataxia), non-celiac gluten/wheat sensitivity (NCGS),
non-IgE-mediated allergies and IgE-mediated allergies such as food allergy, skin allergy, respiratory
allergy (e.g., baker’s asthma), and wheat-dependent exercise-induced anaphylaxis (WDEIA) [1,2].
Additionally, a subgroup of individuals suffering from irritable bowel syndrome (IBS), especially
diarrhea-predominant IBS, appears to be sensitive to wheat products and may profit from adhering to
a gluten-free diet [3,4].
A wide variety of wheat proteins may trigger these hypersensitivities in susceptible individuals with
a certain genetic predisposition (HLA-DQ2/8-positive) or sensitization. The causative factors in wheat are
gluten (gliadins and glutenins, 70–80% of wheat proteins) and non-gluten proteins (albumins/globulins,
20–30% of wheat proteins). Classically, wheat proteins are subdivided according to extractability into
albumins/globulins soluble in aqueous salt solution: gliadins are soluble in aqueous alcohols, and
glutenins soluble in aqueous alcohols only after reduction of disulfide bonds [5]. Gluten comprises
more than one hundred single proteins and serves as a source of nitrogen and amino acids for the
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wheat germ, whereas albumins/globulins mainly contain metabolic and protective proteins such as
enzymes and enzyme inhibitors. Gluten proteins are hydrophobic, compact, and characterized by
repetitive amino acid sequences rich in glutamine and proline, which makes them resistant to human
gastrointestinal enzymes [6]. Based on amino acid sequence similarities, gliadins are subdivided
into the gluten protein types ω5-, ω1,2-, α- and γ-gliadins and glutenins into glutenin-bound
ωb-gliadins, high-molecular-weight (HMW) and low-molecular-weight (LMW) glutenin subunits
(GS) [7]. While CD is caused by gluten only, wheat allergy occurs following sensitization with both
gluten and non-gluten proteins. In the case of NCGS, α-amylase/trypsin-inhibitors (ATIs) belonging
to non-gluten proteins have been identified as activators of innate immunity and adjuvant of several
inflammatory reactions [8,9], but gluten proteins may be involved as well.
The differential diagnosis of wheat hypersensitivities is complex and requires a high level of
clinical suspicion. Especially in inconclusive cases, open or single- or double-blinded oral challenge of
the patients with the suspected triggering factor needs to be performed. A 14-day provocation test
with gluten is necessary to achieve a clear diagnosis in CD patients who have already voluntarily
adopted a gluten-free diet [10]. Stepwise challenges with half-logarithmic dose increments of wheat
proteins at intervals of at least 20 min are needed to diagnose an immediate wheat allergy [11,12].
For WDEIA, gluten ingestion is combined with exercise or other cofactors [13]. The diagnosis of NCGS
and diarrhea-predominant IBS is known to be especially difficult due to the lack of specific biomarkers
and frequent placebo or nocebo effects [2,14,15]. Therefore, a double-blind, placebo-controlled food
challenge is regarded as the gold standard to establish whether wheat is involved in symptom
induction [16], although this is difficult to undertake in daily clinical practice [3].
A number of different materials, for example, wheat bread [17] or cookies [18], udon noodles [19],
wheat-containing daily meals [4], and wheat gluten as is [13], as gastrosoluble capsules [16,20] or
added to bakery products such as muffins [21] have been used for oral challenge. However, the
amount and composition of wheat proteins used in these materials were often not determined or
indicated. For example, commercial wheat gluten (vital gluten) has been frequently assumed to
consist of 100% gluten proteins, but the protein content is typically only about 70–80% based on fresh
weight [21]. The gluten-containing foods used for the oral challenge should be indistinguishable from
the gluten-free placebo in taste, smell, texture, and appearance, and contain comparable amounts
of carbohydrates, dietary fiber, fat, and protein. The challenge food should provide adequate
immunoreactive protein in a reasonable portion size, be easily applicable, closely replicate the usual
form of the food, and its qualitative and quantitative composition should be known [2,11]. A dose of
8 g of gluten with a defined ATI content (at least 3 g ATIs per 100 g of gluten) is recommended for
diagnosis of NCGS [2]. Already in 2004, the European Academy of Allergy and Clinical Immunology
demanded that challenge tests should be carried out with standardized foods guaranteeing the safety
of patients, practical feasibility, and the comparability of results between different study centers [22].
Despite several meetings of expert groups, no standardized preparation has so far been developed for
the diagnosis of wheat hypersensitivities, although there is a clear need, especially for NCGS where
the diagnosis still relies on exclusion of all other possible causes as long as specific biomarkers for
NCGS have not been identified. Therefore, the aim of this study was to thoroughly characterize wheat
gluten and prepare a well-defined wheat gluten hydrolysate (called “pepgluten” in the following),
which fulfills the recommendations stated above and is suited for oral food challenge in clinical and
scientific studies on wheat hypersensitivities.
2. Materials and Methods
2.1. Reagents and Materials
All reagents and chemicals were purchased from Merck (Darmstadt, Germany), Sigma-Aldrich
(Steinheim, Germany), AppliChem (Darmstadt, Germany), or Serva (Heidelberg, Germany) in
analytical grade or higher. Water for reversed-phase high-performance liquid chromatography
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(RP-HPLC) was purified with an Arium 611VF water purification system (Sartorius, Goettingen,
Germany). Prolamin Working Group (PWG)-gliadin [23] used for calibration was kindly provided
by Prof. Dr. Peter Koehler, chairman of the PWG. Wheat gluten “vital” (batch no. 1607220051) was
obtained from Hermann Kröner GmbH (Ibbenbueren, Germany) and contained ≤8% moisture, ≤0.9%
ash and ≥78% protein (nitrogen × 6.25, based on fresh weight) according to the manufacturer’s product
specification sheet (called “gluten” in the following). Pepsin capsules for use as a dietary supplement
(153 mg pepsin, corresponding to 3 × 106 albumin digestion units per capsule) were purchased
from Dr. Clark Store (Chula Vista, CA, USA). Sodium hydroxide (“baker’s brine”) was provided by
Minerva (Calbitz, Germany). Vinegar essence (Surig®, Speyer & Grund, Meerane, Germany, 25% acetic
acid), mineral water (Adelholzener, Siegsdorf, Germany, in a glass bottle) and different fruit juices
and smoothies were obtained from a local supermarket. According to the label, the mineral water
contained 508 mg/L salts (nitrate < 0.3 mg/L). Acetic acid (pH 3.0) was prepared by mixing 900 mL
mineral water and 100 mL vinegar essence.
2.2. Standard Analyses
The moisture and ash contents were determined according to International Association for Cereal
Science and Technology (ICC) Standard Methods 110/1 and 104/1, respectively. The crude protein
content (nitrogen × 5.7 for wheat) was analyzed according to ICC Standard Method 167 using a
TruSpec Nitrogen Analyzer (Leco, Kirchheim, Germany) calibrated with ethylenediamine- tetraacetic
acid (EDTA). The content of starch was determined according to AOAC Official Method 996.11 using
the Total Starch Assay Kit (Megazyme, Bray, Ireland) [24]. The analysis of total dietary fiber was
carried out with the Total Dietary Fiber Assay Kit (Sigma-Aldrich, Steinheim, Germany) based on a
combination of enzymatic and gravimetric methods. The fat content was determined gravimetrically
after extraction in hydrochloric acid (25%, v/v) and addition of toluene [25]. All analyses were done in
triplicates each for gluten and pepgluten.
2.3. Contents of Albumins/Globulins, Gliadins and Glutenins in Gluten
The extraction of modified Osborne fractions was adapted from Wieser et al. [26] as follows:
Gluten (20.0 mg, n = 3) was first extracted with 3 × 1.5 mL of salt solution (0.4 mol/L NaCl with
0.067 mol/L Na2HPO4/KH2PO4, pH 7.6, at 20–22 ◦C) to obtain albumins and globulins (ALGL). In a
separate experiment, gluten (20.0 mg) was stepwise extracted with 3 × 1.5 mL 60% (v/v) ethanol to
obtain a mixture of ALGL and gliadins (GLIA) and then with 3 × 1.5 mL glutenin extraction solvent
(50% (v/v) 1-propanol and 0.05 mol/L Tris-HCl, pH 7.5, with 2 mol/L (w/v) urea and 0.06 mol/L (w/v)
dithiothreitol (DTT)) at 60 ◦C under nitrogen to obtain glutenin subunits (GLUT). Each extraction step
was performed by vortex mixing for 2 min and magnetic stirring for 30 min followed by centrifugation
(3750× g, 25 min, 22 ◦C). The corresponding three supernatants were combined, made up to 5.0 mL
with the respective solvent and filtered (0.45 μm).
2.4. RP-HPLC for Gluten Proteins
The quantitation of protein fractions was performed by RP-HPLC on a Jasco XLC instrument
(Jasco, Gross-Umstadt, Germany) with a C18 column (AcclaimTM 300, 2.1 × 150 mm, 3 μm, 30 nm,
Thermo Fisher Scientific, Braunschweig, Germany) at 60 ◦C. Elution solvents were 0.1% (v/v)
trifluoroacetic acid (TFA) in water (A) and 0.1% (v/v) TFA in acetonitrile (B) at a flow rate of 0.2
mL/min with the following gradient: 0 min 0% B, 0.5 min 24% B, 20 min 56% B, 20.1–24.1 min 90% B,
24.2–30 min 0% B. The injection volumes were 20 μL (ALGL, GLUT) and 10 μL (ALGL + GLIA) and
protein absorbance was detected at 210 nm. PWG-gliadin [23] dissolved in 60% (v/v) ethanol was used
for external calibration. The contents of ωb-gliadins, HMW-GS and LMW-GS were calculated relative
to the total area of GLUT as described earlier [27]. To obtain the GLIA content, the chromatogram of the
ALGL fraction was subtracted from that of the ALGL + GLIA fraction using the Chrompass software
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(version 1.2, Jasco, Gross-Umstadt, Germany). Then, the contents of ω5-, ω1,2-, α- and γ-gliadins were
calculated from the absorbance area of each type relative to the total area.
2.5. Optimization of Gluten Hydrolysis
Different ratios of enzyme (E), gluten (G) and solvent (S) were tested. The first assay was
performed according to Dorum et al. [28] (E:G:S = 1:25:1667). Gluten (3.8 g) was suspended in 260 mL
HCl (0.01 mol/L, pH 2.0, 37 ◦C) under magnetic stirring, 153 mg pepsin (1 capsule) were added and
stirred for 120 min at 37 ◦C. The next assays were performed with acetic acid as solvent prepared
by mixing mineral water with acetic acid essence until pH 3.0 was reached. To reduce the ratio of
solvent, different incubations (120 min at 37 ◦C each) were done using E:G:S ratios of 1:25:200, 1:25:150
and 1:25:100. Aliquots (0.5 mL) were taken from all assays for analysis before addition of the enzyme
(0 min) and after 10, 20, 40, 60, 90, and 120 min and heated for 10 min at 95 ◦C to inactivate pepsin.
The remaining portions of the hydrolysates obtained after 120 min were lyophilized. In order to reduce
the amount of enzyme, different incubations at 37 ◦C were performed using E:G:S ratios of 1:50:200,
1:100:400 and 1:200:800. After 120 min, aliquots (0.5 mL) were taken and inactivated as described above.
2.6. Preparation of Pepgluten
Twenty-five capsules (3.8 g pepsin) were dissolved in 380 mL acetic acid (pH 3.0) at 37 ◦C. Gluten
(95 g) was added (E:G:S = 1:25:100) and magnetically stirred for 120 min at 37 ◦C. The assay was cooled,
frozen and lyophilized. The dried digest was mixed with boiling mineral water (200 mL) and heated
for 10 min, cooled, frozen and lyophilized. The dried material was milled (A10, IKA-Werke, Staufen,
Germany) and stored in a vacuum desiccator over baker’s brine until a constant weight was reached.
2.7. RP-HPLC for the Gluten Hydrolysates
The 0.5 mL aliquots (see Section 2.5) were diluted 1:20 with 0.1% (v/v) TFA, filtered (0.45 μm) and
50 μL of the filtrates were analyzed on a Thermo Finnigan Spectra System (Thermo Fisher Scientific)
with ChromQuest software using an Aeris Peptide XB-C18 column (2.1 × 150 mm, 3.6 μm, Phenomenex,
Aschaffenburg, Germany). Elution solvents were 0.1% (v/v) TFA in water (A) and 0.1% (v/v) TFA in
acetonitrile (B) at a flow rate of 0.2 mL/min at 22 ◦C and a detection wavelength of 210 nm with the
following linear gradient: 0 min 0% B, 5–60 min, 0–40% B, 60.5–66.5 min 90% B, 70–76 min 0% B.
2.8. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Gluten and gluten hydrolysates were characterized by SDS-PAGE on a homogeneous NuPAGE
10% polyacrylamide-Bis-Tris gel (10 × 1 mm wells Invitrogen, Carlsbad, CA, USA) [29,30]. A mixture of
proteins was used as size standard (PageRulerTM Unstained Protein Ladder, Thermo Fisher Scientific).
Gluten samples (4 mg each) were mixed with 1.0 mL of extraction buffer (293.3 mmol/L sucrose,
246.4 mmol/L Tris-HCl, 69.4 mmol/L SDS, 0.51 mmol/L EDTA, 0.22 mmol/L Coomassie blue,
0.177 mmol/L phenol red, 0.105 mmol/L HCl, pH 8.5) containing DTT (50 mmol/L), incubated
for 12 h, heated to 60 ◦C for 10 min and centrifuged (5000× g, 5 min, 20 ◦C). Ten μl of the
supernatant were applied to the slots. The running buffer (MES buffer) consisted of 50 mmol/L
2-(N-morpholino)ethanesulfonic acid (MES), 50 mmol/L Tris-HCl, 3.5 mmol/L SDS, 1 mmol/L EDTA
and 5 mmol/L DTT (pH 7.7). The running time was 30 min at 200 V and 115 mA. After the run, protein
bands were fixed for 30 min in 12% (w/w) trichloroacetic acid, stained for 30 min with Coomassie
blue and destained twice, first with methanol/acetic acid/water (50/10/40, v/v/v) and then with
methanol/acetic acid/water (10/10/80, v/v/v). The gels were scanned, the images converted to
grayscale, the lanes of interest plotted as x/y-diagrams and the peaks integrated using the Gel DocTM
EZ gel documentation system (Bio-Rad Laboratories, Munich, Germany).
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2.9. Enzyme-Linked Immunosorbent Assay (ELISA)
The gluten content in the samples (gluten and pepgluten) was quantitated by a commercial
competitive ELISA kit based on the R5 monoclonal antibody (RIDASCREEN® Gliadin competitive,
R-Biopharm, Darmstadt, Germany). The kit is intended to measure gluten contents in the 20 mg/kg
and not in the 700 g/kg range, which is why the standard extraction procedure was modified. Gluten
and pepgluten (10 mg, n = 3) were extracted with 2.5 mL Cocktail [31] at 50 ◦C for 40 min followed
by the addition of 7.5 mL 80% (v/v) ethanol, shaking at 22 ◦C for 60 min and centrifugation (3750× g,
10 min, 22 ◦C). The resulting supernatant was subsequently diluted 1:100 and 1:50 with 60% (v/v)
ethanol and finally 1:50 with the diluted sample buffer of the kit, resulting in a dilution factor of
2.5 × 107. The following ELISA procedure was performed according to the kit manual in a separate,
closed room where the surfaces had been cleaned with 60% ethanol (v/v) to prevent contamination
with gluten. The absorbances were measured at 450 nm (Expert 96 microplate reader, Asys Hitech,
Eugendorf, Austria) and the gluten concentrations calculated from the calibration curve using the cubic
spline function of the RIDA®SOFT Win software (version z9996, R-Biopharm, Darmstadt, Germany).
2.10. Quantitation of ATIs
The contents of ATIs were determined based on five ATI-specific marker peptides by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) and stable isotope dilution assays (SIDA)
with 13C- and 15N-labelled peptides as internal standards [32]. In brief, 10 mg of gluten and pepgluten
(n = 3) were extracted twice with ammonium bicarbonate (0.5 mL, 50 mmol/L, pH 7.8). The combined
extracts were lyophilized. After addition of the internal standards, the reconstituted ATI extract was
reduced with tris(2-carboxyethyl)phosphine, alkylated with chloroacetamide, hydrolyzed with trypsin,
lyophilized and re-dissolved in 1 mL of 0.1% (v/v) formic acid. Targeted LC-MS/MS was carried out
with an UltiMate 3000 HPLC system (Dionex, Idstein, Germany) coupled to a triple-stage quadrupole
mass spectrometer (TSQ Vantage, Thermo Fisher Scientific) exactly as described by Geisslitz et al. [32].
2.11. Descriptive Sensory Analysis
Ten healthy panelists (7 women and 3 men) with no history of known taste or smell disorders
were trained in the sensory evaluation of aqueous solutions of the standard taste compounds sucralose
(sweet), sodium chloride (salty), monosodium L-glutamate (umami), citric acid (sour), and caffeine
(bitter) [33]. They gave written informed consent to participate in the sensory tests and had participated
in sensory analyses for at least one year. The analyses were performed in a sensory panel room with
separated booths at 20–22 ◦C. First, a descriptive analysis of the appearance, color and aroma of
pepgluten was performed. Then, 2 g of pepgluten were mixed into 100 mL of different beverages
with a small kitchen mixer. The beverages compared were mineral water, multivitamin juice, a
mixture (70:30) of multivitamin juice and bitter lemon, grapefruit juice and different vegetable and
fruit smoothies. The panel compared taste and aroma of the beverages with and without pepgluten.
2.12. Statistical Analysis
The software SigmaPlot 12.0 (Systat Software, San Jose, CA, USA) was used to assess significances
of differences between the analytical parameters determined in both samples (gluten and pepgluten)
with one-way analysis of variance (ANOVA) and Tukey’s test at p < 0.05.
3. Results
3.1. Composition of Gluten
The qualitative and quantitative composition of gluten was determined to fulfill one of the
most important requirements for oral food challenge materials. The nitrogen content of gluten
was 126.1 mg/g, which corresponded to 718.8 mg/g crude protein using the conversion factor of
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5.7 recommended for wheat proteins (ICC Standard Method 167). Further components in gluten
were starch (107.7 mg/g), water (62.3 mg/g), dietary fiber (49.6 mg/g), fat (41.5 mg/g), and ash
(7.9 mg/g), as seen in Table 1. The residue of 12.2 mg/g was very low (within the precision of the
analytical methods used) and contained non-identified minor constituents that were not analyzed.
The immunological determination of the gluten content using the R5 monoclonal antibody resulted
in a gluten content of 646.6 mg/g, which corresponds to 90% of crude protein. Targeted LC-MS/MS
SIDA based on five ATI-specific marker peptides revealed that 32.6 mg/g total ATIs were present in
gluten, with CM3 (11.9 mg/g) and 0.19 + 0.53 (10.5 mg/g) as predominant ATI types.
Table 1. Composition of gluten and pepgluten. ATIs: α-amylase/trypsin-inhibitors.
Constituent Gluten Pepgluten
(mg/g) 1 (mg/g) 1
Crude protein (nitrogen × 5.7) 718.8 ± 1.8 A 707.1 ± 2.5 A
Starch 107.7 ± 3.5 A 104.2 ± 1.0 A
Water 62.3 ± 0.3 A 59.2 ± 1.9 B
Fat 41.5 ± 2.7 A 46.6 ± 0.7 A
Dietary fiber 49.6 ± 4.7 A 40.5 ± 4.3 A
Ash 7.9 ± 0.1 A 10.9 ± 0.1 B
Residue 12.2 31.5
Gluten 2 646.6 ± 34.8 A 372.0 ± 36.3 B
ATIs (sum) 32.6 A 22.4 B
ATI 0.19 + 0.53 10.5 ± 1.6 A 10.6 ± 1.4 A
ATI 0.28 2.0 ± 0.2 A 1.9 ± 0.1 A
ATI CM2 1.7 ± 0.3 A 1.6 ± 0.1 A
ATI CM3 11.9 ± 0.4 A 2.7 ± 0.1 B
ATI CM16 6.5 ± 1.1 A 5.6 ± 0.9 A
1 Results are given as mean ± standard deviation of triplicate determinations and different superscript letters
designate significant differences between the two samples (one-way analysis of variance (ANOVA), Tukey’s test,
p < 0.05, 2 Gluten content determined by R5 competitive enzyme-linked immunosorbent assay (ELISA).
3.2. Composition of the Protein Fraction in Gluten
SDS-PAGE of gluten, seen in Figure 1A, lane G, showed the typical protein bands known from
wheat flours including the following gluten protein types and ranges of Mr (according to known amino
acid sequences): HMW-GS (67–88 × 103), ω5-GLIA (49–55 × 103), ω1,2-GLIA (39–44 × 103), LMW-GS,
α-GLIA and γ-GLIA (28–39 × 103) and ALGL (10–25 × 103).
Figure 1. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of gluten (G) and
different peptic digests incubated at 37 ◦C for 10 min, 20 min, 40 min, 60 min, 90 min, 120 min,
180 min and 240 min at an E:G:S ratio of 1:25:100 (A). Area (%) relative to the total area of selected
bands according to molecular weight ranges of marker M (B). HMW-GS, high-molecular-weight
glutenin subunits, LMW-GS, low-molecular-weight glutenin subunits, M, molecular weight marker, Mr,
relative molecular weight, α-GLIA, α-gliadins, γ-GLIA, γ-gliadins, ω5-GLIA, ω5-gliadins, ω1,2-GLIA,
ω1,2-gliadins.
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The contents of ALGL, GLIA, and GLUT present in gluten were determined according to a
combined extraction/RP-HPLC method developed for the analysis of wheat flour [26]. An advantage
of RP-HPLC is that each gliadin and glutenin protein type is separated largely as a subgroup and can
be quantitated without major overlap. As an example, the elution regions of ω5-, ω1,2, α-, and γ-GLIA
are shown in Figure 2A for PWG-gliadin, which was used for calibration. However, the method had
to be modified, because, in contrast to flour, gluten proteins strongly agglomerated after the initial
extraction of ALGL with salt solution. Therefore, the following extraction of GLIA with 60% ethanol
was not reproducible (coefficient of variation > 20%) and the procedure was divided into two separate
experiments: First, ALGL were extracted from gluten with salt solution using three extraction steps.
Second, gluten was extracted with 60% ethanol using three extraction steps to obtain a mixture of
ALGL and GLIA. Then, GLUT were extracted three times with glutenin extraction solvent from the
residue of ALGL + GLIA. Single corresponding extracts were combined into the three fractions ALGL,
ALGL + GLIA and GLUT and analyzed by RP-HPLC, as seen in Figure 2B–D.
Figure 2. Reversed-phase high-performance liquid chromatography (RP-HPLC) for gluten proteins
of prolamin working group (PWG)-gliadin (A), the ALGL fraction (B), the ALGL + gliadins (GLIA)
fraction (C) and the glutenin subunits (GLUT) fraction (D). AU210, absorbance units at 210 nm, ALGL,
albumins and globulins, HMW, high-molecular-weight glutenin subunits, LMW, low-molecular-weight
glutenin subunits, α, α-gliadins, γ, γ-gliadins, ω5, ω5-gliadins, ω1,2, ω1,2-gliadins, ωb, ωb-gliadins.
For the quantitation of GLIA, the value of ALGL had to be subtracted from the value of the
ALGL + GLIA fraction. GLIA were predominant (402.1 mg/g), followed by GLUT (213.8 mg/g) and
ALGL (27.7 mg/g), as seen in Table 2. The gluten content, as sum of GLIA and GLUT, amounted to
615.9 mg/g and the ratio of GLIA to GLUT was 1.88. The contents of gluten protein types were also
calculated from the respective areas, again using the ALGL + GLIA chromatogram minus the ALGL
chromatogram. The ω5-GLIA and ω1,2-GLIA were most affected by co-eluting ALGL, as 72.5% of
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ALGL were eluted in the region of ω5-GLIA and 27.5% in the region of ω1,2-GLIA. Corresponding
proportions of ALGL, shown in Figure 2B, areas a and b, were subtracted from ω5- and ω1,2-GLIA,
respectively, as seen in Figure 2C. The elution profiles of α- and γ-GLIA from PWG-gliadin isolated
from a mixture of 28 wheat cultivars [23] and of gluten (mixture of unknown cultivars), seen in
Figure 2A,C, were almost identical. In total, α-GLIA (208.8 mg/g), γ-GLIA (149.2 mg/g) and LMW-GS
(149.1 mg/g) belonged to the major protein types, while ω5-GLIA (16.3 mg/g), ω1,2-GLIA (27.8 mg/g),
ωb-GLIA (9.7 mg/g) and HMW-GS (55.0 mg/g) were minor components, as shown in Table 2.
Table 2. Composition of the protein fraction in gluten and pepgluten.
Protein Gluten Gluten Digestion Assay Pepgluten
(mg/g) 1 (mg/g) 2 (%) (mg/g)
ALGL 27.7 ± 0.8 26.3 3.6 25.4
GLIA 402.1 ± 5.4 382.0 52.1 368.6
ω5 16.3 ± 1.1 15.5 2.1 15.0
ω1,2 27.8 ± 0.6 26.4 3.6 25.5
α 208.8 ± 2.9 198.4 27.1 191.4
γ 149.2 ± 1.2 141.7 19.3 136.7
GLUT 213.8 ± 6.1 203.1 27.7 196.0
ωb 9.7 ± 0.5 9.2 1.3 8.9
HMW-GS 55.0 ± 1.5 52.3 7.1 50.5
LMW-GS 149.1 ± 3.9 141.6 19.3 136.6
Gluten 3 615.9 ± 2.9 585.1 79.8 564.6
Residue 75.2 71.4 9.8 68.9
Capsule 4 - 50.0 6.8 48.2
Sum 718.8 ± 1.8 732.8 100 707.1 ± 2.5
1 Results are given as mean ± standard deviation (n = 3), 2 calculated from 95 g gluten and 5 g pepsin
capsule, 3 sum of GLIA and GLUT, 4 protein content in the pepsin capsule, ALGL, albumins and globulins,
HMW, high-molecular-weight glutenin subunits, LMW, low-molecular-weight glutenin subunits, α, α-gliadins, γ,
γ-gliadins, ω5, ω5-gliadins, ω1,2, ω1,2-gliadins, ωb, ωb-gliadins.
3.3. Optimization of Gluten Hydrolysis
The first experiment was performed to test the activity of the commercial pepsin dietary
supplement. Each capsule (203 mg weight on average) contained 153 mg pepsin (manufacturer’s
information). The analysis of nitrogen (177.7 mg/g) indicated that the capsules exclusively consisted
of protein (101.3 ± 0.1%, n = 3), including the main component pepsin (≈75%) and also gelatin for
pill preparation. Gluten was first incubated for 120 min at 37 ◦C at an E:G:S ratio of 1:25:1667 [28]
using hydrochloric acid (0.01 mol/L, pH 2.0). The analysis of aliquots taken during the whole
digestion period by RP-HPLC (for the gluten hydrolysates) indicated that gluten proteins were
extensively degraded with an endpoint at 120 min. After that time, there was no further increase in
absorbance areas.
Having thus confirmed the activity of the pepsin capsules, hydrochloric acid was replaced
by food-grade acetic acid (acetic acid essence mixed with mineral water to obtain pH 3.0) and
the solvent volume was decreased (E:G:S ratios of 1:25:200, 1:25:150 and 1:25:100) to speed up the
following drying process. RP-HPLC and SDS-PAGE analyses revealed that the progress of gluten
degradation was only marginally different compared to the E:G:S ratio of 1:25:1667. SDS-PAGE, shown
in Figure 1A, confirmed that gluten proteins (Mr = 30–100 × 103 in a reduced state, according to the
marker) were successively degraded during incubation and that the hydrolysis reached an endpoint at
120 min, because there was no further significant change compared to 180 min, as seen in Figure 1B.
While gluten had an approximate distribution of 9% of proteins with Mr = 85–200 × 103 (HMW-GS), 9%
(Mr = 60–85 × 103, ω5- and ω1,2-gliadins), 48% (Mr = 30–60 × 103, α- and γ-gliadins and LMW-GS),
20% (Mr = 15–30 × 103), 10% (Mr = 10–15 × 103) and 4% (Mr < 10 × 103), this distribution fundamentally
changed to 1%, 1%, 6%, 23%, 38% and 31%, respectively, after an incubation time of 120 min. The gel
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thus confirmed extensive degradation of gluten proteins and revealed that about 70% of the hydrolysate
was composed of gluten fragments with Mr of 15 × 103 and below.
RP-HPLC revealed that gluten did not contain any fragments, as seen in Figure 3A, whereas the
gluten hydrolysate showed a complex fragment mixture after 120 min, see in Figure 3B.
To test whether the amount of pepsin could be reduced, the following E:G:S ratios were tested:
1:50:200, 1:100:400 and 1:200:800. SDS-PAGE after an incubation time of 120 min each (not shown)
indicated that fragments with high Mr were generally more dominant than in the digests with
E:G:S = 1:25:100. Moreover, the lyophilized material suspended in mineral water remained glutinous.
Altogether, the following optimized procedure for gluten hydrolysis was used for further experiments:
E:G:S ratio of 1:25:100 with food-grade acetic acid (pH 3.0) as solvent and an incubation at 37 ◦C for
120 min.
Figure 3. RP-HPLC (peptide system) of the peptic hydrolysis of gluten after incubation at 37 ◦C for
0 min (A) and 120 min (B). The ratio of enzyme to gluten to solvent was 1:25:100. AU210, absorbance
units at 210 nm.
3.4. Preparation and Characterization of Pepgluten
The final gluten hydrolysate (called “pepgluten”) was prepared from 95 g gluten digested
with 3.8 g pepsin (25 capsules weighing 5 g) in 380 mL acetic acid (pH 3.0) at 37 ◦C for 120 min
(E:G:S = 1:25:100). After freezing, the preparation was lyophilized. The inactivation of the enzyme
by heating was not performed in acetic acid to avoid partial deamidation of glutamine side chains,
which might influence the immunoreactivity of pepgluten. Therefore, pepsin was inactivated by
suspending the lyophilized digest in boiling mineral water for 10 min. An additional reason for this
procedure was that heating created a more realistic material for gluten challenge tests, because most
gluten-containing foods such as bread or pasta are also baked or cooked before consumption. After the
second lyophilization, the dry material was milled and stored in a desiccator over sodium hydroxide
(baker’s brine) until constant weight. Pepgluten was not separated into soluble and insoluble parts, as
had been done previously by Frazer et al. [34] (FIII and FVI) and others, who subsequently studied only
the soluble part. Thus, the proportions of gluten proteins remained unchanged, which was important
for the calculation of gluten equivalents in the hydrolysate.
The yield of dried pepgluten (92.6 g) was 92.2%, based on the amounts of non-volatile substances
used for the digestion (95 g vital gluten, 5.1 g pepsin capsules and 0.3 g salts in the mineral water).
Considering the frequent transfers of solutions and substances during the processes of digestion,
freeze-drying, heating, milling and storage, the obtained yield appeared to be satisfactory. Compared to
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gluten as starting material, there were no significant differences between both materials for contents of
protein (707.1 mg/g), starch (104.2 mg/g), fat (46.6 mg/g), dietary fiber (40.5 mg/g) and only slight
differences in water (59.2 mg/g) and ash (10.9 mg/g) contents due to drying and addition of salts from
the mineral water, as seen in Table 1. The gluten content of the hydrolysate (372 mg/g) determined by
the R5 competitive ELISA, shown in Table 1, was reduced compared to gluten. The contents of ATIs
0.19 + 0.53, 0.28, CM2 and CM16 were not significantly different, but the content of CM3 was lower
(2.7 mg/g) in pepgluten compared to the starting material (11.9 mg/g).
Finally, the contents of gluten equivalents in the hydrolysate were calculated based on its crude
protein content (707 mg/g = 100%) considering the proportions of gluten proteins and pepsin capsule
proteins in the digestion assay, as shown in Table 2. Accordingly, 1 g of pepgluten contained gluten
equivalents derived from 369 mg GLIA and 196 mg GLUT resulting in 565 mg total gluten equivalents.
Further protein components of pepgluten were derived from ALGL (25 mg/g), residual proteins
(69 mg/g) and pepsin capsule proteins (48 mg/g), as seen in Table 2.
3.5. Descriptive Sensory Analysis
The pepgluten powder was slightly brownish in appearance and had a flour- and sourdough-like
aroma with a residual slightly pungent note originating from acetic acid. When mixed into mineral
water (2 g in 100 mL), the drink was turbid and had a dough-like aroma and bitter taste. The intensity
of aroma and taste was less noticeable in a turbid multivitamin juice, which appeared to be suitable for
an open challenge test. If necessary, the endogenous bitter taste can be completely covered by mixing
multivitamin juice with bitter lemon (70:30 v/v) or by using grapefruit juice. Different vegetable or
fruit smoothies also allowed the complete camouflage of the preparation.
4. Discussion
Due to its glutinous properties, wheat gluten is difficult to handle for oral food challenge
and in cell-based assays for clinical investigations, because these only tolerate aqueous solvents.
Therefore, gluten is commonly applied in form of the soluble portions of peptic [34,35], tryptic [35],
chymotryptic [5], peptic-tryptic [8,36,37], peptic-chymotryptic [37] or peptic-tryptic-chymotryptic [28]
hydrolysates, sometimes in combination with further enzymes such as elastase or carboxypeptidase
to mimic human gastrointestinal digestion as closely as possible. Gluten contains very low amounts
of arginine and lysine (preferential cleavage sites for trypsin) and cleavage after aromatic amino
acid residues phenylalanine, tryptophan, and tyrosine (preferential cleavage sites for chymotrypsin)
is often impeded by a following proline residue [6]. Pepsin cleaves before or after phenylalanine,
tryptophan, tyrosine, and leucine and has the broadest repertoire of cleavage sites of the three enzymes,
especially considering the content of repetitive sequences rich in proline and glutamine that are
typical of gluten proteins [38]. Therefore, pepsin was selected to prepare pepgluten. For patient
safety [11,12], the procedure was carried out in a kitchen using only food-grade ingredients: gluten
(baking ingredient), pepsin (dietary supplement), acetic acid essence (for meals and salads) and mineral
water in a glass bottle.
The composition of gluten proteins in the commercial gluten used as a starting material was
similar to that expected from wheat flours [7]. Due to the stretched conformation of reduced gluten
proteins, their SDS-PAGE mobility is known to be restricted compared to the globular proteins used in
the marker, so that, e.g., HMW-GS (Mr: 67–88 × 103 based on known amino acid sequences) appeared
between Mr: 85–120 × 103, as has been reported before [5,30]. The contents, elution profiles of GLIA
and GLUT and their ratio (1.88) were very similar to those reported for common wheat flour [39].
In contrast, ALGL, usually present in wheat flours with contents of 150–200 mg/g, were almost absent
due to the washing steps during gluten-starch separation. Judging by the overall gluten protein
composition, the gluten sample appeared to be representative. The most important conclusion of the
analytical characterization was, however, that commercial gluten contains a much lower amount of
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gluten proteins (≈62%) than is typically assumed (100%). This implies that the true amount of gluten
applied would have to be reconsidered in many cases.
Pepgluten showed no significant differences to gluten in the contents of protein, starch, fat,
dietary fiber, and ATIs 0.19 + 0.53, 0.28, CM2 and CM16 and only slight differences in water and ash
contents due to drying and addition of mineral water. Only CM3 appeared to be susceptible to peptic
hydrolysis, because the content of the marker peptide decreased to about 23%. The immunological
quantitation of gluten in the hydrolysate by R5 competitive ELISA only resulted in about 58% recovery
compared to the starting material. This reduced recovery after enzymatic digestion is a well-known
general effect regardless of type of ELISA and antibody and has been reported for peptic-tryptic gliadin
(63% recovery) [37], peptic wheat flour gluten proteins (47% recovery) [35], peptic-tryptic gliadin
(56% recovery), and peptic-tryptic glutenin (23% recovery) [36]. It is uncertain whether ELISA, even in
a competitive format, is the most robust assay to determine partially hydrolyzed gluten [36], which
is why the calculation of gluten equivalents in the hydrolysate was performed based on results for
crude protein and RP-HPLC. Further insight into the composition of pepgluten may be gained using
untargeted proteomics approaches.
Pepgluten has many potential applications, e.g., as material for oral food challenge for CD patients
who started a gluten-free diet prior to appropriate diagnosis [10], for wheat allergy [11] and WDEIA
patients [13,40], and for NCGS and IBS patients [2,3]. It is also suitable for in vitro testing on, e.g.,
human monocytes [8] or for studies on small intestinal permeability with subsequent detection of
gluten fragments in urine samples [41]. The commonly used lactulose/mannitol (LAMA) test [42] to
assess permeability (“leaky gut”) does not appear to be well suited as an indicator for the intestinal
passage of larger molecules [10], so that an oral food challenge with pepgluten and detection of gluten
fragments in blood, urine, or feces might be more meaningful.
5. Conclusions
Commercially available wheat gluten was extensively characterized and used as a starting material
to prepare a well-defined, food-grade wheat gluten hydrolysate (pepgluten). Since no material was
removed during the procedure, the peptic hydrolysate had a composition very similar to the original
gluten and contained all components relevant for wheat hypersensitivities including ATIs. Based
on food-grade ingredients only, it is deemed to be suitable for oral food challenge tests. Pepgluten
fulfills important criteria for challenge materials, because its composition is known, it is easy to
apply and, mixed with suitable beverages, it is indistinguishable from placebo samples regarding
appearance, smell, taste and texture. Altogether, pepgluten is appropriate as standard preparation for
oral provocation tests and clinical investigations in the field of wheat hypersensitivities.
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Abstract: The gluten-free diet is effective in the majority of celiac disease (CD) patients, but it is
burdensome and may influence quality of life (QoL). The aim of the study was to analyze the social
and emotional fears and worries influencing the QoL of female CD patients following a gluten-free
(GF) diet, as well as to indicate the sociodemographic interfering factors. The study was conducted
on a group of 251 female CD patients, while emotional, social and worries subscales of the Celiac
Disease Questionnaire (CDQ) were applied, as well as purchase-related emotions and behaviors were
assessed. Respondents declaring worse economic status obtained significantly lower scores in the
emotional, social and worries subscales of the CDQ than respondents declaring better economic status,
while for other factors (CD duration, GFD adherence, BMI, place of residence and educational level)
no significant association was stated in the multi-factor analysis. Moreover, respondents declaring
worse economic status more often declared that a bad mood affected their purchase decisions than
did respondents declaring better economic status. It was stated, that the economic status of CD
patient could be one of the most important factors influencing their social and emotional fears and
worries. It may be supposed that low economic status may lead some CD patients to choose to relieve
stress by purchasing GF products instead of other products.
Keywords: celiac disease (CD); quality of life (QoL); gluten-free diet; disease duration; place of
residence; educational level; economic status; body mass index (BMI)
1. Introduction
Celiac disease (CD) is diagnosed in almost 1% of the global population, but a high percentage of
affected individuals are undiagnosed [1]. It is an autoimmune disease, defined as an inflammatory
disorder of the small intestine characterized by persistent gluten protein intolerance [2,3]. In CD
patients, gluten exposure leads to enteropathy with mucosal surface damage and, as a consequence,
nutrient malabsorption [4]. The only therapeutic approach for CD is a gluten-free diet (GFD) [5], and
strict adherence is necessary to normalize the mucous membrane of the small intestine and to improve
the impaired absorption [6].
GFD is effective in the majority of CD patients, but it is burdensome and may influence the quality
of life (QoL) of patients [6]. After diagnosis, some patients may feel overwhelmed and the disease
itself may affect their QoL [7]. Also, following GFD is commonly associated with certain difficulties in
coping with information overload and in the implementation of recommendations influencing dietary
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behaviors [5]. As a result, the two main aspects of the QoL of CD patients, both associated with specific
eating habits, concern the quality of their social and family life.
One of the most common difficulties for CD patients is the eating-out experience. CD patients
are concerned about the possibility of finding gluten-free (GF) food products or dishes in restaurants,
as well as about the possibility of cross-contamination of available GF products [5]. Moreover, they may
feel socially isolated when they must decline an invitation to a regular restaurant [8]. In the study
by Zarkadas et al. [9], almost 80% of members of the Canadian Celiac Association stated avoiding
restaurants due to this reason, while in a further study by Zarkadas et al. [10] over 70% declared
being frustrated as a result of limited choices on restaurant menus, as well as almost 90% declared
limited choices at fast food restaurants and almost 80%—a limited choice of restaurants. However,
knowledge about GFD, as well as the GF product market has recently been increasing sharply [11].
Therefore, the situation for CD patients may be changing in the context of available restaurant GF
products and dishes.
It is crucial to involve family members to prevent interference with their relationships with the CD
patient, because GFD inevitably affects eating practices at home. A patient on a GFD needs assurance
that gluten is absent from a product or dish, as well as that GF products are not contaminated [12].
Moreover, adherence to GFD is difficult for some patients; and therefore, the support of their relatives
is also important [13].
This situation may also be gender-related, as in many countries women are responsible for their
family meal preparation, and also for the family grocery shopping decisions [14]. This is observed inter
alia in Poland [15] and has been indicated in Polish studies as an important determinant for consumer
behaviors [16]. Given that for CD men family support in following the diet is natural, CD women may
suffer from a lack of such support and thus their need for support may be higher than it is for men [17].
Furthermore, some CD patients may also experience psychological, emotional and economic stress
caused by everyday implications of GFD [8]. In some studies, this percentage is higher in women than
in men [17].
Many studies analyzed the gastrointestinal symptoms of CD, CD screening and management
strategies, and GFD adherence in CD patients. However, only limited data describing the QoL
associated with the social and emotional components of GFD are available for CD patients [18].
Therefore, the aim of the study was to analyze the social and emotional fears and worries influencing
the QoL of female CD patients following a GFD, as well as to indicate the sociodemographic
interfering factors.
2. Materials and Methods
2.1. Ethics Approval Statement
The study was conducted according to the guidelines laid down in the Declaration of Helsinki.
The study was approved by the Ethics Committee of the Faculty of Human Nutrition and Consumer
Sciences of the Warsaw University of Life Sciences (No. 20/2017; 19.06.2017). All the participants
provided their informed consent to participate.
2.2. Participants
The study was conducted on a group of CD patients. Participants were recruited online by a
nationwide search via local CD and GFD societies. The combined methods of purposive sampling




- aged ≥ 18 years old;
- CD diagnosed and biopsy-confirmed by a physician;
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- declared regular meal preparation at home;
- declared regular purchase of GF products.
Exclusion criteria were:
- any data missing in the completed QoL questionnaires;
- lack of informed consent to participate.
As a result, 158 of the 409 volunteers were excluded due to not meeting the inclusion criteria
(Figure 1).
Figure 1. Participants inclusion to the study.
2.3. Study Design
Subjects were interviewed using the Computer-Assisted Web Interview (CAWI) method.
The questionnaire applied was divided into two main parts. The first part included the Celiac Disease
Questionnaire (CDQ), developed by Häuser et al. [19] on the basis of the Health-Related Quality of Life
Questionnaire (HRQOL), as a specific form for adult CD patients. The second part included questions
regarding purchase-related emotions and behaviors, as well as attitudes toward GF product attributes.
CDQ consists of four subscales–emotional subscale, social subscale, worries subscale and
gastrointestinal subscale [19]. The Polish version of CDQ was applied in the present study, while it
was, in some points, modified due to the aim and scope of the study. In the study, emotional, social
and worries subscales were included, as the aim of the study was to assess the social and emotional
fears and worries influencing the QoL, and not the gastrointestinal symptoms. Moreover, from the
worries subscale, two questions directly associated with medical conditions were excluded on the
basis of the pilot study so as not to cause discomfort and anxiety in the respondents and because
they were not associated with the aim of the study. The excluded questions were related to cancer
as a CD complication (“How many times during the last 2 weeks did you worry about or were you
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afraid of getting cancer as a result of your CD?”) and to the possibility of CD inheritance (“How
many times during the last 2 weeks were you concerned that your children could inherit or may
have inherited your CD?”). A similar approach was applied in the study by Tovoli et al. [20], as a
cancer-related question was also excluded. For test-retest reproducibility of the applied tool, a priori
assumed criteria of Pearson correlation coefficients (R > 0.7, as recommended by DeVellis [21]) were
obtained. The present study represents the first time the tool has been applied on a Polish population.
This was based on the consent of the author of the CDQ [19] to apply the tool, obtained via e-mail.
Evaluation of the quality of data obtained on the basis of the CDQ included the floor and ceiling
effects, item internal consistency and internal consistency reliability assessment (Cronbach’s alpha
coefficient > 0.7, as recommended by DeVellis [21]).
Among the questions regarding purchase-related emotions and behaviors, as well as attitude
toward GF product attributes, there were 10 close-ended questions: Two of these were associated with
purchase-related emotions and behaviors (included in the present study) and eight were associated
with attitude toward GF product attributes (not related to the aim of the present study). The questions
were formulated as follows: (1) “In the past 2 weeks, how many times did your mood affect your
purchase decisions associated with GF products?”; (2) “In the past 2 weeks, how many times did you
buy GF products to improve your mood?”. For these questions, GF products were defined as products
naturally free of gluten, pre-packed GF products and non-pre-packed GF products, such as those
served in restaurants, according to Regulation (EU) No 828/2014 [22].
The additional part of the questionnaire included questions related to disease characteristics,
including CD duration since diagnosis and GFD adherence. CD duration since diagnosis was declared
by respondents in months/years. GFD adherence was assessed on a 4-point scale, as had been applied
for GFD adherence in CD patients by inter alia Häuser et al. [2], van Hess et al. [23], or Kautto et al. [24].
In order to facilitate assessment, the four categories were translated into the following descriptions
of adherence to GFD: (1) very poor; (2) good, but occasionally eat dishes containing gluten (at
home or outside home); (3) very good, but occasionally eat dishes containing gluten (only outside
home); (4) excellent. The translation of categories into descriptions was performed on the basis of
commonly stated difficulties in adhering to GFD outside the home [13] and its influence on general
GFD adherence [25]. An additional category was added for respondents who refused or were not able
to assess their behavior.
The other questions in the additional part of the questionnaire were related to height and weight,
in order to calculate Body Mass Index (BMI) [26]. Moreover, questions about the sociodemographic
characteristics of respondents were included: gender, age, educational level, place of residence,
occupational status and individual economic status (self-assessment).
2.4. Statistical Analysis
The statistical analysis included assessment of the normality of distribution (conducted using
the Shapiro-Wilk test). Differences between groups were identified using the multi-factor analysis
of variance (ANOVA) for the main effects and interaction effects. The Cronbach’s alpha coefficient
was applied to verify the internal reliability of data. The level of p ≤ 0.05 was accepted as significant.
The analysis was conducted using Statistica software version 8.0 (StatSoft Inc., Tulsa, OK, USA).
3. Results
3.1. Characteristics of the Analyzed Group of Patients
The characteristics of the CD patients are presented in Table 1. The median age of the patients
was 33 years old (range 18–63; non-parametric distribution of data). Over half of the respondents were
highly educated and they reported that they were employed (77%) or they were students (10%) while
the study was being conducted. Furthermore, a high level of self-reported adherence to GFD was
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observed. Slightly over half of the respondents lived in big cities (cities over 100,000 inhabitants–size
corresponding to the size of a Polish provincial capital).
Table 1. Characteristics of the study sample (n = 251).
Characteristics Category Number of Respondents (%)
CD duration
Over 3 years 130 (45.0)













Town up to 100,000 residents 72 (28.7)
Cities over 100,000 residents 130 (51.8)
Educational level
Primary and secondary 61 (24.3)
Postgraduate 57 (22.7)
University degree 133 (53.0)
Economic status




Very good 25 (10.0)
1 GFD (gluten-free diet) adherence: (1) very poor; (2) good, but occasionally eat dishes containing gluten (at home
or outside home); (3) very good, but occasionally eat dishes containing gluten (only outside home); (4) excellent;
(0) difficult to say; 2 n = 249.
3.2. Descriptive Statistics for the CDQ
The emotional, social and worries subscales data in the analyzed group of CD individuals are
presented in Table 2. The floor effect was found to be negligible for all subscales, whereas the ceiling
effect for the social subscale was higher, which suggests a tendency to score near the top of the subscale.
The Cronbach’s alpha coefficient demonstrated the good internal reliability of the data (≥0.7). In the
case of item-scale correlation, the results were attributed to consistency levels from acceptable to good,
and this was considered satisfactory [27].









Mean ± SD 27.2 ± 9.6 36.1 ± 9.7 19.6 ± 6.1
95% CI (26.2–28.2) (34.9–37.3) (19.6–20.4)
Median 26.0 1 38.0 1 19.0 1
Min–max 7.0–49.0 8.0–49.0 6.0–35.0
25th–75th 22–33 29–45 14–24
Data quality Floor effect % 1 0 0






(corrected for overlap) 0.41–0.66 0.38–0.74 0.25–0.48
Pearson item-scale




Cronbach’s alpha 0.88 0.88 0.74
1 non-parametric distribution (verified using Shapiro-Wilk test—p ≤ 0.05); 2 according to Everitt & Skrondal [28].
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3.3. Social and Emotional Fears and Worries Influencing the QoL of Female CD Patients Following a GFD
The scores for emotional subscale of the CDQ categorized by CD duration, GFD adherence,
BMI and sociodemographic characteristics are presented in Table 3. Respondents declaring worse
economic status obtained significantly lower scores in the subscale than respondents declaring better
economic status, while for other factors no significant association was stated in the multi-factor analysis.
Table 3. Emotional subscale data categorized by CD duration, GFD adherence, BMI and
sociodemographic characteristics.




Over 3 years 27.1 ± 7.8 27.0 (7.0–47.0)
0.8851Below 3 years 27.2 ± 8.3 26.0 (11.0–49.0)
GFD adherence 3
1 26.0 ± 1.4 26.0 (25.0–27.0) 2
0.6714
2 27.1 ± 8.5 24.5 (18.0–48.0) 2
3 25.2 ± 6.9 23.0 (14.0–42.0)
4 27.5 ± 8.2 27.0 (7.0–49.0)
0 23.6 ± 7.0 22.0 (15.0–35.0)
BMI category
Underweight 25.7 ± 9.0 25.0 (7.0–43.0)
0.5127Normal weight 27.3 ± 8.1 27.0 (11.0–49.0) 2
Overweight 27.8 ± 7.2 27.0 (14.0–48.0)
Place of residence
Village 28.5 ± 6.7 29.0 (13.0–49.0)
0.5299Town up to 100,000 residents 26.2 ± 9.1 23.5 (7.0–48.0)
Town over 100,000 residents 27.2 ± 7.9 26.0 (11.0–46.0)
Educational level
Primary and Secondary 25.1 ± 7.6 23.0 (7.0–43.0) 2
0.0594Postgraduate 25.9 ± 8.0 25.0 (11.0–48.0)
University degree 28.6 ± 8.1 28.0 (11.0–49.0)
Economic status
Very bad and bad 21.5 ± 7.3 21.0 (11.0–42.0) 2
0.0015Average 26.5 ± 7.8 25.0 (7.0–49.0)
Good and very good 29.1 ± 7.8 28.0 (13.0–46.0)
1 multifactor analysis of variance (ANOVA); 2 non-parametric distribution (verified using Shapiro-Wilk test—p ≤
0.05); 3 GFD (gluten-free diet) adherence: (1) very poor; (2) good, but occasionally eat dishes containing gluten
(at home or outside home); (3) very good, but occasionally eat dishes containing gluten (only outside home); (4)
excellent; (0) difficult to say.
The scores for social subscale of the CDQ categorized by CD duration, GFD adherence, BMI and
sociodemographic characteristics are presented in Table 4. Respondents declaring worse economic
status obtained significantly lower scores in the subscale than respondents declaring better economic
status, while for other factors no significant association was stated in the multi-factor analysis.
The scores for worries subscale of the CDQ categorized by CD duration, GFD adherence, BMI and
sociodemographic characteristics are presented in Table 5. Respondents declaring worse economic
status obtained significantly lower scores in the subscale than respondents declaring better economic
status, while for other factors no significant association was stated in the multi-factor analysis.
The purchase-related emotions and behaviors data regarding question about mood affecting
purchase decisions categorized by CD duration, GFD adherence, BMI and sociodemographic
characteristics are presented in Table 6. Respondents declaring worse economic status more often
declared that their mood affected their purchase decisions (obtained significantly lower scores for
the Likert scale) than did respondents declaring better economic status, while for other factors no
significant association was stated in the multi-factor analysis.
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Table 4. Social subscale data categorized by CD duration, GFD adherence, BMI and
sociodemographic characteristics.




Over 3 years 35.2 ± 9.6 36.0 (8.0–49.0) 2
0.2012Below 3 years 36.9 ± 9.7 39.0 (14.0–49.0) 2
GFD adherence 3
1 36.5 ± 14.9 36.0 (26.0–47.0) 2
0.2526
2 38.1 ± 9.6 41.0 (14.0–49.0) 2
3 34.8 ± 10.8 37.0 (14.0–49.0)
4 36.2 ± 9.5 38.0 (8.0–49.0)
0 30.3 ± 10.4 27.0 (17.0–46.0)
BMI category
Underweight 35.9 ± 10.8 38.5 (8.0–49.0) 2
0.5055Normal weight 36.5 ± 9.1 38.0 (14.0–49.0) 2
Overweight 35.1 ± 11.0 39.0 (11.0–49.0) 2
Place of residence
Village 37.4 ± 9.1 40.5 (17.0–49.0) 2
0.2662Town up to 100,000 residents 34.2 ± 9.5 33.0 (15.0–49.0) 2
Town over 100,000 residents 36.7 ± 9.9 39.0 (8.0–49.0) 2
Educational level
Primary and Secondary 33.9 ± 10.6 33.0 (8.0–49.0) 2
0.3328Postgraduate 35.8 ± 9.4 39.0 (11.0–49.0) 2
University degree 37.3 ± 9.3 39.0 (14.0–49.0) 2
Economic status
Very bad and bad 28.9 ± 11.2 27.0 (8.0–48.0)
0.0023Average 35.7 ± 9.6 37.0 (11.0–49.0) 2
Good and very good 38.2 ± 8.7 40.0 (16.0–49.0) 2
1 multifactor analysis of variance (ANOVA); 2 non-parametric distribution (verified using Shapiro-Wilk
test—p ≤ 0.05); 3 GFD (gluten-free diet) adherence: (1) very poor; (2) good, but occasionally eat dishes containing
gluten (at home or outside home); (3) very good, but occasionally eat dishes containing gluten (only outside home);
(4) excellent; (0) difficult to say.
Table 5. Worries subscale data categorized by CD duration, GFD adherence, BMI and
sociodemographic characteristics.




Over 3 years 19.1 ± 6.5 18.0 (7.0–35.0) 2
0.3352Below 3 years 20.0 ± 6.7 20.0 (6.0–35.0) 2
GFD adherence 3
1 18.0 ± 2.8 18.0 (16.0–20.0) 2
0.2462
2 21.0 ± 7.1 21.0 (8.0–34.0) 2
3 19.1 ± 7.7 18.0 (8.0–34.0)
4 19.7 ± 6.3 19.0 (7.0–35.0)
0 14.3 ± 8.9 13.0 (6.0–33.0) 2
BMI category
Underweight 19.8 ± 7.0 19.0 (8.0–35.0)
0.7485Normal weight 19.6 ± 6.4 19.0 (6.0–35.0) 2
Overweight 19.5 ± 7.2 20.0 (7.0–33.0)
Place of residence
Village 20.2 ± 7.2 20.0 (8.0–35.0)
0.0816Town up to 100,000 residents 18.1 ± 6.0 18.0 (6.0–33.0)
Town over 100,000 residents 20.2 ± 6.6 20.0 (7.0–35.0)
Educational level
Primary and Secondary 18.7 ± 6.9 17.5 (8.0–35.0) 2
0.7919Postgraduate 19.7 ± 6.4 20.0 (6.0–34.0)
University degree 19.9 ± 6.6 19.0 (8.0–35.0) 2
Economic status
Very bad and bad 14.8 ± 5.1 15.0 (6.0–24.0)
0.0015Average 19.3 ± 6.7 19.0 (7.0–34.0) 2
Good and very good 20.9 ± 6.3 21.0 (8.0–35.0)
1 multifactor analysis of variance (ANOVA); 2 non-parametric distribution (verified using Shapiro-Wilk
test—p ≤ 0.05); 3 GFD (gluten-free diet) adherence: (1) very poor; (2) good, but occasionally eat dishes containing
gluten (at home or outside home); (3) very good, but occasionally eat dishes containing gluten (only outside home);
(4) excellent; (0) difficult to say.
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Table 6. Purchase-related emotions and behaviors data regarding question about mood affecting
purchase decisions (In the past 2 weeks, how many times did your mood affect your purchase
decisions associated with GF products?) categorized by CD duration, GFD adherence, BMI and
sociodemographic characteristics.




Over 3 years 4.2 ± 1.8 3.0 (1.0–7.0) 2
0.7272Below 3 years 4.2 ± 1.9 4.0 (1.0–7.0) 2
GFD adherence 3
1 5.0 ± 0.0 5.0 (5.0–5.0) 2
0.1981
2 4.8 ± 1.8 5.5 (2.0–7.0) 2
3 3.9 ± 1.9 3.0 (1.0–7.0) 2
4 4.2 ± 1.9 4.0 (1.0–7.0) 2
0 3.1 ± 1.8 3.0 (2.0–7.0) 2
BMI category
Underweight 4.4 ± 2.0 4.0 (1.0–7.0) 2
0.3959Normal weight 4.2 ± 1.9 4.0 (1.0–7.0) 2
Overweight 4.0 ± 1.9 3.0 (1.0–7.0) 2
Place of residence
Village 4.4 ± 1.9 4.0 (1.0–7.0) 2
0.2567Town up to 100,000 residents 3.9 ± 1.8 3.0 (1.0–7.0) 2
Town over 100,000 residents 4.3 ± 1.9 4.0 (1.0–7.0) 2
Educational level
Primary and Secondary 4.4 ± 1.8 4.0 (1.0–7.0) 2
0.4635Postgraduate 3.9 ± 1.7 3.0 (1.0–7.0) 2
University degree 4.2 ± 2.0 4.0 (1.0–7.0) 2
Economic status
Very bad and bad 3.2 ± 1.7 3.0 (1.0–6.0) 2
0.0029Average 4.0 ± 1.8 3.0 (1.0–7.0) 2
Good and very good 4.6 ± 1.9 5.0 (1.0–7.0) 2
1 multifactor analysis of variance (ANOVA); 2 non-parametric distribution (verified using Shapiro-Wilk
test—p ≤ 0.05); 3 GFD (gluten-free diet) adherence: (1) very poor; (2) good, but occasionally eat dishes containing
gluten (at home or outside home); (3) very good, but occasionally eat dishes containing gluten (only outside home);
(4) excellent; (0) difficult to say; 4 seven point Likert scale, while (1) is attributed to “all of the time” and (7)—to
“none of the time”.
The purchase-related emotions and behaviors data regarding question about purchasing GF
products because of mood categorized by CD duration, GFD adherence, BMI and sociodemographic
characteristics are presented in Table 7. For the analyzed factors, no significant association was stated
in the multi-factor analysis.
Table 7. Purchase-related emotions and behaviors data regarding question about purchasing GF
products because of mood (In the past 2 weeks, how many times did you buy GF products to improve your
mood?) categorized by CD duration, GFD adherence, BMI and sociodemographic characteristics.




Over 3 years 3.9 ± 1.5 4.0 (1.0–7.0) 2
0.7936Below 3 years 3.9 ± 1.7 3.0 (1.0–7.0) 2
GFD adherence 3
1 5.0 ± 0.0 5.0 (5.0–5.0) 2
0.2695
2 3.9 ± 1.6 3.5 (1.0–7.0) 2
3 3.3 ± 1.4 3.0 (1.0–7.0) 2
4 4.1 ± 1.7 4.0 (1.0–7.0) 2
0 3.1 ± 1.4 3.0 (2.0–6.0) 2
BMI category
Underweight 4.1 ± 1.8 4.0 (1.0–7.0) 2
0.5132Normal weight 4.0 ± 1.6 3.0 (1.0–7.0) 2
Overweight 3.7 ± 1.6 3.0 (1.0–7.0) 2
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Table 7. Cont.




Village 4.4 ± 1.7 4.0 (1.0–7.0) 2
0.0847Town up to 100,000 residents 4.0 ± 1.6 3.0 (1.0–7.0) 2
Town over 100,000 residents 3.8 ± 1.6 3.0 (1.0–7.0) 2
Educational level
Primary and Secondary 4.1 ± 1.6 3.5 (1.0–7.0) 2
0.3801Postgraduate 3.6 ± 1.7 3.0 (1.0–7.0) 2
University degree 4.0 ± 1.6 4.0 (1.0–7.0) 2
Economic status
Very bad and bad 3.2 ± 1.2 3.0 (1.0–7.0) 2
0.0605Average 3.8 ± 1.6 3.0 (1.0–7.0) 2
Good and very good 4.2 ± 1.7 4.0 (1.0–7.0) 2
1 multifactor analysis of variance (ANOVA); 2 non-parametric distribution (verified using Shapiro-Wilk
test—p ≤ 0.05); 3 GFD (gluten-free diet) adherence: (1) very poor; (2) good, but occasionally eat dishes containing
gluten (at home or outside home); (3) very good, but occasionally eat dishes containing gluten (only outside home);
(4) excellent; (0) difficult to say; 4 seven point Likert scale, while (1) is attributed to “all of the time” and (7)—to
“none of the time”.
4. Discussion
4.1. The Influence of CD Duration and Gender on the QoL of Patients
CD patients experience, due to their diagnosis and applied therapy, a number of problems related
to their physical activity, lifestyle and eating behaviors that may affect their general QoL. However,
in the review by Kurppa et al. [29], it was stated that additional factors that may affect health-related
QoL of CD patients are: age at diagnosis, gender, comorbidities, dietary compliance, availability of GF
products, and general knowledge about CD.
Nevertheless, the influence of some factors, e.g., age at diagnosis, on the QoL of CD patients
may be contradictory, in various studies. Häuser et al. [2] and Zarkadas et al. [9] reported that
diagnosis of CD at a younger age may lead to better health-related QoL, whereas Ciacci et al. [30] and
Wagner et al. [31] indicated the reverse relationship.
In our own study, in order to verify the influence of CD duration, a similar assessment was
conducted. Those patients with a CD duration below and over 3 years were compared, as 3 years of
following a GFD is indicated as the time needed for CD adults to achieve mucosal recovery [32] and,
moreover, the first 3 years of disease duration were defined in a cohort study of CD patients as a period
characterized by increased mortality [33]. However, neither for emotional, social or worries subscales
nor for purchase-related emotions and behaviors was the influence of disease duration reported.
Therefore, in the studied group, other factors, including sociodemographic ones, had to be
considered. One of the important sociodemographic factors is gender, for which, in general, CD women
experience poorer general well-being than CD men [34]. A similar situation has also been observed for
other diseases or health conditions, such as hypertensive patients [35], patients undergoing coronary
angiography [36], or patients with diagnosed bipolar disorder [37]. In all these studies, the QoL was
measured using HRQOL questionnaires and was lower for female than for male respondents.
4.2. The Influence of GFD Adherence and BMI on the QoL of Patients
Considering the problem of the low QoL of female patients, the aim of the study was to assess
the social and emotional fears and worries influencing the QoL of CD patients, in particular for the
sub-group of female respondents, being those who experience especially decreased QoL, in comparison
with male respondents. Moreover, as following a GFD is not only the recommended approach [38]
but also influences the general QoL of CD individuals, a homogenous group of CD female patients
following the GFD was studied.
In general, the majority of CD patients have a good QoL while they follow the GFD [29],
but untreated patients have a significantly poorer QoL [39]. However, while general diet following
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influences the QoL of CD patients, dietary adherence level does not have such influence, as comparisons
of non-adherent and strictly adherent patients have not demonstrated any significant differences [40];
neither were such differences confirmed in our analyzed group. This may be explained by the fact that
even adherent CD patients may have some gastrointestinal symptoms, as may non-adherent ones [41];
so in general, they may be used for such symptoms.
In general, there have so far been no studies analyzing the influence of BMI on the QoL of CD
patients. However, for other diseases, such an influence is sometimes stated, and in the context of CD,
results observed for gastrointestinal diseases may be used for comparative purposes. For inflammatory
bowel diseases, a longitudinal natural history data study showed that obesity was associated with
decreasing QoL [42]. Similarly, in a study of an elderly patients group diagnosed with inflammatory
bowel diseases, both being underweight and obese were associated with unfavorable health-outcomes,
since being underweight was associated with a lower QoL and obesity was associated with a higher
risk of depression [43]. The negative impact of both low and high body mass may be confirmed by
results from a cross-sectional analysis of the Swiss Inflammatory Bowel Diseases cohort study, as QoL
was globally affected in anorexic patients, while in obese ones decreases in the systemic QoL and social
QoL scores were stated [44]. These observations for inflammatory bowel diseases are in agreement
with the results observed for the general population, as the meta-analysis of Ul-Haq et al. [45] provided
evidence that QoL is decreased in obese individuals.
However, not all studies conducted for gastrointestinal diseases indicate such associations.
For women with irritable bowel syndrome, the reverse relationship was observed and normal body
mass was associated with lower QoL when compared with overweight respondents [46]. Similarly,
our study did not indicate any influence of BMI on the emotional, social and worries subscales, or on
purchase-related emotions and behaviors in CD patients.
4.3. The Influence of Sociodemographic Characteristics on the QoL of Patients
The number of patients with diagnosed CD is constantly increasing [47] and with this the necessity
for permanent changes to eating behaviors which may impacts upon lifestyles. For our group of
female CD patients following the GFD, the main sociodemographic factor influencing their social and
emotional fears and worries was economic status. Neither for place of residence, nor for educational
level the influence was stated, while economic status influenced not only the emotional, social and
worries subscales of the CDQ, but also respondents declaring worse economic status more often stated
that a mood affected their purchase decisions.
In the literature, there is almost no information about the influence of socioeconomic status on
the factors associated with the QoL of CD patients. This aspect is especially important, given that the
prices of GF products are higher than the prices of regular ones. However, a number of people follow
a strict GF diet, even if they have no specific medical conditions that require this, so the market for GF
products is currently increasing [48]. Such a situation, in which the market is increasing (generating
higher supply and higher accessibility) but where the prices are still high is very specific and may be
burdensome for low-income CD individuals. This is confirmed by other authors, who have reported
that GFD may be expensive and challenging for CD patients [49].
The results of our study suggest that not only do low economic status patients not reduce seeking
stress-relief in shopping, a strategy commonly observed in the general population [50], but rather
they may purchase GF products even more often to improve their mood than do other respondents.
This may result from the fact that a properly followed GFD is the primary therapeutic approach [38],
so CD patients consciously choose to spend extra money on GF products, instead of spending on
other goods. Thus, they consciously purchase the GF products that they need, but at the same time,
they sub-consciously satisfy their other needs.
At the same time, lower scores for the emotional, social and worries subscales indicate the lower
QoL of CD patients of lower economic status than for those of higher economic status—a situation that
is not surprising. However, lower QoL in low-income CD patients may induce the above stress-relief
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response, while their economic status means that they mainly go grocery shopping, especially for
GF products.
The lack of influence of CD duration, GFD adherence and BMI, as well as place of residence and
educational level may be associated with the prominent influence of other interfering factors in the
case of CD, such as the influence of economic status. This means that economic status in CD patients
must be treated as a dominant factor, creating observable associations and influencing social and
emotional fears and worries.
4.4. Limitations of the Study and Future Perspectives for the Research
Although the observed associations are interesting, the potential limitations of our study should
be noted. Other factors that were not analyzed in the present study may also influence the QoL of CD
patients. Among such factors, age and age at diagnosis may be highlighted, as in pediatric patients
it has been observed that age is associated with GFD adherence [51,52], as is age combined with
educational level at diagnosis [53]. Another factor that may influence the QoL of CD patients may be
dietary counseling, as GFD adherence may result from the patient’s knowledge and understanding of
the rules of GFD [54].
A self-report method carries with it several limitations associated with three areas—respondents,
instrument of data collection and contextual factors. Moreover, our relatively small size sample does
not allow generalization of our findings.
It would be interesting to conduct a similar study with a group of male CD patients, in order
to compare results for men and women, as it has been claimed that there are general gender-related
differences in the clinical presentation of CD [55]. Also, conducting a similar study with a group
of children would be interesting, as it is especially challenging for children, in particular teenagers,
to adhere to GFD [56].
5. Conclusions
1. The economic status of a CD patient could be one of the most important factors influencing their
social and emotional fears and worries.
2. Although the low economic status of CD patients may lead to a lower QoL in terms of social and
emotional fears and worries, it does not reduce the purchasing of GF products to improve mood.
3. It may be supposed that low economic status may lead some CD patients to choose to relieve
stress by purchasing GF products instead of other products.
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16. Olewnik-Mikołajewska, A.; Guzek, D.; Głąbska, D.; Gutkowska, K. Consumer behaviors toward novel
functional and convenient meat products in Poland. J. Sens. Stud. 2016, 31, 193–205. [CrossRef]
17. Rodríguez Almagro, J.; Rodríguez Almagro, D.; Solano Ruiz, C.; Siles González, J.; Hernández Martínez, A.
The experience of living with a gluten-free diet: An integrative review. Gastroenterol. Nurs. 2018, 41, 189–200.
[CrossRef] [PubMed]
18. Pouchot, J.; Despujol, C.; Malamut, G.; Ecosse, E.; Coste, J.; Cellier, C. Validation of a French Version of the
Quality of Life “Celiac Disease Questionnaire”. PLoS ONE 2014, 9, e96346. [CrossRef] [PubMed]
19. Häuser, W.; Gold, J.; Stallmach, A.; Caspary, W.F.; Stein, J. Development and validation of the Celiac Disease
Questionnaire (CDQ), a disease-specific health-related quality of life measure for adult patients with celiac
disease. J. Clin. Gastroenterol. 2007, 41, 157–166. [CrossRef] [PubMed]
20. Tovoli, F.; Granito, A.; Negrini, G.; Guidetti, E.; Faggiano, C.; Bolondi, L. Long term effects of gluten-free diet
in non-celiac wheat sensitivity. Clin. Nutr. 2017. [CrossRef] [PubMed]
21. DeVellis, R.F. Scale Development; Sage Publications: Newbury Park, NJ, USA, 1991.
22. Regulation (EU) No 828/2014 of 30 July 2014 on the Requirements for the Provision of Information to
Consumers on the Absence or Reduced Presence of Gluten in Food. Official Journal of the European
Union L 228/5. Available online: https://eur-lex.europa.eu/eli/reg_impl/2014/828/oj (accessed on
29 September 2018).
23. Van Hees, N.J.; Van der Does, W.; Giltay, E.J. Coeliac disease, diet adherence and depressive symptoms.
J. Psychosom. Res. 2013, 74, 155–160. [CrossRef] [PubMed]
24. Kautto, E.; Rydén, P.J.; Ivarsson, A.; Olsson, C.; Norström, F.; Högberg, L.; Carlsson, A.; Hagfors, L.;
Hörnell, A. What happens to food choices when a gluten-free diet is required? A prospective longitudinal
population-based study among Swedish adolescent with coeliac disease and their peers. J. Nutr. Sci. 2014,
3, e2. [CrossRef] [PubMed]
89
Nutrients 2018, 10, 1414
25. Leffler, D.A.; Dennis, M.; Edwards George, J.B.; Jamma, S.; Magge, S.; Cook, E.F.; Schuppan, D.; Kelly, C.P.
A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin. Gastroenterol.
Hepatol. 2009, 7, 530.e2–536.e2. [CrossRef] [PubMed]
26. WHO. Body Mass Index—BMI. Available online: http://www.euro.who.int/en/health-topics/disease-
prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi (accessed on 10 August 2018).
27. Kline, P.A. (Ed.) Computing test-reliability. In Handbook of Test Construction: Introduction to Psychometric
Design; Methuen & Co.: New York, NY, USA, 1986; pp. 118–132.
28. Everitt, B.S. The Cambridge Dictionary of Statistics, 2nd ed.; Cambridge University Press: Cambridge, UK, 2002.
29. Kurppa, K.; Collin, P.; Mäki, M.; Kaukinen, K. Celiac disease and health-related quality of life. Expert Rev.
Gastroenterol. Hepatol. 2011, 5, 83–90. [CrossRef] [PubMed]
30. Ciacci, C.; D’Agate, C.; De Rosa, A.; Franzese, C.; Errichiello, S.; Gasperi, V.; Pardi, A.; Quagliata, D.;
Visentini, S.; Greco, L. Self-rated quality of life in celiac disease. Dig. Dis. Sci. 2003, 48, 2216–2220. [CrossRef]
[PubMed]
31. Wagner, G.; Berger, G.; Sinnreich, U.; Grylli, V.; Schober, E.; Huber, W.D.; Karwautz, A. Quality of life in
adolescents with treated coeliac disease: Influence of compliance and age at diagnosis. J. Pediatr. Gastroenterol.
Nutr. 2008, 47, 555–561. [CrossRef] [PubMed]
32. Rubio-Tapia, A.; Rahim, M.W.; See, J.A.; Lahr, B.D.; Wu, T.T.; Murray, J.A. Mucosal recovery and mortality in
adults with celiac disease after treatment with a gluten-free diet. Am. J. Gastroenterol. 2010, 105, 1412–1420.
[CrossRef] [PubMed]
33. Corrao, G.; Corazza, G.R.; Bagnardi, V.; Brusco, G.; Ciacci, C.; Cottone, M.; Sategna Guidetti, C.; Usai, P.;
Cesari, P.; Pelli, M.A.; et al. Mortality in patients with coeliac disease and their relatives: A cohort study.
Lancet 2001, 358, 356–361. [CrossRef]
34. Casellas, F.; Rodrigo, L.; Vivancos, J.L.; Riestra, S.; Pantiga, C.; Baudet, J.S.; Junquera, F.; Puig Diví, V.;
Abadia, C.; Papo, M.; et al. Factors that impact health-related quality of life in adults with celiac disease:
A multicenter study. World J. Gastroenterol. 2008, 14, 46–52. [CrossRef] [PubMed]
35. Carvalho, M.A.; Silva, I.B.; Ramos, S.B.; Coelho, L.F.; Gonçalves, I.D.; Figueiredo Neto, J.A. Quality of life of
hypertensive patients and comparison of two instruments of HRQOL measure. Arq. Bras. Cardiol. 2012, 98,
442–451. [CrossRef] [PubMed]
36. Gijsberts, C.M.; Agostoni, P.; Hoefer, I.E.; Asselbergs, F.W.; Pasterkamp, G.; Nathoe, H.; Appelman, Y.E.;
de Kleijn, D.P.; den Ruijter, H.M. Gender differences in health-related quality of life in patients undergoing
coronary angiography. Open Heart 2015, 2, 000231. [CrossRef] [PubMed]
37. De la Cruz, M.S.D.; Lai, Z.; Goodrich, D.E.; Kilbourne, A.M. Gender Differences in Health-Related Quality of
Life in Patients with Bipolar Disorder. Arch. Womens Ment. Health 2013, 16, 317–323. [CrossRef] [PubMed]
38. Theethira, T.G.; Dennis, M. Celiac disease and the gluten-free diet: Consequences and recommendations for
improvement. Dig. Dis. 2015, 33, 175–182. [CrossRef] [PubMed]
39. Viljamaa, M.; Collin, P.; Huhtala, H.; Sievänen, H.; Mäki, M.; Kaukinen, K. Is coeliac disease screening in risk
groups justified? A fourteen-year follow-up with special focus on compliance and quality of life. Aliment.
Pharmacol. Ther. 2005, 22, 317–324. [CrossRef] [PubMed]
40. Hopman, E.G.; Koopman, H.M.; Wit, J.M.; Mearin, M.L. Dietary compliance and health-related quality of
life in patients with coeliac disease. Eur. J. Gastroenterol. Hepatol. 2009, 21, 1056–1061. [CrossRef] [PubMed]
41. Hallert, C.; Grännö, C.; Grant, C.; Hultén, S.; Midhagen, G.; Ström, M.; Svensson, H.; Valdimarsson, T.;
Wickström, T. Quality of life of adult coeliac patients treated for 10 years. Scand. J. Gastroenterol. 1998, 33,
933–938. [CrossRef] [PubMed]
42. Seminerio, J.L.; Koutroubakis, I.E.; Ramos-Rivers, C.; Hashash, J.G.; Dudekula, A.; Regueiro, M.; Baidoo, L.;
Barrie, A.; Swoger, J.; Schwartz, M.; et al. Impact of Obesity on the Management and Clinical Course of
Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2015, 21, 2857–2863. [CrossRef] [PubMed]
43. Slagboom, J.; Asscher, V.; Meijer, L.; Waars, S.; Van der Meulen-de Jong, A.; Maljaars, J. P299 Relation of body
mass index and health outcomes in elderly patients with inflammatory bowel disease (IBD). J. Crohn’s Colitis
2018, 12, S251–S252. [CrossRef]
44. Greuter, T.; Porchet, F.; Fournier, N.; Biedermann, L.; Schreiner, P.; Scharl, M.; Schoepfer, A.; Safroneeva, E.;
Straumann, A.; Rogler, G.; et al. P192 Extreme body mass indices are frequent in inflammatory bowel disease
patients and are associated with higher disease activity in Crohn’s disease, but not in ulcerative colitis:
A cross-sectional analysis of the Swiss IBD cohort study. J. Crohn’s Colitis 2018, 12, S195. [CrossRef]
90
Nutrients 2018, 10, 1414
45. Ul-Haq, Z.; Mackay, D.F.; Fenwick, E.; Pell, J.P. Meta-analysis of the association between body mass index
and health-related quality of life among adults, assessed by the SF-36. Obesity 2013, 21, 322–327. [CrossRef]
[PubMed]
46. Sherwin, L.B.; Ozoji, O.M.; Boulineaux, C.M.; Joseph, P.V.; Fourie, N.H.; Abey, S.K.; Zhang, X.;
Henderson, W.A. Gender and Weight Influence Quality of Life in Irritable Bowel Syndrome. J. Clin. Med.
2017, 6, 103. [CrossRef] [PubMed]
47. Rajpoot, P.; Makharia, G.K. Problems and challenges to adaptation of gluten free diet by Indian patients with
celiac disease. Nutrients 2013, 5, 4869–4879. [CrossRef] [PubMed]
48. Singh, J.; Whelan, K. Limited availability and higher cost of gluten-free foods. J. Hum. Nutr. Diet. 2011, 24,
479–486. [CrossRef] [PubMed]
49. Pourhoseingholi, M.A.; Rostami-Nejad, M.; Barzegar, F.; Rostami, K.; Volta, U.; Sadeghi, A.; Honarkar, Z.;
Salehi, N.; Asadzadeh-Aghdaei, H.; Baghestani, A.R.; et al. Economic burden made celiac disease an
expensive and challenging condition for Iranian patients. Gastroenterol. Hepatol. Bed Bench 2017, 10, 258–262.
[PubMed]
50. Davenport, K.; Houston, J.E.; Griffiths, M.D. Excessive eating and compulsive buying behaviours in women:
An empirical pilot study examining reward sensitivity, anxiety, impulsivity, self-esteem and social desirability.
Int. J. Ment. Health Addict. 2012, 10, 474–489. [CrossRef]
51. Comino, I.; Fernández-Bañares, F.; Esteve, M.; Ortigosa, L.; Castillejo, G.; Fambuena, B.; Ribes-Koninckx, C.;
Sierra, C.; Rodríguez-Herrera, A.; Salazar, J.C.; et al. Fecal Gluten Peptides Reveal Limitations of Serological
Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients. Am. J. Gastroenterol.
2016, 111, 1456–1465. [CrossRef] [PubMed]
52. Moreno, M.D.L.; Rodríguez-Herrera, A.; Sousa, C.; Comino, I. Biomarkers to Monitor Gluten-Free Diet
Compliance in Celiac Patients. Nutrients 2017, 9, 46. [CrossRef] [PubMed]
53. Ciacci, C.; Cirillo, M.; Cavallaro, R.; Mazzacca, G. Long-term follow-up of celiac adults on gluten-free diet:
Prevalence and correlates of intestinal damage. Digestion 2002, 66, 178–185. [CrossRef] [PubMed]
54. Muhammad, H.; Reeves, S.; Ishaq, S.; Mayberry, J.; Jeanes, Y.M. Adherence to a Gluten Free Diet Is Associated
with Receiving Gluten Free Foods on Prescription and Understanding Food Labelling. Nutrients 2017, 9, 705.
[CrossRef] [PubMed]
55. Bardella, M.T.; Fredella, C.; Saladino, V.; Trovato, C.; Cesana, B.M.; Quatrini, M.; Prampolini, L. Gluten
intolerance: Gender- and age-related differences in symptoms. Scand. J. Gastroenterol. 2005, 40, 15–19.
[CrossRef] [PubMed]
56. Meyer, S.; Rosenblum, S. Activities, Participation and Quality of Life Concepts in Children and Adolescents
with Celiac Disease: A Scoping Review. Nutrients 2017, 9, 929. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




The Effect of Gluten-Free Diet on Health and the Gut
Microbiota Cannot Be Extrapolated from One
Population to Others
Jose F. Garcia-Mazcorro 1, Giuliana Noratto 2 and Jose M. Remes-Troche 1,*
1 Instituto de Investigaciones Medico Biológicas, Universidad Veracruzana, Calle Agustín de Iturbide,
Salvador Díaz Mirón, Veracruz 91700, Mexico; josegarcia_mex@hotmail.com
2 Department of Nutrition and Food Science, Texas A&M University, 2253 TAMU, College Station, TX 77843,
USA; gnoratto@tamu.edu
* Correspondence: jose.remes.troche@gmail.com; Tel.: +1-229-931-8011
Received: 27 August 2018; Accepted: 1 October 2018; Published: 4 October 2018
Abstract: Gluten-related disorders (GRD) affect millions of people worldwide and have been related
to the composition and metabolism of the gut microbiota. These disorders present differently in
each patient and the only treatment available is a strict life-long gluten-free diet (GFD). Several
studies have investigated the effect of a GFD on the gut microbiota of patients afflicted with GRD
as well as healthy people. The purpose of this review is to persuade the biomedical community
to think that, while useful, the results from the effect of GFD on health and the gut microbiota
cannot be extrapolated from one population to others. This argument is primarily based on the
highly individualized pattern of gut microbial composition and metabolic activity in each person,
the variability of the gut microbiota over time and the plethora of factors associated with this
variation. In addition, there is wide variation in the composition, economic viability, and possible
deleterious effects to health among different GFD, both within and among countries. Overall,
this paper encourages the conception of more collaborative efforts to study local populations in an
effort to reach biologically and medically useful conclusions that truly contribute to improve health
in patients afflicted with GRD.
Keywords: celiac disease; gluten-free diet; gut microbiota
1. Introduction
Human beings are superorganisms or holobionts (i.e., hosts with associated life forms) that have
evolved over millions of years collectively as a unit, yet independently [1]. From all microbial niches
in the body, the digestive tract has received the mostattention in part due to its role in health and
immunity [2]. Many different host-associated (e.g., age, sex, health status) and environmental factors
are known to affect the composition of the gut microbiota but growing evidence suggests that diet
is one of the main contributors [3–5]. Diet is particularly relevant in newborns and infants, where
nutrition is not only vital for growth and development but can also have life-long consequences,
a phenomenon closely linked to the gut microbiota [6,7].
The gut microbiota has been studied in a context of health and disease for over a century now.
Generally, the gut microbiota is in balance with its host and shows certain resilience to change
from one state to another (e.g., from healthy to diseased), although this phenomenon is still not
well understood [8,9]. For example, while different diseases have been related to different states of
“dysbiosis” of the gut microbiota (for example, allergies, inflammatory bowel diseases, diabetes, obesity
and gluten-related disorders, see [10]), a cause–and–effect relationship can hardly be established in
part because of the well-known high inter-individual variability, a phenomenon occurring even among
Nutrients 2018, 10, 1421; doi:10.3390/nu10101421 www.mdpi.com/journal/nutrients92
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closely related individuals [11]. Nonetheless, great progress has been achieved in understanding causal
relationship between the host and its microbes [12].
The purpose of this review is to warn against extrapolation of results in the context of an effect
of gluten-free diet (GFD) on health and the gut microbiota. Indeed, any metabolic response needs
to be investigated specifically within population groups to increase our understanding of whether
dietary treatments are effective in that group. Although the issue of extrapolation is true in all research
in Nutritional Sciences, it is often overlooked and not emphasized enough among clinicians and
clinical scientists.
2. Gluten-Related Disorders and Celiac Disease
Gluten-related disorders (GRD) comprise a variety of different disorders such as celiac disease
(CD), non-celiac gluten sensitivity (NCGS), gluten allergy and others, where the body reacts negatively
upon exposure to dietary gliadins, a class of proteins that are a component of gluten in wheat and
other cereals. Clinically, GRD often range from mild presentations (such as asymptomatic CD) to very
serious and life-threatening conditions in some people such as refractory CD and lymphoma [13].
From all GRD, CD has been the most studied and is currently considered to be the most common
chronic enteropathy worldwide [14]. In people with CD, a significantly enhanced autoantibody
response to the transglutaminase 2 (TG2) enzyme, also known as tissue transglutaminase (tTG), is a
hallmark of the pathogenic process that primarily affects the architecture of the enterocyte lining of
the small intestine [15] but can also affect other organs such as the liver, kidney, lymph nodes and
muscles [16,17]. Interestingly, other autoantibodies may also be involved, especially in extraintestinal
manifestations, such as anti-ganglioside, anti-synapsin I and anti-actin antibodies [18]. Patients with
CD present either typical or atypical symptoms [19] and CD is believed to perpetuate other maladies
and often presents simultaneously with other autoimmune diseases [20–23]. Despite the great progress
in CD research, new key emerging findings suggest previously unknown features of CD pathogenesis,
for example at the transcriptome level of immune cells [24].
The global prevalence of CD based on serologic test results is 1.4% and based on biopsy results
is 0.7% [25]. The prevalence of CD varies with sex, age, and location and, in some regions and
populations, it can be as high as 5.6% [26]. While different treatments are under study (e.g., using
prolyl endopeptidases and vaccines [17,27]), the only effective treatment available to date for patients
with CD and other GRD is a strict life-long gluten-free diet (GFD). Interestingly, GFD is being adopted
worldwide by a growing number of people with and without GRD for weight control and the rather
misconceived perception that this diet is healthier [28]. However, whether a GFD is healthier remains
highly controversial (see Section 5.2).
3. GRD and the Gut Microbiota
The fact that genetic susceptibility is not determinant for the presentation of CD (30–40% of the
population have the required genotype but the prevalence of CD is only about 1%) has prompted
research to discover what other factors can predict the clinical manifestation of the disease [21].
For example, there is enough evidence to suggest that the gut microbiota (especially Bacteria) plays a
role in the onset and clinical manifestations of CD [29–38] and probably other GRD. Although the exact
mechanisms involved in the relationship of the gut microbiota and gut diseases are currently unknown
(a relationship that is likely to be highly individualized as well), fellow colleagues have suggested an
interesting proposal involving first a microbial dysbiosis (e.g., after antibiotic therapy), independent
of gluten sensitivity, which then drives an activation of the innate immune system resulting in the
secretion of pro-inflammatory molecules, epithelial barrier disruption, and an increased transfer of
gluten peptides, a cascade that ultimately may lead to CD development [15]. Interestingly, CD may
also be related with non-bacterial members of the gut microbiota such as yeasts [39,40], although the
mechanisms may involve quite different mechanisms such as inter-kingdom interactions [41]. As in
the case of other intestinal maladies, the main objective of these studies is to better understand the
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host–microbiota relationship during the disease (often compared to healthy counterparts), thus helping
find new routes for treatment. For instance, the growing body of literature about host–microbiota in CD
patients has prompted the use of some probiotics (e.g., Lactobacillus spp.) to treat GRD, particularly CD,
with promising results (e.g., suppression of pro-inflammatory cytokines, reduction of mucosal damage,
and enhanced production of SCFAs [31,42–45]). Other studies have shown a potential of probiotics to
modulate the indigenous gut microbiota in patients with CD with inconsistent results [46,47].
4. Effect of GFD on the Gut Microbiome
The effect of GFD on the gut microbiome and related parameters has been studied in patients
afflicted with GRD (particularly with CD) and in healthy subjects (Table 1). Please note that most of
these studies have important limitations including small sample sizes and the use of low-throughput
techniques (e.g., culturetechniques and non-sequencing based molecular techniques) that allow the
analysis of a few bacterial groups that are not representative of the whole microbiota (Table 1,
please note that great progress has been achieved in the field of gut microbiota culturomics [48]).
The small sample sizes are particularly worrying because of the clinical variations of CD presentation.
These limitations by themselves should be considered as warning signs by the biomedical community
every time someone attempts to extrapolate results among different populations, especially in cases
where there are patients involved because individuals are highly unique in terms of their gut
microbiome (Figure 1).
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Figure 1. Results of the effect of gluten-free diet (GFD) on health and the gut microbiota cannot be
extrapolated from one population to others. Genetic predisposition to CD is present in about 30–40%
of the whole population (non-blue silhouettes) but affects clinically only about 1% of the population
(red silhouettes). Each individual in either population harbors a highly specific microbiome in the gut
(represented here by hypothetical data in pie charts where each color represents a different microbial
group) that shows a unique pattern of change after consuming a GFD. The individualized microbiome
and its response against dietary or therapeutic challenges is due to multiple sources of variation at the
population (e.g., genetics andliving habits), individual (e.g., age andsex) and experimental (e.g., type
and time on GFD) level.
Before discussing the issues with extrapolation and the main arguments against extrapolation
of results, it is important to briefly discuss about the nature of microbes and their identification.
First, while we tend to think that members of the same “species” should share a great deal of similar
characteristics, this is far from being true for most (if not all) microbial species [62]. Second, when
dealing with reference gene sequences (e.g., 16S rRNA gene sequences), it has been a long tradition
to group these sequences into something we call Operational Taxonomic Units (OTUs), which are
simply groups of sequences based on sequence similarity, based on the belief that a given OTU would
comprise similar organisms. However, OTUs show extensive mixed phylogenetic and ecological
signals [63] and in fact current trends suggest that OTUs should be replaced by exact sequence
variants [64]. Third, there is extensive horizontal gene transfer (i.e., movement of genetic material
between different organisms, for example genes associated with antibiotic resistance) among the
many members of the gut microbiota that happens at mostly unknown rates [65], a phenomenon
shaped principally by ecology rather than geography or phylogeny [66] that likely generates “new”
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microbes de novo. Fourth, there are different techniques to identify microorganisms (e.g., culture
and culture-independent), each with its own advantages and disadvantages to truly depict the real
microbial ecosystem inside the gut [67]. Finally, there are technical issues that are difficult to overcome,
for example the fact that bacteria are not evenly distributed in stools [68], that mucus and lumen
contain widely distinct microbial ecosystems [69], and that the microbiota is different throughout the
intestinal tract and different fromwhat is found in feces [70].
5. The Issue of Extrapolation
The main objective of this paper is to critically argue against extrapolation in the context of an
effect of GFD on health and the gut microbiota (Figure 1). Extrapolation of results from one population
to another is incorrect and risky for various reasons, both strictly statistical and scientific. As it will
become clear throughout this manuscript, this concern is particularly important in the context of
gut microbial ecology, health and disease. On a recent review of the relationship between the gut
microbiota and dietary nutrients, Shortt et al. [71] acknowledgedthe fact that animal-derived data
can hardly be extrapolated to humans, and there is a well-known bias to choose male rodents in
studies from different fields of science [72], including microbial ecology [3]. However, the problem
with extrapolating results among human populations is barely mentioned in the literature, even in
papers from our own research group [73]. We do not generally mention this because we consider it to
be common knowledge and implicit in the results of our publications. However, we strongly believe
that this concern should be discussed, especially within the context of health benefits derived from a
change in the gut microbial ecosystem.
5.1. Individuality and Over Time Variability of the Gut Microbiota
Each human being harbors a unique blend of trillions of microorganisms and viruses in the gut and
other organs, and growing evidence suggest that colonization starts before birth [74]. The microbiota
is not only highly different among individual subjects but it also shows a highly individualized
response to environmental challenges such as antibiotic perturbation [75]. One study showed that
variation in composition of the microbiota across different body sites was consistently larger than
technical variability (e.g., PCR primers, 16S rRNA gene region, sequencing platform) across studies [76].
Overall, this means that the many different analyses showing inter-individual variation are biologically
meaningful and not the result of technical artifacts.
The question of why the microbiota is so unique in each individual deserves thorough examination.
The first studies on the gut microbiota soon revealed that each subject harbors a unique blend of
microbes [77]. Microbial carriage varies between subjects down to the species and strain level [78,79].
Virtually all host-associated and environmental factors can have an effect on an individual’s gut
microbiota, either individually or collectively. Sex is also an important but often neglected topic in
gut microbial ecology [80]. This is important because some GRD are known to be more prevalent
in women [81]. On top of the well-known high inter-individual differences, there is considerable
horizontal gene transfer happening inside the gut [64], which have the potential of increasing the
uniqueness of each individual microbiome, and some microbes show bistable abundance distributions
that are affected differently than the rest [82].
Another reason each individual is unique is because they live in vastly different geographic and
sociocultural regions having unique foods and dietary habits. For example, Mexican people possess
one of the most genome-wide variation, a fact that can affect biomedical traits as well as disease
presentation, progression and response to treatment [83]. Interestingly, one seminal study about
inflammatory bowel disease (IBD) and the gut microbiota showed that the patient’s geographical
origin was strongly associated with disease presentation and involvement of specific microbes [84].
Different studies have evaluated the gut microbiota over short periods of time but very few
studies have analyzed changes in the gut microbiota over long periods of time. One study showed a
pronounced variability in an individual’s microbiota across months, weeks and even days, and that
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only a small fraction of all taxa appear to be present across all time points (in this study, 396 time points
were analyzed [85]). Interestingly, baseline populations (i.e., before any major dietary or other change)
can also predict the response of the gut microbiota in some situations [86].
5.2. Dietary Differences in Gluten-Containing and GFD
Gluten-containing foods provide many nutrients (e.g., prebiotics such as inulin) which may
not be equally abundant in gluten-free foods. The potential issues associated with GFD have been
discussed since the 1950s [87] and the concern that a GFD could produce potentially adverse effects
in the microbiota solely based on a marked reduction in intake of naturally occurring prebiotics has
been raised [88]. On the one hand, a recent review showed that long-term morbidities associated
with CD, such as nutritional deficiencies, impaired bone health, and reproductive abnormalities,
can substantially improve after strict adherence to a GFD [89]. However, a study in Italy reveals an
overall low nutritional quality of gluten-free bakery products [90], and gluten-free products contribute
to imbalanced diets in children from Spain [91]. In addition, a recent review showed that reduced
intake of calcium, vitamins and fiber as well as enhanced consumption of fat and carbohydrates
have been consistently reported in patients on GFD [92]. Moreover, there is evidence that some
gluten-free foods are not enriched and may be deficient in several nutrients, including dietary fiber,
folate, iron, niacin, riboflavin, and thiamine [93,94], although this would not necessarily lead to dietary
deficiency of these nutrients because other gluten-free foods such as vegetables, beef, eggs and cheese
are rich in these compounds. Other studies evaluating the nutritional composition of processed
gluten-free products have demonstrated higher levels of lipids, trans-fat, protein, and salt compared
to their gluten-containing counterparts. Furthermore, recent evidence has shown that patients under
a GFD are at risk of metabolic syndrome and hepatic steatosis [95] and the concerns regarding the
association between micronutrient deficiencies and increased exposure to toxins such as arsenic in
GFD [96]. Moreover, some varieties of GFD do not necessarily lead to a healthier physiological state.
Ercolini et al. [97], for example, showed that changing from an African-style GFD to an Italian-style
GFD provoked significant changes in the salivary microbiota and metabolome of Saharawi (Western
Sahara) celiac children and, more importantly, that these changes suggested metabolic dysfunction.
Another issue with GFD is its availability and costs. While some regions in the industrialized
world have the luxury of having access to a wide variety of foods and dietary ingredients, most
regions of the world have limited access to different foods. This translates into wide differences in
GFD, even within the same geographical region. Importantly, not all gluten-free products are certified
(http://www.gfco.org/) and some supposedly gluten-free products are actually contaminated with
gluten [98]. Moreover, the mere availability of dietary foods in one region does not imply that all
people have access to it. In México, for example, differences in income may involve as much as
27-fold difference between the average incomes of the top and the bottom deciles, a difference that
stark contrasts with the average ratio of 10 to 1 in the Organization for Economic Co-operation
and Development (OECD 2014, https://www.worldeconomicsassociation.org/newsletterarticles/
inequality-in-mexico/). Therefore, the purchasing power is likely to be involved in the maintenance of
life-long GFD.
An interesting argument emerged from one anonymous reviewer during the review process.
Indeed, other grains such as corn and rice are the primary grains consumed in many different countries.
In the case of maize, which is often used as an alternative to elaborate GFD for CD patients, there are
some maize prolamins (called zeins) containing amino acid sequences that resemble the wheat gluten
peptides that may in fact be clinically relevant [99]. The case of rice is also interesting, especially
because several countries in Asia have considerably reduced their consumption of rice [100] and
increased the consumption of other grains. In addition, it has been recognized that CD epidemiology
has changed, in particular in areas where previously CD was unrecognized or rare such as India, China
and Latin America. Several hypotheses may explain this phenomenon such as a change in the pattern
of food consumption to try to beat malnutrition that has led to a wheat–rice shift in poor countries,
99
Nutrients 2018, 10, 1421
but dysbiosis and genetic predisposition may be also related [101]. Overall, we agree with the notion
that the cost and availability of GFD may be of lesser clinical importance in some regions of the world.
Aside the availability and costs, there is substantial variation in prescribing rates of gluten-free
foods [102] and many GFD followers find it challenging to follow the GFD [103]. Interestingly,
psychological state has been shown to predict adherence to a GFD in Australia and New Zealand [104].
Finally, a proportion of CD patients with chronic voluntary gluten ingestion do not show a relapse of
clinical signs and villous atrophy despite chronic voluntary gluten ingestion [105], thus suggesting high
inter-individual variability. This phenomenon is of great importance for the biomedical community,
especially considering the variety of gluten-containing and GFD around the world (in other words,
it is likely that not all diets have the same healing effect on regenerating enterocyte architecture and
therefore health).
6. Conclusions
The microbes that inhabit the human body are unique for each individual and vary widely
over time due to multiple interrelated factors. The fact that the effect of GFD on health and the gut
microbiota cannot be extrapolated to other populations is often neglected in the literature but can also
apply to any dietary intervention in all other gastrointestinal maladies (e.g., IBD) associated with the
gut microbiota. This paper shall not be taken as a discouragement to perform more studies on this
topic; on the contrary, as mentioned above, this paper ultimately seeks to encourage the conception of
more collaborative efforts to study local populations in an effort to reach useful conclusions that truly
contribute to improve health in patients afflicted with GRD and other maladies. This paper also strives
for more awareness among the medical community regarding potential negative effects of switching
patients to a GFD without adequate dietetic and medical supervision.
Author Contributions: All authors contributed equally to the conception and writing of this paper.
Funding: This research was funded by the Mexican National Council for Science and Technology (CONACYT,
Mexico, FOSIS 2015-262023).
Conflicts of Interest: JF Garcia-Mazcorro is an employee of MNA de México. JM Remes-Troche has received
speaker’s fees, travel support, and participated in medical board meetings with Takeda Mexico, Asofarma
and Menarini.
References
1. Douglas, A.E.; Werren, J.H. Holes in the hologenome: Why host-microbe symbioses are not holobionts. mBio
2016, 7. [CrossRef] [PubMed]
2. Maslowski, K.M.; Mackay, C.R. Diet, gut microbiota and immune responses. Nat. Immunol. 2011, 12, 5–9.
[CrossRef] [PubMed]
3. Turnbaugh, P.J.; Ridaura, V.K.; Faith, J.J.; Rey, F.E.; Knight, R.; Gordon, J.I. The effect of diet on the human gut
microbiome: A metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 2009, 1. [CrossRef]
[PubMed]
4. Faith, J.J.; McNulty, N.P.; Rey, F.E.; Gordon, J.I. Predicting a human gut microbiota’s response to diet in
gnotobiotic mice. Science 2011, 333, 101–104. [CrossRef] [PubMed]
5. Wu, G.D.; Chen, J.; Hoffmann, C.; Bittinger, K.; Chen, Y.Y.; Keilbaugh, S.A.; Bewtra, M.; Knights, D.;
Walters, W.A.; Knight, R.; et al. Linking long-term dietary patterns with gut microbial enterotypes. Science
2011, 334, 105–108. [CrossRef] [PubMed]
6. Conlon, M.A.; Bird, A.R. The impact of diet and lifestyle on gut microbiota and human health. Nutrients
2015, 7, 17–44. [CrossRef] [PubMed]
7. Le Doare, K.; Holder, B.; Bassett, A.; Pannaraj, P.S. Mother’s milk: A purposeful contribution to the
development of the infant microbiota and immunity. Front. Immunol. 2018, 9, 361. [CrossRef] [PubMed]
8. Lozupone, C.A.; Stombaugh, J.I.; Gordon, J.I.; Jansson, J.K.; Knight, R. Diversity, stability and resilience of
the human gut microbiota. Nature 2012, 489, 220–230. [CrossRef] [PubMed]
100
Nutrients 2018, 10, 1421
9. Sommer, F.; Anderson, J.M.; Bharti, R.; Raes, J.; Rosenstiel, P. The resilience of the intestinal microbiota
influences health and disease. Nat. Rev. Microbiol. 2017, 15, 630–638. [CrossRef] [PubMed]
10. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The impact of the gut microbiota on human health:
An integrative view. Cell. 2012, 148, 1258–1270. [CrossRef] [PubMed]
11. Turnbaugh, P.J.; Hamady, M.; Yatsunenko, T.; Cantarel, B.L.; Duncan, A.; Ley, R.E.; Sogin, M.L.; Jones, W.J.;
Roe, B.A.; Affourtit, J.P.; et al. A core gut microbiome in obese and lean twins. Nature 2009, 457, 480–484.
[CrossRef] [PubMed]
12. Turnbaugh, P.J.; Bäckhed, F.; Fulton, L.; Gordon, J.I. Diet-induced obesity is linked to marked but reversible
alterations in the mouse distal gut microbiome. Cell. Host Microbe 2008, 3, 213–223. [CrossRef] [PubMed]
13. Forrest, E.A.; Wong, M.; Nama, S.; Sharma, S. Celiac crisis, a rare and profound presentation of celiac disease:
A case report. BMC Gastroenterol. 2018, 18, 59. [CrossRef] [PubMed]
14. De Re, V.; Magris, R.; Cannizzaro, R. New insights into the pathogenesis of celiac disease. Front. Med.
2017, 4, 137.[CrossRef] [PubMed]
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Abstract: Celiac disease (CD) can only be treated by rigorous life-long gluten-free diet (GFD). The
study included 102 mothers and their CD children treated with GFD for at least two years. Frequency
and cause of diet failure in children treated at present (54 children) and 10 years ago (48 children) were
compared. Dietary adherence was evaluated serologically (tTG), while diet management difficulties
were examined by means of a questionnaire. The study shows that one-third of patients fail to follow
GFD, more often 10 years ago than now (40% vs. 26%; p < 0.05), mainly children aged 13–18 (54%
vs. 40% now; p < 0.05). Younger children (up to 12) are less likely to abandon the diet (27% vs. 8%;
p < 0.05). In this age group non-intentional diet failure prevails, while teenagers interrupt their diet
intentionally (45% vs. 33%; p = ns (small population of children in this groups)). Currently, the
most common causes of teenage diet failure are the absence of symptoms after consuming a small
amount of gluten and, even more often, troublesome diet administration. Previously, the absence of
peer acceptance prevailed. With this study we found that: 1. In West Pomerania, every fourth CD
child does not follow GFD. 2. For years, teenagers have failed to follow GFD due to the absence of
symptoms after consuming small amounts of gluten. 3. The incidence of non-intentional failure to
follow GFD has significantly decreased over years, which indicates better dietary care.
Keywords: gluten-free diet; celiac disease; children; teenagers
1. Background
Celiac disease (CD) is a genetically conditioned, immunologically mediated chronic intestinal
disease, in which in genetically predisposed people the consumption of gluten leads to the
disappearance of intestinal flora [1]. This results in reduced nutrient absorption. The disease frequency
is steadily increasing—in Europe and America it affects 1% of people. The only effective way of its
treatment is life-long strict adherence to a gluten-free diet (GFD) [1]. The gluten-free diet consists in the
complete elimination of products derived from wheat, rye, and barley and products processed from
these cereals. They are replaced by naturally gluten-free products (maize, rice, oats, buckwheat, lamb,
meat, fish, vegetables, fruit) or by products from which gluten has been removed. Adherence to GFD
leads to the regeneration of intestinal villi after a period of 6 to 24 months. The life-long GFD secures a
child's proper development and protects them from ailments such as abdominal pain, flatulence, loose
stools, constipation, iron deficiency anemia, low stature, and osteoporosis. In adults with CD, it also
reduces the risk of cardiovascular diseases and intestinal tumors [1,2].
The most reliable method to control GFD adherence are serological tests and small intestine
biopsy [1]. It is recommended to determine serum tissue transglutaminase concentration in IgA
class (IgA-tTG), while in patients with selective IgA deficiency—in IgG class (IgG-tTG) [1]. The
determination of tTG concentration in patients treated with GFD is commonly referred to as the ‘lie
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test’ because it allows to identify people who do not follow the diet. Being an invasive test, endoscopic
small intestine biopsy is not recommended to confirm non-adherence to GFD.
Some researchers suggest using nutritional history to assess the GFD adherence. However, it does
not allow to identify patients who non-intentionally fail to adhere to GFD, therefore its importance for
monitoring procedures is low. Leffler et al. proposed a seven-point questionnaire to identify patients
who did not adhere to GFD (Celiac Dietary Adherence Test, CDAT). The test assesses their knowledge
of the disease, which, according to Leffler, is highly correlated with serological test results [3]. In 2017,
a new method was proposed to confirm the consumption or nibbling of gluten by people with CD. The
method consists in determination of gluten immunogenic proteins in urine [4]. This is a very attractive
proposal as the test is non-invasive.
Adherence to GFD is troublesome [5]. The patients or their guardians are required to have
extensive knowledge about CD and the GFD requirements. The changes in eating habits affect not
only the patient, but often their whole family. According to Meyer et al., in order to better manage
CD the daily routines of young patients should be carefully examined to help them strictly comply
with GFD [6]. The GFD preparation time is much longer than that of a diet containing gluten [7]. Also,
it is much more expensive than traditional nutrition, which limits its availability to many patients.
Fortunately, in some countries the costs of GFD are partially refunded [8,9]. It was noted that in
such countries the patients who receive products free of charge follow the GFD requirements more
often [7,10]. For the low-income adult patients the high cost of GFD products is a barrier to diet
adherence [11]. On the other hand, the studies of Humayun et al. and Leffler et al. did not confirm the
significant influence of the GFD price on the frequency of the GFD adherence, except for those CD
adult patients who openly declared that the high price of products made it difficult for them to follow
the diet [3,7].
In the opinion of some authors, the following factors contribute to the better adherence to GFD:
good knowledge of the disease and its treatment, higher education level, better social situation of
the family, female sex, young age, high self-esteem, good grades at school, good availability and
labelling of products, good contact with a doctor and a dietitian, and finally, membership in the Coeliac
Society [5,7,11–13]. The Coeliac Society members understand the disease better and know how to
prepare gluten-free meals. They also receive stronger day-to-day support (meetings, help in obtaining
GFD products, partially reimbursed youth camps) [7,10,14].
The factors responsible for not adhering to GFD are: poor taste of gluten-free products, their high
price and low availability (especially during travel and social meetings), the patient's adolescence, the
absence of immediate symptoms after consuming small amounts of gluten, and low awareness of the
disease [5,11,13].
Better awareness of the factors that have significant impact on the GFD adherence can improve
the supervision of CD patients.
The aim of this study was to determine the incidence and causes of non-adherence to GFD by
children with CD treated now and 10 years ago.
The first analysis of the causes of failure to adhere to GFD was carried out in 2006–2007 with
a view to improving the effectiveness of CD treatment, as it had been observed that many patients
discontinued GDF after years of adherence. In recent years, GFD has become popular in Poland
and therefore the conclusions concerning the patients’ failure to adhere to GFD 10 years ago are no
longer relevant. Unfortunately, it has been observed that teenagers still tend to discontinue their GFD.
Therefore, in the 2016–2017 study, the questions about the reason for failure to follow GFD were again
included in the CD patients’ medical history.
2. Materials and Methods
The study covered 102 children (64 girls) with coeliac disease (CD) treated with GFD. All patients
were diagnosed in accordance with the applicable criteria: elevated antibodies anti–endomysium
(EMA) and anti-tissue transglutaminase (tTG) as well as duodenal atrophy of intestinal mucosa [1].
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There were no patients with selective IgA deficiency in the study group, therefore antibodies were
determined only in the IgA class. At the time of their CD diagnosis the mean IgA-EMA concentration
was 1:120 (range: 1:170–1:10) and IgA-tTG was 171 RU/mL (range: 297 RU/mL–38 RU/mL). During
the first two years after the diagnosis, serological indicators (EMA and tTG) normalized in all patients,
in most of them already in the first year of treatment. It is believed that in patients treated with
GFD, a two-year period is sufficient to fully normalize the antibodies concentration and the intestinal
mucosa [15].
The patients were recruited during their GFD treatment, two years or more after the diagnosis,
during control tests performed routinely twice a year. The mean time of the GFD treatment before
their inclusion in the study was 104 months (28 months–208 months).
During the medical interview, patients made a declaration concerning their dietary adherence.
If they reported that they did not follow the diet, they were asked to give reasons. Five probable
causes were specified: poor taste of the diet, its high price, troublesome dietary regime (understood
as problems with the purchase of gluten-free diet, its labelling, the inability to eat outside the home),
difficulties in relationships with peers (due to being rejected by the peer group) and the absence of
symptoms after consuming gluten products. Each patient was asked to choose which of the reasons
was the most relevant to them, i.e., which led to deliberately abandoning of GFD. In the case of the
youngest children (under seven years of age), dietary declarations were made by their guardians
(in this study all of them were mothers). Older children with CD and their guardians jointly chose the
most important reason for their failure to follow GFD.
The tests performed during each control visit included serum assays of tissue transglutaminase
(tTG) in the IgA class. The presence of tTG antibodies in serum confirmed that the CD patient had
consumed gluten. Patients who claimed to adhere to GFD and in whose blood tTG antibodies were
found were considered as those who non-intentionally failed to adhere to GFD. In 33 children who
did not follow GFD, the average IgA-tTG concentration was 126 RU/mL (264 RU/mL–22 RU/mL).
In children adhering to GFD the IgA-tTG concentration was below 20 RU/mL.
Patients were divided into two groups: children (0–12 years old) and teenagers (13–18 years old)
(Table 1). The frequency and reason for non-adherence to GFD was compared between children treated
now (54 children) and 10 years before (48 children).
Table 1. Number of children covered by the study in 2006–2007 and in 2016–2017.
Child’s Age (years) Number of Children Σ
2006–2007 2006–2007 2016–2017
0–12 26 24 50
13–18 22 30 52
0–18 48 54 102
EMA was determined by indirect immunofluorescence test (standard < 1:10), while IgA-tTG was
assayed by ELISA (standard < 20 RU/mL). The obtained results were subjected to statistical analysis.
The Student’s t-test was used for independent trials.
The survey did not require the permission of the PUM (Pomeranian Medical University) Bioethical
Committee. The relevant opinion was obtained from the Chairman of the Committee in 2006.
All subjects had given their informed consent for inclusion before they were included in the study.
3. Results
It has been shown that children with CD are now more likely to adhere to GFD than before.
In 2016–2017, 26% of children did not adhere to GFD, whereas 10 years earlier, in 2006–2007, as many
as 40% failed to do so (p < 0.05) (Figure 1). Those were mainly children aged 13–18 (40%) by age
(cumulative assessment of 2006–2007 and 2016–2017 studies) now and 54% a decade ago; p < 0.05).
Younger children (up to 12 years) were less likely to miss the diet (8% at present and 27% a decade
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ago; p < 0.05). At that age, the incidence of non-intentional GFD failure was larger: 4% at present (1 of
24 children) and 19% previously (5 of 26 children) (Figure 2). Teenagers often intentionally interrupt
their diet: 33% now (10 of 30 children) and 45% a decade ago (10 of 22 children) (Figure 2). Currently,
the most common reason for the teenage diet failure is the lack of symptoms after consuming a small
amount of gluten products, while the inconvenience of GFD regime is less common (Figures 3 and 4).
In 2006–2007, the main reason for GFD non-adherence was the difficulty in peer relations (rejection by
peer groups), while the absence of symptoms after occasional gluten intake or troublesome dietary
regime were less common (Figures 3 and 4).
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Figure 1. Proportion of children failing to adhere to gluten-free diet (GFD) by age and time of study.
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Figure 2. Incidence to intentional and non-intentional failure to adhere to gluten-free diet (GFD).
* GFD—gluten-free diet.
109
Nutrients 2018, 10, 1424
 
0 2 4 6 8 10
Peer rejection due to GFR*
Absence of symptoms after
consuming small amounts of gluten
Troublesome daily GFD* regime
Bad taste of GFD*












Figure 3. Reasons for non-adherence to gluten-free diet (GFD) by age. * GFD—gluten free diet.
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Figure 4. Reasons for GFD non-adherence by time of study. * GFD—gluten-free diet.
4. Discussion
The analysis shows that currently every fourth child with CD does not adhere to GFD (Figure 1).
Ten years ago, in 2006–2007, the failure to adhere to GFD was more common, and was reported by as
many as 40% of the respondents. Studies in other countries have shown that between 30% and 75% of
patients fail to follow GFD [7,11,14,16]. In Polish multi-center studies conducted in 2010—2013 and
covering 277 children with CD, it was found that GFD was not observed by 25% of patients, of whom
19% had abandoned the diet intentionally [17].
Currently, teenagers are five times more likely not to adhere to GFD than younger children
(40% vs. 8%). In 2006–2007, teenagers consumed gluten only twice as often as younger children
(54% vs. 27%). Similar observations were made by other researchers [5,12,18]. What has clearly
decreased in recent years is the incidence of dietary failure among younger children, who most often
fail to follow GFD unintentionally (Figure 2). In this group, the intentional failure to adhere to the diet
was primarily a consequence of their parents' inability to provide them with a sufficient amount of
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gluten-free products. In those years, the access to such products was much more difficult than today.
Currently, CD families are better prepared to adopt GFD. The improved ability of parents and children
to identify gluten-free products is a consequence of better dietary support, greater involvement of
the Coeliac Society (regular meetings, publications), improved labelling of gluten-free products and a
more convenient way to obtain them (online shopping).
Both 10 years ago and now, the majority of CD teenagers intentionally fail to adhere to GFD
(Figure 2), which has also been found out by other authors [5]. Currently, the main reason for
their failure to adhere to GFD is that they believe that the systematic low intake of gluten does
not affect their health, as it does not cause any intestinal symptoms which they experienced before
(Figures 3 and 4). Unfortunately, non-adherence to GFD at this age does not correlate well with the
presence of the CD symptoms.
In younger children (<3 years), the consumption of even the smallest amounts of gluten usually
result in intestinal symptoms, most commonly abdominal pain or abnormal stools. Teenagers, seeing
that such a co-incidence no longer occurs, start to believe that they can consume gluten in small
amounts. There are patients who are able to precisely define the amount of gluten that cause the
symptoms. Therefore, they try to consume smaller amounts, which in their opinion does not harm
their health. In this group of patients, dietary errors are caused by insufficient knowledge of CD and
its treatment. They need to be informed about the CD again. It seems that such information should be
provided to every juvenile patient once they enter adolescence. It should be particularly pointed out
that, at this age, eating small amounts of gluten may not cause such intestinal discomfort as previously,
but it still remains detrimental to their health. We try to persuade these patients to adhere strictly
to GFD by showing them that their growth rate has been slowed down, anemia induced by iron
deficiency has occurred, bone density has decreased (in densitometric evaluation), and antibodies
indicating CD activity have appeared in serum. In some cases, we repeat endoscopic tests of fragments
from the duodenum in order to show that intestinal villi atrophy has reoccurred in their duodenum.
We explain that these are the complications due to the young patient's failure to adhere to GFD and that
they have appeared independently from the absence of intestinal discomfort. Systematic monitoring
of teenagers' dietary adherence is absolutely essential, even if they have had a history of strict GFD
adherence. Other authors also believe that the lack of immediate symptoms after consumption of small
amounts of gluten is an important factor in teenagers' failure to adhere to GFD [5].
Ten years earlier, in 2006–2007, the main cause of non-adherence to GFD by teenagers was peer
rejection due to their different dietary regime. These children were stigmatized by other children and
isolated from the group. In order not to be socially excluded, teenagers with CD intentionally consumed
gluten products while in social situations. None of these children changed their behavior throughout
the treatment period (up to 18 years), despite having been informed about the adverse effects of such
behavior. Similar teenagers’ attitudes have also been described by other authors [5,6,16,19]. Swedish
studies have found that girls are more likely than boys to follow GFD [20].
In our 2016–2017 study, none of the children reported the above as a reason for non-adherence
to GFD. This is a consequence of a change in social customs. Today, GFD has become popular in
Poland and it is used by many people who do not suffer from CD. Similar trends have also been
observed in other countries where the frequency of GFD consumption far exceeds the number of CD
patients [19,21,22].
Younger children have never reported this problem. In kindergartens and schools, they consumed
gluten-free products and that fact did not have any negative impact on their peer relations.
At present, just like 10 years ago, the second most frequent reason for non-adherence to
GFD is its troublesome administration, as reported by both younger children and adolescents
(Figures 3 and 4). By the troublesome use of GFD we mean a number of difficulties encountered by a
patient in everyday life. These are: problems with buying GFD and with label reading, as well as the
inability to eat out, which makes travelling and social gatherings more difficult. In the years 2006–2007
in Poland the purchase of gluten-free products was possible only in specialist shops located in large
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cities. That significantly hindered access to gluten-free food for the residents of small towns and
villages. It forced people to prepare gluten-free products (bread, cakes, pasta) on their own at home.
There were no possibilities to order gluten-free meals outside one’s place of residence. The children
went on trips with their own bread, which significantly limited their ability to travel. The only form of
organized tourism were camps organized by the Coeliac Society, but they were not widely available.
The situation is now much better. Most families buy gluten-free products online, and in many towns
and cities there are gluten-free food stands in supermarkets. There is a wide offer of children and
youth camps serving gluten-free menu that are organized not only by the Coeliac Society. However,
the possibility of eating out is still very limited, even though the situation has improved considerably
in recent years. Currently, GFD has become ‘trendy’ in Poland, it is chosen by many people, not only
by the CD patients. In many restaurants you can order gluten-free menu. Unfortunately, most of
such places are usually located in large towns, which still hampers the CD patients’ mobility. Similar
difficulties are also highlighted by other authors from other countries [5,7,13,23]. In Wolf et al. studies,
difficulties with eating outside the home were more frequently reported by teenagers than by adults
(87% vs. 74%) [24]. In our study on teenagers, that was the main factor indicating the troublesome
character of the diet. Parents of younger children (<12 years old) reported difficulty in reading labels
on gluten-free products, their high price, and difficult access.
When buying gluten-free products, patients can benefit from a mobile application containing
an inventory of gluten-free products available in a given country [25]. Such an application has been
available in Poland since spring 2017. It is free of charge for patients with CD belonging to the Coeliac
Society. In Canada, as many as a quarter of patients reported that it would be very helpful to include a
list of 100 most frequently purchased gluten-free products in their mobile applications. Silvester et al.
have shown that in the USA only 25% of adults with CD are able to recognize the majority of gluten
products from the list (14 out of 17 products) [14].
In our studies none of the CD patients gave a high GFD price as the main reason for not following
it. That was another, but not the most important, reason. During the 2006–2007 study, all Polish
children with CD received a cash allowance to buy GFD. Unfortunately, today the allowance is not
available to the majority of children. Many authors point out that the high price of GFD is an important
reason for not adhering to GFD by many patients [11,13,26]. It is also an essential factor affecting the
quality of life of adult patients with CD [27].
None of the examined groups of children indicated the illegible labelling of the gluten-free
products as the most important reason for not adhering to GFD, which has also been reported by other
researchers [7,8,13].
Strict adherence to GFD is most common among patients with greater knowledge of their
disease [24]. They are ‘extremely vigilant’ in selecting the right products. They eat meals only at home,
as they are afraid to eat out. They are constantly using the Internet and mobile applications to help
them buy GFD products. They are more likely to experience anxiety and fatigue. Their quality of life
(QoL) is significantly lower than that of patients who are ‘less vigilant’ in the choice of GFD [24]. This
applies to teenagers as much as to adults, more often to women [27]. This is a negative consequence of
strict adherence to the diet and points to the need to provide psychological and emotional support
for the patients with CD. The opposite results were obtained by other researchers in their studies
on adults which revealed better quality of life reported by patients strictly adhering to GFD [5,28].
The discrepancies between the two findings have been explained by Nachman et al. who showed
that in the first year of strict adherence to GFD the quality of life of adult CD patients was higher
(symptoms disappeared), but then it significantly decreased (probably due to the difficulty in strict
maintenance of GFD) [29]. Mazzone et al. demonstrated that children and teenagers with CD were
more likely to experience emotional and behavioral problems, particularly loneliness and depression,
than their healthy peers [30]. Parents rated the quality of life of their CD children lower than the
children themselves [31].
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5. Conclusions
Over the last 10 years, an increase in the number of children with celiac disease adhering to the
gluten-free diet has been observed in the West Pomeranian region. Similarly, to other countries, today
every fourth child with celiac disease does not follow a gluten-free diet.
For years, it was teenagers who most often failed to adhere to the gluten-free diet. The lack
of awareness of the course of the disease, the increasing independence from parents, the need to
buy food and prepare meals for themselves, the need to better organize everyday life as well as the
environmental pressure are the factors resulting in more frequent failure to follow GFD. Teenagers
require psychological support and repeated instruction explaining to them that they cannot eat even
the smallest amounts of gluten, even though it does not cause any intestinal symptoms at this age, but
unfortunately is harmful to their health.
Over the years, the frequency of non-intentional non-adherence to the gluten-free diet has
significantly decreased as a result of better dietary care.
Systematic medical and dietary supervision contributes to more effective treatment of children
with celiac disease, which in turn ensures their proper development and prevents complications.
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Abstract: Gluten-related disorders (GRDs) are common chronic enteropathies and increasing evidence
suggests an involvement of the gut microbiota. We examined the gut microbiota in Mexican people
afflicted with GRDs. Ultra-high-throughput 16S marker sequencing was used to deeply describe the
duodenal and fecal microbiota of patients with celiac disease (CD, n = 6), non-celiac gluten sensitivity
(NCGS, n = 12), and healthy subjects (n = 12) from our local area. Additionally, we also investigated
the changes in gut microbiota after four weeks on a gluten-free diet (GFD) in a subset of patients
from whom paired samples were available. Despite a high inter-individual variability, significant
differences in various microbial populations were identified. The linear discriminant analysis (LDA)
effect size (LEfSe) method revealed that the genus Actinobacillus and the family Ruminococcaceae were
higher in the duodenal and fecal microbiota of NCGS patients, respectively, while Novispirillum was
higher in the duodenum of CD patients (p < 0.05, LDA score > 3.5). Interestingly, paired samples from
NCGS patients showed a significant difference in duodenal Pseudomonas between the baseline period
(median: 1.3%; min/max: 0.47–6.8%) and the period after four weeks on GFD (14.8%; 2.3–38.5%,
p < 0.01, Wilcoxon signed-rank test). These results encourage more research on GRDs in México.
Keywords: gluten-related disorders; celiac disease; gut microbiota; gluten-free diet; Pseudomonas
1. Introduction
The gut microbiota is comprised of thousands of microbial species that vary widely among
individuals [1] and also over time within the same individual due to environmental factors such as
dietary patterns [2]. The gut microbiota helps modulate the immune system [3] and has been associated
with diseases related to the alimentary tract such as obesity and inflammatory bowel diseases [4].
Given the close relationship between the immune system and microorganisms inside the gut, it is
believed that most disorders of the digestive tract bear some relationship with the gut microbiota
although a cause-effect relationship can hardly be established [5].
Gluten-related disorder (GRD) is a general term to describe all maladies triggered by gluten, with
celiac disease (CD) being the most studied. CD is an autoimmune disorder where the consumption
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of gluten leads to an abnormal T cell-mediated immune response and damage to epithelial cells in
genetically susceptible individuals [6,7]. Other factors related to CD include perinatal environmental
factors such as the duration of breastfeeding as well as gut-microbiota interactions [8] and the only
available treatment for GRDs is a life-long consumption of a gluten-free diet (GFD). On the other
hand, non-celiac gluten sensitivity (NCGS) is a different GRD yet it also responds to a gluten-free diet
(GFD) [9,10]. The diagnosis of NCGS is based on the clinical response to GFD and the exclusion of
other syndromes as there is no NCGS-specific biomarker yet identified like in wheat’s allergy (e.g.,
the presence of IgE) or CD (e.g., the presence of TG2 antibodies) [11].
Growing evidence suggests that the gut microbiota is closely related to GRDs, particularly
CD [8,12]; however, a disease-specific microbial signature of GRDs has not yet been defined and
there is a lack of consensus with respect to the specific changes involved in these disorders with
or without dietary gluten [12–15], partly due to the well-known high interindividual variation of
the gut microbiota [16,17]. One study used culture techniques to investigate the effect of GFD on
fecal Bifidobacterium and showed that CD patients have a lower load of this microorganism [18].
However, it is more informative to analyze all (or most) members of the gut microbiota to reach
biologically feasible and clinically useful conclusions. In this regard, several studies have used massive
high-throughput sequencing technologies to do so but have mostly focused on child populations [19,20].
Another study analyzed the fecal microbiota in 21 adults from the Netherlands before, during and after
four weeks on GFD but did so in healthy control volunteers only [21]. Interestingly, the authors showed
that a decreased abundance of Veillonellaceae was a distinctive feature during the consumption of
GFD [21].
In México, CD has a prevalence of ~1% (~1.2 million people) [22], yet we know very little about
CD in terms of its genetic predisposition, clinical presentation, treatment and involvement of the
gut microbiota in Mexican patients [17,23–27]. The purpose of this research is to investigate the gut
microbiota composition and predicted functional profile in Mexican patients with GRDs. To our
knowledge, this work represents the first effort to investigate the gut microbiota in these important
clinical conditions in México. Additionally, we also investigated the changes in the gut microbiota
after four weeks on a gluten-free diet (GFD) in a subset of patients from whom paired samples
were available.
2. Materials and Methods
2.1. Ethical Considerations
This study was conceived with the combined knowledge and expertise of clinical and biomedical
scientists from the Instituto de Investigaciones Medico Biologicas at the Universidad Veracruzana.
Informed consent was obtained from all subjects and the study was approved by the local ethics
committee (IIMB-UV 2016/011).
2.2. Recruitment of Participants
Consecutive newly diagnosed CD and NCGS subjects were recruited and evaluated over six
months from patients attending the Department of Gastroenterology of the Universidad Veracruzana
in Veracruz, México. CD diagnosis was based on the presence of CD-specific antibodies, genetic
markers and histological examination; NCGS diagnosis was made during the patient’s consultation if
subjects had symptoms related to the ingestion of gluten (e.g., bloating, flatulence, altered bowel habits,
and muscle pains) but no CD-specific antibodies and negative biopsies at the baseline (see “2.1 Subject
enrollment” in Supplementary Information for more detailed explanations). Healthy volunteers with
no history of digestive pathologies, lack of CD-specific antibodies and normal biopsies at baseline,
were also included in the study. Blood samples, small bowel (i.e., proximal duodenum) mucosal
biopsies, and fecal samples were obtained from the majority of the subjects although many patients
refused to provide stool samples. As mentioned before, we additionally sought to investigate the
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potential microbial signatures associated with the consumption of certified gluten-free foods, where
adherence to the GFD was defined if the subjects kept the diet >90% of the recorded time using diary
records (see “2.2 GFD intervention” in Supplementary Information).
2.3. DNA Extraction, PCR, and 16S rDNA Sequencing
Biopsy and fecal samples were used to obtain the total genomic DNA samples for further PCR
and sequencing of the 16S rRNA gene (16S rDNA) as shown elsewhere [28,29]. Briefly, we used a
bead-beating coupled with a commercial DNA extraction kit (Wizard® Genomic DNA Purification,
PROMEGA, Madison, WI, USA) and samples were normalized to 100 ng/uL for further analysis.
We used primers 515F (GTGYCAGCMGCCGCGGTAA) and 806R (GGACTACNVGGGTWTCTAAT)
to amplify the V4 region of the 16S rDNA as suggested by the Earth Microbiome Project. Purified PCR
products were used to prepare the DNA libraries using the Illumina TruSeq DNA library preparation
protocol. Sequencing was performed in a MiSeq instrument (Illumina) at Molecular Research LP
(MR DNA, Shallowater, TX, USA) following the manufacturer’s instructions.
2.4. Bioinformatics
The open-source bioinformatics pipeline Quantitative Insights into Microbial Ecology [30] v.1.8
was used for most of the core analyses. Operational Taxonomic Units (OTUs) were chosen using
two approaches. First, using the pick_open_reference_otus.py accordingly to the suggestions by
Rideout et al. [31]. This approach is capable of detecting OTUs that are not necessarily represented in
the reference databases. Further taxonomic and diversity analyses were performed using all OTUs
(i.e., the full OTU table) and a filtered OTU table (OTUs with <0.005% of all sequences were removed
as suggested by Navas et al. [32]. Second, using the pick_closed_reference_otus.py to then be able to
use the OTU table for the prediction of functional metagenome using Phylogenetic Investigation of
Communities by Reconstruction of Unobserved States (PICRUSt) [33]. The GreenGenes database [34]
at 97% similarity was used as the reference 16S database. All sequence and metadata information are
publicly available (NCBI, PRJNA401920).
2.5. Statistical Analysis
A chi-squared test was used to compare the frequencies (e.g., the proportion of women, number
of patients showing a clinical improvement) and the non-parametric Kruskal–Wallis test was used
for comparison of health parameters (e.g., blood parameters) and microbial groups. The linear
discriminant analysis (LDA) effect size (LEfSe, [35]) was used to determine the organisms that explain
the differences in microbiota. Please note that in LEfSe, the idea is that the significant biomarkers
(in this case microbial phylogroups) are ranked based on the effect size (the magnitude of the variation)
rather than on the statistical significance. When comparing two sets of data (e.g., before and after
GFD), the Wilcoxon signed-rank test or the Mann–Whitney test were used. The unique fraction
metric (UniFrac) was used to measure the phylogenetic distance among taxa [36]. Both weighted
and unweighted UniFrac were calculated and analyzed using Principal Coordinate Analyses (PCoA)
because they can lead to different insights into the factors that shape the composition of bacterial
communities [37,38]. The ANOSIM and Adonis tests were used to determine whether the grouping
of samples by a given category (e.g., health status) is statistically significant based on the UniFrac
distances. Two age groups (young < 35 years; old > 35 years) and two body mass index (BMI)
groups (low < 24.5; high > 24.5) were created to evaluate the potential contribution of these factors
to the similarity of bacterial communities. STAMP [39] was used to analyze PICRUSt data using
non-parametric tests.
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3. Results
3.1. Subjects
A total of six patients with CD, twelve patients with NCGS and twelve control subjects were
successfully enrolled over the six months enrollment period (Table 1). Please note that not all samples
were obtained from all subjects mainly because of the lack of compliance, especially with the submission
of stool samples. Among the CD patients, one had a Marsh I classification, two had Marsh II and
three had Marsh IIIa. The impact of these varying baseline scores on clinical development and gut
microbiota is uncertain but something to look for in future studies. The history of CD among relatives
was more common in CD patients, CD patients had lower BMIs and hemoglobin levels and higher
intraepithelial lymphocyte counts (Table 2). There was no difference between the CD and NCGS
patients at baseline with regards to abdominal pain and bloating (Table 2).
Table 1. The health status, age (in years), BMI, sex, and sampling information for all our group of
30 subjects 1.





9 CD 35 27 Woman Yes Yes
16 CD 36 20 Woman Yes Yes
18 CD 62 18 Woman Yes Yes
19 CD 25 23 Woman Yes NA
20 CD 47 25 Woman Yes NA
23 CD 73 21 Woman Yes Only on GFD
1 NCGS 23 28 Woman Yes Yes
3 NCGS 21 24 Woman Only baseline NA
5 NCGS 24 25 Woman Yes Only on GFD
6 NCGS 23 29 Woman Yes Yes
7 NCGS 22 25 Woman Yes NA
8 NCGS 24 27 Woman Yes NA
10 NCGS 27 23 Man Yes Yes
11 NCGS 23 29 Man Yes Only baseline
13 NCGS 37 31 Woman Yes Yes
17 NCGS 59 19 Woman Yes Yes
22 NCGS 34 26 Woman Only baseline NA
24 NCGS 38 24 Woman Yes Only baseline
2 Control 23 33 Man Only baseline NA
4 Control 24 33 Man Only baseline NA
12 Control 23 24 Woman Only baseline NA
14 Control 25 23 Woman Only baseline NA
15 Control 26 21 Woman Yes Yes
21 Control 24 29 Man Yes NA
25 Control 45 28 Woman Yes Only baseline
26 Control 64 24 Man Yes Yes
27 Control 23 25 Man Yes Only baseline
28 Control 39 25 Man Yes NA
29 Control 58 26 Woman Yes NA
30 Control 42 27 Woman Yes NA
1 ID: patients’ internal identification number useful for retrieval of sequence information from the SRA (NCBI). CD:
Celiac Disease; NCGS: non-celiac gluten sensitivity; GFD: gluten-free diet; BMI: body mass index. NA: not available
for analysis.
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Table 2. The baseline clinical, physiological, and other parameters among the groups of subjects 1.
CD (n = 6) NCGS (n = 12) Controls (n = 12) p Value
Proportion of women 100% 92% 50% 0.017
CD in family, % 67% 17% 8% 0.017
DQ2 or DQ8 positive, % 83% 50% 42% 0.217
Severe abdominal bloating
(Likert), % 66% 81% NA 0.121
Severe abdominal pain
(Likert), % 50% 42% NA 0.862
Age in years (median, range) 41.5 (25–73) 24 (21–59) 25.5 (23–64) 0.077
BMI, kg/m2, median (range) 21.8 (18–27) 25.3 (21–30) 25.2 (19–31) 0.050
Hemoglobin, g/dL,
median (range) 12.3 (10.7–12.6) 13.8 (12.1–14.6) 13.8 (12.7–16) 0.050
Total cholesterol, mg/dL,
median (range) 151 (110–222) 207 (116–323) 198 (136–299) 0.100
HDL, mg/dL,
median (range) 38 (35–47) 43 (29–51) 36 (34–70) 0.013
LDL, mg/dL,
median (range) 91.8 (63–161) 109 (75–143) 106 (79–186) 0.409
Triglycerides, mg/dL,
median (range) 69.5 (40–230) 108 (62–270) 154 (83–277) 0.182
AST, median (range) UI/mL 29 (19–37) 23 (8–44) 26 (8–53) 0.523
ALT, median (range) UI/mL 22 (10–39) 19 (11–85) 24 (11–51) 0.895
Eosinophils DLP,
median (range) 5 (0–22) 1.5 (0–13) 3.8 (0–11) 0.392
IEL in duodenum,
median (range) 24 (15–39) 8 (0–22) 6 (0–12) 0.001
1 p values come from the chi-squared test when comparing proportions (e.g., proportion of women) or the
non-parametric Kruskal–Wallis test when comparing all other values. CD: Celiac disease; NCGS: non-celiac
gluten sensitivity; DQ2 and DQ8 are haplotypes within the HLA-DQ serotyping system; BMI: body mass index;
HDL: high density lipoprotein; LDL: low density lipoprotein; AST: aspartate aminotransferase; ALT: alanine
aminotransferase; IEL: intraepithelial lymphocytes; DLP: duodenal lamina propria. NA: not applicable.
3.2. 16S Sequencing and Taxonomic Classification of Sequence Reads
A total of 2.3 million (biopsies, n = 30) and 1.5 million (fecal, n = 14, many patients refused to
provide a stool sample) good-quality 16S rDNA sequences (median length: 300 base pairs) were
obtained from the baseline samples and used for OTU picking and further analyses. A total of
32,800 OTUs were originally detected using the open OTU picking approach (unfiltered OTU table);
the removal of low-abundant OTUs (i.e., OTUs with <0.005% of total reads) yielded 975 and 916 OTUs
(only ~3% of all original OTUs) in biopsy and fecal samples, respectively. It is outside the scope of
this current work to discuss the consequences of removing low abundant OTUs but please be aware
that the so-called rare microbes may in fact be keystone species regulating the function of different
microbial environments, including host-associated microbiomes [40].
3.3. Microbiota at Baseline
3.3.1. Microbiota in Duodenal Biopsy Samples at Baseline
Overall 16S reads were assigned to a total of 27 phyla in all samples but only five phyla
(Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, and Fusobacteria) comprised the vast
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majority (>90%) of reads in most samples (Figure 1), as shown elsewhere. At the phylum level, there
was a significantly lower abundance of Bacteroidetes (p = 0.022, Kruskal–Wallis test) and Fusobacteria
(p = 0.052) in duodenal biopsies from CD patients (n = 30, Figure 2). This lower abundance of
Bacteroidetes and Fusobacteria in CD patients was also true when analyzing the duodenal microbiota
of women only (n = 22, p = 0.028 and p = 0.067, respectively).
Figure 1. The taxonomic composition of duodenal (n = 30) and fecal (n = 14) microbiota at baseline at
the phylum level. Please note that the samples were organized based on the highest abundant phylum
for each subset of subjects. This figure was created using data from the full (i.e., unfiltered) OTU table,
thus, allowing for a more complete taxonomic view of the samples. In the samples IDs: CD (celiac
disease), NCGS (non-celiac gluten sensitivity), CTRL (control subjects), B: duodenal biopsy, F: fecal.
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Figure 2. Bar charts showing the relative proportions of the 16S rDNA reads from the duodenal
microbiota for all the main phyla. (a) Proteobacteria, (b) Firmicutes, (c) Bacteroidetes, (d) Fusobacteria,
(e) Actinobacteria, (f) Others. Significant differences were only found in Bacteroidetes (c) and
Fusobacteria (d), see main text. Bars represent the mean ± SE.
LEfSe analysis confirmed the finding of statistically significant differences in various bacterial
groups among the three groups of subjects at the baseline (Figure 3). For instance, there was a higher
abundance of Actinobacillus (Gammaproteobacteria), Finegoldia (Clostridia), and the phylum TM7 in
NCGS patients, while Sphingobacterium (Bacteroidetes) was higher in the healthy subjects (Figure 3).
The separate LEfSe analysis of samples from women confirmed the higher abundance of TM7 in NCGS
patients and Sphingobacterium in healthy subjects and also revealed significant differences in various
other bacterial groups (e.g., women with CD were deprived of Campylobacterales, Paraprevotellaceae,
and Fusobacteriaceae; see Supplementary Figure S1). The health status of the patients was not related
to significant differences in any index of richness or diversity with the exception of Shannon diversity
index (lower in CD patients; Table 3 and Supplementary Table S1). This overall lack of difference in
alpha diversity was also true when only analyzing samples from women (n = 22).
Figure 3. The LEfSe results from the comparison of the baseline duodenal microbiota. Please note that
the bigger the LDA score, the bigger the contribution to the magnitude of the variation.
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Table 3. The summary of the alpha-diversity indices from the analysis of all OTUs (full OTU table)












(n = 22) p Value
Richness 1127 1177 0.9562 1695 1687 1917 0.8450
PD whole tree 87 91 0.8961 1113 1057 1231 0.8426
Chao1 1746 1831 0.9924 88 86 91 0.9327
Shannon 5.5 5.5 0.8954 5.6 a 4.8 a,b 5.9 a,c 0.0193
Fecal samples Baseline(n = 14)
On GFD
(n = 12) p value
Control
(n = 6) CD (n = 7)
NCGS
(n = 13) p value
Richness 1692 1341 0.2519 1696 1347 1552 0.7946
PD whole tree 101 89 0.3217 99 86 98 0.6694
Chao1 2205 1826 0.2519 2192 1783 2088 0.8086
Shannon 5.5 5.2 0.7425 4.6 5.8 5.4 0.7551
1 p values come from the Kruskal–Wallis test (same superscripts indicate lack of statistically significant difference).
GFD: gluten-free diet; CD: celiac disease; NCGS: non-celiac gluten sensitivity. For clarity and lack of statistical
significant difference for most values, only median values are presented.
The differences in duodenal microbiota at the phylum (e.g., Bacteroidetes) and lower taxonomic
levels (e.g., Actinobacillus) were not enough to differentiate the bacterial communities as a whole,
as evaluated by the PCoA plots of weighted and unweighted UniFrac distances (Supplementary
Figure S2) and this was also true when only analyzing the samples from women. The PICRUSt
predicted metabolic features with the lowest uncorrected p values were flavonoid biosynthesis, dioxin
degradation, and riboflavin metabolism (Figure 4) but after the Bonferroni correction, there was no
significant difference in any metabolic feature.
Figure 4. The box plots showing proportions of sequences for three metabolic features from the
duodenal microbiota at the baseline. Plus (+) symbols represent outliers. Please note that there was no
difference in any metabolic feature. CD: celiac disease, Ctrl: control, NCGS: non-celiac gluten sensitivity.
To summarize the results for the baseline duodenal microbiota, we found significant differences in
the relative abundance of several bacterial groups but these differences were not enough to modify the
diversity parameters (with the exception of Shannon diversity indexes) or predicted metabolic features.
3.3.2. Microbiota in Fecal Samples at the Baseline
Only 14 samples were available for the analysis of fecal microbiota at the baseline. Fecal samples
showed an unexpected high abundance of Firmicutes (~85%) and a low abundance of Bacteroidetes
(~1%) regardless of the disease status (Figure 1). Despite the low number of samples, there was a clear
higher abundance of fecal Ruminococcaceae in NCGS patients, and this difference was significant
according to the LEfSe analysis (Supplementary Figure S3).
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3.4. Effect of GFD on the Gut Microbiota
3.4.1. Effect of GFD on Duodenal Microbiota
All subjects had a GFD adherence above 90%. Sixty-seven percent of CD patients (4/6) and ninety
percent of NCGS patients (9/10) reported a global improvement of symptoms after four weeks on
GFD but this difference was not significant (p = 0.247, chi-squared test). There was also no difference
in any other clinical or physiological parameter with the exception of abdominal pain (lower during
GFD in CD patients, Table 4).
Table 4. The clinical, physiological, and other parameters before and after four weeks of consumption
of a gluten-free diet1.
CD (n = 6) NCGS (n = 12) Controls (n = 12)
















151 (110–222) 160.5(103–210) 207 (116–323) 185 (140–245) 198 (136–299) 175 (189–207)
HDL, mg/dL,
median (range) 38 (35–47) 37.4 (35–37) 43 (29–51) 41 (14–53.5) 36 (34–70) 46 (15–65)
LDL, mg/dL,
median (range) 91.8 (63–161) 104 (65–130) 109 (75–143) 121 (76–135) 106 (79–186) 120 (82–157)
Triglycerides, mg/dL,
median (range) 69.5 (40–230) 118 (38–157) 108 (62–270) 93 (70–217) 154 (83–277) 194 (73–247)
AST, UI/mL,
median (range) 29 (19–37) 21 (13–40) 23 (8–44) 20 (12–52) 26 (8–53) 19 (13–28)
ALT, UI/mL,
median (range) 22 (10–39) 25 (16–38) 19 (11–85) 22 (9–V61) 24 (11–51) 26 (19–33)
Severe abdominal
bloating (Likert), % 66% 0% 81% 25% NA NA
Severe abdominal pain
(Likert), % 50% 0% 42% 14% NA NA
Eosinophils DLP,





12 (0–29) 11 (0–43) 0 (0–22) 7.5 (0–22) 5 (0–20) 7.5 (5–33)
1 The only parameter that showed statistically significant difference was severe abdominal pain (p < 0.05, chi-squared
test). CD: Celiac disease; NCGS: non-celiac gluten sensitivity; GFD: gluten-free diet; HDL: high density lipoprotein;
LDL: low density lipoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; DLP: duodenal
lamina propria. NA: not applicable.
An additional 2.9 million sequences (1.8 million from a total of 24 biopsy samples, and 1.1 million
from a total of 12 fecal samples) were obtained from subjects on GFD. Paired samples were not
obtained for all subjects mainly because of the lack of compliance, especially with the submission of
stool samples (Table 1). Despite an apparently clear distinctive abundance and distribution of phyla in
duodenum between the periods with and without dietary gluten (Figure 5), there was no significant
difference in the abundance of any taxa between the two periods of time (p > 0.1), likely due to the high
inter-individual variability. Additional analyses of relative abundances in paired samples revealed
that each group of patients (controls, CD, and NCGS) displayed a distinctive variation over-time
after consuming the GFD for four weeks (for example, most NCGS patients displayed little change
after the GFD period, Figure 6). Interestingly, and despite a relatively more stable division-wide
composition, 9 out of 10 paired samples of patients with NCGS showed an increase in the duodenal
Pseudomonas on the GFD (Figure 7, baseline median: 1.3%, min/max: 0.47–6.8%; median after four
weeks on GFD: 14.8%, 2.3–38.5%, p < 0.01, Wilcoxon signed-rank test, only subject 7 showed a decrease
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in this group, from 4.3% to 2.5%). This difference in most individuals was specific for Pseudomonas
and not for other members of the duodenal microbiota (Figure 7). In contrast, only half of the paired
samples (3 out of 6) from CD patients showed increases in Pseudomonas but these increases were so
pronounced that they also affected median values (Figure 7). Additional analyses revealed that the
16S sequences from Pseudomonas were not different among the groups of subjects (see Figure S4 in
“3.1 Pseudomonas in duodenum” in the Supplementary Information), thus suggesting that taxonomically
similar Pseudomonas populations react differently in the presence of similar environmental conditions,
in this case, in the absence of dietary gluten. This is particularly relevant in a context of the ecological
significance of microdiversity [41].
Figure 5. The taxonomic composition of duodenal microbiota between the baseline period ((a), n = 30)
and the period after four weeks on GFD ((b), n = 24). Please note that the samples were organized
based on the abundance of the most abundant phylum (i.e., Proteobacteria). In the samples IDs: CD
(celiac disease), NCGS (non-celiac gluten sensitivity), CTRL (control subjects).
Figure 6. The taxonomic composition of duodenal microbiota for all paired samples from the CD
patients (a), controls (b) and patients with NCGS (c). The purpose of this plot is to illustrate the
over time variation within individuals. In samples IDs: CD (celiac disease), NCGS (non-celiac gluten
sensitivity), Ctrl (control subjects).
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Figure 7. The box plots showing the relative abundance of 16S rDNA reads corresponding to the three
most abundant bacterial groups in the duodenum at the genus level. * Significantly higher compared
to the period of gluten consumption (p < 0.05, Wilcoxon signed-rank test). Please note that 90% (9 out
of 10) and 50% (3 out of 6) of paired samples of patients with NCGS and CD (respectively) showed
an increase in Pseudomonas (see main text for more details on this). CD: celiac disease, Ctrl: controls,
NCGS: non-celiac gluten sensitivity, GFD: gluten-free diet.
LEfSe analysis of the taxa at the genus level confirmed the results on Pseudomonas and showed
that other Proteobacteria (e.g., Stenophomonas and Novosphingobium) were significantly more abundant
on the GFD, while Actinomycetaceae was lower before the GFD (Figure 8). On the other hand, LEfSe
did not reveal any taxa significantly associated with either a specific health status or with diet as
class and health status as a subclass. Interestingly, LEfSe analysis revealed that Brevundimonas (a very
low abundant group, <0.5% of all reads) was significantly enriched in CD patients when analyzing
health status as class and diet as a subclass. This result was mainly due to a higher abundance of
Brevundimonas in CD patients on the GFD. Other factors such as age, sex, or BMI were not significantly
associated with the abundance of any bacterial taxa accordingly to the LEfSe analysis; however,
this lack of significance must be taken cautiously because of the low sample size in each subgroup
of patients.
There was no significant difference in the bacterial richness or diversity in the duodenum when
comparing the period at baseline and after four weeks on GFD or health status using either the full
OTU table (Table 3) or the filtered OTU table (Table S1). The ANOSIM and Adonis tests revealed
interesting results to the factors associated with the differences in microbial composition among the
samples based on UniFrac distances (Table 5 and Supplementary Table S2). For example, the diet
factor almost reached a level of significance when analyzing the weighted UniFrac distances (Table 5
and Table S2). Additionally, the grouping of duodenal samples based on health status was found to
be statistically significant when using unweighted UniFrac distances and almost reached a level of
significance when using weighted UniFrac distances (Adonis test, Table 5 and Table S2). The age of the
patients also seemed to contribute to the separation of duodenal communities, especially when using
the filtered OTU table (Table S2). These results were supported by significance in the ANOSIM test
but the associated R values were very low (R < 0.10), indicating that the clustering of samples was
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relatively weak (Table 5 and Table S2). Please note that the analysis of both the full and the filtered
OTU table revealed similar results, thus suggesting that low-abundant OTUs did not play an important
role in the separation or lack thereof of communities.
Figure 8. The LEfSe results of the duodenal microbiota from the comparison of the baseline and the
period after four weeks on a GFD. These results are interesting because they also point out a potential
difference in the Pseudomonas populations.
Table 5. The R and p values resulting from the Adonis and ANOSIM tests from the analysis of all OTUs
(full OTU table) for each variable.
Biopsy Samples Fecal Samples
Adonis Test
Results
Weighted Unweighted Weighted Unweighted
Diet p = 0.053 p = 0.293 p = 0.406 p = 0.877
Disease p = 0.072 p = 0.006 p = 0.323 p = 0.195
Group p = 0.067 p = 0.080 p = 0.417 p = 0.494
Age p = 0.119 p = 0.060 p = 0.299 p = 0.201
BMI p = 0.401 p = 0.082 p = 0.007 p = 0.010
Biopsy Samples Fecal Samples
ANOSIM Test
Results
Weighted Unweighted Weighted Unweighted
Diet R = 0.038 p = 0.106 R = 0.014 p = 0.262 R = 0.009 p = 0.333 R = −0.071 p = 0.952
Disease R = 0.078 p = 0.026 R = 0.058 p = 0.058 R = 0.082 p = 0.136 R = 0.055 p = 0.221
Group R = 0.082 p = 0.039 R = 0.035 p = 0.174 R = 0.039 p = 0.307 R = −0.001 p = 0.482
Age R = 0.083 p = 0.034 R = 0.081 p = 0.032 R = 0.009 p = 0.349 R = 0.009 p = 0.392
BMI R = 0.034 p = 0.230 R = −0.050 p = 0.800 R = 0.132 p = 0.024 R = 0.155 p = 0.018
The variables included Diet (gluten/GFD), Disease (Control/CD/NCGS), Group (six groups of samples comprise
this category: Control, CD and NCGS before and after four weeks of GFD), Age (Young/Old), BMI (high/low).
p values that reached statistical significance (p < 0.05) or were close to reaching significance (p < 0.1) are highlighted
in bold for better visualization.
Considering the differences in relative abundance among the different bacterial groups of the
duodenal microbiota (e.g., the higher Pseudomonas on GFD in CD and NCGS patients), we hypothesized
that the beta diversity analyses for different bacterial populations may offer clues regarding the effect
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on different factors such as the diet and health status. Therefore, we used the Adonis and ANOSIM
tests to compare UniFrac distances for either all non-Proteobacteria OTUs and Pseudomonas OTUs only
(Supplementary Table S3). Despite obtaining low R values, thus suggesting the weak clustering of
communities, this additional analysis revealed that the effect of these factors is different in distinct
populations of microbes. For example, the effect of the BMI was stronger for Pseudomonas populations
(Table S3).
3.4.2. Effect of GFD on Fecal Microbiota
Gluten proteins are not completely digested in the small intestine and several members of the fecal
microbiota have the capacity to metabolize gluten [42]; therefore, the removal of gluten from the diet
may also affect the distal gut microbiota. In this study, however, both diet and health status were not
associated with differences in fecal bacterial richness or diversity (Table 3 and Supplementary Table S1).
LEfSe analysis did not find any indication to suggest a difference in fecal microbial communities
according to diet as the class or diet as a class and health status as a subclass. Interestingly, the LEfSe
approach revealed a diverse group of microorganisms that were significantly enriched in each of
the disease states when using health status as the main class (Figure 9). The family Veillonellaceae,
which was found to be lower in the feces of healthy subjects on GFD [21] and contains sulfite reducer
members [43], was included in this group (higher in CD patients, Figure 9). The analysis of health
status as class and diet as subclass revealed that Proteobacteria (in general, without an indication
of a particular taxon within) was more abundant in CD patients. Beta-diversity analyses of UniFrac
distances showed a significant grouping of fecal samples accordingly to BMIs and this relationship
was also independent of low-abundant OTUs (Adonis test, Table 5 and Table S2).
Figure 9. The LEfSe results of fecal microbiota from the comparison of all three groups of patients
regardless of diet.
3.4.3. Effect of GFD on the Predicted Functional Profile
The closed OTU picking approach yielded a total of 4958 OTUs in biopsies and fecal samples.
PICRUSt revealed no significant difference in the predicted functional profile of duodenal or fecal
microbiota accordingly to diet or health status. Interesting results were found (for fecal samples only)
when analyzing the group factor (six groups, control, CD and NCGS patients before and on GFD).
For example, the proportions of genes related to the propanoate metabolism were higher in CD patients
on a GFD (see “3.2 Predicted functional profile” in Supplementary Information) but caution must be
exerted because of the low sample size in each subgroup of patients.
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4. Discussion
Increasing evidence suggests a role of the gut microbiota in the onset and clinical development of
GRDs but this phenomenon has been mostly studied in Europe. This study sheds light for the first
time into the complex host-microbiota interactions in control subjects and patients with CD and NCGS
from México. Additionally, this study offers relevant clues regarding the potential effect of GFD on
health and gut microbiota.
The gluten metabolism is an interesting physiological phenomenon and growing evidence
suggests a strong involvement of the gut microbiota [44]. However, each individual carries a highly
specific group of microorganisms even at the strain level [1], and therefore such an involvement must be
highly individualized. More importantly, the response of these unique communities to environmental
factors (e.g., dietary changes, antibiotic administration) is also unique and may never return to the
exact same baseline state before the challenge [45]. Finally, the region where the individuals live is an
important factor, in fact, one study showed important interactions between the patients’ geographical
location and the clinical and microbiological manifestations of inflammatory bowel disease [16]. In this
study, for example, our results are unlikely to apply to patients with GRDs from other cities, even
within the same state of Veracruz.
From a clinical perspective, four weeks on GFD often improves symptoms and the quality of life
in patients with CD or NCGS and this paper shows that this period of time was also enough to change
the gut microbiota in our group of subjects, for example, duodenal Pseudomonas in NCGS patients.
In contrast, Tjellström et al. [46] showed that fecal short-chain fatty acids output (a direct result of
microbial activity) in CD patients with more than one year on GFD was significantly different compared
to the output in CD patients with less than one year on GFD and CD patients at the presentation, thus
suggesting that a long period of time on GFD may be necessary to fully re-establish the functioning
of the gut microbial ecosystem in some patients. It has also been shown that a subgroup of patients
does not respond positively even while adhering to a strict GFD and that these patients seem to harbor
distinctive microbiota [47]. Here we showed that each individual carries a highly specific gut microbial
composition, that the microbiota is different between healthy subjects and people with GRDs, and
that this microbiota can experience variation due to the removal of gluten. It is important to note
that this change also varies widely among individuals (the most significant and consistent change
was associated with duodenal Pseudomonas in NCGS patients but every individual showed a unique
increase or decrease in the abundance of these and other microorganisms).
The (unexpected) finding of higher abundance of Pseudomonas in some patients during GFD
deserves special attention. For instance, whether the increase in Pseudomonas is beneficial or not
to the integrity of the duodenal mucosa is uncertain. Clinicians often associate Pseudomonas with
diseases because of the pathogenic nature of some strains of P. aeruginosa and other species. However,
Pseudomonas is a highly heterogenic bacterial genus that includes thousands of non-pathogenic, highly
divergent strains inhabiting a wide variety of environments [48]. Unfortunately, very few studies have
paid attention to native gut-associated Pseudomonas [49–52]. The finding that a GFD is associated with
a higher abundance of Pseudomonas in the duodenum could be explained using at least two hypotheses.
First, gluten may lead to a given immunological status in the mucosa that interferes negatively with
the presence of autochthonous Pseudomonas, thus explaining the lower abundance at baseline. Second,
some members of Pseudomonas may act as a protective microbe and its low abundance may prompt
a more sensitive state to dietary allergens. This is supported by the relatively lower abundance of
Pseudomonas in CD and NCGS patients before the GFD (Figure 7).
The possibility that some members of Pseudomonas can act as protective agents suggest that some
strains of Pseudomonas may even be considered as probiotics for patients with some GRDs. Interestingly,
Gao et al. [53] showed that Pseudomonas and other bacteria were reduced in cancerous tissues compared
to adjacent non-cancerous tissues, thus suggesting a protective role in the gut mucosa. Wei et al. [54]
identified an interesting aciduric gluten-degrading enzyme from P. aeruginosa with a therapeutic
potential for CD; yet this does not explain whether GFD would lead to a higher or lower abundance of
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gluten-degrading Pseudomonas (we reasoned that gluten-degrading Pseudomonas populations would
grow preferentially only if gluten consumption offers a selective advantage). One study showed higher
abundances of Pseudomonas in the duodenum of adult CD patients on a GFD compared to controls but
this finding was not discussed at all [55]. This current study also suggests that other non-Pseudomonas
Proteobacteria (e.g., Stenophomonas) deserve attention in terms of gluten degradation and gut health.
This study also shows that the health status in terms of gluten sensitivity may be related to
differences in the distal digestive microbiota. For example, this study showed a higher abundance
of Ruminococcaceae in the fecal microbiota of NCGS patients. Additionally, Veillonellaceae,
a pro-inflammatory taxon that has been shown to be increased in patients with inflammatory bowel
disease and inflammatory bowel syndrome [56–58], was shown to be increased in fecal samples from
CD patients. This adds valuable information to a growing literature showing that the distal microbiota
is also worth looking at in gluten-related disorders [59].
This study has limitations that are relevant to future studies. First, this and other studies
lack a large enough sample size to generalize phenomena and even with bigger samples sizes the
results cannot be extrapolated from one population to others [17]. Second, gluten-free diets vary
widely around the world and these may or may not lead to a microbial state more similar to healthy
controls [13]. Third, 16S sequencing does not inform about the microbe-immune system interaction at
the cell level. In this regard, De Palma et al. [60] showed interesting differences in IgA-coated fecal
bacteria in treated and untreated CD patients, thus suggesting that a simple molecular characterization
of microbes is not enough to fully capture the complex relationship. Fourth, one study showed that
serum concentrations of short-chain fatty acids were similar in the control and CD patients; however,
the authors found an interesting difference between genders [61]. This is particularly important because
the reasons explaining the differences between genders with regards to the clinical presentation and
severity of GRDs and other autoimmune disorders have not been fully clarified. One hypothesis
suggests that infections can induce autoimmune diseases [62]. Finally, we only looked at the bacterial
microbiota here, yet non-bacterial organisms (e.g., yeasts) may play a role in these disorders [63].
5. Conclusions
In summary, this study generates valuable preliminary data about the relationship between the gut
microbiota and gluten-related disorders in Mexican people. Interestingly, the four-week consumption
of GFD was associated with an increased abundance of Pseudomonas in duodenal biopsies of patients
with these disorders, particularly in NCGS patients. This change was noticed despite a general lack of
differences in richness or diversity. Pseudomonas comprises strains with gluten-degrading capabilities
that deserves more attention. It is our hope that these results can contribute to starting to visualize
alternatives for the more effective treatment of afflicted patients in our area.
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Abstract: The importance of a gluten-free diet (GFD) in the treatment of celiac disease and other
gluten-related disorders is undisputable. However, strict GFD often lead to nutritional imbalances
and, therefore, to deficiencies. One of the most common deficiencies from a GFD are an insufficient
amount of Ca, Fe, Mg, and Zn. This is mainly because the most of popular gluten-free (GF) raw
materials are poor in minerals. Although the popularity of GFD is constantly growing, the data
on minerals in GF products are still limited. More importantly, an access to the data is even more
restricted. Therefore, the paper reviews the Ca, Fe, Mg, and Zn contents in hundreds of grain GF
products available worldwide. The data for 444 products from categories of flours, mixes for cooking,
bakery products, cereals, groats, rice, and pasta are obtained from research papers and nutritional
databases. The calculation of the realization of mineral requirements from a portion of each product
with its graphical classification as rich/average/poor source of each mineral is given. The review is
a handbook of minerals for people on a GFD, dietitians, and food producers.
Keywords: gluten-free diet; mineral; deficiency; calcium; iron; magnesium; zinc
1. Introduction
A gluten-free diet (GFD) has been the most popular elimination diet for more than a decade.
The number of people on a GFD is constantly increasing [1]. It results primarily from a “free from”
trend [2] and not from the higher prevalence of gluten-related disorders [3]. In the United States, more
than 100 million people consume gluten-free (GF) products with most of these people lacking any
gluten-related disorders [4].
Although GFD is associated with being more healthy [5], epidemiological studies indicate
nutritional imbalances for people following GFD. They refer both to macronutrients and micronutrients
including minerals. Vici [6] and Gobbetti [7] with coauthors reviewed data from clinical studies on
a nutritional status on a GFD indicating too high intake of energy, sugars, lipids, and saturated lipids
and too low intake of fiber, vitamin D, B-group vitamins, and minerals—Ca, Fe, Mg, and Zn.
Despite the huge popularity of GFD, the data on mineral content in GF products are still limited.
More importantly, an access to such data is even more restricted. The improvement of the nutritional
quality of GFD, which is mentioned by many researchers [7–10], should start in the quality assessment
of available products. The constant expansion of the GF nutritional data together with alimentary
education are key elements for successful therapy in gluten-related disorders. Therefore, the aim of
the study was to develop a database of Ca, Fe, Mg, and Zn in grain gluten-free products available
worldwide. The results are presented in separate tables for each mineral in a way that allows quick
recognition for the products of high content of the nutrient from different categories. The review is
a handbook of minerals not only for people on a gluten-free diet but also for food producers and
dietitians who play a crucial role in the education of patients with gluten-related disorders.
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2. Materials and Methods
2.1. Methods
The data were electronically searched for keywords in different national databases and literature
data. The keywords included in the study were: “gluten-free” (“gluten free”) plus “mineral” (including
“calcium” or “iron” or “magnesium” “or “zinc” or “element” or “microelement” or “macroelement”).
The study was restricted to the publications after 1 January 2005.
Data from nutritional databases are presented as they were found. When producer or ingredients
were given, they are presented. The data obtained from research articles included only products with
detailed material’s description or ingredients or the recipe.
2.2. Data Extraction
Data selection under the study is presented in Scheme 1.
Scheme 1. Data selection scheme.
Literature references were searched in the Scopus while the nutritional databases under the study
were those found on the FAO website [11]. The study includes databases from the United States [12,13],
Australia [14], Canada [15], and several European countries [16–21]. Records with at least one mineral
of interest were analyzed. All commercial products selected from the nutritional databases were
described as “gluten-free” or were signed with the Cross Grain symbol. Products from research studies
had to be described as GF. Raw materials and naturally gluten-free products not described as a GF,
e.g., rice, buckwheat, and groats were omitted.
3. Results & Discussion
A total of 444 GF products were incorporated into the study including 186 products from literature
data (23 articles and book chapters) and 258 GF products from 10 databases. Databases included in
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the study were from the United States (212 products) [12,13], Germany (14 products) [16], Norway
(10 products) [17], Holland (7 products) [18], Australia (6 products) [14], Finland (6 products) [19],
Belgium (2 products) [20], Canada (2 products) [15], and Estonia (1 product) [21].
No GF hits for minerals of interest were found in databases form: Armenia [22], the Czech Republic [23],
Denmark [24], France [25], Greece [26], Iceland [27], Italy [28], Latvia [29], Serbia [30], Slovakia [31], Spain [32],
Sweden [33], Switzerland [34], Turkey [35], and the United Kingdom [36].
The handbook replies only to grain GF products since they should partially consist of the everyday
diet. Even though grain products are not the best source of all analyzed minerals (e.g., Ca), due to their
substantial daily consumption, they significantly realize daily requirements for nutrients.
Moreover, different studies indicate that the proportion of the main nutrients on GFD is improper
and that people on a GFD often omit some assortment of grain products like commercial bakery
products [37]. Only grain products that should consist of the everyday diet were included in the study.
Cookies and snacks, e.g., crackers, were not taken into account. The total number of grain GF products
was significant. Therefore, they were divided into categories shown below.
I—flours
II—mixes for cooking
III—bakery products (e.g., breads, rolls, dinner rolls, crack bread)
IV—cereals (plain and musli flakes)
V—grains and rice
VI—pasta
All included products were described as GF. When the manufacturer or a brand was known,
the ingredients were not presented since consumers can easily recognize these products. When the
producer was unknown, the main ingredients were presented (if applicable).
The daily portion for each category was established. For the I, II, and IV category, it was 30 g,
for V and VI, it was 50 g, and, for III, it was 100 g. The percent of Reference Nutrient Intakes (RNIs)
were calculated for 800 mg, 14 mg, 375 mg, and 10 mg for Ca, Fe, Mg, and Zn, respectively [38].
Moreover, different colors were given to show the contribution of the portion of each product to
realization of daily requirements for minerals (Figure 1). Dark green indicated that these products are
a good source of nutrients (>25% of RNI), bright green indicates a moderate source (10% to 25% of
RNI), and white indicates a poor source (<10% of RNI).
Figure 1. The criteria of product classification to high, moderate, and low contribution to realization of
daily requirements for Ca, Fe, Mg, and Zn.
Tables S1–S4 present the data for Ca, Fe, Mg, and Zn, respectively, in a range of GF products
separately for each category. The data were expressed in mg for 100 g of the edible product
(fresh matter). The data were sorted from the highest to the lowest content of each mineral. If original
data are presented in dry matter and the moisture is given, data were calculated into fresh matter.
The authors of dry matter data were asked for water content data. When they did not answer or
the data were unavailable, the data were calculated for the average moisture of 10% for VI category,
15% for I, II, IV, and V category, and 40% for III category [39,40]. The data for equal products from
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different references were averaged, e.g., the content of Ca in amaranth flour presented in Table S1 was
calculated from values from four references. For these products, the minimum and maximum contents
were presented.
As presented in Table S1, only three products were characterized by high content of Ca. These were
crisp bread [17] and white and brown breads included in the Dutch database [18]. Additionally, 34 were
of moderate contribution to the daily intake of Ca and most of them were bakery products. No data
for calcium were found for a quarter of GF products (113 products). As mentioned above, because of
significant daily consumption of grain products, they contribute to the daily intake of Ca even though
they are not considered a good source of that mineral.
Databases and literature references were well-supplied with Fe data. Only 36 out of 444 products
did not deliver data on iron content (Table S2). A total of 23 products were classified as an important
source of Fe including most from categories of bakery products and pasta. Additionally, 112 products
from all categories were of moderate contribution to daily intake of Fe.
In addition, 63% of selected products (278 items) were not characterized by the content of Mg
(Table S3). From the remaining 166 products, only six bakery products (e.g., crisp breads) were
classified as an important source of magnesium [12,14,16,18,19]. A total of 53 products for the I, III, IV,
and VI category were of moderate content of Mg. None of the products from the II and V category
were regarded as of high or moderate impact on the realization of Mg requirements.
Most of the products (372 items) did not deliver data on Zn content (Table S4). Only eight
products (mostly crisp breads) were classified as of high impact on daily intake of zinc [12,17,19,41–43].
Twenty-nine products from 5 out 6 categories were described as a moderate source of Zn. All products
from category II were assigned as a poor source of zinc.
The content of minerals in food product primarily results from its ingredients especially
raw materials. Thus, in Table 1, contents of Ca, Fe, Mg, and Zn in the most popular GF raw
materials—amaranth, buckwheat, chickpea, corn, millet, quinoa, rice, sorghum, tapioca, and teff
were given. Original data expressed in dry matter were calculated into fresh matter at the level
of 15% water [44]. As shown in Tables S1–S4, most of the GF products available in the worldwide
market were produced from rice and corn, which are not a good source of macro-elements and
microelements. Pseudo cereals like amaranth, quinoa, or teff are e.g., excellent sources of Fe and
Mg, but their characteristic aroma and flavor limit their application in significant quantities in food
products. For example, the most preferable amount of teff in breads should not exceed 10% [45].
Many researchers underline the necessity of the improvement of nutritional quality of GFD by replacing
the low-nutritional GF raw materials with pseudo cereals with high nutritive value or by fortification
with minerals [7–10]. The presented data on the mineral composition in commercial GF products
(Tables S1–S4) along with information on the abundance of cereals and pseudo cereals in minerals
(Table 1) prompt how to mix them in order to obtain nutritionally balanced food or meal. For example,
5% of an addition of acorn flour to the Gluten Free Cornbread Mix produced by The King Arthur Flour
Company Inc. (Norwich, VT, USA) [12] will enrich it in iron by approximately 10%.
Nevertheless, review on recent literature revealed several important drawbacks. One of the most
worrisome is the lack of data on Mg and Zn contents in the majority of GF products. Most of the total
444 foods included in the study did not have data on zinc (84% products). The data on magnesium
was also very limited. In fact, 63% of products had no data on that mineral. Another problem
was the quality of some of the presented results. Data presented from the largest database, USDA,
is open for everybody and it allows manufacturers to describe their products. It can lead to the
overestimation of their products. Thus, the ideal situation is building the databases based on the
analytical determinations like those presented by e.g., Mazzeo and co-authors [56].
In addition, the problem is that the average consumer does not have access to literature
references. Therefore, the actualization of online nutritional databases is the most preferable way
to achieve this goal. The data should be developed at national levels and should be easily accessed.
Nutritional databases should be free, on-line, and regularly updated. Providing the free-of-charge
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nutritional databases should be one of the key responsibilities for national food and nutrition institutes.
The availability and quality of nutritional databases is even more crucial for the assortment of GF
products since GFD is the only efficient treatment for celiac disease and other gluten-related disorders.
Table 1. The content of Ca, Fe, Mg, and Zn in GF cereals and pseudo cereals.




61 4 6.2 6 129 2 1.4 5 1 [46]
153 5 7.6 3 231 1 2.2 2 2 [47]
159 3 7.8 5 237 5 2.9 3 3 [48]
165 1 8.9 4 248 3 3.9 6 4 [49]
170 6 9.6 1 279 6 5.6 1 5 [50]
497 2 16 2 313 4 n.a. * 4 6 [51]
Buckwheat
15 2 2.4 2 173 1 0.9 1 1 [50]
52 1 4.0 1 204 2 1.6 2 2 [51]
Chickpea 93–197 1 4.6–6.7 1 125–159 1 3.7–7.4 1 1 [52]
Corn
Purple < LOQ 1 Purple 2.78 1 Purple 118 1 Purple 2.5 1 1 [46]
Yellow 7 2 Yellow 2.7 2 Yellow 127 2 Yellow 2.2 2 2 [12]
Millet
8 2 3 2 103 1 1.7 2 1 [21]
9 1 4.8 1 114 2 3.4 1 2 [12]
Quinoa
24–127 2 1.2–14 2 22–427 2 1.5 6 1 [46]
26 4 3.6 7 131 4 2.4–4.1 2 2 [53]
28 6 3.7 4 167 7 2.5 3 3 [21]
44 1 4.7 6 176 6 2.5 7 4 [36]
61 5 5.5 1 197 1 2.9 1 5 [49]
66 7 8 3 275 3 3.3 4 6 [50]
80 3 8.9 5 313 5 n.a. 5 7 [51]
Rice
Brown 32 1 White 0.22 1 White n.d. * 2 White n.d. * 3 1 [46]
White < LOQ 1 0.8 3 13 3 0.5 2 2 [53]
10 3 1.2 2 27 1 1.0 1 3 [49]







1 Red 2.2 1 Red 106 1 Red 1.5 1 1 [21]
Red 15 1 Wild 1.27 1 Wild 108 1 Wild 4.3 1 1 [21]











2 3.4 2 162 1 n.a. * 1 1 [49]
28 1 4.4 1 165 2 1.7 2 2 [12]
Tapioca 16
1 1.3 1 1 2 n.a. * 1 1 [49]











180 2 7.6 2 184 2 3.6 2 2 [55]
* 1–7 the superscript numbers refer to references from the last column, n.a.—not available, n.d.—not detected.
4. Conclusions
The handbook of minerals on GFD allows for the quick recognition of the best sources of Ca,
Fe, Mg, and Zn. These are elements that are often deficient when excluding gluten. When analyzing
the mineral composition of GF grain products, it is common to identify that they are rarely rich or
moderate source of minerals. It applies in particular to the most popular GF products made with
starches and refined flours. What is even more disturbing is the limited data on Mg and Zn contents in
GF products. Additionally, access to this information is very restricted. The easily accessed nutritional
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databases for GF products should by developed at a national level and at international levels. Only then
nutritional education, which is a crucial element of treating gluten-related disorders, would be credible
and effective.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/11/1683/
s1, Table S1: Calcium in gluten-free I—flours, II—mixes for cooking, III—bakery products, IV—cereals and flakes,
V—groats and rice, VI—pasta. Table S2: Iron in gluten-free I—flours, II—mixes for cooking, III—bakery products,
IV—cereals and flakes, V—groats and rice, VI—pasta. Table S3: Magnesium in gluten-free I—flours, II—mixes for
cooking, III—bakery products, IV—cereals and flakes, V—groats and rice, VI—pasta. Table S4: Zinc in gluten-free
I—flours, II—mixes for cooking, III—bakery products, IV—cereals and flakes, V—groats and rice, VI—pasta.
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Abstract: Background: There is evidence that digestive motor disorders are frequently present
in untreated celiac disease (CD) patients. Similarly, non-celiac gluten sensitivity (NCGS) can be
associated with gut motor disorders. In both cases, gut dysmotility can improve or be completely
reversed with a gluten-free diet (GFD). Methods: A literature search for motility disorders in CD
and NCGS patients was carried out using the online databases PubMed, Medline and Cochrane.
Results: Esophageal, gastric, small bowel and gallbladder motor disorders are common in both
children and adults with CD. Although the clinical consequences of these disorders are not
clearly defined, gastric dysfunction could affect drug absorption and metabolism in the thyroid
and neurological conditions associated with CD. The impact of a GFD on motility disorders is,
however, controversial. No systematic studies are available on NCGS. NCGS frequently overlaps
with irritable bowel syndrome (IBS) and similar pathophysiological mechanisms may be hypothesized.
Conclusions: Mucosal damage may affect gut motility in untreated CD through perturbation of
hormonal and neuro-immunomodulatory regulation. A persistent low-grade mucosal inflammation
could explain the cases of persistent motor disorders despite a GFD. Further studies are needed to
definitely assess the role of gut motor disorders in NCGS.
Keywords: celiac disease; non-celiac gluten sensitivity; gut motility; gluten-free diet
1. Introduction
Celiac disease (CD) is a permanent, chronic, gluten-sensitive disorder characterized by
small intestinal mucosal injury and malabsorption in genetically predisposed individuals [1].
Self-reported wheat sensitivity without the diagnostic features of CD or wheat allergy has recently
been named non-celiac gluten sensitivity (NCGS) [2]. Unlike CD, NCGS has no specific diagnostic test
available. There is evidence suggesting that abnormal gut motility may frequently be present in CD
and that all of the gastro-intestinal tract, including the gallbladder, can be involved. Several studies
have shown that a gluten-free diet (GFD) can improve or normalize these disorders [3–10].
Not surprisingly, the data on motility disorders in NCGS are just emerging. In addition, a possible
overlap between intestinal bowel syndrome (IBS) and gluten related disorders have been clearly
demonstrated [11]. The aim of this review was to provide an overview of gut motility abnormalities
in these gluten related disorders and to establish the real clinical impact of a GFD on these
functional diseases.
2. Materials and Methods
A review of the literature on motility disorders in CD and NCGS patients was conducted using
the online databases PubMed, Medline and Cochrane. Original research, reviews, and relevant books
Nutrients 2018, 10, 1705; doi:10.3390/nu10111705 www.mdpi.com/journal/nutrients143
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were included in the search. All the validated motility methods, manometry, pH-metry, gastric
emptying studies (scintigraphy, octanoic acid breath testing and ecography), gallbladder ecography
and lactulose breath testing for oro-cecal transit time, were included in this review.
3. Celiac Disease
3.1. Esophageal Motor Disorders
In two successive studies, using standard esophageal manometry, we found motor abnormalities
in 67% of the adult patients examined [5,12]. These alterations consisted of nutcracker esophagus,
a hypotonic lower esophageal sphincter (LES) and frequent repetitive (>3 peaks) contractions.
Interestingly, 50% of celiac patients complained of dysphagia compared with only 9% of controls
(p < 0.001) [12]. In addition, we performed esophageal pH-metry and the acid score was abnormal
in 30% of celiac patients [5]. In 1998, Iovino et al. [13] confirmed that adult celiac patients with
steatorrhea presented a higher prevalence of esophageal symptoms and a lower LES pressure when
compared with celiac patients without steatorrhea and control subjects. Preliminary results from
a more recent South American study demonstrated motility alterations in 83% of CD patients using
esophageal manometry and pH-impedance [14].
3.2. Gastric Emptying Dysfunction
There is evidence suggesting that gastric emptying (GE) may frequently be delayed in CD patients,
although a direct correlation to specific dyspeptic symptoms is not clear. To assess gastric emptying,
different methods are available and they generally agree to demonstrate an altered gastric function in
both children and adults with CD. In 1997, we documented delayed gastric emptying in 50% of the
adult celiac patients examined in a scintigraphic study [5]. Similar results were observed by Perri et al.
in a pediatric population of CD patients by using octanoic acid breath testing (OBT) [7]. Further studies
using ecography and OBT confirmed that gastric emptying was constantly delayed in CD patients
compared with that in healthy controls [8–10]. Recently, we performed OBT on a group of untreated
adult celiac patients and 75% of them showed delayed gastric emptying with no significant correlation
to specific dyspeptic symptoms [15].
3.3. Small Bowel Motility Disorders
Bassotti et al. [3] were the first to manometrically display fasting motor abnormalities, represented
by discrete clustered contractions, giant jejunal contractions and bursts of non-propagated contractions
in both adults and children with CD. Cucchiara et al. [4] evaluated 14 untreated pediatric CD
patients by manometric study, and found that 90% had a reduced postprandial antral motility index,
shorter activity fronts, prolonged small bowel phasic activity and uncoordinated peristalsis. In the
study of 1997 we also performed a gastro-intestinal manometry to assess gastric and small bowel
motility in CD patients [5]. During the fasting period 75% of celiac patients showed abnormal
propagation of activity fronts and clustered contractions. The duration of antral contractile response
to the standard meal was reduced compared with that of control subjects. A more recent study
by Bassotti et al. confirmed that more than 80% of untreated celiac patients had discrete motor
abnormalities of the upper gut in both fasting and fed periods [16].
3.4. Oro-Cecal Transit and Colonic Motor Disorders
Delayed oro-cecal transit in CD patients has been frequently demonstrated by the breath test
method. Spiller et al. [17] first showed increased transit time in CD patients with steatorrhea compared
with that in healthy controls. More recently, Chiarioni et al. [6] found delayed oro-cecal time in 16 adult
CD patients by way of lactulose breath testing. Bai et al. [18] confirmed the results of oro-cecal transit
while colonic transit measured by radiopaque markers (Metcalf method) showed faster transit times in
untreated CD patients. In 2012, Benini et al. [19] showed that mouth-to-cecum transit time was more
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prolonged in CD patients than in controls. The same study performed colonic transit with radiopaque
markers but no differences were found between celiac patients and controls. No studies are available
on ano-rectal motility disorders in CD patients.
3.5. Gallbladder Motility
Gallbladder (GB) motility in CD patients has been studied since the 1970s. The scintigraphy
performed in earlier studies and more recent ultrasonography agree upon delayed GB emptying in
untreated celiac patients [20,21]. These abnormalities were associated with decreased peak plasma CCK
levels and increased basal plasma somatostatin values. Benini et al. [19] performed a study to assess
GB motility by means of ultrasonography and found that GB fasting volume and postprandial residual
volume were significantly higher in CD patients than in controls.
3.6. Pathophysiological Mechanisms of Motility Disorders in CD Patients
It has been hypothesized that mucosal damage and inflammation may affect contractile gut
motility through perturbations of the complex hormonal and neuro-immunomodulatory regulation
of the intestinal mucosa. Low-grade mucosal inflammation and mast-cell infiltration could play
an important role in untreated CD [22], as well as having been observed in patients with irritable
bowel syndrome (IBS) [23]. Earlier studies showed that the secretion of several hormones regulating
gastrointestinal motility could be altered as a consequence of intestinal mucosal damage [24,25].
A decrease in cholecystokinin and an increase in somatostatin have been implicated in gallbladder
dysmotility, while an increase in neurotensin and plasma peptide Y levels has been suggested as
a cause of delayed gastric emptying and esophageal abnormalities [9].
Another underlying mechanism for motor disorders in CD patients may relate to autonomic
nervous system dysfunction [26]. In particular, we observed that extrinsic autonomic neuropathy
could play a role in provoking upper-gut motor disorders in untreated CD patients [5].
3.7. Clinical Consequences of Motility Disorders in CD Patients
As already described dysphagia is a frequent complaint of celiac patients [12,13], although severe
motor disorders and serious nutritional consequences have not been described in these cases.
In addition, gastro-esophageal reflux may be more frequent in CD patients than in the general
population [5], which could suggest a specific therapeutic approach.
Surprisingly, a direct correlation to specific dyspeptic symptoms has not been demonstrated
in the presence of delayed gastric emptying either in children or in adults with CD [5,7,10].
Similarly, small bowel dysmotility and altered oro-cecal transit have not been associated with specific
clinical or nutritional problems.
On the other hand, special attention should be paid to the therapeutic implications of
neurological conditions and thyroid dysfunction frequently associated with CD [27,28]. In these
cases, gut dysmotility and, in particular, delayed gastric emptying could affect drug absorption
and metabolism.
3.8. The Impact of GFD on Digestive Motor Disorders
Several articles have assessed the effects of a GFD on gut motor disorders, with conflicting results
(Table 1). The majority of these studies showed that motor disorders can be completely reversible with
a GFD.
Iovino et al. [13] showed that the prevalence of esophageal symptoms was significantly reduced
in celiac patients after a year of a GFD. According to manometric evaluation, LES pressure was also
significantly greater while on a GFD rather than on free diet.
Using OBT, Perri et al. [7] demonstrated that delayed gastric emptying could be normalized
in the pediatric population afflicted by CD by means of a GFD. Similarly, a more recent OBT
study showed that gluten withdrawal was effective in normalizing the gastric emptying time in
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all adult CD patients [10]. Benini et al. [8], using ultrasonography, showed that, after jejunal
recovery, gastric emptying of the meal containing gluten remained unchanged, whereas emptying of
the gluten-free meal was significantly shortened.
In a manometric small bowel study, four pediatric patients repeated the manometry after six months
of a GFD and the traces had normalized [4]. Furthermore, a GFD normalized mouth-to-cecum transit
in adult patients with CD in the study by Chiarioni et al. [6]. Finally, ecographic studies proved a GFD
normalizes gallbladder motility [19,21].
On the other hand, we recently showed that delayed gastric emptying did not normalize on
a GFD, despite the improved symptom score [15]. In addition, patients on a GFD showed motor
abnormalities, albeit to a lesser extent than untreated CD subjects, in a small bowel manometric
study [16]. In these patients, histological evaluation displayed the persistence of mild mucosal
inflammation. Mouth-to-cecum transit time remained unchanged or more prolonged in CD patients
than in controls after the introduction of a GFD in a lactulose breath testing study [19]. The same
authors observed that duodenal infiltration with lymphocytes and mast cells remained higher than that
in controls after gluten withdrawal.
Table 1 summarizes gut motility results in untreated and treated CD patients.
Table 1. Summary of more significant studies on gut motility in celiac disease (CD).
Authors [Ref] Organs Subjects Methods Findings on GFD
Bassotti [3] Small bowel Adult and children CD Manometry Major frequence of migratingmotor complex No detected






Manometry Nutcracker esophagus, esophageal




Chiarioni [6] OCT Adult CD Lactulose BT Increased OCT OCT normalized
Perri [7] Stomach Children CD Octanoic BT Delayed GE GE normalized
Benini L [8] Stomach Adult CD Ecography Delayed GE GE partiallynormalized
Rocco [10] Stomach Adult CD Octanoic BT Delayed GE GE normalized
Usai [12] Esophagus Adult CD
Manometry Hypotonic LES, repetitive waves No detectedpH-metry
Iovino [13] Esophagus Adult CD Manometry Hypotonic LES Increased LESpressure
Usai Satta [15] Stomach Adult CD Octanoic BT Delayed GE Unchanged GE
Bassotti [16] Small bowel Adult CD Manometry Shorter activity front Unchanged data
Spiller [17] OCT Adult CD Lactulose BT Delayed OCT No detected
Benini F [19] Gallbladder, OCT Adult CD
Ecography




Fraquelli [21] Gallbladder Adult CD Ecography Delayed GB emptying GB emptyingnormalized
Notes: CD: celiac disease; GFD: gluten free diet; OCT: oro-cecal transit; LES: lower esophageal sphincter;
BT: breath test; GE: gastric emptying; GB: gallbladder.
4. Non-Celiac Gluten Sensitivity (NCGS)
Digestive Motor Disorders and NCGS
Although no systematic studies have assessed overall gastro-intestinal and gallbladder motor
disorders in NCGS, some indirect evidences support the hypothesis of a possible derangement of
digestive motor function in these patients [29].
Preliminary results by a pilot study suggest that patients with NCGS can present with colonic
motility alterations that improve after implementation of a GFD [30].
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The complex of symptoms associated with gluten-related disorders and in particular NCGS,
such as diarrhea, constipation or abdominal pain, may overlap and be similar to those caused by
irritable bowel syndrome with diarrhea (IBS-D) [11]. IBS complaints are often part of the NCGS
clinical picture. For subjects diagnosed with NCGS, the ingestion of gluten exerts a direct effect on
the onset of digestive symptoms and the exclusion of gluten is the treatment of choice. Only a portion
of the patients with IBS relate their symptoms to a gluten-containing diet. In a randomized controlled
trial, a gluten-containing diet provoked an increase in the number of bowel movements per day
and higher small bowel permeability compared with a GFD in IBS-D patients [31]. No differences in
overall gastro-intestinal motility were observed after one month of a GFD. Experimental data showed
that transgenic mice, sensitized by gluten, had an altered barrier function and enhanced muscle
contractility [32]. Furthermore, gluten-induced symptoms in IBS-D patients were associated with
increased myosin light chain kinase activity and claudin-15 expression, as described in a recent
trial [33].
On the other hand, it was recently demonstrated that gluten ingestion can exert objective effects
on gastric and gallbladder motility in healthy subjects [34]. The potential role of proteins other
than gluten on gastric and gallbladder motility has been hypothesized. In fact, other wheat components,
such as amylase-tripsin inhibitors or fructans, have been linked to the development of gastrointestinal
symptoms in both patients with NCGS and IBS [35,36].
5. Conclusions
Gut motility is frequently abnormal in untreated CD in both children and adults. Most pediatric
studies address gastro-intestinal motor disorders and show similar findings to those of adult CD patients.
These abnormalities may be independent of the presence and grading of symptoms. Special attention
should be paid to possible nutritional and pharmacological consequences. In the majority of studies,
a GFD improved or normalized these abnormalities. In the case of these disorders persisting while
the patient is on a GFD, the presence of a chronic low-grade mucosal inflammation with permanent
perturbation of the neuro-immunomodulatory regulation may be hypothesized.
Due to the absence of structured studies, data on motility disorders in NCGS are just emerging.
The clinical picture of IBS can overlap with NCGS. Further studies are needed to definitely assess
the role of gut motor disorders in NCGS.
Author Contributions: All authors provided input on the content of the manuscript. All authors read and approved
the final manuscript.
Funding: This review received no external funding.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Kelly, C.P.; Bai, J.C.; Liu, E.; Leffler, D.A. Advances in diagnosis and management of celiac disease.
Gastroenterology 2015, 148, 1175–1186. [CrossRef] [PubMed]
2. Catassi, C.; Elli, L.; Bonaz, B.; Bouma, G.; Carroccio, A.; Castillejo, G.; Cellier, C.; Cristofori, F.; De Magistris, L.;
Dolinsek, J.; et al. Diagnosis of non-celiac gluten sensitivity (NCGS): The Salerno experts’ criteria.
Nutrients 2015, 7, 4966–4977. [CrossRef] [PubMed]
3. Bassotti, G.; Castellucci, G.; Betti, C.; Fusaro, C.; Cavalletti, M.L.; Bertotto, A.; Spinozzi, F.; Morelli, A.;
Pello, M.A. Abnormal gastrointestinal motility in patients with celiac sprue. Dig. Dis. Sci. 1994, 39, 1947–1954.
[CrossRef] [PubMed]
4. Cucchiara, S.; Bassotti, G.; Castellucci, G.; Minella, R.; Betti, C.; Fusaro, C.; Morelli, A.; Bertotto, A.;
Auricchio, S. Upper gastrointestinal motor abnormalities in children with active celiac disease. J. Pediatr.
Gastroenterol. Nutr. 1995, 21, 435–442. [CrossRef] [PubMed]
5. Usai, P.; Usai Satta, P.; Lai, M.; Corda, M.G.; Piras, E.; Calcara, C.; Boy, M.F.; Morelli, A.; Balestrieri, A.;
Bassotti, G. Autonomic dysfunction and upper digestive functional disorders in untreated adult celiac
disease. Eur. J. Clin. Investig. 1997, 27, 1009–1015. [CrossRef]
147
Nutrients 2018, 10, 1705
6. Chiarioni, G.; Bassotti, G.; Germani, U.; Battaglia, E.; Brentegani, M.T.; Morelli, A.; Vantini, I. Gluten-free diet
normalizes mouth-to-cecum transit of a caloric meal in adult patients with celiac disease. Dig. Dis. Sci. 1997,
42, 2100–2105. [PubMed]
7. Perri, F.; Pastore, M.; Zicolella, A.; Annese, V.; Quitadamo, M.; Andriulli, A. Gastric emptying of solids is
delayed in celiac disease and normalizes after gluten withdrawal. Acta Paediatr. 2000, 89, 921–925. [CrossRef]
[PubMed]
8. Benini, L.; Sembenini, C.; Salandini, L.; Dall’O, E.; Bonfante, F.; Vantini, I. Gastric emptying of realistic
meals with and without gluten in patients with coeliac disease. Effect of jejunal mucosal recovery.
Scand. J. Gastroenterol. 2001, 36, 1044–1048. [PubMed]
9. Elli, L.; Bardella, M.T. Motility disorders in patients with celiac disease. Scand. J. Gastroenterol. 2005,
40, 743–749. [CrossRef] [PubMed]
10. Rocco, A.; Sarnelli, G.; Compare, D.; De Colibus, P.; Micheli, P.; Somma, P.; Marotti, B.; Cuomo, R.; Nardone, G.
Tissue ghrelin level and gastric emptying rate in adult patients with celiac disease. Neurogastroenterol. Motil.
2008, 20, 884–890. [CrossRef] [PubMed]
11. Catassi, C.; Alaedini, A.; Bojarski, C.; Bonaz, B.; Bouma, G.; Carroccio, A.; Castillejo, G.; De Magistris, L.;
Dieterich, W.; Di Liberto, D.; et al. The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS)
and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update. Nutrients 2017, 9, E1268. [CrossRef]
[PubMed]
12. Usai, P.; Bassotti, G.; Usai Satta, P.; Cherchi, M.; Plesa, A.; Boy, F.; Morelli, A.; Balestrieri, A.
Oesophageal motility in adult coeliac disease. Neurogastroenterol. Motil. 1995, 7, 239–244. [CrossRef]
[PubMed]
13. Iovino, P.; Ciacci, C.; Sabbatini, F.; Acioli, D.M.; D’Argenio, G.; Mazzacca, G. Esophageal impairment in adult
celiac disease with steatorrhea. Am. J. Gastroenterol. 1998, 93, 1243–1249. [CrossRef] [PubMed]
14. Nachman, F.; Pinto-Sanchez, M.I.; Salím, S.; Hwang, H.J.; Costa, F.; Longarini, G.; Ditaranto, A.; Fuxman, C.;
Vazquez, H.; Moreno, M.L.; et al. Disfuncion esofágica en pacientes con enfermedad celiaca (abstract).
Acta Gastroenterol. Latinoam. 2014, 44, S10.
15. Usai-Satta, P.; Oppia, F.; Scarpa, M.; Giannetti, C.; Cabras, F. Delayed gastric emptying does not normalize
after gluten withdrawal in adult celiac disease. Scand. J. Gastroenterol. 2016, 51, 923–926. [CrossRef] [PubMed]
16. Bassotti, G.; Villanacci, V.; Mazzocchi, A.; Mariano, M.; Incardona, P.; Clerici, C.; Morelli, A.
Antroduodenojejunal motor activity in untreated and treated celiac disease patients. J. Gastroenterol. Hepatol.
2008, 23, e23–e28. [CrossRef] [PubMed]
17. Spiller, R.C.; Lee, Y.C.; Edge, C.; Ralphs, D.N.L.; Stewart, J.S.; Bloom, S.R.; Silk, D.B. Delayed mouth-caecum
transit of a lactulose labelled liquid test meal in patients with steatorrhea caused by partially treated coeliac
disease. Gut 1987, 28, 1275–1282. [CrossRef] [PubMed]
18. Bai, J.C.; Mauriño, E.; Martínez, C.; Vasquez, H.; Niveloni, S.; Solfer, G.; Flores, D.; Boerr, L.A.
Abnormal colonic transit time in untreated celiac sprue. Acta Gastroenterol. Latinoam. 1995, 25, 277–284.
[PubMed]
19. Benini, F.; Mora, A.; Turini, D.; Bertolazzi, S.; Lanzarotto, F.; Ricci, C.; Villanacci, V.; Barbara, G.;
Stanghellini, V.; Lanzini, A. Slow gallbladder emptying reverts to normal but small intestinal transit of
a physiological meal remains slow in celiac patients during gluten-free diet. Neurogastroenterol. Motil. 2012,
24, e79–e80. [CrossRef] [PubMed]
20. Low-Beer, T.S.; Harvey, R.F.; Davies, E.R.; Read, A.F. Abnormalities of serum cholecystokinin and gallbladder
emptying in celiac disease. N. Engl. J. Med. 1975, 292, 961–963. [CrossRef] [PubMed]
21. Fraquelli, M.; Bardella, M.T.; Peracchi, M.; Cesana, B.M.; Bianchi, P.A.; Conte, D. Gallbladder emptying
and somatostatin and cholecystokinin plasma levels in celiac disease. Am. J. Gastroenterol. 1999, 94, 1867–1870.
[CrossRef] [PubMed]
22. Strobel, S.; Busuttil, A.; Ferguson, A. Human intestinal mucosal mast cells: Expanded population in untreated
coeliac disease. Gut 1983, 24, 222–227. [CrossRef] [PubMed]
23. Barbara, G.; Stanghellini, V.; De Giorgio, R.; Corinaldesi, R. Functional gastrointestinal disorders and mast
cells: Implications for therapy. Neurogastroenterol. Motil. 2006, 18, 6–17. [CrossRef] [PubMed]
24. Besterman, H.S.; Bloom, S.R.; Sarson, D.L.; Blackburn, A.M.; Johnston, D.I.; Patel, H.R.; Stewart, J.S.;
Modigliani, R.; Guerin, S.; Mallinson, C.N. Gut-hormone profile in coeliac disease. Lancet 1978, 1, 785–788.
[CrossRef]
148
Nutrients 2018, 10, 1705
25. Sjolund, K.; Alumets, J.; Berg, N.O.; Hakanson, R.; Sundler, F. Duodenal endocrine cells in adult coeliac
disease. Gut 1979, 20, 547–552. [CrossRef] [PubMed]
26. Gibbons, C.H.; Freeman, R. Autonomic neuropathy and coeliac disease. J. Neurol. Neurosurg. Psychiatr. 2005,
76, 579–581. [CrossRef] [PubMed]
27. Casella, G.; Bordo, B.M.; Schalling, R.; Villanacci, V.; Salemme, M.; Di Bella, C.; Baldini, V.; Bassotti, G.
Neurological disorders and celiac disease. Minerva Gastroenterol. Dietol. 2016, 62, 197–206. [PubMed]
28. Centanni, M.; Benvenga, S.; Sachmechi, I. Diagnosis and management of treatment-refractory
hypothyroidism: An expert consensus report. J. Endocrinol. Investig. 2017, 40, 1289–1301. [CrossRef]
[PubMed]
29. Pinto-Sanchez, M.I.; Bercik, P.; Verdu, E.F. Motility alterations in celiac disease and non-celiac gluten
sensitivity. Dig. Dis. 2015, 33, 200–207. [CrossRef] [PubMed]
30. Pinto-Sanchez, M.I.; Basra, D.; McCarville, J.; Deng, Y.; Hansen, S.; Nardelli, A.; Niveloni, S.; Smecuol, E.;
Armstrong, D.; Moayyedi, P.; et al. Improvement of gastrointestinal symptoms and motility in non-celiac
gluten sensitive patients after the gluten free diet (abstract FS193_0136). Presented at Celiac Disease and Other
Small Bowel Disorders, Falk Symposium 193. Amsterdam, The Netherlands, 5–6 September 2014; 156.
Symposia and Workshops 2014. Available online: http://www.falk-foundation-symposia.org/symposia-
and-workshops/2014/?L=1 (accessed on 10 September 2018).
31. Vazquez-Roque, M.I.; Camilleri, M.; Smyrk, T.; Murray, J.A.; Marietta, E.; O’Neill, J.; Carlson, P.; Lamsam, J.;
Janzow, D.; Eckert, D.; et al. A controlled trial of gluten-free diet in patients with irritable bowel
syndrome-diarrhea: Effects on bowel frequency and intestinal function. Gastroenterology 2013, 144, 903–911.
[CrossRef] [PubMed]
32. Natividad, J.M.; Huang, X.; Slack, E.; Jury, J.; Sanz, Y.; David, C.; Denou, E.; Yang, P.; Murray, J.; McCoy, K.D.;
et al. Host responses to intestinal microbial antigens in gluten-sensitive mice. PLoS ONE 2009, 4, e6472.
[CrossRef] [PubMed]
33. Wu, R.L.; Vazquez-Roque, M.I.; Carlson, P.; Burton, D.; Grover, M.; Camilleri, M.; Turner, J.R. Gluten-induced
symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light
chain kinase activity and claudin-15 expression. Lab. Investig. 2017, 97, 14–23. [CrossRef] [PubMed]
34. Massironi, S.; Branchi, F.; Fraquelli, M.; Baccarin, A.; Somalvico, F.; Ferretti, F.; Conte, D.; Elli, L. Effects of
a Gluten-Containing Meal on Gastric Emptying and Gallbladder Contraction. Nutrients 2018, 10, 910.
[CrossRef] [PubMed]
35. Biesiekierski, J.R.; Peters, S.L.; Newnham, E.D.; Rosella, O.; Muir, J.G.; Gibson, P.R. No effects of
gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable,
poorly absorbed, short-chain carbohydrates. Gastroenterology 2013, 145, 320–328. [CrossRef] [PubMed]
36. Mansueto, P.; Seidita, A.; D’Alcamo, A.; Carroccio, A. Role of FODMAPs in patients with irritable bowel
syndrome. Nutr. Clin. Pract. 2015, 30, 665–682. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Mood Disorders and Gluten: It’s Not All in Your
Mind! A Systematic Review with Meta-Analysis
Eleanor Busby 1, Justine Bold 1,*, Lindsey Fellows 1 and Kamran Rostami 2
1 The School of Allied Health and Community, University of Worcester, Worcester WR2 6AJ, UK;
buse1_17@uni.worc.ac.uk (E.B.); l.fellows@worc.ac.uk (L.F.)
2 Department of Gastroenterology, Mid-Central District Health Board, Palmerston North Hospital,
Palmerston North 4442, New Zealand; kamran.rostami@midcentraldhb.govt.nz
* Correspondence: j.bold@worc.ac.uk; Tel.: +44-1905-855-391
Received: 14 October 2018; Accepted: 6 November 2018; Published: 8 November 2018
Abstract: Gluten elimination may represent an effective treatment strategy for mood disorders in
individuals with gluten-related disorders. However, the directionality of the relationship remains
unclear. We performed a systematic review of prospective studies for effects of gluten on mood
symptoms in patients with or without gluten-related disorders. Six electronic databases (CINAHL,
PsycINFO, Medline, Web of Science, Scopus and Cochrane Library) were searched, from inception
to 8 August 2018, for prospective studies published in English. Meta-analyses with random-effects
were performed. Three randomised-controlled trials and 10 longitudinal studies comprising 1139
participants fit the inclusion criteria. A gluten-free diet (GFD) significantly improved pooled
depressive symptom scores in GFD-treated patients (Standardised Mean Difference (SMD) −0.37,
95% confidence interval (CI) −0.55 to −0.20; p < 0.0001), with no difference in mean scores between
patients and healthy controls after one year (SMD 0.01, 95% CI −0.18 to 0.20, p = 0.94). There was a
tendency towards worsening symptoms for non-coeliac gluten sensitive patients during a blinded
gluten challenge vs. placebo (SMD 0.21, 95% CI −0.58 to 0.15; p = 0.25). Our review supports the
association between mood disorders and gluten intake in susceptible individuals. The effects of a
GFD on mood in subjects without gluten-related disorders should be considered in future research.
Keywords: gluten-related disorders; gluten-free diet; coeliac disease; non-coeliac gluten sensitivity;
irritable bowel syndrome; mood disorders; affective disorders; depression; major depressive disorder;
mental health; nutrition
1. Introduction
Mood disorders are a global healthcare burden, with 300 million people now suffering from
depression worldwide [1]. In 2015, the World Health Organisation (WHO) estimated that 4.4% of the
global population were suffering from clinical depression—a 18.4% increase in prevalence since 2005.
On top of this, around 61 million antidepressants are prescribed in a single year in the UK alone [2],
while depressive disorders were ranked as the largest contributor to global non-fatal health loss, as
well as increased suicide risk [3].
Wheat products are now the main source of carbohydrate in the Western diet and contain
high amounts of the protein, gluten. In recent years, reports of gastrointestinal and extra-intestinal
symptoms, due to gluten-containing foods have been on the increase [4]. Coeliac disease (CD)
is characterised by intestinal mucosal damage due to an immune response to gluten peptides,
with clinical improvement after following a gluten-free diet (GFD) [5]. This involves the elimination
of gluten-containing foods from the diet, such as wheat, rye and barley products. CD affects about
1% of the UK population [6] and its global prevalence is on the rise [7]. Moreover, around 10%
of CD patients are affected by psychiatric disorders [8], with a higher proportion of CD patients
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exhibiting depression compared to the general population [9]. However, CD can manifest in a variety
of ways, with symptomatically atypical and silent patient subgroups [10], and hence is thought to
be underdiagnosed [5]. Therefore, it is a possibility that CD may be misdiagnosed, as depression for
example, due to a lack of classical symptoms.
A growing body of evidence suggests that mood symptoms are associated with a spectrum of
gluten-related disorders [9,11,12]. Reports of health improvements after following a GFD in the absence
of CD has led to non-coeliac gluten sensitivity (NCGS) becoming increasingly recognised as its own
clinical entity [13], with evidence indicating a higher prevalence than CD [14]. In contrast to CD, specific
serological markers for NCGS are lacking; only some patients exhibit increased antibodies to gluten
peptides and no mucosal damage is generally observed [15]. Nonetheless, in 1956 it was suggested
that gluten may be associated with mood and psychiatric symptoms in a case series of subjects without
CD [16]. More recently, mood symptoms are frequently reported as a result of wheat ingestion [17]
with ‘low mood’ being a common motivation for gluten avoidance [18] in the absence of both CD
and wheat allergy. Furthermore, recent clinical studies have found raised gluten-related antibodies
in patients with bipolar, major depressive disorder, and schizophrenia [19–21], while episodes of
acute mania may be associated with increased serum levels of antibodies against gliadin [22]. Hence,
there is mounting evidence for a, potentially bidirectional, relationship between gluten sensitivity and
psychiatric disorders.
Numerous theories regarding the aetiology of mood symptoms in those with gluten-related
disorders exist. One theory suggests that an immune response to gluten may lead to depressive
symptoms [23]. Further evidence suggests social exclusion could lead to depression in CD [6] while
another study relates mood symptoms to adjusting to the chronic nature of a physical disease in
general [24]. Contrary to this, Roos et al. found no relationship between gastrointestinal symptoms
and psychological well-being in CD [25], although antidepressants have interestingly been found to
reduce abdominal pain in irritable bowel syndrome (IBS) [26]. Conversely, nutritional deficiencies
may be a causative factor for reduced mood; for instance, B-vitamin supplementation was found to
significantly improve depression in adults with longstanding CD on a GFD [27]. Finally, the ingestion
of FODMAPs (Fermentable Oligo-, Di-, Mono-saccharides And Polyols—short chain carbohydrates
also present in wheat, rye and barley, as well as beans, pulses and certain vegetables), have also
been suggested to increase both physical and psychological symptoms in those thought to be gluten
sensitive [28,29]. Hence, there appears to be a complex and multifactorial relationship between mood
and gluten-related disorders.
Regardless, a GFD has been shown to improve mental health in susceptible individuals. Significant
improvements in mood disorders and psychological well-being have been recognised in patients with
CD [30–32], IBS [33] and NCGS [34] following a GFD, although the magnitude of improvement is found
to be dependent on good dietary adherence [11,35]. Moreover, anti-gliadin IgG antibodies disappeared
in NCGS patients [34] and markers of systemic inflammation were reduced in IBS patients [36], as well
as healthy mice [37] following initiation of a GFD. Hence, a GFD may reduce inflammation and
improve mood, although a relationship between these outcomes remains theoretical.
Whilst the GFD for autism spectrum disorders has been well reviewed [38,39], other reviews
of psychiatric and mood disorders in relation to gluten have focussed on CD and epidemiological,
rather than interventional, evidence [12,40]. Meanwhile, a review on extra-intestinal symptoms in
NCGS [41] included only one study considering psychiatric outcomes [42]. However, a search of
registered protocols did not reveal that any systematic reviews on gluten and mood are planned or
currently in progress. Therefore, we conducted a systematic review of prospective studies with a
gluten challenge or GFD intervention on the prevalence and/or severity of mood symptoms in patients
with or without gluten-related disorders. Our study was underpinned by the following objectives: To
establish whether a relationship exists between mood and gluten; to explore the outcomes of severity
mood symptoms and the prevalence of mood disorders; to assess the impact of the level of adherence
to a GFD on the severity of mood symptoms; to highlight gaps in the research literature; and to
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determine implications for practice in terms of implementing a GFD in those with gluten-related and
mood disorders.
2. Materials and Methods
2.1. Eligibility Criteria
The eligibility criteria for inclusion of studies into our systematic review consisted of the following:
1. All studies evaluating the effect of gluten ingestion or elimination on the presence or severity of
depressive symptoms and other mood disorders, with any gluten-related intervention for any
length of time.
2. As evidence suggests a correlation between mood and level of adherence to a GFD [35,43,44],
dietary adherence must be defined using a validated measure and either specify good adherence
or report data for adherent and non-adherent participants separately.
3. All prospective intervention studies—randomised, non-randomised, longitudinal—which
investigated the change in the severity of mood symptoms as a primary or secondary outcome
using a validated questionnaire. We excluded retrospective and cross-sectional studies, as we
aimed to investigate the relationship between mood and gluten over a specified amount of time
while measuring adherence.
4. Published studies in English.
Further to this, we defined the following eligibility criteria for inclusion of study data into
meta-analysis:
1. Data must be reported as means and standard deviations (SDs), or these values must be
calculatable or estimable using the available data by methods outlined in the Cochrane
Handbook [45].
2. Each study should report a different sample; for different studies utilising the same sample,
as part of a follow-up study or ad-hoc analysis for example, only data from the most relevant
study or the study reporting the largest sample were included.
3. For comparisons between patients and healthy controls, control and patient groups must be
demographically matched by age and gender.
2.2. Search Strategy and Selection Criteria
The scientific databases CINAHL, PsycINFO, Medline, Web of Science, Scopus and the Cochrane
Library were searched using the strategies outlined in Tables S1–S6 in Supplementary File 1. These were
designed using keywords, Medical Subject Heading (MeSH) terms and free text words, such as
gluten-free diet and depression, combined using Boolean operators. The strategies were piloted for
each database and three authors (E.B., J.B. and L.F.) reviewed and amended the search strategy before
E.B. commenced the final search. To ensure all relevant studies were captured, two authors (E.B. and
J.B.) independently screened and selected the studies. In cases of disagreement, a third author (L.F.)
was consulted for the final decision. Reference lists of relevant studies were also searched.
2.3. Data Extraction and Quality Assessment
One reviewer (E.B.) extracted the data according to a data extraction form developed to collect
information regarding study design, population, intervention, controls and outcomes. The data
extraction form included information on authors, country, recruitment methods, number of participants,
methods of measuring adherence, level of dietary adherence, commercial funding and/or conflicts of
interest, study/intervention duration and analysis strategy (ITT—intention-to-treat; PP—per-protocol).
Further data was extracted in order to assess risk of bias (ROB) according to tools developed by the
Cochrane Collaboration; Cochrane’s ROB 2.0 (University of Bristol, Bristol, UK) [46] was used for
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randomised controlled trials (RCTs) and the Risk Of Bias In Non-randomized Studies of Interventions
(ROBINS-I) tool (University of Bristol, Bristol, UK) [47] for all types of non-randomised studies. The
bias domains included in ROBINS-I overlap with the Cochrane ROB 2.0 tool, but instead of assessing
the randomisation process, include the additional domains: Confounding, selection of participants into
the study and classification at intervention. Specific criteria for assessing the risk of bias in each of the
domains in the context of our review are described in Table S7 in Supplementary File 2.
2.4. Statistical Analysis
We performed all meta-analyses with Review Manager (RevMan) 5.3 (The Nordic Cochrane
Centre, Copenhagen, Denmark, 2014). Outcomes are based on random-effects models using mean
differences. Results from the analysis are presented as mean differences along with the 95% confidence
intervals. Statistical significance was set at 0.05 for two-sided p-values. Data was synthesised by
meta-analysis when there was a consistent comparison in two or more studies measuring depressive
outcomes. Where possible, only depressive outcome data from questionnaires not biased towards
physical illness, with no questions related to gastrointestinal health and eating habits, were synthesised
in meta-analysis; data from studies using biased questionnaires containing these types of questions
were reported separately. For continuous data, scores from depression scales were reported as
means and the standardised mean difference (SMD) was used as a summary statistic. The means
of psychometric scales that increased with severity of depression were multiplied by −1 to ensure
that all the scales point in the same direction. Dichotomous data were presented as the percentage
of patients who were depressed with a score above a specified cut-point, which we reported only
when the cut-point score used in the study was based on a validated rather than arbitrary figure.
Risk difference (RD) was used to report the results as this is a measure of absolute effect and more
intuitive to interpret [45], especially for change of scores from baseline. Funnel plots were used to
evaluate publication bias. All forest plots were stratified according to risk of detection bias. We have
highlighted this domain as the key risk of bias domain for our study due to our outcome of interest
being a subjective measurement. We used the Grades of Recommendation, Assessment, Development
and Evaluation Working Group (GRADE Working Group) system [48,49] for grading the quality
of evidence for each outcome according to study design, consistency, directness, imprecision and
reporting bias. We used GRADEpro GTD to build the Summary of Findings (SoF) and GRADE profile
tables [50].
2.5. Heterogeneity and Sensitivity Analyses
Heterogeneity between studies was interpreted according to general guidance [51], which suggest
that I2 values of 25%, 50%, and 75% may indicate low, medium and high heterogeneity, respectively,
while a value of 0% indicates no observed heterogeneity. To address the most important sources of
heterogeneity, we performed planned subgroup analyses considering the effect of CD (CD vs. non-CD
participants), gastrointestinal symptoms (symptomatic vs. asymptomatic), and the presence of the
CD-associated HLA-DQ2/8 genotype (positive vs. negative) on depressive outcome measures. We
also retrospectively performed a subgroup analysis into population sample country of origin after
extracting and analysing the data in order to further investigate heterogeneity. The effect of dietary
adherence (compliant vs. noncompliant participants) was analysed as a separate comparison so as to
include data from Nachman et al. (2010). Sensitivity analyses were performed for: Study searching,
by including abstracts whose results could not be confirmed in subsequent publications; data selection,
by excluding results from studies utilising an ITT approach; study methods, by analysing only studies
with an average intervention time of one year; study quality, by excluding studies at a high risk of bias
in key domain(s); and analysis methods by changing random-effects (RE) for fixed-effects (FE) and
risk differences (RD) for risk ratios (RR) and odds ratios (OR).
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2.6. Missing Data
All studies reporting the necessary outcome data as mean values with SDs were included
in meta-analysis. If the necessary data was not reported in the correct format for meta-analysis,
the corresponding author of the relevant study was contacted via email to request the required data.
If no reply was received, a reminder email was sent three weeks after the initial request and other study
authors were contacted if emails could be retrieved. As a final resort, and if possible, means and SDs
were calculated from the available information (as long as the data were determined to be normally
distributed) according to the methods outlined in Chapter 7 of the Cochrane Handbook version
5.1.0 [45]. Some scores were derived from graphs by optical plot reading using WebPlotDigitizer
(Version 4.1, Ankit Rohatgi, Austin, TX, USA) [52].
3. Results
3.1. Literature Search
The final literature search for all databases was conducted on 8 August 2018 by E.B. These searches
identified 236 papers, three additional citations were identified by a recursive bibliography
search [34,53,54], one study was referred by an expert in the field [55] and one study was already
known by the authors [29]. After excluding records based on duplicate data, title or abstract, fifty-one
were fully reviewed. Finally, 13 studies met the inclusion criteria (Figure 1). The characteristics of
these included studies are summarised in Table 1. A summary of reasons for the studies excluded by
full-text screening are provided in Table S8 in Supplementary File 3.
 
Figure 1. Flow diagram of study selection. #, number.
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3.2. Characteristics of the Included Studies
Of the 13 studies, three were RCTs [42,53,56]. Study participants were subjects with self-reported
NCGS with [42] and without [56] diagnosed IBS, and asymptomatic EmA-positive subjects [53]. Each of
these studies excluded CD either by previous diagnosis [53] or study screening [42,56]. The remaining
10 studies were single arm before-after studies; one of these was a time-interrupted study and one
was a follow-up study. Of these, two reported on the same group of participants; Nachman et al.
(2009) reported the initial study period from baseline to one year at intervals of three months for all
participants, while Nachman et al. (2010) reported baseline, one-year and four-year follow-up results
for a subset of the same participants (n = 53) who continued to follow a GFD for the full four years.
Although using the same sample, both studies were included as they elucidate the short and long-term
effects of a GFD on depressive symptoms. Nevertheless, results from these studies were not pooled in
meta-analysis as they report on the same participants, and hence were analysed separately.
There were differences in the questionnaires utilised to measure the severity of depression
between the included studies. Three studies used questionnaires containing questions related to
gastrointestinal health and eating habits; two used the Beck Depression Inventory (BDI) [57,58], and
one the Hamilton Depression Rating Scale (HDRS) [59]. However, one of these studies reported some
data from a sub-analysis removing these questions [58]. Conversely, nine studies used questionnaires
containing no such questions; four used the Psychological General Well-Being Index (PGWB) [53,60–62],
one the Hospital Anxiety and Depression Scale (HADS) [63], one the Crown-Crisp Experiential Index
(CCEI) [64], one the Children’s Depression Inventory (CDI) [11] and one the State-Trait Personality
Inventory (STPI) [42], while one further study [65] used a modified version of the Zung Self-Rating
Depression Scale (SDS) with such questions removed. Finally, one study simply asked participants to
grade depression as present or absent on each day [56].
3.3. Quality Assessment
Of the RCTs, one study was found to have a low risk of bias and two were found to have a high
risk of bias. Of the non-randomised studies, three were found to have a moderate risk of bias while the
remaining seven were found to have a serious risk of bias. Graphical representations of the summary
of risk of bias for individual studies and across all studies are given in Figure 2, and the analysis of
each domain is detailed in Supplementary File 4.
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Figure 2. (A) Risk of bias graph: Review authors’ judgements about each risk of bias item presented as
percentages across all included studies. (B) Risk of bias summary: Review authors’ judgements about
each risk of bias item for each included study.
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3.4. Data and Analyses
A summary of our findings are presented in Tables S9–S12 in Supplementary File 5.
3.4.1. A GFD vs. A Gluten-Containing Diet
3.4.1.1. Difference in Mean Depression Scores
One RCT compared a GFD to a normal gluten-containing diet in a two-arm study [53] and ten
reports of nine single-arm before-after studies compared depression scores for participants at baseline
(on a gluten-containing diet) and after following a GFD. However, two studies were not eligible for
meta-analysis [59,65] and one study [57] was a follow-up of the same sample from another study [58].
Hence, eight studies with a total of 953 participants were included in meta-analysis. We found that a
GFD significantly reduced depressive symptoms in 953 participants overall (SMD −0.37, 95% CI −0.55
to −0.20; p < 0.0001) (Figure 3A). There was low-medium heterogeneity between the studies overall
(I2 = 38%), but zero heterogeneity between the non-randomised studies and RCTs. Subgroup analyses
(Figure S1, Supplementary File 6) revealed no difference in effect between those with and without
diagnosed CD (p = 0.73) or between those HLA-DQ2/8-positive and HLA-DQ2/8-negative (p = 0.49).
Conversely, there was a significant difference in effect between those with classical, atypical and silent
CD (p = 0.003) with high heterogeneity between subgroups (I2 = 82.5%) (Figure 3B); while classical
CD patients exhibited a significant effect (SMD −0.65, 95% CI −0.96 to −0.34; p < 0.0001), the effect
for silent CD patients was nonsignificant (SMD −0.06, 95% CI −0.38 to 0.26; p = 0.71) and one study
reported a significant effect for atypical CD patients.
Of the studies not eligible for meta-analysis, one reported non-normally distributed data as
medians and IQRs as opposed to means and SDs [59] and one only reported mean scores for patients
positive for depression rather than all participants [65]. One study included in meta-analysis did not
report SDs for the PGWB subcategories [61], so SDs for the mean depression values were estimated
using methods described in the Cochrane Handbook [45] and 95% CI values imputed from an
ad-hoc analysis of the same population sample [66]. Only data for the classical CD patients from
Nachman et al. [58] were used because this was the only data reported for the modified BDI removing
questions to avoid bias due to illness. Moreover, only scores for adherent participants (n = 7) were
used from Simsek et al. [11] as noncompliance was high with 17/24 participants (71%) found not
to follow a strict GFD. Finally, one study providing data for a second follow-up at four years [57]
suggests an insignificant trend towards worsening depressive symptoms relative to one year (p = 0.39),
which remained significant relative to baseline (p < 0.0001) (Figure S2, Supplementary File 6).
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A 
B 
Figure 3. Forest plot demonstrating the difference in mean depression scores between following a GFD
and a gluten-containing diet for (A) all studies (1 RCT comparing two intervention groups and seven
BA studies comparing participant scores at baseline) and (B) subgroup analysis based on symptoms
(classical, atypical and asymptomatic). CI, confidence interval; df, degrees of freedom; GFD, gluten-free
diet; GCD, gluten-containing diet; I2, heterogeneity; IV, inversed variance; Random, random effects
model; SD, standard deviation; Std., standardised; total, number of patients.
3.4.1.2. Change in Number of Participants Positive for Depression
Four reports of three studies compared the number of participants positive for depression at
baseline and after following a GFD. Three were included in meta-analysis (Figure 4). For 110 classical
CD patients, there was a reduction of 31% of patients positive for depression after following a GFD (RD
−0.31, 95% CI −0.52 to −0.10; p = 0.003). All the included data is for classical CD patients following
a GFD for one year; no studies reported this outcome for non-CD patients. We found a significant
difference in effect between the studies reporting results from modified and unmodified questionnaires,
with a significant effect seen for the unmodified questionnaires and a nonsignificant effect in studies
using an unmodified questionnaire.
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Figure 4. Forest plot demonstrating the change the number of CD participants with depression after
following a GFD for one year.
3.4.2. Gluten Challenge vs. Placebo (GFD)
Two RCTs compared the mean depression scores of subjects during the gluten and placebo
challenge periods and were included in meta-analysis [42,56] (Figure 5). We found a trend towards
worsened depressive symptoms during the gluten challenge period compared to placebo, although
this did not reach significance (SMD 0.21, 95% CI −0.58 to 0.15; p = 0.25). Heterogeneity was low
(I2 = 19%). Both used a cross-over trial design with participants acting as their own controls and both
adequately described blinding of participants and researchers. Moreover, both used a per-protocol
(PP) approach in their analyses. Depression scores were derived from a graph by optical plot reading
using WebPlotDigitizer [52].
Figure 5. Forest plot demonstrating the difference in participant depression scores between gluten and
placebo challenges in subjects with self-reported NCGS.
3.4.3. Compliant vs. Noncompliant Participants
Three publications of two studies reported depression scores separately for CD patients
compliant and noncompliant to the GFD; no studies reported separate data for these subgroups
in non-CD patients. However, two of the three studies used the same sample at different follow-up
timepoints [57,58]. Moreover, as there is considerable variation in results and inconsistency in the
direction of effect, no meta-analysis was conducted (Figure 6). Firstly, Nachman et al. [58] found a
nonsignificant difference in mean depression scores between 59 compliant (M −7.9, 95% CI 4.8 to 11.0)
and 25 noncompliant patients (M −6.3, 95% CI 3.6 to 9.5) at year one, although there was a slightly
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lower severity of depressive symptoms in the noncompliant subgroup. Nevertheless, they reported
a significantly higher severity of depression in the noncompliant subjects after four years on a GFD
(p = 0.04), with 27 compliant and 26 noncompliant CD patients having mean scores of 5.8 (95% CI
2.1 to 9.5) and 11.3 (95% CI 7.6 to 15.0), respectively [57]. Conversely, when comparing the number
of patients positive for depression (Figure S3, Supplementary File 6), they consistently reported a
nonsignificant trend towards a lower number of depressed patients in the compliant group, with
no difference between the proportion of depressed patients at one year and four year follow-ups
(p = 0.86; I2 = 0%). On the contrary, Simsek et al. [11] found the severity of depressive symptoms to be
significantly higher in noncompliant, compared to compliant, CD children after only one year on a
GFD (p = 0.005), with seven compliant patients and 17 noncompliant patients achieving mean CDI
scores of 4.75 (SD 3.3) and 12.33 (SD 5.8), respectively.
Figure 6. Mean depression scores in compliant vs. noncompliant CD adults at one year, CD children at
one year, and CD adults at four years after following a GFD.
3.4.4. GFD-Treated Patients vs. Healthy Controls
3.4.4.1. Difference in Mean Depression Scores
Five publications reporting on four studies included an eligible healthy control group, of which
four were included in meta-analysis (Figure 7A). As Nachman et al. [57,58] used the same sample
and healthy controls, the results for the four year follow-up [57] were reported separately. Overall,
we found no difference between the depressive outcome scores between 868 GFD-treated patients
and 400 healthy controls at one year follow-up (SMD 0.01, 95% CI −0.18 to 0.20, p = 0.94) and zero
heterogeneity between the studies (I2 = 0%). Similarly, there was no significant difference at the four
year follow-up between 27 strictly adherent patients and 70 healthy controls (SMD −0.08, 95% CI
−0.52 to 0.36, p = 0.72). Two studies with a healthy control group were not eligible for meta-analysis;
Simsek et al. [11] reported depressive outcome data for their healthy controls as medians and IQRs,
but similarly reported an insignificant difference between patients and controls, while Collin et al. [64]
did not demographically match patients and healthy controls, hence we have not reported their data.
3.4.4.2. Difference in Number Participants Positive for Depression
Three studies [57,58,65] reported the number of GFD-treated participants and healthy controls
positive for depression, of which two were meta-analysed and data from Nachman et al. [57] were
reported as separately (Figure 7B). Only data from patients strictly adherent to the GFD were included.
We found a trend towards an increased prevalence of depression in GFD-treated patients compared
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to healthy controls at one year (RD 0.21, 95% CI −0.16 to 0.58; p = 0.26) and four years (RD 0.10, 95%
CI −0.02 to 0.22; p = 0.12), although these were nonsignificant. There was no significant difference





Figure 7. Forest plots comparing: (A) Mean depression scores in treated patients and healthy controls
and (B) the difference in the no. treated patients and healthy controls positive for depression at one
year and four years after following a GFD.
3.5. Sensitivity Analyses
Various sensitivity analyses were untaken to ensure significant differences were not as a result of
arbitrary decisions throughout the study process (Figures S4–S6 and Tables S13–S14, Supplementary
File 7). Firstly, no significant differences in meta-analysis results were found when interchanging
random-effects for fixed-effects, or risk difference for odds ratio and risk ratio, for the majority of
analyses (Tables S13 and S14). However, there was a difference in the final results for analysis
Section 3.4.4.2. at one year, which became significant when using fixed-effects, as opposed to
random-effects, and odds ratio or risk ratio, as opposed to risk difference. Secondly, removing
studies at an unclear/high risk of detection bias, leaving only those at low risk, did not produce
substantially different results for any applicable comparison (Figure S4). Thirdly, while removing
data from Nachman et al. [58] from our meta-analyses did not significantly alter the results, overall
heterogeneity was reduced from I2 = 38% to I2 = 0% for the main analysis (Figure S5) and from I2 = 52%
to I2 = 13% for the CD subgroup. On the other hand, there was no difference in results or heterogeneity
between using outcome data from Nachman et al. for classical CD patients from the modified BDI and
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the unmodified BDI [58], or all CD patient subgroups from the unmodified BDI [57] (Figure S6). Finally,
the results from a potential conference abstract for a cross-over RCT [67], excluded from our study
due to the lack of a published final article, could not be included in a sensitivity analysis as only the
mean change in the STPI state depression sub-score was reported between gluten and placebo groups
(mean change 0.69, 95% CI −2.15 to 3.53, p = 0.61). Nevertheless, these results for NCGS patients are in
agreement with our meta-analysis in Section 3.4.2.
3.6. Publication Bias
Inspection from the funnel plot that arose from our main analysis (Figure 8) suggests the presence
of publication bias due to location biases [68], with published studies from Finland less likely to find
to find a large effect from a GFD on reducing depressive symptom scores relative to published studies
from other countries.
Figure 8. Funnel plot.
4. Discussion
Our systematic review involved a total of 13 studies and 1139 patients, with meta-analysis on an
eligible sample of 933 patients from non-randomised studies and 99 patients from RCTs, as well as
180 healthy controls. Although we generally found a low level of heterogeneity, a limitation of our
review was the small number of studies available for subgroup analyses that limited our ability to
investigate any heterogeneity. Moreover, despite the fact that we contacted authors for missing data,
no additional data was retrieved. This was either because: The data was no longer available; authors
had retired or moved to another area of research; or a lack of response. Nevertheless, we adhered to
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [69]
guidelines wherever possible (see PRISMA checklist, Table S15 in Supplementary File 8) and assessed
the quality of the individual studies using tools developed and recommended by the Cochrane
Collaboration for both the RCTs and non-randomised studies. Moreover, we applied the GRADE
process [48] to assess the certainty of our conclusions and recommendations based on the evidence
across the studies for each outcome.
A further strength of our systematic review was our comprehensive search strategy, which we
piloted and tailored to numerous databases, and strict application of inclusion and exclusion criteria.
Therefore, we are relatively certain that all relevant studies have been included in our review. Although
diagnosed conditions or disorders were not an exclusion criteria for our study, only studies on
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populations with CD, IBS or NCGS were identified through our searches; no other gluten-related
disorder, such as dermatitis herpetiformis or gluten ataxia, nor any other condition, such as major
depressive disorder, were identified. Moreover, our searches only identified studies assessing
depression, or depression as a subcategory of quality of life; no studies were found that assessed
other determinants of mood or mood disorders. We conducted further, broader searches for other
mood disorders as a sensitivity analysis in attempts to find studies we may have missed in our search
strategy, but identified no further relevant studies. As we found no studies that attempted a GFD
intervention on a sample of patients with depression, despite evidence for significantly higher levels of
gluten-related antibodies in patients with major depressive disorder [19], this would be an interesting
topic for future studies to address in order to help assess the directionality of the relationship between
depression and gluten.
Our first objective was to establish whether a relationship exists between mood and gluten in
those with and without gluten-related disorders. We found that a long-term GFD may significantly
reduce and normalise the severity of depressive symptoms for subjects with CD, IBS and NCGS,
with a medium-large effect for both symptomatic and atypical CD patients, but no effect for
asymptomatic/silent cases [70]. However, the criteria for what constitutes silent CD remains uncertain;
although neuropsychiatric disorders are likely to be included in the definition of atypical CD [71],
there are a variety of pathophysiological differences underlying the clinical spectrum of depressive
disorders [72]. Hence, it is uncertain whether those with depression, but no other symptoms, at baseline
would be classified as having atypical or silent CD. Moreover, one of our included studies found that the
significant improvement in depressive symptoms for the atypical/silent combined subgroup was no
longer significant when the questionnaire was modified to remove questions based on gastrointestinal
symptoms [58]. Conversely, another one of our included studies reported that all asymptomatic CD
participants randomised to the GFD group for the first year of the study refused to crossover to a
follow a gluten-containing diet again, due to a fear of worsening symptoms [53], suggesting that even
subjects who did not report any symptoms at baseline experienced improvements after following a
GFD. Hence, although we established an overall effect, is it difficult to draw many conclusions based
on symptom classification at this time.
Further to this, we assessed the impact of the level of adherence to a GFD on mood symptom
severity. Interestingly, we found a significant difference in mean depression scores in favour of strict
compliance for CD children after one year, whereas the difference for CD adults was nonsignificant
at the same timepoint. This, nevertheless, became significant in favour of compliance at the four
year follow-up. Previous systematic reviews and meta-analyses have consistently found a moderate
association between poorer GFD adherence and worsened depressive symptoms [35,73], though with
high heterogeneity between the studies. However, our nonsignificant finding for adults after the first
year does not support this relationship described by others. On one hand, a standardised method for
measuring adherence to the GFD does not yet exist, and hence there were differences in the methods
utilised by each studies. Alternatively, recent cross-sectional studies suggest that hypervigilance to a
GFD, associated with greater knowledge, was significantly associated with reduced quality of life [44],
and that those with worse economic status were at an increased risk of lower quality of life while
following a GFD [74]. Conversely, the presence of depression has been suggested to weaken the
correlation between GFD adherence and symptoms [43], implying that symptoms may be driven by
factors other than gluten exposure. To summarise, further studies with standardised measurements of
adherence are required before definitive conclusions may be drawn on the effects of gluten-free dietary
adherence on the severity of depressive symptoms.
On the other hand, we found the proportion of participants testing positive for depression
tended to be higher in GFD-treated patients compared to healthy controls at both one and four years,
which was unaffected by the level of compliance. In line with this, previous studies suggest that up
to 30% of CD patients show persistent enteropathy after one year on a GFD [75], potentially due to
consuming trace amounts of gluten via cross-contamination [76,77]. Despite this, recent RCTs suggest
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that a low-FODMAPs diet can further reduce the severity of depressive symptoms in those with
NCGS [29] and CD [78] already on a GFD, although further research is needed in this area. In addition,
while it has been suggested that altered gut microbiota may contribute to the psychiatric effects of a
GFD [29,79,80], results should not be extrapolated from one population to another, due to the highly
individualised pattern of gut microbial composition [81]. In any case, future studies should be mindful
of the shortcomings of only considering mean scores of the sample as a whole, and closer attention
should be paid to patients who may be unresponsive to a GFD in research and practice.
In terms of the short-term effects for gluten on mood, the trend towards increased severity
of depressive symptoms in NCGS patients after only a few days of a blinded gluten challenge
further reinforces our findings that the ingestion of gluten plays a role in the presence of depressive
symptoms—even in those without mucosal gut damage. Although one of our included studies
reported no concurrent differences in gastrointestinal symptom severity between gluten, whey and
placebo challenges [42], other clinical trials on non-CD participants report a significant increase in
physical symptoms when challenging with foods containing wheat [82] and fructans [83]. Additionally,
despite the fact that another RCT found no gluten-specific gastrointestinal symptoms when challenging
NCGS patients already on a low-FODMAPs diet, all patients returned to a GFD at the end of the trial
as they subjectively reported “feeling better” [28]. However, the weaknesses of this study have been
discussed in a previous paper [84]; while the sample is unlikely to be representative of the NCGS
population, the crossover design could have also produced an anticipatory nocebo response [85].
Nonetheless, a proposed mechanism requiring further investigation is that FODMAPs predominantly
trigger GI symptoms whereas gluten is a trigger for neurological and psychiatric symptoms by having
direct effects on the brain [86].
Unfortunately, the overall quality of the evidence base was poor and confounding factors were
problematic. Firstly, while a few studies stated subject antidepressant use as an exclusion criteria,
other studies did not consider this. Secondly, seasonal affective disorder (SAD), a type of depression
with a seasonal pattern, may overlap with other depressive disorders [87], but was not considered or
controlled for in any of the studies. Although the majority of the non-randomised studies planned the
follow-up to be one year after the start of the GFD, this timespan varied between clients, as well as
between studies and none specified the time of year. Moreover, some of the questionnaires utilised,
namely the SDS, HDRS and BDI, contained questions related to gastro-intestinal symptoms and eating
habits, which are likely to introduce bias due to physical illness. Finally, our sample is dominated by
Finnish participants (75.8%), with only 9.4% participants from Italy and 3.6% from the UK, significantly
reducing the applicability of our findings; a GFD may be easier to follow in Finland as there is good
knowledge of CD and easy availability of gluten-free products [88], which may lead to a lower risk of
depression, due to isolation and other issues associated with following a GFD.
Nonetheless, we set out to determine implications for future research, as well as implementation
of GFDs in practice. Firstly, our included studies varied in their criteria for CD diagnosis; whereas one
study relied on EmA-positivity [53], another used biopsy [61] as their criteria for inclusion of silent
CD patients. Moreover, broad subcategories, such as ‘atypical’, were problematic when attempting to
assess specific atypical symptoms, such as depression. Hence, specific standardised criteria for the
classification of the different subtypes of CD, as well as other gluten-sensitive disorders, should be
developed to aid further research in terms of comparability, as well as identification and suitable
treatment of those with CD. Secondly, our finding that the proportion of adults strictly adherent to
the GFD decreased significantly over time is supported by a large recent meta-analysis [35], and is
likely related to the amount of support received by patients. For instance, a RCT found that six months
of psychological counselling improved GFD adherence and reduced depression in CD patients with
depression at baseline [89]. While no studies exist that support or repute our findings that a lower
proportion of children achieved strict adherence than adults, practical tools have been shown to
promote self-management, dietary adherence and well-being in children and adolescents with CD [90].
Hence, the development of both standardised measurement methods and tools to promote dietary
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adherence would be useful for future research, as well as patient management. Moreover, a balance
between dietary adherence and well-being appears important for those following a GFD, with careful
consideration of the level of support available for specific populations in maintaining a GFD diet
over time.
5. Conclusions
Our study confirms that gluten elimination may represent an effective treatment strategy for
mood disorders in individuals with gluten-related disorders, while highlighting specific considerations
for future research and implications for practice. Firstly, standardisation of methods to measure
dietary adherence and mood symptoms with no bias, due to physical illness would greatly increase
the validity and comparability of future research. Secondly, future studies focusing on gluten
and mood in participants without a gut-related disorder, for example, in a population sample
with depression, would contribute to the evidence necessary to determine the directionality of the
relationship. Nevertheless, authors should be mindful of the shortcomings of only considering mean
scores of a sample, with potentially GFD-resistant participants requiring closer attention. In practice,
implementation of a gluten-contamination elimination diet, such as that detailed by Hollon et al. [76],
in which processed foods are eliminated, could prove beneficial for some individuals. Thirdly,
standardisation of the classification for the subtypes of CD, as well as other gluten-sensitive disorders,
should be developed to aid further research in terms of comparability, as well as identification
and suitable treatment of those with CD. Finally, the level of support available to help a patient
in maintaining a GFD diet over time should be carefully considered when recommending a GFD
in practice.
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Abstract: The aim of the present work was to analyze the body composition and dietary profile
of Spanish celiac men and to compare them to control men and celiac women from our previous
studies. Forty-two celiac men (31.5 ± 11.9 years) were recruited and anthropometric measurements
were taken. Analysis of energy consumption, macro- and micronutrient intake and food frequency
consumption was carried out. Celiac men were more overweight and obese than celiac women,
but less than the control population, reporting the same energy intake and macronutrient distribution.
Most micronutrient deficiencies in celiac men were not directly related to a gluten free diet; these were
also observed for the entire population. The least adherence to Dietary Reference Intakes in women
was reported for iron, iodine, potassium and selenium, whereas magnesium intake was higher than
in men. Among celiac participants (both genders), cereal, vegetable and legume consumption was
poor and meat intake was contrastingly excessive. In conclusion, the dietary profile of celiac men is
as unbalanced as that of control men but slightly more than that of celiac women. General nutritional
education should be given to both general and celiac populations, and specific advices to celiac men,
in order to decrease the risk of celiac disease-related pathologies.
Keywords: celiac disease; gluten-free diet; diary recommended intake; food habit; body composition
1. Introduction
Celiac disease (CD) is described as a permanent intolerance to gluten and is the most common
chronic intestinal disease in Europe. Its estimated prevalence in Europe is around 1%, and this only refers
to those that are diagnosed, since a significant number of patients have not been diagnosed yet [1,2].
This intestinal disease is more frequent in women than in men in a 2:1 ratio [3] and thus, in the
vast majority of studies carried out in celiac people, it is common to find a larger number of female
participants than males. Moreover, it must be pointed out that, in general, the male population is
less likely to take part in health promotion programs than women are. Different reasons for this have
been put forward, such as their low recruitment, delayed help-seeking behavior, and less interest and
knowledge about health-related topics and habits [4,5]. As a result, this population cohort is often
undervalued and does not always receive gender-specific healthcare.
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The only effective treatment for celiac disease is a strict lifelong gluten-free diet (GFD). In fact,
small amounts of gluten ingestion can cause important damage-causing disorders in the intestinal
mucosa. Apart from gluten absence, a GFD must guarantee nutritional balance and so prevent
deficiencies. However, when the nutritional composition of GFD of celiac people has been assessed,
imbalanced proportions of macronutrients and several deficiencies in vitamin and mineral content have
been observed [6–11]. Specifically, a GFD is usually accompanied by a low intake of carbohydrates,
iron, calcium, folate, niacin, zinc and fiber and excess of saturated fats.
Some aspects of the GFD profile could be linked to a higher risk of several diseases. For instance,
the relationship between low fiber, high saturated fat intake and cardiovascular diseases and obesity
has been widely described [12,13]. Micronutrient deficiencies are related to comorbidities such as
ferropenic anemia and osteopenia. This fact enhances the importance of complying with not only the
intake recommendations of some key nutrients such as iron, calcium, vitamin D, but also those of other
important molecules that regulate the immune system and help metabolic status to be balanced (zinc,
magnesium, selenium, folate and so on), either in women or in men. In fact, it has been described that
these deficiencies persist in some of these patients, even if they follow a strict GFD [8,10,14,15].
Bearing in mind all the above mentioned, the aim of the present work was to evaluate the body
composition of adult celiac men from a region in Spain and the nutritional composition of the GFD
they followed, as well as compare it with international recommendations, and with dietary habits of
the general population (Spanish adult men). As a second objective, energy and nutrient intake and
dietary habits of celiac men were compared to those reported in our previous studies for celiac women
from the same region.
2. Materials and Methods
2.1. Participants and Procedure
The present study used data from a celiac men cohort recruited between 2007 and 2013 from three
regions of the Basque Country (Araba, Gipuzkoa, and Bizkaia), in the north of Spain, as part of a
prospective SUSFOOD study conducted in collaboration with the Gastroenterology and Endocrinology
Units of Cruces University Hospital and Coeliac Association from the Basque Country. Forty-two
celiac men took part in the study (mean age ± SD: 31.5 ± 11.9); all participants were diagnosed
with celiac disease according to ESPGHAN guidelines and followed a GFD for at least one year.
Exclusion criteria included a history of chronic diseases such as cardiovascular disease, diabetes,
hyperthyroidism/hypothyroidism, hypercholesterolemia, hypertriglyceridemia or high blood pressure
levels, other digestive pathologies that need specific dietary advice, and lack of motivation to participate
in the study. Written informed consent was obtained from all participants, after receiving information
about the survey. This study was approved by the Ethical Committee of Cruces Hospital (CEIC E-08/66)
and the Ethical Committee of the University of The Basque Country (CEISH/76/2011).
Celiac women were recruited simultaneously and their data were collected in the same way as results
from men; in fact, the woman cohort is part of the SUSFOOD study mentioned, which has already been
published [6]. Control men data were obtained from the ENIDE nutritional survey carried out in Spain,
based on 1589 adult men and conducted over the same period of time as the present work (ENIDE).
2.2. Anthropometric Measurements
Anthropometric measurements were collected by trained personnel. Body weight (±10 g) was
measured after voiding using a digital integrating scale (SECA 760). Height was determined to the
nearest 5 mm using a stadiometer (SECA 220). Body Mass Index (BMI) was calculated from weight
and height (kg/m2). The BMI values were categorized according to the World Health Organization
(WHO) criteria as follows: Below 18.5 kg/m2 considered as underweight, 18.5–24.9 kg/m2 as normal
weight, 25–29.9 kg/m2 as overweight and >30 kg/m2 as obese (WHO).
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2.3. Body Composition and Energy Expenditure
Fat mass was estimated by a direct segmental multiple-frequency bioelectrical impedance analysis
method (Inbody 230; Biospace, Seoul, Korea). Two skin electrodes were placed on the feet and two on
the hands. Following the standard procedure, whole-body resistance and reactance were measured.
Fat mass was evaluated from total-body impedance (Z). The guidelines of Gallagher et al. were used as
reference for body fat mass [16].
Weight, height and age were used to calculate individual energy expenditure according to the
Harris-Benedict formula. Standard activity level value was applied.
2.4. Dietary Assessment
Dietary intake was assessed using 3-day 24-h food recalls (24 HR), two on weekdays and one
at the weekend. Sixteen participants filled out a food frequency questionnaire (FFQ). Trained nutritionist-
dieticians recorded the answers of participants. Food portions and amounts were determined by
using photographs of rations and sizes described in the Photo Album, as per the author of [17].
Energy and nutrient intakes were calculated by the nutritional software program “Alimentación y Salud”
(AyS, Software, Tandem Innova, Inc., Huesca, Spain). The composition of specific gluten-free products
for celiac people consumed by the participants was collected from the manufacturers and added into
the food composition database of the program before calculations. As gluten-free product labels did not
indicate micronutrient content (vitamins and minerals), an estimation with homologous gluten-containing
products was carried out.
Dietary reference intakes (DRI) for Spanish population issued by the Spanish Societies of Nutrition,
Feeding and Dietetics (FESNAD) in 2010 were taken as references for the interpretation of the 24 HR [18].
In the case of FFQ, Spanish Society of Community Nutrition (SENC) recommendations were used for
the correct interpretation of the results [19].
Moreover, the results were compared to energy, nutrient and food intake of celiac women [6] and
those of the mentioned Spanish reference population (ENIDE) [20].
2.5. Statistical Analysis
Statistical analyses of results were performed by using the IBM SPSS statistical program,
version 23 (IBM Inc., Armonk, NY, USA). Normality in the distribution was assessed by the
Kolmogorov-Smirnov test, and homogeneity by Levene’s test. Statistical analyses were performed
in order to calculate differences between celiac men and control population were performed with
summary t Student’s test, and those between celiac men and celiac women with Chi-square test. p values
< 0.05 were accepted as significant.
3. Results
3.1. Anthropometric Measurements
Anthropometric data of celiac men from the present study are shown in Table 1.
57.1% of the participants showed normal BMI values and only 4.8% were underweight. In contrast,
38.1% of them were above normal BMI values, 26.2% were overweight, and 11.9% obese. Fat mass
measurements indicated that 52% of the participants had excessive adiposity and 41% were between
normal values. Only three participants (7%) had very low fat mass values.
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Table 1. Characteristic of celiac participants included in the survey.
Characteristic Men
N 42
Age (year) 31.5 ± 11.9
Mean duration of GFD (year) 20.9 ± 11.9
Height (cm) 176.2 ± 6.2
Weight (kg) 75.8 ± 13.9
Fat mass (%) 24.1 ± 8.1
Body-Mass Index
Mean (kg/m2) 24.7 ± 4.1
Underweight < 18.5—no. (%) 4.8
Normal 18.5–24.9—no. (%) 57.1
Overweight 25–29.9—no. (%) 26.2
Obese > 30—no. (%) 11.9
Notes: Values are mean ± SD or percentages; SD, standard deviation; N: sample size; no, number of subjects; GFD,
gluten-free diet.
3.2. Dietary Intakes
3.2.1. Energy, Macronutrients, Fiber and Cholesterol Intake in Celiac Men
Daily energy intake was comparable to that observed in control men in ENIDE study.
Energy distribution among macronutrients was not balanced in celiac men. To be specific, proteins
and fats were consumed in excess (17% and 41% respectively) accompanied by a small amount
of carbohydrates (42%) (Figure 1). When these data were compared to those of the ENIDE study,
no significant differences were observed in energy and macronutrient consumption.
Figure 1. Mean contribution of macronutrients to energy in Spanish celiac (n = 42) and control men
(n = 1589) (ENIDE study, representative at national level of the adult population) compared to the
recommended contribution in a balanced diet proposed by the Federation of Spanish Societies of
Nutrition and Dietetics (FESNAD).
In order to evaluate fat sources, dietary lipid profile was calculated. While saturated fatty acid
(SFA) and monounsaturated fatty acid (MUFA) consumption was similar in celiac men and control
men, polyunsaturated fatty acid (PUFA) consumption of celiac men was lower. In general terms,
saturated and unsaturated fatty acids ratios were reached, as in the ENIDE survey (Table 2) [21].
Cholesterol ingestion was also similar in both groups, higher than that recommended [18].
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Energy (kcal) 2355.4 ± 659.0 2546.8 ± 860.9 NS 2697 ± 445 2401 ± 592 2500 ± 717
Protein (g) 100.2 ± 30.1 109.4 ± 47.7 NS 98.8 ± 22.83 92.4 ± 17.5 92.7 ± 24.9
Carbohydrate (g) 220.7 ± 84.7 242.7 ± 101.8 NS 294 ± 72.3 267 ± 95 315.6 ± 98.5
Fat (g) 114.0 ± 32.2 114.9 ± 46.0 NS 67.9 ± 50.58 97.4 ± 29.7 93.2 ± 36.6
MUFA (g) 52.4 ± 16.1 48.29 ± 22.2 NS - - -
PUFA (g) 13.2 ± 5.8 15.5 ± 8.5 <0.05 - - -
SFA (g) 34.5 ± 11.2 32.71 ± 15.55 NS 34.7 ± 7.7 - -
(PUFA +
MUFA)/SFA 1.93 1.95 - - - -
PUFA/SFA 0.38 0.47 - - - -
Cholesterol (mg) 421.2 ± 132.8 423.82 ± 181.25 NS - - -
Fiber (g) 20.3 ± 7.1 20.94 ± 11.38 NS 30.2 ± 7.7 22.3 ± 6.0 13.7 ± 5.3
Notes: Values are means ± SD; Spanish adult men data were taken from the Spanish dietary nutritional assessment
(ENIDE study, representative of the adult population at national level); SD, standard deviation; NS: non-significant;
PUFA, polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; SFA, saturated fatty acids.
Regarding dietary fiber consumption, celiac men were below recommendations (25–35 g/day).
In fact, fiber consumption of 28% of participants was below 15 g per day and that of 43% between
15.1 and 25 g per day. A similar intake of fiber was also reported in control men, taken from the ENIDE
survey (Table 2).
A comparison of energy intake between celiac men from the present study and celiac women
from our previous studies [6] revealed that while the majority of women (65%) consumed the correct
amounts of calories in their diet, less than half the men (46%) did so (Table 3). Moreover, only 6% of
women consumed calories in excess, which, by contrast, 14% of men did. However, macronutrient
distribution, similar in both genders, was higher than recommendations for proteins and fat intakes,
and lower in the case of carbohydrates.
Table 3. Percentage of celiac men (n = 42) and women (n = 54) that fulfilled energy and macronutrient







Low Adequate Excessive Low Adequate Excessive
Energy intake ±20% of EE 40 46 14 30 65 6 <0.001
Protein 10–15% 0 19 81 0 20 81 NS
Carbohydrate 50–60% 98 2 0 91 9 0 NS
Total Fat 30–35% 0 5 95 4 11 85 NS
SFA <10% 0 17 83 0 33 67 <0.05
MUFA 15–20% 14 31 55 31 37 28 NS
Notes: * Recommended energy and nutrient intake in a balanced diet proposed by the Federation of Spanish
Societies (FESNAD). EE: energy expenditure; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; NS:
non-significant. p value corresponds to differences between celiac males’ and females’ suitable intakes.
Dietary lipid profiles were similar between celiac men and women. In both groups, the highest
percentage of participants consumed excessive SFA and cholesterol, though even more so in men.
Although both groups contained a high proportion of subjects with low fiber intakes (71% in men
vs. 96% in women), there were more men that achieved adequate fiber consumption (26% in men vs.
4% in women).
3.2.2. Micronutrients Intake in Celiac Men
When vitamin and mineral mean intake of celiac participants was compared to that of control
men, differences in eight micronutrient mean consumption were observed (Table 4). Celiac men
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consumed lower amounts of vitamin E, niacin and magnesium than the control group. By contrast,
their riboflavin, B6, zinc, potassium and selenium mean intake was higher.










Celiac Men vs. Spanish
Men (ENIDE Study)
Vitamin A (ug) 802 ± 340 748 ± 338 700 a NS
Thiamin (mg) 2.0 ± 1.4 2.1 ± 6.7 1.2 b NS
Riboflavin (mg) 2.2 ± 1.1 1.5 ± 0.8 1.6 <0.001
Vitamin B6 (mg) 2.7 ± 0.9 2.0 ± 0.9 1.5 c <0.001
Vitamin B12 (ug) 8.1 ± 5.6 7.9 ± 6.1 2 NS
Vitamin C (mg) 143 ± 82 131 ± 81 60 d NS
Vitamin D (ug) 4.4 ± 4.5 4.3 ± 4.5 5 e NS
Vitamin E (mg) 10.8 ± 5.1 14.9 ± 8.4 15 <0.001
Niacin (mg) 38.5 ± 13.6 45.7 ± 39.5 18 f <0.01
Folate (ug) 302 ± 115 296 ± 121 300 NS
Calcium (mg) 939 ± 295 886 ± 345 900 g NS
Iron (mg) 16.5 ± 5.1 16.1 ± 6.5 9 h NS
Magnesium (mg) 323 ± 107 396 ± 139 350 <0.001
Iodine (ug) 117 ± 88 100 ± 50.5 150 NS
Phosphorus (mg) 1580 ± 442 1535 ± 471 700 i NS
Zinc (mg) 12 ± 4.0 10.5 ± 3.7 9.5 j <0.01
Potassium (mg) 3481 ± 980 3045 ± 917 3100 <0.01
Selenium (ug) 93.8 ± 53.5 63.5 ± 35.1 55 <0.001
Notes: Values are means ± SD. Spanish adult men data were taken from the Spanish dietary nutritional
assessment (ENIDE study, representative at national level of the adult population). SD, standard deviation; DRI,
dietary reference intake; FESNAD, Federation of Spanish Societies of Nutrition and Dietetics; NS: non-significant. a
Vitamin A, 800 mg for 16–19 year range men; b Thiamin, 1.1 mg for >60 years old men; c Vitamin B6, 1.4 mg for
16–18 years old and 1.6 mg for >60 years old men; d Vitamin C, 70 mg for >60 years old men; e Vitamin D, 7.5 mg
for >60 years old men; f Niacin, 17 mg for 50–69 years old men; g Calcium, 1000 mg 16–19 years old and for >60
years old men; h Iron, 10 mg for >60 years old men; i Phosphorus, 800 mg for 16–19 years old men; j Zinc: 10 mg for
>60 years old men.
A 67% (2/3) DRI cutoff value for deficient micronutrient intake was set as reported by the
literature [22,23]. According to this cutoff, vitamin A, D and E, iodine, folate and magnesium
were deficient, as a small amount (41–81%) of participants accomplished it (Table 5). In the case
of calcium, zinc, selenium and vitamin C, most participants (around 90% of them) fulfilled 2/3 of the
DRIs. None of the celiac men showed low intakes of vitamin B6, B12, niacin, riboflavin, thiamine,
phosphorus and iron.
Table 5. Percentage of celiac men (n = 42) and women (n = 54) that fulfilled at least 2/3 of DRI






% of Participants that Fulfilled at
Least 67% of Recommendations
% of Participants that Fulfilled at
Least 67% of Recommendations
Vitamin A (ug) 81 89 NS
Thiamin (mg) 98 100 NS
Riboflavin (mg) 98 98 NS
Vitamin B6 (mg) 100 100 NS
Vitamin B12 (ug) 100 100 NS
Vitamin C (mg) 93 96 NS
Vitamin D (ug) 45 52 NS
Vitamin E (mg) 48 61 NS
179







% of Participants that Fulfilled at
Least 67% of Recommendations
% of Participants that Fulfilled at
Least 67% of Recommendations
Niacin (mg) 100 100 NS
Folate (ug) 76 82 NS
Calcium (mg) 86 87 NS
Iron (mg) 100 69 <0.001
Magnesium (mg) 71 91 <0.05
Iodine (ug) 50 20 <0.01
Phosphorus (mg) 100 100 NS
Zinc (mg) 91 98 0.093
Potassium (mg) 98 85 <0.05
Selenium (ug) 93 69 <0.01
Notes: Recommended intake of vitamins and minerals proposed by the Federation of Spanish Societies (FESNAD).
NS: non-significant. p value correspond to differences between celiac men and celiac women’s appropriate intakes.
Several differences were found in mineral intake accomplishment, but not in vitamins,
when comparing celiac men and women habits (Table 5). Celiac women fulfilled magnesium
requirements better than celiac men and, by contrast, iron, iodine, potassium, and selenium DRIs were
better complied by celiac men.
3.3. Food Consumption Frequency of Celiac Men
Figure 2 summarizes main food group consumption frequency. Cereal consumption data indicated
that only 13% of celiac men fulfilled these food group recommendations, which means at least four
servings per day (Figure 2). Moreover, almost half of them (44%) consumed a small or a very small
amount of cereals (fewer than two servings) per day.
The vast majority of participants (84%) did not reach vegetable consumption recommendations
(10 portions/week) [19]. One-third of celiac men did not consume the minimum recommended
two servings of fruit daily. Furthermore, legume consumption was also low in 42% of participants,
which means that they consumed less than two portions of pulses per week.
With regard to animal origin food consumption, almost half of the participants fulfilled the
recommendations of dairy products, 2–3 servings per day, whereas 25% reported an excessive
consumption, which means more than 4 dairy servings per day. Only 19% of celiac men achieved egg
consumption recommended by the SENC, while 38% had an excessive consumption. The ingestion
of fish and derivatives was sufficient in nearly half of celiac men and almost 20% of participants
consumed it in excess. By contrast, meat consumption was excessive in the vast majority of the subjects
(88%), which means that they ate more than 4–5 servings of meat per week.
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Figure 2. Compliance of food frequency consumption in celiac men by servings per day or week,
according to the Spanish Society of Community Nutrition (SENC).
In relation to the foods considered for occasional consumption, it must be pointed out that celiac
men followed the recommendations (data not shown). Participants used olive oil, which is rich in
monounsaturated fatty acids, as their fat source, and discarded other lipid sources such as margarine
or butter as their main lipid source for cooking.
Finally, the analysis of food frequency questionnaires in celiac men and celiac women revealed
similar results. No differences were found in dairy products, grains, vegetables, fruits and meat
consumption. However, when fish and egg consumption were evaluated, a tendency toward higher
percentage of celiac men with excessive consumption of these foods was observed, compared to celiac
women. Concretely, 19% of men consumed fish in excess vs. 6% of women (p = 0.09). Moreover, 37% of
men consumed eggs in excess, whereas 17% of women did so (p = 0.08).
4. Discussion
Male participation in health promotion programs has usually been lower than that of women,
probably due to their lower interest in health-related topics, among other reasons [4,5]. The studies in
the literature comparing men and women’s dietary habits provide different outcomes, attributable to
differences in methodologies, population sizes, regional habits, and recommendations. Some studies
described different patterns of deficiencies either in macro- or micronutrients between genders [24,25].
In the case of celiac disease, even though clinical trials have been published with both female and male
participants, the recruited number of men is usually small. Thus, evidence about celiac men’s body
composition, diet quality, and eating pattern is rather scarce. The present study presents detailed
energy and nutrient intake and dietary habits of a meaningful celiac male group, comparing them to a
male control population and to celiac women from the same geographical region.
Obesity and overweight are rising among celiac patients, which is increasingly of concern to
clinicians [11,26]. In this study, anthropometric data revealed that celiac men showed an alarming
38.1% of overweight and obesity, while 52% of participants showed an excessive fat mass. Nevertheless,
this prevalence was lower than that observed in the control population [27,28]. These results were
consistent with other studies, where celiac men registered similar BMI index values [8,29,30] which
were also lower than those of the control populations [6,7,31,32].
Comparing these results with data from women (only 7.4% of overweight in celiac women),
major gender differences were found. Accordingly, the prevalence of obesity and overweight in
general population is greater for men [33–35]. These differences could, as stated before, be due to the
lesser interest that men pay to health status and its care [4,5]. Nevertheless, it must be pointed out
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that in the case of celiac patients, most studies do not find gender differences in this parameter [8,29].
However, Tucker et al. (2012) [36] found that females were more likely to be obese, when BMI reaches
values of 30 or above.
Even though energy intake of celiac men was similar to that of the control and to celiac men
from other studies [8,20,29,30], our data revealed that 14% of celiac men consumed calories in excess,
more than 120% of their energy expenditure, and 24% of them exceeded 110% of requirements.
These results were not found in women, whose energy intake was suitable in 65% of the participants.
All of the above explains the high percentage of obesity found among male participants from the
present study. By contrast, 40% of the participants were under 80% of their energy expenditure,
reflecting a possible underreporting, as found by others [29,37].
Celiac men showed imbalanced energy distribution, similarly to previous studies, but it must
be pointed out that participants in this study consumed even fewer carbohydrates and more fat
than those of earlier studies [29,30]. However, the macronutrient consumption of Spanish celiac
women and the control population was similar to that observed in the male celiac group studied.
Thus, it seems that imbalanced energy distribution is not GFD-related but could be associated to
geographical dietary habits. Of these, low cereal and vegetable consumption and excessive meat
intake, observed in both men and women [6], as well as in control men [38], could be the main
contributors to the macronutrient imbalance.
With regard to dietary fat sources, SFA, MUFA and cholesterol were consumed in excess,
although adequate fatty acid ratios were reached. These results were similar to those observed
in control population, reinforcing the idea of this not being a GFD-related imbalance. The excessive
consumption of meat (88% participants) and eggs (37%) could justify the results observed. However,
the proportion of men eating excessive SFA and cholesterol was significantly greater than that
of women. Although meat consumption did not differ between men and women, the excessive
consumption of eggs among celiac men could impair these parameters. By contrast, intake of PUFAs
was slightly lower in the male celiac population than in control men. However, 90% of celiac men
participating showed adequate PUFA intake, more than women did. The higher fish consumption
observed in men could be on the basis of this difference.
As far as fiber is concerned, celiac male consumption was low, similar to other studies conducted
with celiac men and control population [8,20,29,30]. The low consumption of vegetables, legumes and
grains could explain, at least in part, this outcome. However, fiber recommendations were more
obeyed by celiac men than by celiac women, due to higher general food intake and thus greater
amounts of plant origin foods.
The celiac population has been associated with an increased cardiovascular risk [39,40].
Although factors influencing the association between CD and cardiovascular disease could be related
to the pathophysiology of CD, there is no doubt that the body composition and dietary pattern of
celiac men described, with high intake of deleterious components, such as SFA, and low intake of
protective ones, such as fiber, play an essential role.
As stated previously, micronutrients have also been a matter of concern for the celiac population.
In our study, some differences in micronutrient mean intake arose between celiac men and their control.
Vitamin E, niacin and magnesium was lower in celiac men than in control men and, by contrast, that of
riboflavin, B6, zinc, potassium and selenium was higher, pointing to a different dietary pattern of this
collective. While mean intakes provided some important information, it was necessary to analyze to
what extent this population was below micronutrient recommendations, in order to identify possible
deficiencies and health-risks.
The percentage of celiac men who complied with micronutrient DRI varied among nutrients,
and also between genders. The most alarming deficiencies reported in this work for celiac men were
those of vitamin D, vitamin E, and iodine, all of them with less than 50% of individuals fulfilling two
thirds of DRI.
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Wild et al. (2010) also reported vitamin D deficient intake in celiac men (no more than 20%
of patients fulfilled the DRI) [8,29,30]. These data were also in accordance with the general population
[8,20,29,30]. Vitamin E and iodine mean intakes were also low for both celiac and control men.
In particular, vitamin E was even lower in celiacs, where only 48% reached the 67% of DRI. Iodine and
vitamin E are not usually analyzed in GFD assessments, but considering their extremely low intake,
specific nutritional advice, and probably supplementation, should be considered for the celiac
male population.
In addition to the aforementioned important deficiencies, other micronutrients, such as folate and
magnesium, were also below recommendations in celiac men (less than 80% achieved two-thirds of
DRI). These data were in agreement with previous studies from the literature [8,30,37].
The comparison between celiac men and women in their adherence to vitamin and mineral
recommendations revealed differences only in some mineral intakes. Less fulfilment of DRIs in women
was reported for iron, iodine, potassium, and selenium, whereas magnesium intake was higher than
that of men. This could be due to the lower energy intake of women [6], which could hinder the
achievement of some mineral intakes. Iron was a special case, because men fulfilled totally the DRIs,
but only 69% of women achieved 2/3, due to more demanding requirements of this mineral at some life
stages for them. Considering the high prevalence of anemia in patients with CD, this is an important
issue to be addressed in women.
In general, it can be stated that micronutrient deficiencies in celiac men were not directly related
to a GFD, and were concerning for the entire population. Only magnesium and vitamin E intake
appeared to be lower than the control, and below recommendations for both groups in the case
of vitamin E. Folate, iodine and vitamin D intakes were the most worrying, giving the anemia,
thyroid disease and osteopenia prevalence of this collective [41,42].
One of the most cited reasons for micronutrient deficiency in a GFD is gluten-free products (GFP)
composition. In fact, gluten-containing grains and foods are a major source of micronutrients [43,44],
and often GFP do not contain the same levels of micronutrients as their counterparts—e.g., thiamine,
riboflavin, niacin, folate, vitamin D, calcium, or iron [10,45–48]. Instead of those GFP, higher gluten-free
whole cereals (amaranth, sorghum, millet, etc.) and pseudocereals (quinoa, buckwheat, etc.) are more
interesting, as they contain the fiber and micronutrients necessary to balance [11,49]. Nevertheless,
fortification of gluten-free flours and GFP could be also of interest, but more research is necessary
in order to correctly identify which nutrients are suitable for general fortification and which for
personal supplementation.
For this purpose, all micronutrients should be addressed in the studies, and the micronutrient
composition of GFP, which needs to be studied in depth, should be incorporated into the databases.
Selenium, iodine and vitamin E intakes are scarcely analyzed in the literature, and they are still
important to ensure the health status of celiac people.
The main limitation of the present study was that micronutrient intake coming from GFP was
calculated according to the micronutrient content of their gluten-containing counterparts. Thus,
data from the present work could represent an overestimation of the real consumption of vitamins
and minerals. Moreover, people participating in this kind of studies are more concerned about health
issues and self-caring, which could also have overestimated the results. Furthermore, the experimental
design did not include a control group of men, and people with comorbidities were excluded from the
study. Nevertheless, this is the first study where dietary habits of a cohort of Spanish celiac men were
compared to those of the control population and to those of Spanish celiac women. It is worth noting
that the sample size was higher than those used in other studies with celiac men.
In summary, inadequacies in terms of both, macro- and micronutrients, in celiac male diets
are found. Some of them also appear in the diet of the control population, pointing to unsuitable
habits of the entire population, but other changes are gender-specific and fewer GFD-dependent.
Effective general recommendations for the global male population should be given, as well as specific
advice for celiac people, principally regarding micronutrient intake. Greater consumption of gluten-free
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cereals or pseudocereals, vegetables, and legumes and less of that of meats should be recommended.
Personalized dietary advice and long-term follow-up for celiac people, in particular for celiac men,
could contribute towards preventing nutrient deficiencies related to dietary imbalance and to obtaining
a better health status, lowering the risk of CD-related pathologies.
Author Contributions: T.G. and I.L. recruited the patients, performed anthropometric measurements and collected
questionnaires. J.C.V. and L.C. designed the experiment. I.C. and A.L. performed the analysis of diet and food
habits. V.N. and E.S. analyzed all data and contributed to statistical analysis. E.S., I.C., V.N. and A.L. wrote
the manuscript.
Acknowledgments: Idoia Larretxi is a fellowship of the University of the Basque Country, UPV/EHU (Euskararen
eta Etengabeko Prestakuntzaren arloko Errektoreordetza). This research was funded by University of the
Basque Country (UPV/EHU) and Basque Government, grant numbers US12/10 and GV2008111042, respectively.
We thank the participation of all patients, and the collaboration of “Asociación de Celiacos de Euskadi (EZE)”,
specifically that of Mireia Apraiz, Beatriz Zulueta, Nerea Segura, Estíbaliz Olabarri Elena Pérez-Estevez,
Lissette Delgado, Aranzazu Sainz-Espiga, Sagrario Martínez and Lorea Martínez-Indart.
Conflicts of Interest: The authors declare that they have no conflict of interest.
References
1. Lionetti, E.; Catassi, C. New clues in celiac disease epidemiology, pathogenesis, clinical manifestations,
and treatment. Int. Rev. Immunol. 2011, 30, 219–231. [CrossRef] [PubMed]
2. Peña, A.; Rodrigo, L. Epidemiology of celiac disease and non-celiac gluten-related disorders. In Advances in the
Understanding of Gluten Related Pathology and the Evolution of Gluten-Free Foods; Arranz, E., Fernández-Bañares, F.,
Rosell, C., Rodrigo, L., Peña, A., Eds.; OmniaScience: Barcelona, Spain, 2015; pp. 27–73.
3. Catassi, C.; Gatti, S.; Fasano, A. The new epidemiology of celiac disease. J. Pediatr. Gastroenterol. Nutr. 2014,
59 (Suppl. 1) (Suppl. 1), S7–S9. [CrossRef]
4. Sharp, P.; Bottorff, J.L.; Hunt, K.; Oliffe, J.L.; Johnson, S.T.; Dudley, L.; Caperchione, C.M. Men’s Perspectives
of a Gender-Sensitized Health Promotion Program Targeting Healthy Eating, Active Living, and Social
Connectedness. Am. J. Men’s Health 2018, 2157–2166. [CrossRef] [PubMed]
5. Galdas, P.M.; Cheater, F.; Marshall, P. Men and health help-seeking behaviour: Literature review. J. Adv. Nurs.
2005, 49, 616–623. [CrossRef] [PubMed]
6. Churruca, I.; Miranda, J.; Lasa, A.; Bustamante, M.; Larretxi, I.; Simon, E. Analysis of Body Composition and
Food Habits of Spanish Celiac Women. Nutrients 2015, 7, 5515–5531. [CrossRef] [PubMed]
7. Bardella, M.T.; Fredella, C.; Prampolini, L.; Molteni, N.; Giunta, A.M.; Bianchi, P.A. Body composition and dietary
intakes in adult celiac disease patients consuming a strict gluten-free diet. Am. J. Clin. Nutr. 2000, 72, 937–939.
[CrossRef] [PubMed]
8. Martin, J.; Geisel, T.; Maresch, C.; Krieger, K.; Stein, J. Inadequate nutrient intake in patients with celiac
disease: Results from a german dietary survey. Digestion 2013, 87, 240–246. [CrossRef] [PubMed]
9. Capristo, E.; Malandrino, N.; Farnetti, S.; Mingrone, G.; Leggio, L.; Addolorato, G.; Gasbarrini, G.
Increased serum high-density lipoprotein-cholesterol concentration in celiac disease after gluten-free diet
treatment correlates with body fat stores. J. Clin. Gastroenterol. 2009, 43, 946–949. [CrossRef] [PubMed]
10. Vici, G.; Belli, L.; Biondi, M.; Polzonetti, V. Gluten free diet and nutrient deficiencies: A review. Clin. Nutr. 2016.
[CrossRef] [PubMed]
11. Theethira, T.G.; Dennis, M. Celiac disease and the gluten-free diet: Consequences and recommendations for
improvement. Dig. Dis. 2015, 33, 175–182. [CrossRef] [PubMed]
12. Phillips, C.M.; Kesse-Guyot, E.; McManus, R.; Hercberg, S.; Lairon, D.; Planells, R.; Roche, H.M. High dietary
saturated fat intake accentuates obesity risk associated with the fat mass and obesity-associated gene in
adults. J. Nutr. 2012, 142, 824–831. [CrossRef] [PubMed]
13. Slavin, J.L. Dietary fiber and body weight. Nutrition 2005, 21, 411–418. [CrossRef] [PubMed]
14. Capristo, E.; Mingrone, G.; Addolorato, G.; Greco, A.V.; Corazza, G.R.; Gasbarrini, G. Differences in metabolic
variables between adult coeliac patients at diagnosis and patients on a gluten-free diet. Scand. J. Gastroenterol.
1997, 32, 1222–1229. [CrossRef] [PubMed]
184
Nutrients 2018, 10, 1713
15. Capristo, E.; Addolorato, G.; Mingrone, G.; De Gaetano, A.; Greco, A.V.; Tataranni, P.A.; Gasbarrini, G.
Changes in body composition, substrate oxidation, and resting metabolic rate in adult celiac disease patients
after a 1-y gluten-free diet treatment. Am. J. Clin. Nutr. 2000, 72, 76–81. [CrossRef] [PubMed]
16. Gallagher, D.; Heymsfield, S.B.; Heo, M.; Jebb, S.A.; Murgatroyd, P.R.; Sakamoto, Y. Healthy percentage body fat
ranges: An approach for developing guidelines based on body mass index. Am. J. Clin. Nutr. 2000, 72, 694–701.
[CrossRef] [PubMed]
17. Russolillo, G.; Marques, I. Food Portion Sizes Album; Imagen Comunicación Multimedia: Madrid, Spain, 2008; 186p.
18. FESNAD. Dietary reference intakes (DRI) for spanish population, 2010. Actividad Dietética 2010, 14, 196–197.
[CrossRef]
19. Aranceta, J.; Serra-Majem, L. Dietary guidelines for the Spanish population. Public Health Nutr. 2001, 4, 1403–1408.
[CrossRef] [PubMed]
20. AECOSAN, Agencia Española de Consumo, Seguridad Alimentaria y Nutrición. Spanish Population Dietary
Intakes. National Health Survey (ENIDE). Available online: http://aesan.msssi.gob.es/AESAN/docs/docs/
evaluacion_riesgos/estudios_evaluacion_nutricional/valoracion_nutricional_enide_macronutrientes.pdf
(accessed on 8 June 2017).
21. SENC. Nutritional objectives for the Spanish population: Consensus from the Spanish Society of Community
Nutrition. Rev. Esp. Nutr. Com. 2011, 17, 178–199.
22. Marshall, T.A.; Stumbo, P.J.; Warren, J.J.; Xie, X.J. Inadequate nutrient intakes are common and are associated
with low diet variety in rural, community-dwelling elderly. J. Nutr. 2001, 131, 2192–2196. [CrossRef] [PubMed]
23. Roman-Vinas, B.; Ribas Barba, L.; Ngo, J.; Martinez-Gonzalez, M.A.; Wijnhoven, T.M.; Serra-Majem, L.
Validity of dietary patterns to assess nutrient intake adequacy. Br. J. Nutr. 2009, 101 (Suppl. 2), S12–S20.
[CrossRef]
24. Arganini, C.; Saba, A.; Comitato, R.; Virgili, F.; Turrini, A. Gender Differences in Food Choice and Dietary Intake in
Modern Western Societies. In Public Health-Social and Behavioral Health; Maddock, J., Ed.; InTech: Hampshire, UK,
2012; ISBN 978-953-51-0620-3. Available online: http://www.intechopen.com/books/public-health-social-and-
behavioral-health/gender-differences-in-foodchoice-and-dietary-intake-in-modern-western-societies (accessed
on 15 October 2018).
25. Rippin, H.L.; Hutchinson, J.; Jewell, J.; Breda, J.J.; Cade, J.E. Adult Nutrient Intakes from Current National
Dietary Surveys of European Populations. Nutrients 2017, 9, 1288. [CrossRef] [PubMed]
26. Valletta, E.; Fornaro, M.; Cipolli, M.; Conte, S.; Bissolo, F.; Danchielli, C. Celiac disease and obesity: Need for
nutritional follow-up after diagnosis. Eur. J. Clin. Nutr. 2010, 64, 1371–1372. [CrossRef] [PubMed]
27. Aranceta Bartrina, J.; Pérez Rodrigo, C. Inequality, health and nutrition in Spain: A regional view of the body
mass index. Nutr. Hosp. 2018, 35, 142–149. [PubMed]
28. López-Sobaler, A.M.; Aparicio, A.; Aranceta-Bartrina, J.; Gil, Á.; González-Gross, M.; Serra-Majem, L.;
Varela-Moreiras, G.; Ortega, R.M. Overweight and General and Abdominal Obesity in a Representative
Sample of Spanish Adults: Findings from the ANIBES Study. Biomed. Res. Int. 2016, 2016, 8341487. [CrossRef]
[PubMed]
29. Wild, D.; Robins, G.G.; Burley, V.J.; Howdle, P.D. Evidence of high sugar intake, and low fibre and mineral
intake, in the gluten-free diet. Aliment. Pharmacol. Ther. 2010, 32, 573–581. [CrossRef] [PubMed]
30. Shepherd, S.J.; Gibson, P.R. Nutritional inadequacies of the gluten-free diet in both recently-diagnosed and
long-term patients with coeliac disease. J. Hum. Nutr. Diet. 2013, 26, 349–358. [CrossRef] [PubMed]
31. Brambilla, P.; Picca, M.; Dilillo, D.; Meneghin, F.; Cravidi, C.; Tischer, M.C.; Vivaldo, T.; Bedogni, G.;
Zuccotti, G.V. Changes of body mass index in celiac children on a gluten-free diet. Nutr. Metab. Cardiovasc.
Dis. 2013, 23, 177–182. [CrossRef] [PubMed]
32. Larretxi, I.; Simon, E.; Benjumea, L.; Miranda, J.; Bustamante, M.A.; Lasa, A.; Eizaguirre, F.J.; Churruca, I.
Gluten-free-rendered products contribute to imbalanced diets in children and adolescents with celiac disease.
Eur. J. Nutr. 2018. [CrossRef] [PubMed]
33. Peralta, M.; Ramos, M.; Lipert, A.; Martins, J.; Marques, A. Prevalence and trends of overweight and obesity
in older adults from 10 European countries from 2005 to 2013. Scand. J. Public Health 2018, 46, 522–529.
[CrossRef] [PubMed]
34. Rodríguez-Rodríguez, E.; López-Plaza, B.; López-Sobaler, A.M.; Ortega, R.M. Overweight and obesity among
Spanish adults. Nutr. Hosp. 2011, 26, 355–363. [CrossRef] [PubMed]
185
Nutrients 2018, 10, 1713
35. Gutiérrez-Fisac, J.L.; Banegas Banegas, J.R.; Artalejo, F.R.; Regidor, E. Increasing prevalence of overweight
and obesity among Spanish adults, 1987–1997. Int. J. Obes. Relat. Metab. Disord. 2000, 24, 1677–1682.
[CrossRef] [PubMed]
36. Tucker, E.; Rostami, K.; Prabhakaran, S.; Al Dulaimi, D. Patients with coeliac disease are increasingly
overweight or obese on presentation. J. Gastrointest. Liver Dis. 2012, 21, 11–15.
37. Hallert, C.; Grant, C.; Grehn, S.; Grännö, C.; Hultén, S.; Midhagen, G.; Ström, M.; Svensson, H.;
Valdimarsson, T. Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years.
Aliment. Pharmacol. Ther. 2002, 16, 1333–1339. [CrossRef] [PubMed]
38. De Batlle, J.; Gracia-Lavedan, E.; Romaguera, D.; Mendez, M.; Castaño-Vinyals, G.; Martín, V.; Aragonés, N.;
Gómez-Acebo, I.; Olmedo-Requena, R.; Jimenez-Moleon, J.J.; et al. Meat intake, cooking methods and
doneness and risk of colorectal tumours in the Spanish multicase-control study (MCC-Spain). Eur. J. Nutr.
2018, 57, 643–653. [CrossRef] [PubMed]
39. Emilsson, L.; Lebwohl, B.; Sundström, J.; Ludvigsson, J.F. Cardiovascular disease in patients with coeliac
disease: A systematic review and meta-analysis. Dig. Liver Dis. 2015, 47, 847–852. [CrossRef] [PubMed]
40. Ciaccio, E.J.; Lewis, S.K.; Biviano, A.B.; Iyer, V.; Garan, H.; Green, P.H. Cardiovascular involvement in celiac
disease. World J. Cardiol. 2017, 9, 652–666. [CrossRef] [PubMed]
41. Lucendo, A.J.; García-Manzanares, A. Bone mineral density in adult coeliac disease: An updated review.
Rev. Esp. Enferm. Dig. 2013, 105, 154–162. [CrossRef] [PubMed]
42. Nijhawan, S.; Katiyar, P.; Nagaich, N.; Saradava, V.; Nijhawan, M.; Gupta, G.; Mathur, A.; Sharma, R.;
Nepalia, S. Prevalence of associated disorders in Indian patients with celiac disease. Indian J. Gastroenterol.
2013, 32, 330–334. [CrossRef] [PubMed]
43. Whitton, C.; Nicholson, S.K.; Roberts, C.; Prynne, C.J.; Pot, G.K.; Olson, A.; Fitt, E.; Cole, D.; Teucher, B.;
Bates, B.; et al. National Diet and Nutrition Survey: UK food consumption and nutrient intakes from the
first year of the rolling programme and comparisons with previous surveys. Br. J. Nutr. 2011, 106, 1899–1914.
[CrossRef] [PubMed]
44. Størsrud, S.; Hulthén, L.R.; Lenner, R.A. Beneficial effects of oats in the gluten-free diet of adults with special
reference to nutrient status, symptoms and subjective experiences. Br. J. Nutr. 2003, 90, 101–107. [CrossRef]
[PubMed]
45. Thompson, T. Thiamin, riboflavin, and niacin contents of the gluten-free diet: Is there cause for concern?
J. Am. Diet. Assoc. 1999, 99, 858–862. [CrossRef]
46. Penagini, F.; Dilillo, D.; Meneghin, F.; Mameli, C.; Fabiano, V.; Zuccotti, G.V. Gluten-free diet in children:
An approach to a nutritionally adequate and balanced diet. Nutrients 2013, 5, 4553–4565. [CrossRef]
[PubMed]
47. Cornicelli, M.; Saba, M.; Machello, N.; Silano, M.; Neuhold, S. Nutritional composition of gluten-free food
versus regular food sold in the Italian market. Dig. Liver Dis. 2018. [CrossRef] [PubMed]
48. Kulai, T.; Rashid, M. Assessment of Nutritional Adequacy of Packaged Gluten-free Food Products. Can. J.
Diet. Pract Res. 2014, 75, 186–190. [CrossRef] [PubMed]
49. Lee, A.R.; Ng, D.L.; Dave, E.; Ciaccio, E.J.; Green, P.H. The effect of substituting alternative grains in the diet
on the nutritional profile of the gluten-free diet. J. Hum. Nutr. Diet. 2009, 22, 359–363. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Gluten-Free Diet and Its ‘Cousins’ in Irritable
Bowel Syndrome
Anupam Rej 1 and David Surendran Sanders 1,2,*
1 Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS
Foundation Trust, Sheffield S10 2JF, UK; anupam.rej@sth.nhs.uk
2 Academic Unit of Gastroenterology, Department of Infection, Immunity and Cardiovascular Disease,
University of Sheffield, Sheffield, S10 2RX, UK
* Correspondence: david.sanders@sth.nhs.uk; Tel.: +0114-226-1179
Received: 11 October 2018; Accepted: 8 November 2018; Published: 11 November 2018
Abstract: Functional disorders are common, with irritable bowel syndrome (IBS) being the
commonest and most extensively evaluated functional bowel disorder. It is therefore paramount
that effective therapies are available to treat this common condition. Diet appears to play a pivotal
role in symptom generation in IBS, with a recent interest in the role of dietary therapies in IBS.
Over the last decade, there has been a substantial increase in awareness of the gluten-free diet (GFD),
with a recent focus of the role of a GFD in IBS. There appears to be emerging evidence for the
use of a GFD in IBS, with studies demonstrating the induction of symptoms following gluten in
patients with IBS. However, there are questions with regards to which components of wheat lead
to symptom generation, as well as the effect of a GFD on nutritional status, gut microbiota and
long-term outcomes. Further studies are required, although the design of dietary studies remain
challenging. The implementation of a GFD should be performed by a dietitian with a specialist
interest in IBS, which could be achieved via the delivery of group sessions.
Keywords: non-coeliac gluten sensitivity; gluten; wheat; low FODMAP diet; irritable bowel syndrome
1. Introduction
Functional disorders are common, with the Rome IV guidelines classifying these disorders into
oesophageal, gastroduodenal, bowel, centrally mediated, anorectal, gallbladder, and sphincter of
Oddi disorders [1]. The commonest and most extensively evaluated functional bowel disorder is
irritable bowel syndrome (IBS), with a reported global pooled prevalence of 11 percent [2]. IBS can be
classified into diarrhoea-predominant (IBS-D), constipation-predominant (IBS-C), mixed (IBS-M)
and unclassified (IBS-U) [1]. The pathophysiology of IBS is not fully understood, but several
pathophysiological mechanisms have been proposed, including visceral hypersensitivity, inflammation,
increased intestinal mucosal permeability, and genetic and psychological factors [3,4]. The impact
of IBS can lead to a significant impact on sufferers, with a reduced quality of life, increased time off
work and greater utilisation of healthcare [5]. It is also associated with several other conditions such as
depression, fibromyalgia, chronic fatigue disorder, and temporomandibular joint disorder [6]. As a
result of this, it is paramount that there are effective treatments for this common condition.
Despite many individuals using medication for the treatment of functional disorders, up to
two-thirds of individuals with functional disorders also use diet or dietary supplements as a therapy [7].
A large proportion of individuals with IBS note that they have dietary triggers, with up to two-thirds
of individuals noting the induction of symptoms after ingestion of food [8–10]. As a result of this, there
has been great interest in the role of dietary therapies in IBS, with a focus recently in a low fermentable
oligo-, di-, and mono-saccharides and polyols (FODMAPs) diet, wheat free diet (WFD) and gluten-free
diet (GFD).
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There has been an increase in the awareness of the GFD over the last decade [11], with the
gluten-free food industry continuing to rise, with more than $15 billion dollars spent in the USA
in 2016 [12]. Whilst GFDs are known as the mainstay of treatment for people with an established
diagnosis of coeliac disease [13], we will explore the emerging evidence for this dietary therapy in
individuals with IBS.
2. Wheat Free Diet
Gluten is found in the endosperm of grass-related grains, including wheat, barley, and rye. In
view of this, it is important to explore the role of a WFD in IBS as many individuals consuming a GFD
maybe avoiding wheat.
Wheat avoidance is common, with a cross-sectional population survey in Australia reporting
wheat avoidance in approximately 10% of individuals [14]. A significant proportion of individuals
with IBS who reduce wheat consumption may have a wheat sensitivity. A large study [15], in which
920 patients with IBS who had a self-reduced wheat consumption, underwent an elimination diet for
4 weeks, subsequently followed by a double-blind placebo-controlled (DBPC) challenge. Out of these
patients, 276 patients (30%) were suffering from a wheat sensitivity, as they were identified as being
asymptomatic on an elimination diet, followed by symptoms during the DBPC challenge.
The same group evaluated the same cohort of patients in a prospective study [16], with a median
follow up of 99 months in 200 patients. A total of 148 patients (74%) were still following a wheat free
diet at follow up, and 127 patients (64%) were on a strict gluten-free diet. A total of 22 of these patients
were randomised to the DBPC wheat re-challenge. A total of 20 of the 22 patients (91%) still reacted to
wheat. This suggests that even in the long term, a subgroup of patients with IBS is likely to have a
persistent sensitivity to wheat.
Confocal endomicroscopy has shown immediate and dramatic mucosal responses to wheat
as an antigen [17]. Another study with 80 participants who reported symptoms related to wheat,
demonstrated systemic immune activation and compromised intestinal epithelial barrier integrity
in these individuals [18]. This may provide a morphological basis for wheat causing symptoms in
individuals with IBS. There is currently little data known on the long-term risks of a wheat free diet in
patients with IBS, with studies required to assess this.
3. Gluten-Free Diet
Many individuals note symptoms following the ingestion of gluten. This has led to the term of
non-coeliac gluten sensitivity (NCGS), being described as early as the 1980s [19]. The mechanism of
induction of symptoms in individuals is unclear, but it has been suggested that gluten proteins may
be insufficiently degraded by gut proteases, which could lead to an innate immune response [20].
However, further research is required to elucidate the mechanism.
Gluten has been demonstrated to generate symptoms in individuals with IBS [21]. A DBPC
trial in 34 patients with a diagnosis of IBS who had improved on a GFD were given either gluten
or placebo in the form of two bread slices plus one muffin per day, with a GFD for up to 6-weeks.
The study demonstrated worsening symptoms on the visual analogue scale (VAS) for overall symptoms
(p = 0.047), pain (p = 0.016), bloating (p = 0.016), stool consistency (p = 0.024), and tiredness (p = 0.001)
with gluten. The same group later performed a study demonstrating no effects of gluten in patients
with NCGS and IBS [22], in contrast to their previous study. This double-blind crossover trial in
37 subjects with NCGS and IBS involved placing participants on a 2-week diet of reduced FODMAPs,
followed by the random allocation to high-gluten (16 g gluten/day), low-gluten (2 g gluten/day
and 14 g whey protein/day), or control (16 g whey protein/day) diets for 1 week, followed by a
washout period of at least 2 weeks. The authors concluded that there were no dose-dependent effects
of gluten on patients placed on a low FODMAP diet. However, the findings of this study may be
explained by the study design and participants. As participants knew they were going to receive either
high-gluten, low-gluten, or control, there may have been an anticipatory nocebo response which may
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have accounted for these findings. Secondly, participants at baseline had a high VAS, which may not
be truly representative of this group.
There have also been other double-blind placebo-controlled trials evaluating the effect of gluten
on IBS. A study in 148 patients with IBS involved commencing individuals on a GFD, followed by
packages containing powdered gluten or gluten-free powder [23]. Symptomatic improvement was
different in the gluten-containing group in comparison to the placebo group, with symptoms being
controlled in 25.7% in the gluten-containing group, compared to 83.8% in the placebo group. Another
DBPC trial in India [24] showed similar findings. A total of 60 patients with IBS completed this
study, in which participants underwent a GFD for 4 weeks, followed by a re-challenge of placebo
(gluten-free breads) or gluten (whole cereal breads). The study demonstrated that participants in the
gluten intervention group scored higher in terms of abdominal pain, bloating, and tiredness (p < 0.05).
Randomised controlled trials (RCT) have demonstrated the benefit of a GFD. An RCT [25]
in 45 patients with IBS-D, in which participants were allocated to either a 4 week trial of a GFD
or gluten-containing diet, demonstrated an increase in bowel movements per day in those on a
gluten-containing diet (p = 0.04). Interestingly, individuals taking a gluten-containing diet were noted
to be associated with a higher small bowel permeability, with small bowel permeability greater in
HLA DQ2/8 positive than negative patients (p = 0.018). A GFD was noted to have a greater effect of
bowel movements per day in HLA DQ2/8 positive than negative patients (p = 0.019). It is, therefore,
possible that gluten affects the bowel barrier function on IBS, with HLA DQ2/8 being a susceptible
factor. A prospective study [26] in 41 patients also demonstrated a clinical response (reduction in
IBS-Symptom Severity Score from 286 to 131, p < 0.001) in individuals with IBS-D placed on a 6 week
GFD. Interestingly, from this study, 21 out of the 29 individuals (72%) in the study planned to continue
this diet in the long term, with individuals noted to still be on the diet at a mean of 18 months.
The majority of patients taking a GFD in IBS appear to be adherent to the diet. A study [27] in
35 patients with IBS noted that in those individuals who responded to a GFD, 64% (7 out of 11 patients)
were still adherent. This data are similar to patients with coeliac disease, where full adherence has
been reported at 65 percent and partial adherence at 31 percent [28]. This may suggest the ease of
implementation of a GFD in IBS. Additionally, the GFD is an exclusion diet, which is defined as the
exclusion of one or two foods from the diet, in comparison to an elimination diet, which involves
the removal of a selection of foods [29]. This may help with ease of implementation of the GFD
in comparison to elimination diets, such as the low FODMAP diet. However, there have been no
direct comparisons in the literature between the low FODMAP diet and GFD with regards to ease
of implementation.
Individuals who maintain a GFD have the option of purchasing specialised gluten-free products.
For individuals with coeliac disease consuming a GFD, it has been demonstrated that the majority
of individuals purchase gluten-free products [30]. A study in the UK demonstrated that gluten-free
foods were 4 times more expensive than non-gluten-free alternatives (p < 0.0001), with regular and
quality supermarkets stocking a median of 22 items, in comparison to nil in budget supermarkets [31].
This may suggest that cost may limit the purchase of specialised gluten-products, especially for
individuals from lower socioeconomic classes. However, it is important to note that alternatively there
are naturally occurring foods free of gluten, which do not require the purchase of specialist products
to maintain a GFD. Therefore, it is uncertain whether a GFD is more expensive to implement than a
standard diet, and there is no literature to date on this in patients with IBS.
Recently a combination of the low FODMAP diet and GFD (LF-GFD) demonstrated benefit in
patients with coeliac disease and co-existing functional symptoms [32]. This randomised double-blind
study recruited patients with coeliac disease on a GFD for at least one year, with a negative plasma
tissue transglutaminase (TTG) value with IBS symptoms fulfilling the Rome III criteria. A total of 50
participants were randomly allocated to an LF-GFD or GFD only. Participants received a structured
dietary plan from a nutritionist for a 21-day period. A significant reduction in the VAS for abdominal
pain was noted in the LF-GFD group versus the regular GFD group (p < 0.01). The general well-being
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increased in both groups, although a higher improvement was noted in the LF-GFD combination
group (p = 0.03) [32]. Further studies are required to assess whether this could be an effective therapy
for individuals with coeliac disease and IBS, as well as long-term studies being required.
4. Unanswered Questions
Despite the growing evidence for a GFD, a number of questions remain. Little is known about
the potential effect of nutritional deficiencies in patients with IBS undergoing a GFD, with data being
extrapolated from individuals on a GFD as a result of coeliac disease. A prospective validated 5-day
food diary [33], in which 139 patients with coeliac disease were invited to fill, demonstrated similar
intake of nutrients and energy to comparator populations, but a higher proportion of carbohydrate
intake was obtained from non-milk extrinsic sugars and intakes of non-starch polysaccharides were
low. Another study in 47 individuals with coeliac disease on a GFD, estimated three-day food records.
Lower than recommended intakes of fibre and calcium in men and women was noted [34]. A GFD has
been demonstrated to be poor in alimentary fibre, as well as micronutrient deficiencies being noted [35].
Whilst macronutrient and micronutrient deficiencies have been demonstrated on a GFD, these may
not necessarily be a result of the GFD itself. It may be that the changes seen are reflective of overall
community dietary habits and pre-existing individual eating habits, rather than the GFD alone [36,37].
For example, a cross-sectional population-based study in the UK [38] demonstrated that over 95% of
men and women were not adherent to fibre recommendations. A significant reduction in energy intake
has also been demonstrated in individuals following traditional dietary advice [39]. Additionally, it is
unknown whether individuals with IBS will have the same macro- and micro-nutrient deficiencies
as individuals on a GFD for coeliac disease, and this may differ on the level of gluten restriction
implemented by individuals.
As can be seen, macro- and micronutrient deficiencies can occur with any diet, and this highlights
the importance of dietetic involvement in the implementation of dietary therapies and is supported
by other reviews [40,41]. It has been shown that whilst the vast majority of physicians gave patients
advice about the improvement of diet or dietary habit for IBS [42], only a minority would recommend
referral to a specialist dietitian [43]. The GFD for IBS should be implemented by a dietitian with a
specialist interest in IBS, with physicians referring to dietitians for assessment. This is on the basis
that the evidence base for dietary therapies for IBS has been derived from dietitian-led studies rather
than physician-led dietary advice [41]. Whilst a GFD diet may be beneficial for some individuals with
IBS, it is important that the most appropriate dietary therapy is identified by a dietitian through a
detailed history involving the patient. This is important as there is evidence also for the use of a low
FODMAP diet and WFD [44], with the NICE [45] and BDA [46] guidelines being recommended as
first-line dietary therapies for IBS currently. The implementation of dietary therapies can also lead
to the development of obsessive behaviours and orthorexia nervosa [47], highlighting the need for
dietetic input to prevent this. Whilst a dietitian-led approach is advised, this is likely to lead to a
strain on existing resources though, with the need for novel methods to increase efficiency if able.
In IBS patients undergoing a low FODMAP diet (n = 364), dietitian-led group education has been
demonstrated to be clinically effective [48], and this method could potentially be a cost-effective way
to implement a GFD to patients with IBS. It is important to note, however, that there is little data
evaluating group therapies versus one-to-one for a GFD in IBS to date.
Studies have explored the effect of the gut microbiota in individuals on a GFD in healthy
individuals, as well as in individuals with coeliac disease [49–52]. A study in ten healthy
individuals [52] using faecal samples assessed the effect of a GFD over 4 weeks on gut composition
and microbiota. Bacterial populations regarded to be beneficial for health such as Bifidobacterium
proportions were shown to decrease after the consumption of a GFD, raising potential concerns
of a GFD. Additionally, Faecalibacterium prausnitzii proportions were shown to decrease after the
consumption of a GFD in this study, with these bacteria known to be an important butyrate-producer
in the colon, with butyrate being known as a key modulator of colonic health [53]. It has also been
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suggested that taxon-specific shifts as a result of the GFD may explain the benefits of a GFD seen in
patients with IBS. A study [49] in 21 healthy individuals consuming a GFD over 4 weeks demonstrated
stable inter-individual variation in the gut microbiota, with a shift of taxon-specific differences, most
marked with Veillonellaceae. Veillonellaceae is considered to be a pro-inflammatory family of bacteria,
and a decrease in its abundance on the GFD could be one of the mediators of the benefit observed
in patients with IBS on a GFD. The GFD appears to affect species particularly involved in starch
and carbohydrate metabolisms [49]. It is unclear whether this would occur in a population of IBS
patients and, therefore, studies are required to assess this. Assessment of the effect of a GFD on the
gut microbiota in both the short and long term is required in patients with IBS. Currently, the role of
the GFD on the gut microbiota is unclear. The changes seen could be due to a GFD, or they could be
due to other dietary alterations made whilst on a GFD. In the studies mentioned above [49,52], faecal
flora was analysed. The faecal flora is highly organised and spatially organised [54], leading to an
uneven distribution in stool samples [55], which suggests that faecal samples are unlikely to be truly
representative of the gut microbiota. Sample sizes used in the studies have been small and individuals
tend to be unique in terms of their gut microbiota [55]. It is also important to note that these studies
focussed on the gut bacteriome, rather than the virome and mycobiome and, therefore, may not be
truly representative of the entire microbiota. Further studies are required to explore the effect of the
GFD on the microbiome, with the assessment of both short-term and long-term changes.
A recent systematic review and meta-analysis assessing the efficacy of a GFD in IBS [40] concluded
that there was insufficient evidence to recommend a GFD to reduce IBS symptoms. Participants in
the two studies [21,23] included in the review were intolerant of gluten in addition to IBS, which may
suggest that these studies were not fully representative of the entire IBS population. As only two RCTs
were deemed suitable for review, this led to a small sample size (n = 111), giving insufficient evidence
for the reviewers to recommend this diet. However, as seen in Table 1, there have been a number of
studies in addition to these assessing the role of the GFD in IBS [21,23–27,56–58]. It would be difficult
to include all these studies in a meta-analysis as it would be difficult to combine the data from all these
studies due to the heterogeneity of these studies. Studies assessing the GFD in IBS have used different
methods of delivering a GFD, such as using feeding studies in some trials and dietary advice in others.
In feeding studies, different doses of gluten have also been used. Different primary outcomes have
been assessed, different population groups have been enrolled, as well as different study durations.
As can be seen in Table 1, the studies have been performed in a wide variety of geographic locations
which may lead to divergent results as different geographic locations may employ the GFD differently,
which also may potentially have an impact on their resident gut microbiota [55]. The design of these
studies is important as this may result in different outcomes. For example, the studies by Biesiekierski
and colleagues [21,22], assessing the role of a GFD in IBS, led to different outcomes as mentioned
earlier, which could be attributed to study design.
Studies have focussed on patient symptoms to determine response using validated questionnaires
such as the IBS-SSS [59], rather than objective biomarkers. Currently, the evidence does not suggest one
biomarker in IBS, but rather a panel of biomarkers [60]. Currently, even using a panel of biomarkers has
a poor sensitivity and specificity and, therefore, has limited the use of biomarkers to assess response
to dietary therapies in IBS [60,61]. Therefore, further research is required in this area before objective
biomarkers can be used to assess response to therapies in IBS. It appears from Table 1 that there
are several individual trials demonstrating the benefit of a GFD in IBS, demonstrating the growing
evidence base for its use in IBS.
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There have been a relatively smaller number of patients recruited to studies assessing the GFD in
IBS. This is likely to be an issue for dietary studies in general, with a lack of pharmaceutical support
for dietary therapy trials in comparison to pharmaceutical trials, as well as IBS not being a priority
area for research [40]. Significant challenges remain, with a lack of guidelines for dietary trials, unlike
drug trials which are closely regulated [62]. Issues also remain with regards to blinding, for example,
as the GFD is well known to the general public, with up to 5 percent of individuals taking a GFD on
their own volition [63,64]. In addition, other challenges remain in designing dietary trials, including
difficulties in manipulating the diet and the adherence and modification of dietary habits. It is also
difficult to practically implement the findings from dietary trials to the real world [65].
It is unclear which component of wheat leads to symptom generation. Several components
have been suggested as the causal agent, including gluten, alpha-amylase trypsin inhibitors (ATIs),
wheat germ agglutinins (WGAs), and fructans, which are part of the low FODMAP diet [66]. Studies
have been performed to try to elucidate the pathophysiological mechanisms of these components in
symptom generation. Gluten has been demonstrated to alter bowel barrier functions in patients with
IBS. The expression of tight junction proteins (ZO-1, occludin, and claudin-1) have been demonstrated
to be significantly lower in the colonic mucosa of individuals on a gluten-containing diet, especially
in individuals who are HLA DQ2/ 8 positive [25]. Tight junction proteins, claudin-2, 8 and 15, as
well as myosin light chain kinase (MLCK)-myosin II regulatory light chain (MLC) pathway have been
demonstrated to be important in intestinal physiology and barrier function, regulating paracellular
permeability. A study [67] evaluating biopsies from 27 patients with IBS-D demonstrated alterations in
MLC phosphorylation and claudin-15 and claudin-2 expression with gluten with intestinal permeability
changes. This also could potentially explain permeability responses to gluten challenge in patients with
IBS [67]. ATIs have been demonstrated to be strong induces of the innate immune responses, in vitro
and in vivo, via the activation of the toll-like receptor 4, with the release of pro-inflammatory cytokines
leading to intestinal inflammation [68]. WGA is the best-studied cereal grain lectin. When delivered
in vitro, WGAs have been demonstrated to stimulate monocytes and macrophages, which have the
ability to initiate and maintain inflammatory responses [69]. WGA has been demonstrated to affect
enterocyte permeability in vitro. However, it is important to note that human data demonstrating
WGA on inflammatory markers are lacking [69]. FODMAPs are short-chain carbohydrates which
are rapidly fermentable and poorly absorbed, increasing the small bowel water content, passing
unaltered into the colon, where they are rapidly fermented, generating gas and distention [70].
Similar physiological responses to FODMAPs has been demonstrated in both healthy individuals and
patients with IBS, indicating that colonic hypersensitivity to distention in patients with IBS is likely to
be the pathophysiological mechanism [71]. FODMAPs are considered to be beneficial to epithelial cell
integrity and health [72].
A recent study has suggested that fructans rather than gluten are responsible for symptoms
seen in patients with IBS. The study [73] in 59 individuals who had already self-instituted a GFD
involved a double-blind crossover challenge, in which individuals were randomly assigned to diets
containing fructans, placebo, and gluten for 7 days, followed by a minimum 7 day washout period.
The overall gastrointestinal symptom rating scale (GSRS) score for participants consuming fructans
was significantly higher than those consuming gluten (p = 0.049).
It is likely that there is a significant overlap between dietary therapies used in IBS including the
GFD, WFD, and low FODMAP diet. They are likely to be ‘dietary cousins’, with each diet being needed
to be tailored to the individual patient after a detailed assessment by a dietitian. There appears to be a
spectrum of gluten-related disorders, as seen in Figure 1.
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Figure 1. The spectrum of Gluten Related Disorders. EMA: endomysial antibodies; TTG: tissue
transglutaminase; IBS: irritable bowel syndrome; LFD: low fermentable oligo-, di-, and mono-
saccharides, and polyols diet; GFD: gluten-free diet; WFD; wheat-free diet.
It is important to note that there are several other dietary therapies which are being explored in
patients with IBS. As the evidence is growing for gluten in generating symptoms in IBS, it is possible to
hypothesise that other foods may also contain harmful molecules for patients with IBS. Some dietary
therapies have focussed on diets with a primary focus on bioactive food molecules, such as the low
capsaicin diet, low amine/histamine diet, and low food chemical diet [47]. Additionally, there are diets
in addition to the low FODMAP diet focussing on the carbohydrates like the specific carbohydrate
diet and paleo diet. Likewise, there are diets in addition to the GFD focussing on proteins, such as
reduced resistant protein diet. However, to date, there is little evidence for the use of these diets in
patients with IBS [47].
5. Conclusions
There appears to be emerging evidence for the use of a GFD in IBS. A number of unanswered
questions remain, including the effect on the gut microbiota in both the short and long term, as well as
the effect on short- and long-term nutritional adequacy. This dietary therapy should be implemented
by a dietitian with a specialist interest in IBS, which could be done through group clinics, although
research is required to validate this. There is likely to be an overlap with other dietary therapies such
as the low FODMAP diet, with which component of wheat leading to the induction of symptoms still
being unclear. Further research is required on the use of a GFD in IBS, but dietary studies are likely to
be challenging, with blinding and funding being some of the issues.
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Abstract: Gluten seems a potentially important determinant in type 1 diabetes (T1D) and type 2
diabetes (T2D). Intake of gluten, a major component of wheat, rye, and barley, affects the microbiota
and increases the intestinal permeability. Moreover, studies have demonstrated that gluten peptides,
after crossing the intestinal barrier, lead to a more inflammatory milieu. Gluten peptides enter
the pancreas where they affect the morphology and might induce beta-cell stress by enhancing
glucose- and palmitate-stimulated insulin secretion. Interestingly, animal studies and a human
study have demonstrated that a gluten-free (GF) diet during pregnancy reduces the risk of T1D.
Evidence regarding the role of a GF diet in T2D is less clear. Some studies have linked intake of a GF
diet to reduced obesity and T2D and suggested a role in reducing leptin- and insulin-resistance
and increasing beta-cell volume. The current knowledge indicates that gluten, among many
environmental factors, may be an aetiopathogenic factors for development of T1D and T2D. However,
human intervention trials are needed to confirm this and the proposed mechanisms.
Keywords: beta cell; beta-cell stress; celiac disease; gluten-free diet; high-fat diet-induced obesity;
intestinal permeability; islet of Langerhans; NOD mouse; type 1 diabetes; type 2 diabetes
1. Gluten
During the recent years, there has been a tremendous increase in the number of GF products
available with the promise of diverse health benefits. The incidence of celiac disease (CD) was
estimated to be 33.6 per 10,000 person-years in a recent retrospective cohort study from the United
Kingdom [1]. Non-celiac gluten sensitivity is thought to be more common, although the precise
number is unknown [2–5]. Consumption of gluten is believed to affect many aspects of human health
and is hypothesised to contribute to the diabetes pandemic, in which the number of people suffering
from diabetes have quadrupled since 1980 to an estimated 422 million in 2014 [6]. Gluten entered our
diet about 10,000 years ago in Mesopotamia when our ancestors began eating cereals. Today cereals
are an essential food source around the world and more than 50% of the worlds daily caloric intake is
derived from consumption of cereals [7].
Wheat, rye, and barley contain high amounts of gluten in their endosperm storage tissue.
Chemically, gluten is classified as a prolamin, containing monomeric gliadins and polymeric glutenins.
Glutenins can be subdivided into low and high molecular weight proteins while gliadins are
divided into α-, γ-, and ω-gliadins [8]. The major amino acid constituents of gluten are proline,
glutamine, and hydrophobic amino acids [9], which make gluten resistant to complete degradation
by gastric, pancreatic, and brush-border enzymes [10,11]. α-gliadin contains some of the most toxic
peptides in gluten, as evidenced by in vitro studies, and their effect has been mapped to specific
domains in the structure [12]. The effect of the peptides are diverse and include gut-permeating [13],
cytokine-releasing [14], and cytotoxic [15] effects. The 33-mer from α-gliadin is the most immunogenic
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gluten peptide discovered so far, as it contains three overlapping T cell epitopes [16], and processing
by APCs is not required before T cell presentation [17]. The 33-mer is resistant to degradation by
intestinal peptidases [18,19] and was recently identified in all of the modern and old cultivars of wheat
and spelt analysed [20].
2. Gluten and T1D
T1D is initiated when autoreactive T cells destroy the insulin-producing beta cells in the pancreas
leading to hypoinsulinaemia, and hyperglycaemia; however, the aetiology and pathogenesis are still
not fully understood. T1D is classified as a multifactorial disease in which the genetic background,
as well as environmental factors, are important determinants. Approximately 50% of the genetic risk
of the disease is explained by the HLA class II region [21], and the haplotypes HLA-DR3-DQ2 and
HLA-DR4-DQ8 are the most important individual genetic risk factors known [22].
In the period from 1990–1999, the average annual increase in the incidence of T1D was 2.8% in
children aged ≤14 years [23]. Another epidemiological study predicted that the incidence would
double between 2005 and 2020 in European children below five years of age [24].
A key question is why the incidence of T1D is increasing now when gluten was introduced
10,000 years ago. Among many possible reasons, such as an increased exposure to other diabetogenic
environmental factors, a recent study in non-obese diabetic (NOD) mice, an animal model of autoimmune
diabetes, found that modern wheat sources are more diabetogenic that old wheat sources [25].
2.1. The Role of Environmental Factors
Environmental factors are important in the pathogenesis of T1D. First, the incidence of T1D has
been rising globally at a pace that cannot be explained by genetic drift [23,24]. Second, increasing
incidence has been observed in population groups that have migrated from regions with low incidence
of T1D to regions with high incidence [26]. Third, a six-fold gradient in the incidence of T1D is observed
between Russian Karelia and Finland, although the frequency of the high-risk HLA-DQ genotypes
is equal in the two populations [27], and similar gradients between neighbouring countries are also
known [23]. Fourth, monozygotic twins are most often discordant for T1D [28,29]. Fifth, T1D develops
in less than 10% of subjects with HLA-conferred risk genotypes [30], although all risk genotypes are
most likely not identified yet.
Many environmental factors have been associated with increased susceptibility to T1D, including
physiological stress, vaccines, toxins, cow milk [31], and dietary gluten. Evidence for a viral aetiology
has grown during the recent years [32–35] exemplified by the Diabetes virus detection (DiViD) study
that demonstrated low-grade enterovirus infection in islets from the majority of the newly diagnosed
T1D patients investigated but not in any of the non-diabetic controls [36]. In this regard, the hygiene
hypothesis is central, stating that children who are exposed to microorganisms will develop strong
immunity against these, which will dampen the harmful effects from them, but also protect the child
from T1D [37].
Thus, T1D is a multifactorial disease where many environmental factors are likely to contribute to
the pathogenesis, including gluten.
2.2. GF Diet, Early Evidence and Timing
Early studies in NOD mice [38] and biobreeding (BB) rats [39], which are animal models for
autoimmune diabetes, suggested that cereals might have a role in the aetiopathogenesis of T1D.
Later, a study in NOD mice demonstrated that a lifelong GF diet compared to a gluten-containing
standard (STD) diet reduced the incidence of autoimmune diabetes from 64% to 15%, although insulitis
score was not significantly reduced [40], and subsequent studies in NOD mice demonstrated similar
results [41,42]. In a more recent study in NOD mice, we showed that the incidence of autoimmune
diabetes could be reduced even further, to 8%, together with reduced insulitis in offspring, by keeping
the mothers on a GF diet exclusively during pregnancy [43]. Similar, but smaller effects on incidence
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and insulitis in NOD mouse offspring were demonstrated by keeping the mice GF in utero and in
early postnatal life [44]. The GF diets used it these studies had the gluten protein replaced with
other proteins (meat, casein, or egg white) while keeping an equal content relative to the STD diets of
protein, fat, and components that may influence the risk of diabetes such as milk and soybean [40,43].
Although the major difference between the GF and STD diets was gluten, small differences were
present between other dietary components. Human evidence for the existence of an early time-window
for the introduction of gluten and tolerance induction includes the BABYDIAB and Diabetes and
Autoimmunity Study in the Young (DAISY) cohort studies. These studies showed that the risk of
islet autoimmunity increased if gluten was introduced before the age of three months compared with
receiving only breast milk during this period [45] or first exposure to gluten between age four and six
months [46], after adjustment for covariates. Moreover, it was shown that breastfeeding during the
introduction of gluten was associated with decreased risk of islet autoimmunity in children at high
risk of T1D [46]. Recently, we published a study based on the Danish National Birth Cohort, which
demonstrated that maternal ingestion of low versus high amounts of gluten during pregnancy reduced
the risk (2-fold) of T1D in their children, after adjustment of covariates [47]. Other cohort studies
showed no association between intake of GF diet during pregnancy and T1D, again after adjustment of
covariates [48,49]. In two Danish studies, a GF diet was administered to children after T1D diagnosis
and the children showed improvements in disease parameters including prolonged partial remission
periods and reduced HBA1c compared to control children with T1D matched by diabetes duration and
age [50,51]. Another study investigated how children at increased risk of T1D responded to six months
of GF diet followed by six months of gluten-containing diet (diets were not matched for carbohydrate
content etc.) [52]. Following the GF diet, the children showed improved glucose tolerance and insulin
sensitivity (non-significant) but unchanged titres of islet autoantibodies. Following the months of the
gluten-containing diet, the study reported a decreased insulin sensitivity. Hence, a GF diet may have a
preserving effect on beta-cell function on older children with T1D.
In summary, the studies suggest that a GF diet may have the potential to reduce the risk of T1D.
Interestingly, a GF diet seems to be most effective when applied in utero, and timing of the introduction
of gluten is apparently critical. Moreover, a few studies indicate that a GF diet, when applied to older
children with T1D, may preserve the beta cells to some extent.
2.3. GF Diet and the Intestine
The intestinal microbiota seems to play an important role in the pathogenesis of T1D but causality
is still unclear. Patients with T1D have an increased intestinal permeability [53–56] and show a
decrease in bacteria that maintain the intestinal permeability [57,58]. Perturbation of the intestinal
microbiota in childhood is thought to disturb the developing immune system and may thus be a
pathogenic factor [59,60]. NOD mice fed a GF versus a STD diet had overall fewer bacteria as well
as fewer aerobic and microaerobic bacteria in caecum [41]. In a similar study, NOD mice on a GF
diet showed decreased Bifidobacterium, Tanerella and Barnesiella species and increased Akkermansia
species in faeces [42]. A GF diet during pregnancy and early postnatal life has been demonstrated
to induce pronounced differences in the intestinal microbiota of NOD mouse mothers and offspring,
including increased numbers of bacteria from the phylae Akkermansia, Proteobacteria, and TM7 [44].
The mucin-degrading Akkermansia is of special interest in T1D. For example, NOD mice treated with
vancomycin from an early age had increased proportions of Akkermansia and reduced incidence of
autoimmune diabetes [61]. In addition to the association to T1D, Akkermansia species reversed the
increased intestinal permeability in Apolipoprotein E (Apoe)−/− mice and decreased the entry of
lipopolysaccharide (LPS) into the circulation [62]. Interestingly, a study in children from the BABYDIET
study showed that Bacteroides-dominated children were more likely to develop islet autoantibodies
and had decreased potential to butyrate production compared to Akkermansia-dominated children [63].
Short-chain fatty acids (SCFAs) are produced by bacteria during breakdown of dietary fibre and include
butyrate, acetate, and propionate. Butyrate and acetate diminish the intestinal permeability [64,65],
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and butyrate can boost the number and function of regulatory T cells (Tregs) [65,66], which are known
to suppress inflammatory responses. Acetate can reduce the proportion of autoreactive T cells [65].
Thus, a GF diet may improve the intestinal microbiota and permeability (Figure 1), but more
studies are needed in order to gain knowledge about mechanisms and causality.
2.4. GF Ddiet and the Immune System
We and others have conducted a range of animal studies, which suggest that a GF diet modulates
the innate and adaptive immune system (Table 1).
Table 1. An overview of some of the effects that a gluten-free (GF) diet has on the immune system in
animal models of type 1 diabetes (T1D).
Immunological Effects of a GF versus a STD Diet in Utero in NOD Mice References
↑M2 macrophage gene expression in intestine. [44]
↓DC (CD11b+CD11c+) numbers in PLN, MLN and spleen. [44]
↓TH1 cell (IFNG+CD4+) numbers in spleen. [67]
↓TH17 (RORGT) gene expression in colon. [43]
↓gdTCR cell (IL22+gdTCR+) numbers in spleen. [67]
↑Treg cell (FOXP3+CD4+) numbers in PLN. [44]
↑T cell (α4β7+CD4+/CD8+) numbers in PLN. [44]
↓proinflammatory cytokine gene expression in intestine. [44]
↓T cells (gdTCR+, CD4+, CD8+ and FOXP3+) inflammatory cytokine profile in spleen, PLN, MLN and ILN. [67]
Immunological Effects of a GF versus a STD Diet Postnatally in Animal Models of T1D References
↓NK cell (activated) (NKG2D+NKp46+/DX5+) numbers in PLN (BALB/c mice) and spleen (NOD mice). [68,69]
↓DC (CD11b+CD11c+) numbers in PLN and MLN (BALB/c mice). [69]
↓DC (CD11b+CD11c+) numbers in colon (NOD mice). [70]
↓DC (activated) (CD40+/CCR7+/MHCII+ on CD11c+) numbers in different lymphoid organs (BALB/c mice). [69]
↑DC (tolerogenic) (CD103+CD11b+) numbers in PLN (BALB/c mice). [69]
↓TH cell (CD4+) numbers in colon (NOD mice). [70]
↓TH1 cell (IFNG+CD4+) numbers in MLN (BB rats). [71]
↓TH17 cell (IL17+CD4+) numbers in PLN (BALB/c mice). [72]
↓TH17 cell (IL17+CD4+) numbers in colon (NOD mice). [70]
↓T cell (CD3+) proinflammatory profile (BALB/c mice). [73]
↓CTL (activated) (NKG2D+CD8+) numbers in PLN (NOD mice). [69]
↑: increased; ↓: decreased.
A GF diet reduced the natural killer (NK) cell activity in pancreatic lymph nodes (PLNs) from Bagg
albino (BALB/c) mice and in spleen from NOD mice compared to mice on a STD diet [68]. Another
study in NOD mice confirmed this observation in spleen and found reduced activity of cytotoxic T
lymphocytes (CTLs) in PLN [69]. Besides NK cells, macrophages from mice have been shown to
produce proinflammatory cytokines (interleukin (IL)6, IL12 and tumor necrosis factor alpha (TNFA),
among others) upon gliadin stimulation [74]. Dendritic cells (DCs) may also be affected by a GF diet,
as the diet reduced the proportions in thePLN and mesenteric lymph node (MLN) and increased the
proportions of tolerogenic DCs in PLN in BALB/c mice [69]. This study also found downregulation of
DC activation markers in lymphoid organs from the GF mice. This is supported by a study showing
that gliadin stimulation of bone marrow-derived DCs from BALB/c mice resulted in maturation of the
cells, as seen by evaluation of activation markers and chemokines (keratinocyte-derived cytokine (KC)
and macrophage inflammatory protein 2 (MIP-2)) [75]. Moreover, gliadin stimulation may increase
the expression of toll-like receptor (TLR)4, 7, 8 and interferon alpha (IFNA) in DCs of DQ8 transgenic
mice [76]. As for the adaptive immune system, we have shown that a GF diet reduced the proportion
of T helper (TH)17 cells in PLN of BALB/c mice [72] and dampened the inflammatory profile of
T cells [73]. A wheat-free versus a wheat-based diet has been shown to reduce the proportion of TH1
cells in MLN from young diabetes-prone BB rats [71]. Three studies in NOD mice found that a GF
diet during pregnancy alleviated T1D in the offspring and that the mechanisms were likely to involve
changes in the immune system. The first study showed that the intestines from the offspring exposed
to the GF diet in utero had an increased gene expression of immunosuppressive M2 macrophages
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and reduced expression of proinflammatory cytokines [44]. This study also showed that the GF
diet increased the proportion of Tregs in PLN and decreased the proportion of DCs in PLN, MLN,
and spleen in the offspring. Moreover, the traffic of T cells between PLN and the gut-associated
lymphoid tissue (GALT) was increased. Recently, we demonstrated that a GF diet during pregnancy
reduced the expression of interferon gamma (IFNG) in TH cells and IL22 in gamma delta T receptor
(gdTCR)+ T cells from spleen of NOD mouse offspring [67]. This is of interest because IFNG [77] and
IL22 [78] might have a role in T1D. Furthermore, we demonstrated a reduced inflammatory profile
in subpopulations of T cells from lymphoid organs of offspring exposed to a GF diet in utero [67].
In another study, we observed that the gene expression of TH17 cells was reduced in colon from
NOD mice exposed to a GF diet in utero [43]. These results were confirmed in NOD mice fed an anti-
diabetogenic diet compared to a wheat-based diet from a young age [70]. The mice showed reduced
numbers of TH17 cells, besides reduced numbers of activated TH cells and DCs and reduced incidence
of autoimmune diabetes. Taken together, a GF diet has a dampening effect on the innate and adaptive
immune system, as evidenced in different animal models (Table 1).
Human evidence of the effect of gluten on the immune system is more limited. Early evidence
includes a study from 1987 demonstrating increased titres of anti-gliadin antibodies at the onset
of T1D in 54% of patients with no signs of CD and in none of the healthy controls [79]. Moreover,
a study in children with T1D and no CD showed that rectal gluten application resulted in an increased
percentage of epithelium and lamina propria CD3+ and gdTCR+ cells in 26% of the patients compared
to approximately 15% of the healthy controls [80], indicating that some T1D patients have an abnormal
mucosal immune response towards gluten. In another study, 47% of the included patients with T1D
and no CD and none of the healthy controls displayed increased proliferation of peripheral blood
mononuclear cells (PBMCs) after stimulation with wheat polypeptides, and the cytokine response was
a proinflammatory TH1/TH17 [81]. On the other hand, CD4+ cells from children with pre-T1D and
multiple islet autoantibodies compared to healthy controls showed decreased proliferative responses
after gliadin stimulation [82]. DCs may be affected by gluten as well. This is shown in a study where
gliadin stimulation of monocyte-derived DCs from healthy donors resulted in increased expression of
maturation markers (CD80, CD83, CD86, and HLA-DR molecules), increased production of chemokines
and cytokines (TNFA, IL6, IL8, IL10 among others), increased capacity to stimulate proliferation of
allogeneic T cells, as well as reduced endocytic activity [83].
Thus, the studies suggest that a GF diet reduces inflammation in the intestines and pancreas,
involving many cell types of the immune system (Figure 1).
2.5. GF Diet, Risk of T1D and CD
CD is a chronic autoimmune disease that results in inflammation of the intestinal submucosa and
destruction of the intestinal epithelium. The following clinical signs are typically observed: increased
numbers of intraepithelial lymphocytes, villus atrophy, and crypt hyperplasia. The treatment consists
of a strict GF diet and if not initiated it will lead to undernourishment. The pathogenesis is thought
to start with binding of gliadin to the chemokine receptor CXCR3 on enterocytes, which results in
increased intestinal permeability by myeloid differentiation primary response 88 (MyD88)-dependent
zonulin release and crossing of the lamina propria by gliadin [13]. At this site, tissue transglutaminase
(tTG) deamidates glutamine residues in gliadin to glutamate, which mediates high affinity of gliadin
to HLA-DQ2/DQ8 on APCs and thus activation of CD4+ T cells specific for gliadin [84,85]. Next,
production of proinflammatory cytokines and activation of CD8+ T cells specific for gliadin are thought
to further worsen the damage to the intestine [86].
Interestingly, human studies indicate that T1D and CD are comorbid diseases and they share
the genetically predisposing haplotypes HLA-DQ2/DQ8. The risk of developing other autoimmune
diseases is increased for patients with CD, in particular for those diagnosed early (<16 years of age [87])
(<18 years of age [1]). The prevalence of CD is 5–10% in patients with T1D [88–92]; however, the risk is
lower in patients compliant to a GF diet [87]. The majority of NOD mice [93] and 12% of patients with
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T1D are seropositive for anti-tTG [94]. In addition, NOD mice on a STD versus a GF diet have reduced
villus height and increased infiltration of intraepithelial lymphocytes (enteropathy) [95], and human
subjects exhibit signs of enteropathy already from the pre-diabetic stage [54]. Jejunal biopsies from
children with T1D versus healthy controls were stimulated with gliadin [96]. The result was increased
proportions in lamina propria of intraepithelial T cells and increased expression of CD25+ (IL2RA),
CD80+ (co-stimulatory), intracellular adhesion molecule 1 (ICAM-1), and crypt HLA-DR. Thus, NOD
mice and patients with T1D exhibit signs of CD, which underlines that the two diseases are associated
and indicates that gluten may be a common environmental factor. This is supported by a study in
NOD mice, which showed that a GF versus a STD diet decreased intraepithelial infiltration of T cells,
expression of IFNG, enteropathy and incidence of autoimmune diabetes [95]. Moreover, we recently
published a study showing that young NOD mice exposed to a GF versus a STD diet in utero had
persistently reduced titres of anti-tTG in serum together with increased villus-to-crypt (V:C) ratios
(improved enteropathy) [67], indicating that a GF diet during pregnancy may not only ameliorate T1D
but also dampen the symptoms of CD in the offspring.
Hence, studies in animals and humans with T1D indicate that a GF diet may reduce the signs of
CD and that the prenatal period may be of special importance (Figure 1).
2.6. Mucosal Tolerance Induction by Gliadin
A study showed that BB rats fed wheat gluten neonatally versus at weaning were protected
from autoimmune diabetes [97]. It was later demonstrated that NOD mice exposed to a diet with
a three times higher content of gluten compared to a normal diet in utero and the rest of their lives
were protected from autoimmune diabetes to the same extent as those on a GF diet [98]. The authors
proposed that the high amount of gluten might result in mucosal tolerance or unresponsiveness,
which was also seen in a human monocyte cell line regarding LPS in high doses and long exposure
times [99]. More recently, administration of gliadin intranasally to four-week-old NOD mice was
shown to decrease the incidence of autoimmune diabetes and insulitis and increase the numbers of
gdTCR+ cells and forkhead box P3 (FOXP3)+CD4+ Tregs in mucosal lymphoid organs [100]. Intestinal
gdTCR+ cells are important for the induction of peripheral Tregs and during induction of mucosal
tolerance they seem to have a central role in maintenance of tolerance [101]. Tregs are functionally
deficient in patients with T1D [102]. The hypothesis on mucosal tolerance induction against gluten is
backed by an exploratory registry-based case-control study that we conducted, which demonstrated
that occupation with grain crops, i.e., by bakers, was associated with lower incidence of T1D [103].
We speculated that the lower incidence among workers occupied with grain crops was due to nasal
mucosal exposure to gluten during work and hence tolerance induction.
These studies show that a possible strategy in the prevention of T1D may be induction of mucosal
tolerance against gluten, but human intervention studies are needed to confirm this.
2.7. GF Diet and the Beta Cell
From studies in NOD, C57BL/6 (B6), and BALB/c mice, we demonstrated that gliadin peptides
cross the intestinal barrier after oral gavage and thereafter localise to the pancreas and to a smaller extent
the islets [104]. The ability of gluten peptides to cross the intestinal barrier has been independently
confirmed [105]. Gliadin does also seem to cross the intestinal barrier in humans, evidenced by
observations of gliadin in breast milk and serum from healthy mothers [106]. Gluten peptides are
likely in close contact with the beta cells because of the high degree of vascularisation in islets [107].
In vitro studies on INS-1E insulinoma cells and isolated rat islets showed that gliadin increased
glucose-stimulated insulin-secretion (GSIS) by closing ATP-dependent K-channels [108]. This could be
part of the pathogenesis of T1D by means of gliadin-mediated beta-cell hyperactivity and thus increased
expression of islet antigens and autoimmunity [109]. A gluten-containing STD versus a GF diet is known
to increase insulitis in animal models of T1D [39,40,43,44,67], and inflammatory cell-stress increases
the expression and enzyme activity of tTG [110]. tTG has been shown to induce posttranslational
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modifications of human islet antigens and thereby increase the affinity to HLA-DQ [111]. Thus, it is
likely that a GF diet reduces the tTG activity in islets and reduce insulitis. Interestingly, NOD mice
exposed to a GF diet exclusively in utero had increased numbers of islets throughout the prediabetic
phase, besides reduced insulitis and autoimmune diabetes incidence [67]. The finding is in agreement
with an older study in BB rats, which were fed a diet based on hydrolysed casein versus a diet based
on cereals from early life [39]. The rats had increased total islet area and numbers, together with lower
insulitis and autoimmune diabetes incidence.
Altogether, it is likely that a GF diet reduces beta-cell stress and this may result in increased
numbers of islets, besides reduced insulitis and autoimmune diabetes incidence, an effect that has also
been observed when the diet was applied in utero (Figure 1).
 
Figure 1. Gluten free (GF) diet and the development of type 1 diabetes (T1D)—a hypothesis. (A) A GF
diet decreases the intestinal permeability and increases the villus-to-crypt (V:C) ratio, thereby preventing
food particles such as gliadin peptides from crossing the intestinal barrier and reacting the pancreas.
A GF diet increases the number of Akkermansia bacteria, among other changes, and the amount of
short-chain fatty acids (SCFAs) such as butyrate. (B) A GF diet modulates the innate and adaptive
immune system resulting in reduced interferon gamma (IFNG) secretion from CD4+ T helper (TH) cells,
reduced interleukin (IL)22 secretion from gamma delta T cell receptor (gdTCR)+ T cells, and lower
numbers of activated (NKG2D+) natural killer (NK) cells, among other things. TH17 cell numbers are
reduced and immunosuppressant M2 macrophage numbers and forkhead box P3 (FOXP3)+ regulatory T
cell (Treg) numbers are increased. (C) A GF diet reduces beta-cell stress by reducing the insulin secretion.
This may preserve the number of islets, reduce insulitis, and ameliorate T1D.
3. Gluten and T2D
T2D is associated with obesity and the incidence is expected to increase between 2010 and 2030 [112].
Overall, T2D is a result of insulin resistance and beta-cell dysfunction [113]. Although insulin resistance is
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often present in obese subjects, their beta cells initially compensate by increasing the insulin production [114]
and mass [115]. Eventually beta-cell dysfunction occurs, resulting in hyperglycaemia and diabetes [116].
As for T1D and CD, genetic susceptibility genes are important disease determinants in T2D, and so far
studies have found over 40 associated genes, although only a few of them have been verified in several
patients and laboratories including peroxisome proliferator activated receptor gamma (PPARG), ATP
binding cassette subfamily C member 8 (ABCC8), and potassium voltage-gated channel subfamily J
member 11 (KCNJ11) [117].
3.1. The Role of Environmental Factors
The rising incidence [6,112] and the observation that monozygotic twins are often discordant
for T2D [29,118,119] indicates that environmental factors, besides genetic susceptibility genes, are
important for the development of T2D. Obesity, a result of imbalance between energy intake and
expenditure because of excess intake of food and insufficient physical activity [120], most likely
plays a causal role in the pathogenesis of T2D [121]. According to the thrifty gene hypothesis,
genes that were advantageous for accumulation of adipose tissue during times of caloric excess
in the previous hunter/gatherer period might explain the present rise in the incidence of T2D in
populations with caloric excess [122]. The intrauterine environment may be of special importance,
in which pesticides [123], hormonal agents, patterns of feeding and undernutrition are potential
determinants [120]. In this context, the thrifty phenotype hypothesis should be mentioned. It suggests
that poor foetal and early postnatal nutrition leads to insulin resistance and beta-cell dysfunction in
the adult, which, in combination with the effects from ageing and obesity, manifests in T2D [124].
3.2. GF Diet, Leptin Resistance and the Link to Obesity
Leptin resistance is likely involved in the pathogenesis of obesity and thus T2D [125,126]. Leptin
resistance has been hypothesised to be the result of insufficient genetic adaptation to a cereal-based
diet [127], as humans began consuming cereals only 10,000 years ago. The hypothesis was tested in
piglets receiving a palaeolithic diet, i.e., a diet containing nuts, vegetables etc., versus a cereal-based
diet from the age of 2–17 months [128]. Following this period, the palaeolithic piglets showed reduced
body weight, subcutaneous fat thickness, and pancreatic lymphocyte numbers but increased insulin
sensitivity. Interestingly, clinically relevant concentrations of trypsin- and pepsin-digested wheat
gluten was demonstrated to hinder the binding between leptin and its receptor, indicating that gluten
could be linked to leptin resistance and obesity [125].
3.3. GF Diet and the Intestine
Obesity and T2D are associated with intestinal dysbiosis [129]. Obese subjects have changes
in the intestinal microbiota (↑phylum Firmicutes and ↓phylum Bacteroides) [130], which, as seen in
mice, increase the capacity of the microbiota to harvest energy and increase fat stores [131]. A large
study in T2D patients showed a reduced abundance of bacteria (Roseburia, among others) capable of
producing the SCFA butyrate [132]. SCFAs have been demonstrated to prevent high-fat (HF) diet-induced
obesity in B6 mice [133] and studies in Caco-2 epithelial cells showed that butyrate may decrease
intestinal permeability [64], which is increased in T2D patients [134,135]. Interestingly, gliadin stimulation
of intestinal tissue from mice and humans increased the permeability [13], and studies in different
mouse strains found that oral gavage of gluten peptides resulted in accumulation in extraintestinal
organs [104,105]. Regarding the intestinal permeability, B6 mice fed a gluten-free high-fat (GF-HF) diet
versus a gluten-containing HF diet showed improved intestinal barrier function [136]. Moreover, the
GF-HF mice showed changes in the intestinal microbiota (↑genus Lactobacillus and ↓genera Clostridium XI,
Coriobacteriaceae and Dorea) associated with improved health [137–140]. Moreover, the abundance of
Akkermansia species was reduced in GF-HF versus HF mice, which is puzzling for several reasons. First,
increased intestinal permeability and leakage of LPS to the circulation may be reversed by the bacterial
species Akkermansia muciniphila, as shown in Apoe−/− mice [62]. Second, B6 mice receiving oral gavage
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of the bacterium showed reduced HF diet-induced metabolic disorders i.e., metabolic endotoxaemia,
adipose tissue inflammation, insulin resistance, and fat mass gain [141]. Third, Akkermansia muciniphila is
found in lower abundance in intestines of pre-T2D patients compared with healthy controls [142].
Studies in mice show that the early onset of HF diet-induced hyperglycaemia is associated
with increased leakage of LPS and gram-negative bacteria from the intestine to the adipose tissue,
which is thought to continuously fuel metabolic bacteraemia and endotoxaemia [143], and may
contribute to low-grade inflammation, insulin resistance, beta-cell dysfunction, and, thus, T2D. This
is relevant because intake of gluten seems to both increase the intestinal permeability and lead to a
disease-associated intestinal microbiota. The intake of gluten could therefore contribute to T2D by the
above-mentioned mechanism.
Thus, studies in mouse models of T2D indicate that a GF diet may improve the intestinal barrier
function and lead to a healthier microbiota, both of which could alleviate the disease by reducing
passage of inflammatory gluten peptides, bacterial products etc. (Figure 2).
3.4. GF Diet, the Beta Cell and Adipose Tissue
Signalling through the pattern-recognition receptor TLR4, which is expressed on most cell
types [144], has been associated with insulin resistance [145] and beta-cell dysfunction in T2D [146].
This is relevant because gliadin may activate signalling through this receptor [147]. Thus, gliadin
may induce insulin resistance and beta-cell dysfunction through TLR4 and possibly also through
other innate immune receptors. Moreover, we have demonstrated that gliadin peptides affect the
beta cells directly, as the peptides increase GSIS in rat islets and INS-1E cells and potentiate the fatty
acid-stimulated insulin secretion in INS-1E cells [108].
These studies imply that a GF diet may alleviate insulin resistance as well as beta-cell stress and
dysfunction in T2D (Figure 2). However, the results need further confirmation.
3.5. GF Diet, the Immune System, Obesity and T2D
We have shown that intravenous injections with enzymatically degraded gluten increase the
body weight of NOD mice [108]. Likewise, rats fed a casein-based versus a gluten-based diet for
two weeks had reduced liver lipogenesis [148]. Moreover, B6 mice fed a GF-HF versus a HF diet
for eight weeks had reduced concentrations in serum of the proinflammatory adipokines leptin and
resistin and increased concentrations of the anti-inflammatory adipokine adiponectin, together with
reduced body weight, epididymal fat stores, fasting glucose, and insulin [149]. This indicated that
gluten could directly contribute to obesity and hence T2D. The improved glucose homeostasis in the
GF-HF mice was thought to involve a reduced inflammatory profile leading to increased expression
of PPARG, an important regulator of lipid metabolism, and thus increased expression of adiponectin
and glucose transporter 4 (GLUT-4) i.e., improved insulin sensitivity [149]. Similar observations were
seen in another study in B6 mice fed a GF diet [105], both in normal and HF settings. The study
also showed that increased thermogenesis and energy expenditure were behind the observed effects.
We showed that long-term feeding of B6 mice with a GF-HF versus a HF diet increased the beta-cell
volume and improved the glucose tolerance [150], which we believe could be a result of beta-cell rest,
as we have shown that gluten potentiates the fatty acid-stimulated insulin secretion [108]. Not all
animal studies have been able to demonstrate these anti-obesity and anti-diabetes effects from a GF
diet. As an example, Apo−/− mice were fed a GF diet in utero and until 16 weeks of age, but no
effect was observed on body weight, glucose tolerance, insulin levels, and plasma lipids; however,
a transient change was seen in the intestinal microbiota [151]. Thus, the effects of a GF diet on obesity
and T2D have been tested only in a few animal studies, some of which indicate that a GF diet may
have the potential to reduce obesity and T2D (Figure 2).
In a randomised, crossover study, T2D patients were fasted and received a test meal differing
in the protein sources whey, casein, cod, and gluten [152]. After eight hours, the patients from the
gluten-group showed increased incremental area under the curve (AUC) for plasma glucose compared
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to patients from the other groups. Moreover, the patients eating gluten showed increased incremental
AUC for fatty acids and triglycerides compared to patients receiving whey. The national health
and nutrition examination survey (NHANES) study, which consists of a number of cross-sectional
surveys carried out every second year, demonstrated higher high-density lipoprotein (HDL), smaller
waist circumference and self-reported weight loss in persons on a GF diet [153]. Further human
evidence includes a study in children with autism spectrum disorder on a GF casein-free diet versus
a regular diet for three months, showing lower body weight and body mass index [154]. A recent
prospective cohort study from the USA based on the Nurses’ Health Study I and II and the Health
Professionals Follow-Up Study found an inverse association between intake of gluten and risk of
T2D [155]. The analyses were adjusted for relevant covariates such as fibre and folic acid, which are
often low in a GF diet, and the association was slightly weakened after adjustment of cereal fibre.
Excluding gluten from the diet will mediate exclusion of other potential anti-diabetogenic factors;
hence, this study is not conclusive and should be followed up with an intervention study. In summary,
a few intervention studies have shown that a GF diet may alleviate obesity and T2D in humans
(Figure 2). On the other hand, a recent prospective cohort study report that a GF diet is associated with
T2D. Thus, larger intervention studies clarifying the effect of a GF diet on T2D patients are needed.
Figure 2. Gluten-free (GF) diet and the development of type 2 diabetes (T2D)—a hypothesis. A GF diet
decreases intestinal permeability thereby preventing food particles such a gliadin from crossing the
intestinal barrier and reaching the adipose tissue and pancreas. A GF diet increases the proportion
of Lactobacillus and decreases the proportion of Akkermansia, Dorea, Clostridium, and Coriobacteriacae.
In the blood, a GF diet decreases the level of proinflammatory cytokines and adipokines and increases
the anti-inflammatory adiponectin. A GF diet reduces obesity and improves the regulation of lipid
metabolism by upregulating peroxisome proliferator activator receptor alpha (PPARA) and peroxisome
proliferator activator receptor gamma (PPARG) in adipose tissue. This, in turn, leads to increased
insulin sensitivity and improved glucose tolerance, which is further improved by reduced beta-cell
stress and increased beta-cell volume.
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4. Conclusions
In this review, we looked at the role of dietary gluten as a contributing factor in the aetiopathogenesis
of T1D and T2D. Gluten has multiple effects in the body starting in the intestine where it affects the
composition of the microbiota, may induce enteropathy in T1D, and increases the intestinal permeability,
all of which seem to improve with a GF diet. In animals, gluten has been found to cross the intestinal
barrier together with LPS among other substances and may accumulate in different tissues including
islets and adipose tissue. In animal beta cells, gluten peptides induce insulin secretion, an effect that
is potentiated by palmitate, suggesting that gluten peptides may induce beta cell-stress, -dysfunction,
-loss, and autoimmunity, and thus contribute to both T1D and T2D. Moreover, gluten peptides may also
contribute to leptin- and insulin resistance, regarding obesity and T2D. Primarily animal studies have
shown that a GF diet dampens the innate and adaptive immune system leading to a less inflammatory
profile. In T1D, the timing of gluten introduction to children is most likely critical, and the efficiency
of gluten exclusion during pregnancy, combined with early introduction of gluten postnatally, should
be investigated as a prevention strategy in an intervention study. Interestingly, animal studies suggest
that a GF diet in utero may also reduce the risk of CD and report changes in the pancreas morphology
including increased numbers of islets. Postnatally, a GF diet remains an interesting therapeutic option
for the prevention and treatment of T1D, but more human intervention studies must be carried out.
Mucosal tolerance induction of gluten is another potential strategy in reducing the risk of T1D but this
also needs further exploration.
In T2D, the evidence for an alleviating effect of a GF diet is more uncertain especially regarding the
few human studies that have been conducted, although animal studies report improvements of both
obesity and T2D. A GF diet is typically low in fibres and other antidiabetogenic nutrients, and studies
investigating the long-term effects on obesity and T2D of gluten specifically are therefore needed.
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Abstract: Our aim was to evaluate the intake of foods containing fermentable oligo/di/mono-
saccharides and polyols (FODMAP) as a possible factor that induces gastrointestinal symptoms in
treated celiac disease (CD) patients. We collected seven-day weighed food records for 104 CD patients
and 91 healthy volunteers. All evaluated food items were from sources with high and low content of
FODMAP, which were divided into cereals and sweets, sweeteners and soft drinks, fruits, dried fruits,
and vegetables. Nutrient intake was calculated using the food database of the European Institute
of Oncology. The symptoms reported were assessed by a Rome IV Irritable bowel syndrome (IBS)
diagnostic questionnaire and by specific questions for the evaluation of functional gastrointestinal
disorders (FGIDs). The 12% of CD patients met IBS symptoms criteria as opposed to 6% of controls
(p = 0.09) and 27% of patients reported FGIDs symptoms vs. 22% of healthy controls (p = 0.42).
The intake by CD patients was significantly higher than healthy volunteers for: sweeteners and
sugars with low content of FODMAP (p = 0.0007), fruits, dried fruits, and vegetables high in FODMAP
(p = 0.003) and low in FODMAP (p = 0.04) when compared to controls. CD patients had a lower intake
of cereals and sweets with a high content of FODMAP (p = 0.00001). Healthy volunteers consumed
significantly higher alcoholic beverages and fats high in FODMAP (both p < 0.044). The mean daily
intake of other food categories did not differ between both groups. Even though CD patients had
a low intake of gluten-free cereals high in FODMAP, they still consumed a significant amount of
fruits and vegetables high in FODMAP. The clinical effect of a concomitant gluten-free diet and
low-FODMAP diet should be prospectively evaluated as a supportive therapy in CD patients.
Keywords: FODMAP intake; celiac disease; irritable bowel syndrome; gluten-free diet; gastrointestinal
symptoms
1. Introduction
Celiac disease (CD) is a chronic autoimmune enteropathy triggered by dietary exposure to gluten
and is characterized by villous atrophy. CD is considered the most common chronic enteropathy
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in Western countries with an estimated prevalence ranging from 0.5 to 1% [1,2]. An altered T cell
mediated immune response triggered by gluten has a central role in the pathogenesis of CD. Genetic
predisposition plays a key role in the development of CD and the presence of the HLA DQ2 and/or DQ8
haplotypes is a necessary (but not sufficient) factor [3,4]. CD patients may present with gastrointestinal
symptoms, extra-intestinal symptoms, or no symptoms at all. The classical clinical symptoms include
diarrhea, steatorrhea, and weight loss due to malabsorption [5].
Gluten is a complex of high molecular-weight proteins found in the endosperm of grass-borne
grains including wheat, barley, and rye [6]. The treatment of CD is the withdrawal of gluten from
the diet (i.e., a gluten-free diet, GFD), which usually silences symptoms and normalizes serological
and histological signatures. CD is considered a lifelong disorder and, if left untreated, is associated
with increased morbidity and mortality [7,8]. Despite the strict adherence to a GFD, there is a group
of CD patients who keep suffering from functional gastrointestinal disorders (FGIDs) [9]. FGIDs
include irritable bowel syndrome (IBS) and non-specific gastrointestinal symptoms (pain, diarrhea,
bloating, nausea, vomiting). IBS is currently identified to be a global problem with a prevalence of
11%, which specifically affects women as compared to men (14.0% vs. 8.9%, respectively) [10,11].
IBS is characterized by a multiplicity of clinical symptoms such as abdominal pain, bloating,
and changes in bowel habits including constipation and/or diarrhea. It also compromises the patients’
abilities and quality of life, which implicates an increase in healthcare provision costs, use of drugs,
and absence/leave from work [12].
The criteria for diagnosing gastrointestinal disorders have been revised by the Rome Foundation
in their latest update (Rome IV, 2016). The pathogenesis of IBS is multi-factorial and may be
connected to visceral hyper-sensitivity, alterations of the gut-brain axis and the microbiota, post
infectious consequences, and environmental and genetic factors [13]. IBS can be suspected in patients
suffering from persistent abdominal pain associated with more than one condition: defecation,
change in the frequency of defecation, and change of stool form [14]. Moreover, IBS can be
classified as IBS-C (predominant constipation), IBS-D (predominant diarrhea), and IBS-M (mixed) [15].
Nowadays medication (antispasmodics, bulking agents, probiotics, laxatives, or anti-depressants), diet,
and lifestyle adjustments have been the main therapeutic options for IBS [16].
In recent years, data supporting that the dietary restriction of fermentable oligo/di/mono-
saccharides and polyols (FODMAP) for the management of IBS symptoms have emerged [17–19].
Studies evaluating a low-FODMAP diet in patients with IBS have consistently shown symptomatic
benefits in the majority of patients [20]. However, one study that compared the diet commonly used
in these patients vs. a low-FODMAP diet failed to demonstrate differences in the improvement of
the symptomatology [21]. The use of the low-FODMAP diet has been evaluated in other digestive
pathologies with contradictory results. Pedersen et al. showed some degree of improvement in
functional gut symptoms of patients with inflammatory bowel disease (IBD) [22] while Cox et al.
showed exacerbated functional gastrointestinal symptoms in patients with IBD [23]. On the other
hand, Testa et al. were able to demonstrate that a low-FODMAP diet could be one option to counteract
abdominal symptoms in patients with IBS, non-active IBD, or CD on a GFD, which improves their
quality of life [24].
The main dietary sources of FODMAP include fructose in honey, apples, and pears, fructans in
wheat, rye, onion, and garlic, galactans in cabbage and legumes, lactose in milk and dairy products,
and polyols including sorbitol and mannitol in stone fruits, mushrooms, and artificial sweeteners [25].
Among FODMAP, fructans and galacto-oligosaccharides are considered prebiotics. Prebiotics are
non-digestible selectively fermented dietary fibers that promote the growth of positive bacterial genera
in the gastrointestinal tract. Prebiotics such as inulin-type provides health benefits to the host [26].
These non-digestible food ingredients are also extensively employed in the food industry [27]. The main
feature of these carbohydrates is their poor absorption in the small bowel. This is due to different
reasons including reduced or absent digestive enzymes or by their slow transport across the intestinal
mucosa. Undigested and unabsorbed FODMAP have the peculiarity to be highly osmotic and rapidly
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fermented by bacteria in the gut, which causes distension, bloating, cramping, and diarrhea, which are
all symptoms found in IBS [28]. Moreover, high concentrations of FODMAP in the ileum and proximal
colon exert osmotic pressure, which draws greater amounts of water into the lumen [29]. Fermentation
as produced by short-chain FODMAP intensifies the luminal H2 and CH4 production and causes pain
in the lumen. This gas production can be measured with a breath test, which shows an increase between
0–5 h after the ingestion of FODMAP [30]. As proposed mechanisms, it has been recently shown as
a link between FODMAP and inflammation induction in vivo [31]. Zhou et al. [32] reported that a
high-FODMAP diet could increase the serum lipopolysaccharide level and intestinal inflammation
together with visceral hypersensitivity. On the contrary, a diet low in FODMAP could reduce LPS
levels and the inflammatory status.
Nowadays, it is of great interest to evaluate if persistent gastrointestinal symptoms in celiac
patients, classified as FGIDs and IBS, can be provoked by the ingestion of FODMAP. We aimed to
evaluate the intake of foods containing FODMAP in a group of patients with CD compared with the
intake of healthy volunteers.
2. Materials and Methods
2.1. Patients
The participants were recruited among patients referred to the Center of Prevention and Diagnosis
of Celiac Disease Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. All the
subjects were recruited between October 2012 and August 2014 and the data were collected during the
same period. Over that time, during their annual medical examination, the patients were screened for
their adherence to GFD by using the celiac diet adherence test (CDAT) [33].
The enrolment process of CD patients and healthy individuals has been previously
described [34,35]. All patients included in the study fulfilled the Rome IV questionnaire criteria
for IBS, functional dyspepsia, and functional bloating [15]. In detail, each patient was asked if they
have had recurrent abdominal pain arising for at least 6 months and being present at least once a
week in the last 3 months, which is associated with changes in the stool’s volume and consistency.
The presence of diarrhea and/or constipation associated with abdominal pain was confirmed in case
of presence of IBS. They were also asked for the presence of dyspepsia and/or any other functional
symptoms such as bloating (for FGIDs). The exclusion criteria were: CD diagnosis less than two years,
the presence of metabolic or chronic disease (e.g., diabetes mellitus, Crohn’s Disease, cardiovascular
and neuro-vascular disease, cancer, neuro-degenerative disease, and rheumatoid arthritis), pregnancy
or lactation, vegetarianism, or veganism. A group of healthy volunteers was recruited among students,
researchers, and professors of the Universities of Parma, Parma, and University of the Studies, Milan.
For healthy volunteers, CD was excluded by means of serological tests (anti-tissue transglutaminase
IgA). Exclusion criteria for the healthy participants were the same as for the CD patients except for the
diagnosis of CD.
The final sample included 104 celiac patients and 91 healthy controls. All the participants who
agreed to participate signed a written informed consent and were enrolled in the study. The local
Ethics Committee for Human Research of the City of Milan approved the protocol. The study was
registered at ClinicalTrials.gov (ID NCT01975155).
2.2. Dietary Records
The total food and beverage consumption was assessed by using a food diary filled in daily
for a total of seven days, which was previously described [36]. The participants were trained on
how to record all of the food consumed by a nutritionist. The participants were asked to send their
completed seven-day weighed food record to the Department of Food and Drugs of the University of
Parma. A nutritionist reviewed the diaries and, in case of any error or omission, the participants were
contacted by phone to clarify the issues.
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The nutrient intake was calculated by using a Microsoft Access application (version 2003,
Microsoft Corp, Redmond, WA, USA) linked to the European Institute of Oncology’s food database,
which covered the nutrient composition of 900+ Italian foods [37], integrated with the nutrient
composition of 60 gluten-free foods available in the Italian market [38]. When a food recorded
in a participant’s seven-day weighed food record could not be found in the database, an alternative
food was appropriately chosen based on similarities in energy and nutrient composition. The output
consisted of the mean daily intake of energy and food items for each individual.
Food items of interest for the FODMAP intake evaluation were grouped into the following food
categories (a summary of food sources of FODMAP, as reported in the literature, is provided in Table 1):
pasta, bread (including crackers and salty snacks), other cereals (including corn, quinoa, buckwheat,
and rice), fruits, vegetables and legumes, sweeteners (honey, saccharin, fructose, barley malt syrup),
and sweets (including biscuits, sweet snacks, breakfast cereals, ice cream, candies, and chocolate),
dried fruits, oil and fats, dairy products (including milk, yogurt, cream, cheese), soft drinks, juices,
coffee/tea, and alcoholic beverages [18]. The categories of foods high and low in FODMAP content
were also grouped in larger or macro-categories: cereals and sweets, sweeteners and soft drinks, fruits,
dried fruits, and vegetables. For each individual, the mean daily intake of each food macro-category,
i.e., low and high-FODMAP contents, was calculated.
Table 1. Foods with high and low amounts of FODMAP †.
Food Category High in FODMAP Low in FODMAP
Alcoholic beverages Sweet wine, rum, vodka, whiskey Beer, red wine, rosè wine, white wine,sparkling wine, gin
Cereals Wheat, barley, rye, bran, whole wheatflour, spelt, Kamut® (Khorasan wheat)
Quinoa, rice, buckwheat, pearl millet, corn,
gluten-free flour, bulgur, sourdough spelt bread,
cornflakes, puffed rice
Sweets Apricot jam, peach jam, blackberry jam,plum jam, milk chocolate
Strawberry jam, peanut butter, lactose-free ice
cream, gluten-free sweets
Sweeteners Honey, saccharin, fructose, malt syrup Aspartame, sucrose, sugar, brown sugar
Fruit
Apple, apricot, avocado, ripe banana,
blackberry, litchi, mango, white peach,
yellow peach, pear, persimmon,
pomegranate, blackcurrant, cranberry,
plum, watermelon, cherry
Banana, blueberry, strawberry, raspberry, melon,
white melon, kiwi, orange, mandarin orange, red
grapes, black grapes, green grapes, lemon,
coconut, pineapple, loquat, papaya, prickly pear,
passion fruit, grapefruit
Dried fruit Raisin, dried date, apple, apricot, fig,mango, pear, plum, cashew nut, pistachio
Hazelnut, pine nut, walnut, flax seed, sunflower
seed, dried banana, coconut, dried cranberry,
dried coconut
Fats Butter, margarine, cream, lard
Olive oil, extra-virgin olive oil, sunflower oil,
almond oil, peanut oil, linseed oil, sesame oil, rice
oil, palm oil, coconut oil, colza oil, soybean oil
Dairy products Milk, yogurt, fresh cheese, semi-agedcheese, aged cheese
Lactose-free milk, lactose-free yogurt, lactose-free
cheese, feta, cottage cheese, Parmesan
Soft drinks Apple juice, orange juice, apricot juice,pear juice, peach juice, pomegranate juice
Pineapple juice, lemon juice, cranberry juice,
vegetables juice, orange fresh-squeezed juice
Vegetables
Red radicchio, green radicchio, artichoke,
asparagus, cauliflower, red cabbage, green
cabbage, sauerkraut, pea, snow pea,
mushroom, garlic, leek, onion, Jerusalem
artichoke, bean, white bean, lupine bean,
broad bean (Vicia fabai), chickpea,
broccoli, beet
Pepper, carrot, eggplant, zucchini, potato, sweet
potato, tomato, lettuce, fennel, fennel leaves,
spinach, chard, radish, green bean, turnip,
chicory, rocket, stick, watercress, endive, valerian,
olive, sweet corn, chestnut, pumpkin flower,
cucumber, chives, chili pepper, ginger, Brussels
cabbage, soy sprout, bean sprout, healing herb,
okra, truffle, green alga, celery, pumpkin
† Examples of foods classified as having the high and low amount of FODMAP. FODMAP: fermentable
oligo/di/mono-saccharides and polyols.
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2.3. Statistical Analysis
Data were accordingly described as mean ± SD or median (with interquartile range), according
to variables’ distribution (evaluated by the Shapiro-Wilk test). The Pearson chi-square test was used
to compare the number of individuals reporting IBS and FGIDs in between both studied groups.
The daily nutrient intake data of energy, water, and FODMAP-containing foods were computed and
tabulated. To reduce the effect of implausible extreme values on the analysis, we checked that the
ratio of total energy intake determined from the food record to the basal metabolic rate (determined
by the Harris-Benedict equation) of each participant was not in the first or the last percentile of the
distribution. The dietary data were compared between the control patients and the celiac disease
patients by using the independent sample Student’s t-test or the Wilcoxon rank-sum test. STATA® v.
13.1 (StataCorp, College Station, TX, USA) was used in all the analyses. Statistical significance was set
at a 5% α-level.
3. Results
Patients
Patients in the CD group were older (p = 0.0002) and there was a higher percentage of females in
both groups (82.7% and 68.1% of CD patients and controls, respectively). Both groups were comparable
regarding their mean BMI (22.4 ± 3.3 and 22.2 ± 3.0 for the CD and control group, respectively) and
daily energy intake (2054.8 kcal (397.3) and 2044.7 kcal (329.3)), respectively. When analyzing the
prevalence of gastrointestinal symptoms in both groups, we found out that 12% of CD patients suffered
from IBS when compared with 6% of the controls (p = 0.09) while 27% of CD patients suffered from
FGIDs symptoms (5.77% functional dyspepsia, 10.58% functional bloating) against 22% of controls
(p = 0.42). Approximately 10.5% of CD patients did not suffer from either IBS, functional dyspepsia,
or functional bloating (Figure 1).
Figure 1. Presence of gastrointestinal symptoms. Data are shown as a percentage of individuals
reporting IBS and FGIDs symptoms between both studied groups. IBS: Irritable bowel syndrome,
FGIDs: Functional gastrointestinal disorders, CD: Celiac disease.
Regarding the dietary intake, a slightly higher total food intake was observed in the CD group,
but the energy and water intake were similar between both groups (Table 2). A higher intake of foods
with high FODMAP content was observed in the controls (p < 0.001) while a higher intake of foods
with low FODMAP content was observed in CD patients (p < 0.001).
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(n = 104) p Value
†
Food intake, g/day 1569.5 ± 337.0 1656.5 ± 284.2 0.05 ‡
Energy intake, kcal/day 2054.8 (397.3) 2044.7 (329.3) 0.68
Water intake, mL/day 742.8 (400.0) 647.1 (452.6) 0.52
High-FODMAP, g/day 681.4 (261.0) 457.4 (208.4) 0.00001
Low-FODMAP, g/day 835.1 (364.8) 1119.6 (366.9) 0.00001
High-FODMAP, % 45 (10) 28 (10) 0.00001
Low-FODMAP, % 54 (10) 71 (10) 0.00001
Data as median values (IQR) unless otherwise is indicated. a data as mean ± SD. † p value for the Wilcoxon
rank-sum test unless otherwise is indicated. ‡ p value for the t-test for two independent groups.
The analysis of FODMAP-containing food intake according to food categories is shown in Tables 3
and 4. The consumption of high-FODMAP foods was higher in the control group with the exception
of fruits, which was higher in the CD group. In turn, low-FODMAP food consumption was greater
in the CD group. A larger amount of high-FODMAP cereals (p = 0.0001), high-FODMAP sweets
(p = 0.0001), high-FODMAP alcoholic beverages (p = 0.0001), and high-FODMAP fats (p = 0.0447) was
observed in the control group when compared to celiac patients. Instead, the CD group consumed
significantly higher amount of cereals with low FODMAP content (p = 0.0001), low-FODMAP sweets
(p = 0.0001), low-FODMAP sweeteners (p = 0.0099), fruit both high and low in FODMAPs (respectively
p = 0.001 and p = 0.0158), and low-FODMAP juices (p = 0.0228). The mean daily intake of the other
food categories did not differ between the two groups (Table 3).
Table 3. Daily intake of food categories containing low and high amounts of FODMAP by celiac
patients and healthy controls.
Food Categories (g/day)
Healthy Controls Celiac Patients








Alcoholic beverages, g/day 5.7 (57.1) 21.4 (64.2) 0 (5.7) 6.7 (61.1) 0.0001 0.22
Cereals, g/day 228.0 (61.1) 171 (30.7) 0 (0) 222.7 (95.1) 0.0001 0.0001
Sweets, g/day 22.8 (32.1) 2.1 (11.4) 2.8 (9.1) 35.7 (51.6) 0.0001 0.0001
Sweeteners, g/day 0 (1.6) 6.4 (8.8) 0 (1.2) 8.2 (11.7) 0.49 0.0099
Fruits, g/day 45.7 (108.7) 85.7 (115.7) 100.4 (126.8) 116.4 (128.0) 0.001 0.0158
Dried fruits, g/day 0 (0.2) 0 (2.1) 0 (0) 0.5 (4.1) 0.53 0.28
Fats, g/day 3.3 (6.7) 25.7 (14.4) 2.4 (5.6) 26.0 (13.6) 0.0447 0.25
Dairy, g/day 188.6 (211.4) 7.4 (16.4) 196.2 (184.2) 7.5 (17.6) 0.61 0.85
Juices, g/day 1.4 (47.1) 0 (2.8) 25.7 (67.8) 0.7 (34.2) 0.49 0.0228
Vegetables, g/day 55.0 (87.4) 236.2 (146.4) 73.1 (85.8) 245.8 (139.6) 0.21 0.60
Data as median values (IQR). * p value for comparisons between groups regarding high-FODMAP foods. ** p value
for comparisons between groups regarding low-FODMAP foods.
When the foods containing FODMAP were grouped into large categories (i.e., cereals and sweets,
sweeteners and sugars, fruits, dried fruits, and vegetables), a higher consumption of cereals and sweets
with high FODMAP content was present in the control group (p = 0.00001) while CD patients showed
significantly higher consumption of fruits, dried fruits, and vegetables with high FODMAP content
(p = 0.003). In addition, other large categories of foods with low FODMAP content were significantly
more consumed by the CD patients as compared to the control group (Table 4). Lastly, no correlation
between FODMAP intake and gastrointestinal symptoms was found.
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Table 4. Daily intake of grouped food categories containing low and high amounts of FODMAP by
celiac patients and healthy controls.
Food Categories
Healthy Controls (n = 91) Celiac Patients (n = 104)








Cereals & sweets, g/day 253.7 (74.2) 28.6 (37.4) 3.6 (11.4) 265.8 (103.4) 0.00001 0.00001
Sweeteners & sugar, g/day 14.2 (47.1) 9.0 (14.4) 28.6 (73.6) 15.4 (38.5) 0.64 0.0007
Fruits, dried fruits &
vegetables, g/day 135.0 (185.2) 360.7 (175.2) 181.3 (126.0) 399.8 (232.1) 0.003 0.04
Data as median values (IQR). * p value for comparisons between groups regarding high-FODMAP foods. ** p value
for comparisons between groups regarding low-FODMAP foods.
4. Discussion
This is the first time that a classification is made in relation to food consumption, according to
the amount of FODMAP in patients with CD. In our study, 12% of CD patients met the Rome IV
symptom criteria and 27% suffered from FGIDs symptoms. The data available confirms that the
prevalence of IBS-type symptoms among the group of celiac patients is higher than that in a group of
control subjects [39]. While it was true, CD patients showed a low intake of high FODMAP cereals,
which reflects treatment with a GFD. We observed that the intake of high FODMAP fruits in this group
could in some way be associated with the higher percentage of CD patients reporting IBS and FGIDs
symptoms as compared to controls [40].
When CD is diagnosed, there is usually the assumption that gastrointestinal symptoms will
resolve once gluten is eliminated from the diet. Instead, it has been demonstrated that some celiac
patients carry on suffering of gastrointestinal symptoms one year after diagnosis even with their
correct adherence to GFD and normalization of serum tTG levels [9]. Such a finding also includes the
fact that celiac patients do not report great quality-of-life scores as compared to those of the healthy
population [41]. Therefore, the hypothesis that only mucosal inflammation may have a sensitizing
effect or predispose to IBS-type symptoms is not the only way to run. The diet can play a pivotal role in
the induction of IBS symptoms [42] especially FODMAP [43]. IBS is a common syndrome characterized
by abdominal discomfort or pain and is associated with altered bowel habits [14]. Currently, once
major organic gastrointestinal disorders have been excluded, specialists focus on the possible link
between an “IBS” clinical picture and molecules such as α-amylase/trypsin inhibitors (resistance
molecules contained in cereals to fend off pests and parasites) or dietary habits such as the intake of
lactose, dietary nickel, poorly absorbed, and short-chain carbohydrates (i.e., FODMAP). FODMAP are
contained in different types of cereals such as wheat, barley, rye, and derived products and sweets
and sweeteners such as honey, saccharin, and fructose. There are two other categories that contain
high levels of FODMAP including several types of fruits/dried fruit (such as apple, apricot, peach,
pear, watermelon, and plum) and vegetables (such as artichoke, asparagus, cauliflower, onion, garlic,
and beans). In addition, dairy products are given attention for their high FODMAP content (lactose):
milk, yogurt, fresh cheese, semi-aged cheese, and aged cheese. At present, no data is available about
FODMAP intake in CD patients [44,45].
In our study, a group of celiac patients was compared with a group of healthy subjects with
regard to their intake of FODMAP through foods containing different (low and high) levels of them.
We recorded all the foods and beverages consumed during a week and then consumed foods that
were classified as being high or low in FODMAP content. We used such an approach since the
direct measurement of FODMAP content by means of reliable analytical methods in common foods is
unavailable yet. As expected, CD patients had a lower intake of cereals and sweets containing high
FODMAP levels (including the gluten-containing grains forbidden to celiac patients) as compared to
healthy volunteers. Conversely, patients had a higher intake of low FODMAP cereals including cereals
allowed in GFD such as rice, corn, and pseudo cereals. Interestingly, a significantly higher intake of
fruits (both high and low in FODMAP) was found in the CD patients. Moreover, when all vegetable
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foods, i.e., fruits, dried fruits, and vegetables were grouped together, we observed a significantly
high intake of both categories in CD patients when compared to healthy volunteers. This suggests
a greater level of attention about a healthy diet paid by CD patients than controls. However, since
cereals contain fructans, fruit and vegetables are two food categories with a high content of FODMAP.
This high intake of fruits rich in FODMAP might partly explain the tendency to a higher number
of CD patients reporting IBS and FGIDs symptoms when compared to controls. When comparing
sweeteners intake, both groups had a comparable low intake of high-FODMAP foods. This suggests
that fructose as a sweetener was not commonly used by all the volunteers. In fact, only 12 out of
91 controls and 11 out of 104 CD patients made use of it (data not shown). By contrast, CD patients
consumed more low-FODMAP sweeteners such as sugar and aspartame than controls. Lastly, the
results suggest that patients with CD did not exclude or limit dairy products with a high content of
FODMAP, which shows a pattern similar to that of the control group. Of note, milk and its derivatives
provide important nutrients due to its content of vitamins, minerals, and macronutrients essential for
the growth, development, and maintenance of tissues [46]. On the other hand, the benefits of the fatty
component of dairy products have been demonstrated and elicit a greater bioavailability of high-value
nutrients and also show anti-inflammatory properties [47–49]. The presumed anti-inflammatory
benefits described in dairy products could potentially be the reason, at least in part, why some CD
patients can tolerate them despite the secondary lactose intolerance described in some of them.
Currently, little is known about the level of FODMAP intake in different population groups.
Nevertheless, it is of great interest to confirm a potential relationship between specific dietary
carbohydrates and gastrointestinal symptoms [25]. FODMAP have been reported as triggers of
gastrointestinal symptoms in IBS, Crohn’s disease, and ulcerative colitis with the hypothesis being that
the rapid fermentation and passage of FODMAP through the gastrointestinal tract leads to an increase
in intestinal permeability [50]. Particularly in IBD patients who have superimposed IBS, the luminal
distension (caused by the fermentation of FODMAP by bacteria in the distal small and proximal large
bowel) can cause gastrointestinal symptoms such as bloating, distension, cramping, and diarrhea [51].
There are few antecedents on the long-term effectiveness, acceptability, and nutrient adequacy of a
diet with low FODMAP content. Studies have evaluated retrospectively and prospectively changes in
the gastrointestinal symptomatology [52–54] while long-term nutritional characteristics of a diet with
low FODMAP content had not been studied. O’Keeffe et al. [55] evaluated the long-term impact of
the low FODMAP diet on clinical response, nutritional adequacy, dietary acceptability, and quality of
life related to foods. The authors concluded that the education provided in relation to a diet with low
FODMAP content is effective in the management of IBS by allowing the maintenance of a nutritionally
adequate diet among patients. However, one unintended consequence associated with FODMAP
restriction is its impact on the gut microbiota. Probiotic supplementation with Bifidobacterium is
associated with a reduction in IBS symptoms but the low FODMAP diet markedly reduces luminal
Bifidobacterium concentration [56]. It is likely that both interventions can be successful in specific
groups of patients [30]. In this sense, Staudacher et al. [19] showed that a low-FODMAP diet was
associated with adequate relief of symptoms in patients with IBS when compared to the placebo and
concomitant administration with probiotics (Bifidobacterium) could be administered to restore these
bacteria in patients on a low-FODMAP diet.
For the first time, this study evaluated the intake of low or high-FODMAP foods in CD patients
affected by IBS and FGIDs symptoms. As limitations, we would like to mention that our results
were obtained through food diaries in a seven-day period, which is a period of time that is short
and does not allow conclusions about the long-term impact of this dietary pattern. Even though the
recording period is short, the participants accurately reported and weighed all the consumed food
and beverages. Moreover, in a previous publication on almost the same participants, we compared
this tool to a food frequency questionnaire and demonstrated that the two tools were correlated
especially in terms of food groups [34]. The study of the diet during a longer period of time could
provide relevant knowledge regarding dietary characteristics in patients with CD. Because of the
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explorative nature of our study, we could not find any causative relationship between the intake
of FODMAP-rich foods and the presence of gastrointestinal symptoms in our patients. However,
the clinical effect of a GFD together with low-FODMAP diet should be prospectively evaluated as
a supportive therapy for CD patients. In this sense, our group has recently reported that a GFD
associated with a low-FODMAP content is beneficial as a supportive therapy for a group of CD
patients with persistent gastrointestinal symptoms [57]. When consolidated data on the FODMAP
content of foods become available, it will allow the investigation of specific FODMAP groups among
oligosaccharides, disaccharides, monosaccharides, and polyols that are more consumed by CD patients
than by controls.
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Abstract: Celiac disease (CD) is a genetically conditioned autoimmune process that appears in
susceptible people. It can affect people of any age, and slightly predominates in females. It has
a fairly homogenous global distribution, with an average prevalence of 1–2%, the frequency having
increased in recent decades. The only effective treatment is a strict and permanent gluten-free diet
(GFD), although the level of compliance is poor, at about 50% of cases. To monitor the effectiveness
of the GFD, several procedures involving various approaches are employed: (a) Periodic visits
by expert Nutritionists; (b) Clinical follow-up; (c) Serological time controls of specific antibodies;
(d) Serial endoscopies with collection of duodenal biopsies; (e) Use of structured questionnaires;
and (f) Determination of gluten peptides derived from gluten in faeces and/or urine. All of these
procedures are useful when applied, alone or in combination, depending on the cases. Some patients
will only need to consult to their doctors, while others will require a multidisciplinary approach to
assess their compliance with the GFD. In children, normalization of duodenal mucosa was achieved
in 95% of cases within two years, while it is more delayed in adults, whose mucosa take longer time
(3–5 years) to heal completely.
Keywords: celiac disease; gluten-free diet; effectiveness; adherence; nutritionists; clinic; serology;
duodenal biopsies; structured questionnaires; peptides derived from gluten in faeces and urine
1. Introduction
Celiac disease (CD) is defined as a systemic autoimmune process that appears as a consequence of
a permanent intolerance to gluten and that affects genetically predisposed people. It is widely, although
unevenly, distributed throughout the world, affecting all ethnicities, with an average prevalence of
1–2% in the general population, its frequency having increased notably in recent years [1].
A gluten-free diet (GFD), followed strictly and permanently throughout life, is the only currently
available treatment that successfully controls most cases of this disease. It is remarkably effective in the
vast majority of cases, producing a significant clinical improvement not only in digestive symptoms,
but also in the extra-intestinal symptoms associated with CD, causing its progressive disappearance,
and the associated slow and sustained decrease in intestinal lesions [2,3].
Permanent adherence to a GFD is difficult, and largely unnoticed but repeated transgressions,
as well as frequent contaminations may occur, all of which delay patient recovery in some way. This
was confirmed in a meta-analysis published in 2018 [3]. If the transgressions are frequent, various
types of associated long-term complications may appear, including a variety of malignancies [4].
Physicians involved in the management of CD should insist strongly to their patients that
compliance with the GFD is fundamental and is the cornerstone of the success of this treatment.
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They need to explain this concept convincingly to the patients, as well as the main features of the GFD,
with the greatest possible clarity and simplicity at the time of diagnosis.
It has not yet been well established which person or doctor who should carry out the follow-up to
confirm the adherence to the GFD: it could be the gastroenterologist, the primary care physician, or an
expert dietician [5]. Clinical control by family physicians and gastroenterologists is considered to be
very similar, in the sense of them being able to achieve high rates of adherence to GFD [6].
The available evidence indicates that consulting with a dietician can be useful, especially when
gluten contamination is suspected. However, joint monitoring by a dietician and a doctor may not be
better, than the control that either one can offer separately [7]. The final decision will depend, not only
on the availability of an expert dietician in different centres, but also on the collaboration that exists
between the gastroenterology services and primary care physicians.
Patient associations or support groups can provide help with trying to achieve proper compliance
with the diet. These associations offer detailed information about the importance of a strict GFD and
answer all questions related to the characteristics of gluten-free foods and different recipes. They also
organize regular meetings, during which patients can share information about CD with other patients
and thereby improve compliance with their diet [8].
In general, it is reckoned that fewer than 50% of patients, mainly those from the adult celiac
population, manage to keep strictly to a GFD. Generally, better dietary adherence is achieved (in 90–95%
of cases, on average in the paediatric population, or in those people whose disease is diagnosed in
early childhood [9].
There are clear differences in the prevalence of CD between Caucasians and South East Asian
people, that may be due to different reasons, such as socioeconomic status, healthcare facilities,
associated infections, presence of villous atrophy and others, and the adherence to GFD in general is
irregular, but if it were strict, it would possibly be similar in both ethnicities, but for the moment, there
are scarce information for this.
The main objective of the present study is to review the usefulness of the diverse available
methods to use in different clinical situations and phases of CD evolution following a GFD, pointing
out its strengths and weak points, in order to facilitate its selection, both in children and adults.
2. Control of the Follow-Up of the GFD
Compliance with the GFD can be evaluated through different approaches, and various health
professionals, may participate or collaborate to carry this out, in line with the following study
procedures:
1. Periodic control visits by an expert dietician
2. Regular consultations with a gastroenterologist/family doctor
3. Structured specific questionnaires
4. Regular control of serum antibody titres for CD
5. Serial endoscopies with duodenal biopsies
6. Determination of derived peptides from gluten, in faeces/urine
2.1. Periodic Interviews Conducted by Dieticiass
The dieticians are the health professionals best placed to assess the degree of compliance with
the GFD. They should try to participate and collaborate actively in the follow-up of celiac patients,
whenever possible maintaining a close collaboration with nutritionists and gastroenterologists, ideally
carrying out their task during the same visit and, as far as is practicable, simultaneously in the same
consulting room.
However, many patients tend to have consultations only with their gastroenterologist or family
doctor, and these are also effective at achieving strict adherence to the GFD. On the other hand,
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patients with more complex needs will require a multidisciplinary approach, including various medical
specialists, to assess their associated diseases and their compliance with the GFD.
2.2. Evolutionary Clinical Follow-up
The disappearance or improvement of symptoms, might not seem a very accurate method,
although an indicative one, for trying to evaluate adherence to the GFD during a consultation with the
doctor. This evaluation can be done either by the gastroenterologist who diagnosed the patient, or by
the family doctor who controls their evolution, facilitating their outpatient visits, reducing the number
trips to the hospital and generally shortening the wait.
The lack of improvement with the GFD, or the persistence of symptoms, are generally related
to irregular, or poor dietary compliance, or, clearly, with continued gluten consumption, specially in
adolescents [10]. The main cause, in addition to any frequent transgressions, is the inadvertent intake
of gluten. This is mainly due to “cross-contamination”, which arises from eating at a table with other
people who eat bread or other wheat products and who often inadvertently drop small fragments
of foods that have been contaminated with flour residues during their preparation or handling, etc.
It may also be due to the “hidden gluten” that is present in some products that are not adequately
labelled [11,12]. People with a basic elementary education and/or with little understanding of how
to follow a GFD, or who have little motivation, often believe that they are following the diet strictly,
although in practice, they are frequently making mistakes [13].
The follow-up and control visits serve to assess the improvement in the initial symptoms and to
collect evidence of new ones. On many occasions at the time of diagnosis there is an overlap of the
patient’s discomfort with the symptoms of irritable bowel, which, naturally, do not improve with the
implementation of a GFD, unlike the case in many celiac patients [14]. The persistence of previous
symptoms, or the appearance of new ones, may be related to CD itself, to a complication that has
arisen, or to the presence of a new, associated disease.
A series of alarm symptoms have been described, such as the rapid deterioration in the general
state of health, accompanied by striking weight loss, the presence of high fever, serious diarrhoea,
or signs of intestinal obstruction, all of which require an exhaustive clinical and analytical study to be
carried out in search of important associated complications, such as an evolution towards refractory
forms of the disease, or the development of a primary intestinal T-cell lymphoma [15–17].
CD usually presents a broad spectrum of related symptoms, not only digestive, but also
extra-intestinal. It has a clear predominance in females compared with men, with an average ratio
of 2:1 in most series described. It is more prevalent in adults than in children. Children are more
likely to exhibit typical symptoms along with a higher frequency of villous atrophy (VA) and higher
antibody titres related to tissue Trans-Glutaminase (tTG) than in adults. Delay in diagnosis is also less
in children than in adults in general. Curiously, this pattern is more evident in children under three
years of age, and the differences between all other age groups decrease, or disappear with age, such
that adolescents behave like adults in all the aspects discussed [18].
Children may have reduced bone mass at the time of diagnosis. However, they are more likely
than adults to achieve a full recovery of their bone mass, 6–12 months after the starting on their GFD.
Generally, it is not necessary to perform bone mineral density (BMD) explorations in paediatric patients
who have been newly diagnosed with CD without complications. It is recommended to monitor the
weight and height of children regularly, at every visit, in order to evaluate them properly, and to try to
help them attain normal growth and skeletal development [19].
The main cause of a drop in BMD in CD patients is probably vitamin D deficiency, but it may
arise for other reasons. However, the risk of fractures in patients with CD is not very high, and the
predictive value of the systematic performance of BMD is not sufficient to identify individuals at high
risk of fractures. It seems reasonable to measure BMD periodically in adult patients with CD, especially
in those with a high risk of osteoporosis, such as in post-menopausal women, men older than 55 years,
and people known to have osteopenia prior to the diagnosis of CD [20]. Further studies are needed
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to establish the true efficacy and cost-effectiveness of the periodic performance of BMD, in all adult
patients with CD at the time of diagnosis, and to identify the frequency of follow-up with which this
exploration should be carried out [21].
Autoimmune diseases are frequently associated with CD and can appear at any time during the
follow-up, especially in adults, with a clear predominance in females. Physicians should be aware of
the possible related autoimmune diseases and other illnesses associated with CD, so they can detect
them systematically and early during follow-up visits [22].
CD is associated with many various diseases with which it often shares a genetic base. Type 1
Diabetes Mellitus (T1DM), is one disease, which occurs particularly frequently in children. Many of
them present it in a silent or oligo-symptomatic way, for which reason, it is recommended to perform
an annual follow-up screening for the presence of associated CD in children with T1DM, since its
average prevalence is high, occurring in 5–10% of juvenile diabetic patients [23]. T1DM is diagnosed
in 90% of patients before CD is confirmed [24]. Patients with T1DM and symptoms associated with
CD, show clear clinical improvement overall when they follow a GFD. Increases in the rate of growth
and in haemoglobin levels are often observed in these children. There is an improvement in control of
diabetes mellitus, as confirmed by the reduction in the frequency of hypoglycaemic episodes and the
reduced daily need for insulin [25–27].
There is also an increased risk of developing non-Hodgkin lymphoma in individuals with relatives
affected with CD. The same may be said about the presence of various associated neurological diseases,
above all cerebellar ataxia [28,29].
It is highly recommended and mandatory to carry out screening studies for CD in first and second
grade relatives, especially if they present clinical symptoms. The index case must be informed about
this family risk and its implementation is recommended for all first-and second-degree relatives [30,31].
The periodic determination of a series of laboratory tests is very important, in order to be able
to detect the presence of nutritional deficiencies and the development of diseases and associated
complications. The basic laboratory tests that should be done at each visit include, amongst others,
a CBC with leukocyte formula, blood glucose, cholesterol and triglycerides, measurements of levels of
iron, transferrin, ferritin, vitamin B12, folates, calcium, alkaline phosphatase, and liver function tests.
Likewise, the serum levels of thyroid stimulating hormone (TSH), anti-thyroid antibodies and
levels of dihydroxy—vitamin D should be determined, in case they exhibit an associated deficiency.
This will be complemented with the determination of the antibody titre against deamidated gliadin
peptides (DGPs) of the IgA type and/or the tTG, also of the IgA type, and occasionally by determining
the endomysial antibodies (EMAs) [31].
Women of childbearing age must be checked regularly by their gynaecologist, especially those
presenting menstrual disorders, infertility problems, or those who have a history of recurrent
miscarriages [32].
Hypersplenism can affect more than a third of adult patients with CD, but it is not a complication
in paediatric patients. The incidence of hyposplenism is correlated with the duration of pre-exposure
to gluten and is higher in concomitant autoimmune disorders and premalignant conditions. Based on
these associated factors, the function of the spleen can be determined in a select group of adult patients
with CD and a previous history of associated major infections or episodes of thromboembolism [33].
The count of red blood cells with small surface irregularities (marks or notches) is a useful
diagnostic tool, involving a precise, quantitative and low-cost method. The conjugated protein
vaccines should be administered to patients with significant hyposplenism, defined as more than 10%
of erythrocytes with irregularities on their surface or fewer than 10% of IgM memory type B cells [34].
2.3. Structured Questionnaires
Structured short questionnaires are used as an alternative to consultations with a dietician to
obtain a rapid assessment of the adherence to the GFD. It is easy to complete this type of questionnaire
in the patient’s usual clinic. The responses are highly correlated with antibody levels and the presence
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of VA in duodenal biopsies and useful for monitoring. In general, questionnaires are easy to administer
and often complement each other. They not only assess the quality of life, in a general or specific way,
but also are able to estimate the changes occurring after the follow-up of the GFD. However, all of them
must be validated in different countries and diverse clinical contexts before they can be applied and
come into general use. Leffler et al. have developed a simple questionnaire to assess adherence to GFD
in adults with CD. It consists of seven structured questions about compliance and is scored on a Likert
scale from 1 to 5, so that summing the values obtained gives an overall score from 7 to 35. Values less
than 13 are considered to show good compliance, while those over 17, represent intermediate or low
adherence. It is easily applied and is a very useful tool that can be included as part of the monitoring
of adult patients, but not of children. This scoring system is known as “CDAT score” from (Coeliac
Dietary Adherence Test) [35].
2.4. Periodic Evaluation of Serum Antibody Levels
Levels of antibodies circulating in the blood, which are usually used to diagnose CD, including
DGPs and tTG, are related to the levels of gluten consumed. It is expected, therefore, that there will
be a decrease in their titres a few weeks or months after a strict GFD is initiated. The sustained or
sporadic consumption of foods containing gluten increases these values and thereby the persistence of
high levels of gluten-related antibodies, suggests a lack of adherence to GFD [36].
Periodic serological tests for PDGs DGP and/or tTG may be useful for controlling the degree
of compliance with a GFD [37]. However, the normalization of antibody titres cannot identify the
existence of small dietary transgressions, so its use is limited to indicating a lack of compliance, but is
of no value for evaluating whether there is strict adherence to the GFD.
The diagnostic security of the various commercial kits used is lower in clinical practice than the
values reported in the medical literature in general, especially in the patients with mild VA or those
with patchy lesions.
A collaborative multinational study revealed a high variability in levels of tTG, which is very
striking with respect to diagnostic sensitivity (ranging from 69% to 93%), and somewhat less in
terms of specificity (from 96% to 100%), among the 20 participating laboratories. This once again
demonstrates the need for better standardization of the various techniques available for determining
the tTG antibodies [38–41].
CD is often diagnosed in adults even when the values of positive antibody are very low (5–10%
according to various series), or even zero, especially in cases that present with lymphocytic enteritis
but not VA. The serology of such cases is entirely without value for monitoring because the levels of
antibodies present at the start of the GFD are normal [42–44].
This does not usually occur in children, who, in most cases, have very high titres. Levels of
tTG more than 10 times the normal value indicate the existence of significant VA. In these cases
it is not considered necessary to perform duodenal biopsies in order to confirm the diagnosis of
CD, as recommended in the new criteria drawn up by experts of the European Society of Paediatric
Gastroenterology, Hepatology, and Nutrition (ESPGHAN), which were published in 2012 [45].
Subsequent follow-up studies have confirmed the safety and efficacy of this diagnostic strategy
for children. It is recommended following a diagnosis based on raised levels of tTG, if it is confirmed by
a positive determination of EMA in a second blood sample, and the presence of at least one symptom
indicative of CD. This could avoid unnecessary risks and the costs related to endoscopy in at least 50%
of the children worldwide who present with CD. Carrying out genetic studies to determine related
HLA-II markers (HLA-DQ2 and DQ8) is not essential for obtaining a safe diagnosis [46].
The evaluation of antibody titres in these cases is a good, and indeed the only currently available
method of monitoring. It is recommended that titres be measured every six months. Most children
presenting with CD exhibit a gradual, progressive and continuous decrease in titres over time, their
values becoming normalized within 1–2 years of starting the GFD.
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2.5. Periodic Endoscopic Controls with Taking of Duodenal Biopsies
CD exhibits marked differences in children and adults, not only at the time of diagnosis, but also
in the degree of response to the GFD and in their histological recovery. These are clearly higher in
children (95% on average) than in adults (50%) after two years of monitoring [43,44].
Examining the histology of the small intestine continues to be the best procedure for evaluating
with certainty the healing of the intestinal mucosa. Complete recovery from VA confirms that the GFD
has been followed strictly and effectively, independently of the evolution of the serological titers of the
antibodies, or of the symptoms that the patients present. Intestinal biopsies taken during follow-up
are important in adults who have persistent VA, even in the absence of symptoms and with negative
serology [47].
Adult patients are usually less symptomatic than children, most of them exhibiting atypical forms
of the disease. For this reason, clinical-based monitoring is not usually of much value. Changes in
serology are also not very marked, so the best way of assessing the effectiveness of the GFD is to
perform periodic duodenal biopsies. These are not needed for children, because, in most cases, they
achieve complete mucosal recovery earlier than do adults [48].
The guidelines published by the American College of Gastroenterology (ACG) include the
recommendation to perform follow-up duodenal biopsies in adults, two years after the start of the GFD,
in order to assess mucosal healing. However, its implementation is not recommended as a routine
procedure for children [2]. Clinical guides published by the British Society of Gastroenterology are
less demanding and suggest that there is little evidence to determine whether the clinical results differ
significantly depending on the result of repeated biopsies. In the absence of results of a cost-benefit
analysis of repeated biopsies and the lack of prospective studies in this regard, they postulate
that follow-up biopsies are not generally necessary for asymptomatic patients who are successfully
following a GFD and for whom there are no data to suggest an increased risk of developing VA-related
complications [49].
One of the benefits of carrying out repeated biopsies in adult patients with CD is the ability to
separate patients into two groups: those whose mucosa recovers completely and who can be monitored
with less strict controls, and those with persistent VA, who require more frequent clinical control. It is
clear that the persistence of VA is generally associated with a higher frequency of complications related
to CD and adverse medium- and long-term outcomes.
Even patients who have persistent mild forms of lymphocytic enteropathy (Marsh I type
or duodenal lymphocytosis) while following a GFD can also present nutritional deficiencies or
complications. It takes 2–5 years for the mucosa of adult celiac patients with AV in their biopsies to
recover. Therefore, the control biopsies can be programmed for adult patients over that period, taking
into account that it is better to carry them out after the third or fourth year after initiation of the GFD
to avoid too many unnecessary repetitions [50].
Mucosal recovery is defined, from the histological point of view, as the reestablishment of the
normal height of the intestinal villi, taken as a ratio of villus height to crypt depth of at least 3:1
according to what is observed when comparing with non-celiac subjects. Monitoring the intra-epithelial
lymphocyte count was not considered appropriate, because it is not exclusively related to gluten
consumption, since it can also have other causes [51].
Usually the comparative evaluation of duodenal biopsies of the same patient, is mainly focused
on the finding of the presence of an architectural damage (mainly VA). These parameters have been
summarised following the Marsh-Oberhuber (MO) classification [52] and strongly influence to the
gastroenterologists in their clinical/therapeutic decisions, especially when the histological pattern is
unmodified [53].
Elli et al. reported the results of an interesting study including two different methods of comparing
duodenal biopsies. One was the classical MO score and the second one compared the areas covered by
each MO grade and expressed as percentages, the final grade being calculated from the analysis of
ten power fields per duodenal biopsy. They studied 69 patients (17 males 52 females, age at diagnosis
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36 ± 15 years) who underwent repeated duodenal biopsies. According to the classical MO scale,
32 patients (46%) did not present VA during one year follow-up, while 37 (54%) showed VA, among
whom, 26 improved the grade of severity and 11 retained the same one. Of these latter, according to the
second method, eight patients were considered improved, two showed a worsened duodenal damage
and only one remained unchanged; the evaluation changed in 91% of cases. The authors suggest that
the use of the second method provides a good additional information about the progression/regression
of the mucosal damage, especially in unmodified cases following the GFD [54].
In 2010, Rubio-Tapia et al. described the results of a retrospective follow-up study with repeated
biopsies in a large series of 241 adult patients with CD and VA at diagnosis. They reported that mucosal
recovery in their patients was 34% (95% CI: 27–40%) at two years and 66% (95% CI: 58–74%) at five
years. However, most of the patients (82%) presented a clinical improvement that was not significantly
correlated with the recovery of the mucosa (p = 0.7), unlike the serological response, which did have
a significant association (p = 0.01) In the same study, poor compliance with the GFD (p < 0.01), the
presence of a severe CAD diagnosis, defined by the intensity of diarrhoea and weight loss (p < 0.001),
and complete VA at the start (p < 0.001), were significantly correlated with a lack or delay of mucosal
recovery. There was a nearly significant association between the disappearance of VA and a reduction
in all-cause mortality (hazard ratio (HR) = 0.13, 95% CI: 0.02–1.06, p = 0.06), adjusted for age and
sex. The authors recommended that most adults with CD should be followed up by endoscopy and
periodic biopsies [55].
In another study, conducted by Lebwohl et al., published in 2013, the authors tried to establish
whether there is an association between the presence of AV and increased mortality. They studied
a series of 7648 patients with CD for a mean follow-up time of 11.5 years. A total of 3317 (43%) of them
had persistent atrophy. There were 606 deaths (8%) in the entire series. Patients with persistent VA
had no greater risk of mortality than those with normal mucosa (HR = 1.01; 95% CI: 0.86–1.19). This
pattern was the same for children and adults, including patients older than 50 years of age. However,
follow-up biopsies are useful for confirming diagnoses or in cases of refractory CD [56]. A description
of the different published studies evaluating the adherence of the GFD and its impact on the duodenal
mucosal healing and the survival in relation to persistence of VA is shown (Table 1).
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bowel bacterial overgrowth; RCD: refractory celiac disease; CDAT: celiac dietary adherence test; tTG: tissue
trans-glutaminase; DGP: deamidated gliadin peptides; Compl.: compliance; AUC: area under the curve; pts:
patients; VA: villous atrophy.
The endoscopic capsule does not play any role in the follow-up of mucosal lesions in CD, since it
does not allow biopsy samples to be taken. However, it is of use for detecting complications, especially
when the appearance of an intestinal lymphoma or haemorrhages of unknown origin is suspected [57].
2.6. Determination of Peptides Derived from Gluten in Feces and Urine
Although the importance of controlling the follow-up of the GFD for effectiveness is clearly
accepted by everyone, there are currently no unanimously accepted clinical guidelines that guarantee
the results, nor are there adequate procedures to assess the adherence of the patients to the diet,
and the transgressions that occasionally occur. Serological tests are very sensitive and specific to
a diagnosis, but their effectiveness decreases with follow-up and they are not able to provide an
adequate evaluation. It is difficult to ensure that repeated endoscopies are conducted, since they are
inconvenient and invasive tests, so their application in practice is complicated. Recently, immunogenic
gluten peptides (IGPs) have been identified that can be determined from faeces and urine. These have
been proposed as simple, non-invasive markers, to be measured when frequent transgressions and/or
contamination of the GFD are suspected. Their determination is simple and represents a new tool with
which to determine compliance with the GFD objectively, at any time during the follow-up of patients
with CD who are receiving treatment [58].
Several prospective studies have been carried out that have confirmed the efficacy of the
determination of IGP in faeces. In a Spanish study of 188 patients with CD who were on a GFD,
Comino et al. found that 56 patients (29.8%) had high levels of IGPs in their faeces, and that there were
significant associations with age (39.2% over 13 years) and gender (a predominance of males in this
evaluation). However, they found no correlation with antibody levels, or with the responses to the
dietary questionnaires administered [59].
The determination of levels of IGPs in urine has been equally useful and simple as a way of
monitoring the adherence of patients to the GFD. A highly effective lateral flow technique is used to
detect the presence of the monoclonal antibody G12, which is the most immunogenic within the group
of IGPs. This same procedure can be applied to the determination of the gluten content in food and in
some beverages, such as beer [60,61].
3. Refractory Celiac Disease
Refractory celiac disease (RCD) is defined as the presence of persistent or recurrent symptoms of
CD, accompanied by signs of malabsorption, with continued VA, despite the patient following a strict
GFD for more than one year, in the absence of other complications, such as intestinal lymphoma. It is
rare, affecting 1–2% of adult patients with CD and is divided into two categories: type I and type
II [62,63].
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In type I RCD, the lymphocyte infiltration of the mucosa of the small intestine is similar to that
found in patients with CD before treatment with the GFD. In contrast, in type 2 RCD, the CD3 (+)
intraepithelial lymphocytes present an abnormal immunophenotype, with a lack of expression of
surface cells with CD8 (+) markers and that also feature oligoclonal or monoclonal type growth.
Their differences are not only immunophenotypic, but also involve their clinical behaviour, their
response to medical treatment, and their prognosis. Type 1 RCD is the more frequent (60–80% of cases),
and it responds better to treatment and has a better prognosis, while type 2 is the opposite, responding
poorly to various treatments, being associated with a high frequency of intestinal lymphoma, and with
greater mortality [64–66].
In a recent study of 57 patients who presented with RCD, in which immunosuppressive treatments
had failed in more than half of the cases, oral treatment with budesonide in open capsules, dissolving
their contents in apple juice at a dose of three 3-mg capsules per day, produced significant clinical
improvement in 93% of cases, and histological improvement in 89% of cases, of both types [67].
Follow-up of both types of RCD should be frequent and complete, multidisciplinary, and based
mainly on the findings of duodenal biopsies. These should be performed at regular intervals and with
general examinations to rule out associated complications.
4. Indicative Timetable for Conducting the Evaluations
Once the diagnosis of CD has been confirmed and the treatment with GFD explained in depth
by the gastroenterologist and the nutritionist, it is recommended to draw up a schedule of periodic
review visits every six months during the first year, to evaluate the overall response to the GFD. This
will be done from the clinical point of view, as well as from an analytical and serological perspective.
In principle, it is not considered necessary to repeat the duodenal biopsies during the first year because,
with a few exceptions, they are of little use.
After the first year, if the symptoms persist, the antibody titres remain elevated or if poor
adherence to the GFD is confirmed, the possibility that the patient has RCD may be considered,
in which case the surveillance and controls should be increased, applying the specific protocols of each
hospital or the currently available clinical guidelines.
If this eventuality has been ruled out, and it is considered worthwhile to evaluate mucosal
healing in adult patients, a control endoscopy can be arranged, with a biopsy taken after the third
year of follow-up. In children, it is not considered necessary to perform provocation tests or duodenal
control biopsies.
5. Conclusions
In clinical practice, CD that presents with digestive and/or extra-intestinal symptoms, but can
also be oligo-symptomatic or occur in a silent way, is usually suspected from the finding of a positive
serology and is confirmed by performing duodenal biopsies.
The effectiveness of compliance with the GSD by celiac patients can be monitored by a nutritionist
or dietician through the repeated administration of questionnaires. However, these are not always
available in all centres.
It must also be principally clinical, when the disappearance of the symptoms is evident,
a significant improvement having been achieved. However, this is not sufficient for the other cases.
Serological controls are only effective when the basal levels of the related antibodies are very high,
but they are not useful when changes are small.
Carrying out periodic duodenal biopsies is useful but has the disadvantage of being an invasive
procedure and, like serology, is more useful in cases with significant VA and that are not associated
with clinical improvement or serological changes.
Finally, determination of the IGPs in isolated samples of faeces or urine has proved useful for
controlling transgressions of the GFD.
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However, some of these processes must be employed in order to monitor and encourage
patient compliance and to rule out possible any associated shortcomings and/or the appearance
of new complications.
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Abstract: The gluten-free diet is the only effective treatment available for celiac disease. However,
it is difficult to adhere to and a closer look on the diet’s implementation and indications reveals
several ambiguities: Not only is there controversy on the threshold of gluten that can be tolerated in
the frame of a strict gluten-free diet, but it is also unclear whether the gluten-free diet is an appropriate
treatment in patient subgroups with asymptomatic or potential celiac disease. Reports from a number
of research groups suggest that a certain proportion of patients may effectively develop tolerance to
gluten and thus become suitable for gluten reintroduction over time. In this review, we set out to
create an overview about the current state of research as regards the definition of a strict gluten-free
diet in terms of the gluten thresholds considered tolerable and the indication for a gluten-free diet in
the absence of histological abnormalities or symptoms. Furthermore, we discuss the concept that
a gluten-free diet must be followed for life by all patients.
Keywords: gluten; adherence; serology; villous atrophy; mucosal recovery; threshold
1. Introduction
Celiac disease (CD) is an autoimmune disorder triggered by the ingestion of gluten.
As a consequence of dietary exposure to gluten, genetically susceptible individuals develop
autoimmune reactions resulting in histological changes in the small intestine. These are characterized
by duodenal villous atrophy and intraepithelial lymphocytosis (IEL), leading to malabsorption and
gastrointestinal as well as extraintestinal symptoms [1]. The clinical presentation of CD is diverse,
with a considerable number of patients being asymptomatic. The classical form of CD is characterized
by an overt malabsorption syndrome that features chronic diarrhea, steatorrhea, weight loss, and failure
to thrive in children. Gastrointestinal symptoms as well as extraintestinal symptoms such as fatigue,
osteopenia, iron deficiency, anemia and neurological/psychological disorders such as depression
may be present [1,2]. On the other hand, in the non-classical form of CD patients present only one or
few gastrointestinal or extraintestinal symptoms [2]. Table 1 shows the characteristics of different
clinical presentations.
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Table 1. The spectrum of clinical presentations of celiac disease.
Clinical Features Celiac Disease
Classical Non-Classical Asymptomatic Potential
Malabsorption syndrome
diarrhea, steatorrhea, weight loss/growth
failure, with or without anemia
+ − − −
Gastrointestinal symptoms




+/− +/− − −
Serology (tTG/EMA) + + + +
Histological alterations (Marsh) + + + −
tTG, anti-transglutaminase antibodies; EMA, anti-endomysial antibodies.
A lifelong gluten-free diet (GFD) has long been considered the only effective treatment for CD.
Strict adherence to a GFD has been shown to lead to partial—if not complete—healing of the duodenal
mucosa along with resolution of symptoms and signs of malabsorption [2]. It has been observed that
mucosal recovery takes more time and is more frequently incomplete in adults than in children [3,4].
There remain, however, open issues regarding not only the tolerable threshold of gluten ingestion but
also the appropriateness of a lifelong indication to GFD, particularly in patients with subclinical and
potential CD. Considering the impact on the patients’ quality of life posed by a restrictive GFD [5,6],
its necessity should be reviewed carefully when prescribing it.
First of all, the natural course of CD is not as clearly understood as one might think. It is still
unclear if a strict GFD needs to be followed throughout the whole life in all patients or if tolerance
may develop in certain patients. While the GFD generally leads to clinical improvement, mucosal
abnormalities may persist, but do not add up to functional malabsorption as clinical symptoms
decline. Rubio-Tapia et al. observed mucosal recovery in about 35% two years after starting a GFD
and in about 66% after five years; however, 82% improved clinically. In line with these findings,
clinical improvement of symptoms was not a reliable marker of mucosal recovery (p = 0.7) [7]. On the
other hand, cases of patients who—in many cases on their own—interrupt the GFD and remain
symptom-free have been reported in some studies [8].
Furthermore, while there are strong data supporting the benefits of a GFD in patients with
symptomatic CD or CD irrespective of symptomatology, the outcome of GFD within the subgroups of
asymptomatic and potential CD is mostly unclear. In these patients, the response to GFD can neither be
measured in terms of symptom relief—nor in terms of mucosal healing for potential CD. For this reason,
the issue of the actual role of the GFD in the prevention of CD-related complications (e.g., refractory
disease, intestinal lymphoma) and other immune disorders should be addressed. In view of the
scattered data on the risk of CD-related complications in these patient groups, the prescription of
a GFD needs to be critically debated.
The aim of this article is to critically review existing literature data on the therapeutic and
prognostic role of the GFD in CD in order to give an overview about the current clinical indications for
the GFD and future perspectives for celiac patients.
2. Methods
A comprehensive literature search was carried out on PubMed to identify peer-reviewed
articles on GFD in CD published until August 2018. Search strategies included the following key
words: celiac disease, gluten-free diet, adherence, autoimmune disorders, gluten re-challenge,
gluten tolerance, gluten contamination, celiac disease complications, lymphoproliferative disorders,
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and enteropathy-associated T-cell lymphoma. A manual search was also carried out on the
bibliographies of the identified articles. The most relevant original research articles in the English
language, including randomized controlled trials and observational studies (prospective and
retrospective) were selected by the authors and are discussed in the following sections.
3. Gluten-Free Diet: How Strict Should It Be?
Current guidelines suggest that the GFD should be strict, with complete avoidance of gluten
containing products and attention to cross-contaminations [2].
Gluten contamination, even within the frame of a strict GFD, cannot be entirely avoided: Plenty
of products contain hidden gluten, such as sausages, soups, soy sauce and ice cream. But even in
gluten-free-labeled products there are traces of gluten. This is mostly due to cross-contamination with
gluten-containing products that are processed or stored in the same place [9]. The term “gluten-free”
thus generally refers to an amount of gluten that is thought to be harmless and does not imply
total absence of gluten. In fact, the amount of gluten deriving solely from cross-contamination in
a supposedly GFD may range from 5 to 50 mg per day [10,11]. The level of gluten content in food
products is expressed as parts per million (ppm, corresponding to mg/kg). Gibert et al., collected
consumption data of gluten-free products by CD patients in order to estimate the average gluten
exposure of celiac patients who follow a GFD. Taking into account different dietary habits in European
countries (Norway, Germany, Italy, Spain) they concluded that a limit of 20 ppm for products naturally
gluten-free and 100 ppm for products rendered gluten-free would be acceptable [12]. According
to the current guidelines of the European Commission a commercially sold product may be called
“gluten-free” if it contains less than 20 ppm gluten (20mg/kg) [13].
Several studies have tried to establish a safe threshold of daily gluten intake, as summarized in
Table 2. A prospective, multicenter, placebo-controlled, double-blind, randomized gluten challenge
trial by Catassi et al., found that the chronic ingestion of small amounts of gliadin leads to
a dose-dependent relapse in symptoms: children diagnosed with CD who had followed a GFD
for at least three months were given small amounts of gluten for a period of four weeks [14]. Patients
who had received 100 mg gliadin/day (= about 200 mg of gluten or the equivalent of 2–5 g wheat flour)
displayed minimal morphometric changes in the jejunal histology. Patients who had ingested 500 mg
gliadin per day showed significantly more histological abnormalities. Additionally, some patients
became positive to antibodies again and experienced a symptom relapse. These results support the
findings of a previous study by Ciclitira et al., who found no changes in mucosal histology after
the infusion of 10 mg gliadin, minimal changes after 100 mg of gliadin and significant changes after
an additional 500 mg of gliadin [15].
A further prospective, double blind, placebo-controlled trial by Catassi et al., analyzed the effects
of daily ingestion of 0, 10, or 50 mg gluten for 90 days [9]. While the villous height to crypt depth ratio
of the placebo group raised by 9%, no difference was found in the 10 mg group and a −20% was found
in the group receiving 50 mg gluten/day. The IEL count did not differ significantly between the three
groups. Catassi et al., concluded that the ingestion of contaminating gluten should be kept lower than
50 mg/day in the treatment of CD [9,16].
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Two systematic reviews aimed to determine the safe maximum gluten intake. Hischenhuber et al.,
suggested that the maximum daily gluten intake should lie between 10 and 100 mg [11]. Akobeng
and Thomas included thirteen studies and similarly found that the amount of tolerable gluten varied
widely between the studies, ranging from patients who tolerated an average of 34–36 mg gluten per
day to others who developed symptoms and/or histological abnormalities when consuming 10 mg
gluten per day [17]. The results of these systematic reviews show that there is no single definitive
threshold for gluten intake but that a daily intake of <10 mg is unlikely to cause mucosal abnormalities
(see also Table 2).
More Than A Strict Gluten-Free Diet
Several research groups have observed that in a considerable portion of patients complying to
a presumed strict GFD, complete mucosal recovery and/or resolution of symptom do not occur [5,19–22].
These results led to questions regarding the efficacy of the GFD in obtaining histological remission.
The first step in patients with signs of non-responsive CD should be the evaluation of the GFD
by a trained dietitian to unveil possible unwitting intake of gluten. However, current methods and
questionnaires still rely on the patients’ subjective assertions and not able to accurately measure dietary
compliance [23]. A relatively new method to monitor GFD compliance is the detection of gluten
immunogenic peptides that can be found in the urine and feces after gluten consumption. This offers
an objective method to assess the dietary adherence and has shown to be very sensitive [24–26].
While most patients tolerate trace gluten under the 20 ppm threshold, a subgroup might react
even more sensitively. It has therefore been suggested that a more-than-strict GFD regimen has the
potential to induce mucosal recovery in these patients [27]. The Gluten Contamination Elimination
Diet (GCED) is a diet that was developed to remove even minute amount of gluten from the diet,
consisting of a more restrictive dietary regimen focusing on the use of naturally gluten-free products
rather than processed gluten-free food [27–29].
Hollon et al., identified 17 patients not responsive to GFD. Before starting the GCED, all subjects
were assessed by a dietitian who excluded hidden gluten ingestion. After completing the GCED for
3–6 months, 82% responded to the GCED and became asymptomatic [28].
Zanini et al., investigated if complete mucosal recovery can be achieved by adopting this restrictive
diet or, alternatively, after a prolonged time of GFD [29]. In this small study, after three months of
GCED, no changes in villous height and crypt depth were observed as compared to two years of
GFD. Only a slight, though significant decrease in IELs and T-cells with a distinctive T-cell receptor
(TCR) on their surface, so called TCRγδ+ cells, was found. The study suggested that the intraepithelial
lymphocytosis persisting in CD patients during GFD cannot completely be eliminated even on a GCED
and is furthermore independent of the duration of adherence to a standard GFD. Whether gluten
contamination is unavoidable despite GCED, or a three-month period of GCED was too short, could
not be clarified by the study, possibly also due to the small sample size [29]. Given the scarce data,
there is insufficient evidence to recommend a gluten contamination elimination diet on a routine
basis in patients with CD. However, it should be considered in patients who are not responsive to
traditional GFD.
4. Does the Gluten-free Diet Prevent the Development of Autoimmune Diseases and of Celiac
Disease Complications?
4.1. Diet and Autoimmune Diseases
Patients with CD are at increased risk for various autoimmune disorders, particularly diabetes
mellitus type I and autoimmune thyroiditis but also autoimmune hepatitis, rheumatoid arthritis and
Sjögren’s syndrome among others [30–32]. The same applies vice versa: Patients with autoimmune
diseases have a significantly higher prevalence of CD than the healthy population—a Norwegian
study found that around 5% patients with type 1 diabetes also have celiac disease [30]. The association
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between CD and other autoimmune conditions is presumably caused by a common genetic background
(the presence of predisposing human leucocyte antigen (HLA) class II haplotypes), but the direct
role of gluten exposure in the development of associated autoimmune conditions is still a matter of
debate [33].
There are a number of contradictory studies concerning the association between the development
of an additional autoimmune disorder and the duration of gluten exposure. Initially, it was
hypothesized that strict adherence to GFD could prevent the development of further autoimmune
diseases in patients with celiac disease. A cross-sectional study by Ventura et al., in 1999 showed an
association between the prevalence of autoimmune disorders in CD patients and the age at diagnosis
of CD, suggesting that duration of exposure to gluten might be a predictor of the development of
other autoimmune conditions [34]. However, more recent studies tend to argue against a connection:
A study by Sategna et al., found no correlation between the duration of exposure to gluten and the
prevalence of autoimmune diseases [35]. Similar results were shown in a Finnish study in 2005 [31] as
well as by a follow-up study by the same group [36].
All in all, current data allow for the assumption that the GFD has no definite role in the prevention
of development of other autoimmune conditions.
4.2. Diet and Celiac Disease Complications
In children, early detection and treatment of celiac disease are of utmost importance to prevent
complications such as poor growth, decreased bone mineral density, and enamel defects which can
be irreversible [37,38]. But even for adults, a diagnostic delay is associated with decreased quality of
life, more days of sickness, and frequent use of medicines and health care services [39]. The GFD is an
effective tool against gastrointestinal and extraintestinal manifestations as well as complications such
as malabsorption and osteoporosis [39–41].
Another complication is refractory CD which is defined as the persistence of clinical signs
of CD, as well as villous atrophy, despite adherence to a strict GFD for at least 12 months [1].
Of the two subtypes of refractory CD, type II is associated with a worse prognosis in view of the
high risk of development of malignancy. The enteropathy-associated T-cell lymphoma (EATL) is
a lymphoproliferative disorder that typically develops in the setting of refractory CD. This is a rare
type of T-cell lymphoma that arises from intraepithelial T-cells in the small intestine. A higher risk
for developing other malignancies, including small bowel adenocarcinoma, has been reported in the
setting of CD, but the underlying pathogenesis is still unclear [42–46].
Given the poor prognosis and limited therapeutic options available for type II refractory CD and
EATL, research focused on both early diagnosis and identification of risk factors. The role of the GFD
for the prevention of EATL development is controversial. From a pathophysiological point of view,
EATL develops from aberrant intestinal lymphocytes that proliferate clonally independently of gluten
exposure—a longer exposure to gluten, and thus a prolonged immune activation in the intestinal
mucosa, may in fact contribute to create a favorable environment to the development and proliferation
of aberrant lymphocytes [47]. However, the natural history of CD and the actual prognostic effect of
the GFD are difficult to investigate and mainly based on retrospective data analysis.
Observational studies investigating the association between undiagnosed CD and mortality risk
showed contradicting results, possibly also due to difficulty of differentiating between undiagnosed
asymptomatic CD from mono-/oligosymptomatic or symptomatic CD based on medical record and
patients reports. Rubio-Tapia et al., reported an up to 4-fold increased mortality rate in undiagnosed
CD during 45 years of follow up, suggesting both a possible role of gluten exposure in the development
of malignancies and the necessity of very long follow-ups in order to investigate this area [42].
Similarly, a German study showed an excess in mortality, particularly due to cancer, in patients with
elevated transglutaminase antibody levels [43]. On the other hand, population-based study like that
by Lohi et al., could not find an excess of mortality in unrecognized CD, though reporting a tendency
to die from lymphoproliferative disorders, stroke and respiratory diseases [48]. In a case-control study
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published in 2011, Olén et al., assessed the characteristics of CD patients with particular attention
to their diet compliance and compared it with the risk of developing malignant lymphoma [49].
They could not find an association between the development of lymphoma and non-compliance to
GFD even though they could not entirely exclude a moderate effect. A study by Biagi et al., suggested
the amount of exposure to gluten to be a relevant risk factor for developing malignancies such as
EATL [50]. This hypothesis was based on an indirect link: the authors observed that reported mortality
rates in CD patients were higher in Southern than in Northern Europe and correlated with the gluten
content of the typical diet of each country. Hence, it was presumed that the amount of dietary gluten
ingested (before and after diagnosis) was responsible for a higher incidence of complications and
higher mortality.
Given the ambiguity that exists, we cannot exclude a causal association between duration
and amount of gluten consumption and the development of refractory celiac disease (RCD) and
malignancies. It therefore remains essential to advise and stress the importance of a strict GFD
to patients with celiac disease. Further research and in particular prospective studies about the
aforementioned linkage are needed in order to clarify the role of gluten exposure in this setting.
5. Gluten-Free Diet in Potential Celiac Disease
Potential CD is characterized by positive endomysium and/or anti-transglutaminase antibodies
and a normal intestinal histology [1]. It is important to emphasize the distinct difference between
potential and asymptomatic celiac disease. While all other forms of celiac disease are characterized by
intestinal mucosal abnormalities, patients with potential celiac disease do, by definition, not display any
histological abnormalities. Individuals with potential CD are often identified as a result of screening or
incidental findings on routine examinations (e.g., screening of first-degree relatives or after diagnosis
of related autoimmune diseases). The question arises whether individuals with potential CD benefit
from a GFD or if the GFD results in a social and economic burden and a risk of malnutrition devoid of
health benefits for this subgroup of patients.
First of all, it must be pointed out that individuals with potential CD may not always be completely
asymptomatic and a GFD could be of benefit even in the absence of histologically evident mucosal
changes [51,52]. Moreover, the adequacy of histology sampling has to be reviewed before classifying
a patient with positive serology as potential CD, since at least four duodenal biopsies (according to
some guidelines even six biopsies) are required to ensure an adequate diagnosis and some subjects
may show histological changes only in the duodenal bulb [2,53,54]. It is a matter of debate if a reference
pathologist should be consulted in contradictory cases. This claim is substantiated by data revealing
a high interobserver variability in histopathology [55–57].
Kurppa et al., studied the effects of a GFD in screening-detected asymptomatic patients with
CD [51]. They included also 40 patients positive to IgA-anti-endomysium antibodies that were at risk
for CD (potential CD), who were randomized to either group A following a GFD or group B continuing
a normal diet for a year. Despite the fact that all subjects prior to the study described themselves as
“asymptomatic”, only group A improved significantly on the Gastrointestinal Symptoms Rating Scale.
However, social functioning was impaired by the GFD. The authors concluded that even apparently
asymptomatic patients with positive antibodies benefit from a GFD.
In another study, Mandile et al., evaluated the effect of GFD on clinical symptoms and mucosal
histology in children with potential CD [58]. After one year on GFD no significant differences
were observed in terms of Marsh grade, lamina propria CD25+ cells, CD3+ and γδ+ intraepithelial
lymphocytes density and intestinal anti-TG2 deposits. However, about half of the patients reported
improved clinical symptoms. A similar result was observed by Volta et al. [52]. Patients with potential
CD that showed symptoms improved clinically by following a GFD.
On the other hand, it is interesting to assess the question how many patients with positive CD
serology and normal histology will eventually develop CD characteristic celiac histology. Biagi et al.,
found only 35% to have developed a flat mucosa in the course of their disease. However, 29% of those
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with a normal histology decided to switch onto a GFD early on in the course, making it impossible
to judge on their further natural course [59]. Interestingly, a reversal of CD serology has also been
observed, especially in children [60]. Auricchio et al., studied 210 children with potential CD of which
175 were left on a gluten-containing diet [61]. Antibodies and clinical symptoms were checked twice
a year and a small bowel biopsy was taken every second year. They found that 37% of the subjects
showed fluctuation and 20% normalization of antibody production over the years, most of them
(67%) without ever displaying mucosal damage during 9 years of follow-up. They concluded that
a GFD might not always be necessary for individuals with potential CD. Volta et al., after collecting
data from 77 adult patients from CD, proposed to prescribe a GFD only to clinically symptomatic
patients with potential CD due to the observed improvement of symptoms after gluten withdrawal [52].
In asymptomatic patients who remained on a gluten-containing diet, progression to overt CD could
merely be observed in 1 of 16 patients during a 5-years follow up. A possible rational approach in
view of available data is shown in Figure 1.
Figure 1. Rational approach to patients with potential CD.
6. Is There A Way Towards Gluten Reintroduction in Celiac Disease?
In recent years, there has been active debate on whether the GFD should be continued lifelong
in all celiac patients. Data on the natural history of CD suggest that an excess of mortality, possibly
derived from lymphoproliferative disorders, may be subsequent to higher/longer exposure to dietary
gluten [7,33,51,62]: On this basis, the GFD should be continued indefinitely not only to prevent clinical
relapse and malabsorption, but also to prevent complications.
Nevertheless, there are a number of studies published during the last 30 years that showed proof
for the existence of a “latent” form of CD, where symptoms and histologic changes disappear in the
course of disease despite consumption of a GFD. As early as 1989, a Finnish study tried to evaluate the
possibility of development of gluten tolerance in children: 38 post pubertal children with CD were
rebiopsied before a gluten challenge was carried out [63]. Eleven percent did not relapse (clinically
and histologically) after 2 years, indicating a possible recovery from CD in this small subgroup.
Matysiak-Budnik et al., in 2007 conducted a retrospective analysis of clinical symptoms, mucosal
recovery and laboratory findings of patients diagnosed with CD in childhood who, despite diagnosis,
251
Nutrients 2018, 10, 1796
did not follow a GFD but resumed a normal diet and remained clinically silent [64]. They found that
about a fifth of CD patients developed long-term latency (normal duodenal histology) after gluten
reintroduction. Patients who remained clinically silent but displayed histological abnormalities were
at increased risk for osteoporosis. The authors therefore concluded that a GFD is advisable in patients
with asymptomatic CD, but that a subgroup of celiac patients may actually become gluten tolerant
over time. However, tolerance could be transient and therefore demands regular follow-up. In fact,
two “gluten-tolerant” patients actually showed clinical and mucosal relapse during the follow up.
Hopman et al., performed a follow-up with 77 patients who had been diagnosed with CD for
over ten years [65]. Gluten consumption, symptoms, bone mineral density and antibodies were
examined. Two thirds adhered to GFD, 15% were partially compliant and 23% followed a regular
gluten-containing diet. Interestingly, biopsies revealed a normal mucosal histology in four of eight
patients on gluten-containing diet and in all patients who were partially compliant. The authors
concluded that development of tolerance to gluten was possible in some patients with CD. They suggest
a regular follow-up to determine if this tolerance is permanent or not.
Although poor adherence to the GFD is the major predictor of persistence of mucosal lesions at
follow-up histology, a recent study by Norsa et al., showed no excess in mortality among celiac patients
with a long history of CD with poor or no adherence to the GFD, also reporting a proportion of patients
of almost 30% with no relapse of villous atrophy despite chronic voluntary gluten ingestion [8].
Who Could Benefit Most from Gluten Reintroduction?
Screening-detected CD patients are a subgroup of patients that experience more difficulty
accepting the diagnosis and permanent dietary restriction since its justification, in the absence of
symptoms, is less evident than in symptomatic patients that experience immediate improvement
in health when adhering to GFD [66]. They report a decreased perception of health on a GFD [6]
and may feel less motivated to adhere to the diet than symptomatic patients [67]. Accordingly,
a recent study published in August 2018 studied the long-term health and treatment outcomes in
screening-detected CD patients [66]. At a median of 18.5 years after diagnosis, 236 patients completed
follow-up questionnaires. With regard to clinical symptoms and quality of life, the screening-detected
subgroup showed more anxiety and lower general well-being than CD patients that had been
diagnosed due to clinical suspicion. In this group of patients, the GFD is recommended in order
to avoid long-term consequences of malabsorption. Moreover, epidemiological data on the excess
mortality of CD complications linked to gluten exposure have been questioned [8,48].
In other words, considering the reported proportion—20–30% of CD patients able to develop
a gluten tolerance over time and the limited risk of developing osteoporosis and complications over
a short time of histological relapse of villous atrophy—it needs to be questioned whether a gluten
reintroduction (or “re-challenge”) under careful follow-up could be a rational therapeutic option in
patients with asymptomatic celiac disease. As follow-up, lifelong assessments including histology
would be needed, in order to detect a possible relapse and worsening of mucosal histology. More
research is needed before this option can be implemented into the clinical routine, however.
7. Conclusions and Future Perspectives
In patients affected by CD, the GFD ensures improvement of clinical symptoms and signs of
malabsorption in the vast majority of cases. Despite extensive research aimed at developing alternative
therapies for CD, the GFD remains the only effective treatment available to date [68]. However, it is not
easy to follow and may result in a psychological and social burden for patients [5,6]. For this reason,
the GFD should be prescribed only once CD diagnosis has been established by means of serology and
duodenal histology.
In potential CD, the diet should be reserved to subjects reporting symptoms, while those
asymptomatic can be maintained on a gluten-containing diet but should be followed up on
a regular basis.
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In patients with symptomatic CD, the diet should be followed strictly in view of the risk for
complications such as osteoporosis and other consequences of malabsorption. Gluten exposure neither
appears to be linked to the onset of other autoimmune disorders nor has an increased risk for
malignancies been shown in asymptomatic CD so far. The current literature available, however,
does not provide enough evidence to safely recommend a gluten-containing regimen in asymptomatic
CD. More research on this topic is needed before introducing a gluten re-challenge for asymptomatic
CD patients into the clinical routine.
The natural history of CD on a gluten-containing diet is still far from understood: It is unclear
whether the large group of patients with mild or asymptomatic CD is indeed at risk of developing
long-term-complications such as EATL. Further studies aimed at investigating the effects of gluten
reintroduction in CD are required to identify the subgroup of patients that may develop gluten
tolerance over time, without increasing the risk for CD related complications.
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Abstract: The primary and proven therapy, in cases of celiac disease (CD), is a rigorous gluten-free
diet (GFD). However, there are reports of its negative effects in the form of nutritional deficiencies,
obesity, and adverse changes in body composition. The study aimed to assess the impact of a GFD
on the body composition of children with CD. In a case-controlled study (n = 41; mean age 10.81 y;
SD = 3.96) children with CD, in various stages of treatment, underwent medical assessment. The
control group consisted of healthy children and adolescents, strictly matched for gender and age
in a 1:1 case-control manner. More than half of the examined children (n = 26) followed a GFD. CD
children had significantly higher mean values of the fat free mass (FFM% = 80.68 vs. 76.66, p = 0.015),
and total body water (TBW% = 65.22 vs. 60.47, p = 0.012), and lower mean values of the fat mass
(FM% = 19.32 vs. 23.34, p = 0.015). Children who were on a GFD presented slightly higher, but
not statistically significant, mean values of FM and FFM, than children who did not follow dietary
recommendations (FM [kg] = 7.48 vs. 5.24, p = 0.064; FM% = 20.81 vs. 16.73, p = 0.087; FFM [kg] =
28.19 vs. 22.62, p = 0.110). After minimum one year of a GFD, CD children showed significantly higher
values of FFM [kg] (p = 0.001), muscle mass (MM) [kg] (p < 0.001), TBW [L] (p < 0.001) and body cell
mass (BCM) [kg] (p < 0.001). Furthermore, CD children who were on a GFD presented a significantly
higher increase in weight (p = 0.034) and body mass index (BMI) (p = 0.021). The children adhering to
a GFD demonstrate a tendency towards higher indices of selected body composition components.
Keywords: celiac disease; body composition; gluten free diet; children
1. Introduction
Celiac disease (CD) is a diet-dependent disease and one of the most common food intolerances
in Europe posing significant health-related problems [1]. The disease may manifest itself at any age,
yet it is frequently diagnosed in children up to 5 years of age, three in four cases being identified in
female subjects. It is estimated that for each case diagnosed, there are 5 undetected cases [2], which
is partly linked to the high prevalence of subclinical CD [3]. The expected global prevalence of CD
is in the range from 0.2% to 5.6% [4]. In Europe, the relevant rate generally varies from 0.5% to 1%
(in some countries reaching the level of 3%), and in Poland CD affects approximately 0.8% of the whole
population. In the age group of 2.5–15 years, the condition affects 1 in 80 to 1 in 300 children [5,6].
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CD is a life-long autoimmune enteropathy due to gluten sensitivity [7]. In CD patients the
ingestion of gluten leads to an enteropathy with an impairment of the mucosal surface and abnormal
absorption of nutrients [8]. In the case of patients with diagnosed CD, basic therapy involves the
life-long adherence to a gluten free diet (GFD). The diet is designed to eliminate any type of food,
drink or even medication containing wheat, rye or barley [9,10]. Early diagnosis and treatment
make it possible to prevent numerous complications and to effectively eliminate physical and mental
development impairments in children with this condition. Compliance with dietary recommendations
closely correlates with symptom relief, improved condition of the mucous membrane, and consequently
the patient’s improved nutritional status. Some studies confirm the effectiveness of a GFD in patients
with celiac disease [9,11], yet other researchers argue that the use of this diet alone may contribute to
nutritional deficiencies or to excessive body mass [12–14]. Therefore, systematic monitoring of both the
nutritional status and body composition appears to be an important part of the therapy in CD [15,16].
The monitoring of dietary compliance is associated with a high chance of healing intestinal lesions and
correction of specific body compositional abnormalities, expressed by normalizing fat mass, muscle
mass, and bone mass. [16–18]. The changes in lean body mass take longer and, probably, are related
more to improvement in the inflammatory state than to changes in absorption of food intake [16].
In practice, body composition assessment can be based on measurements of skin fold thickness,
and methods of bioelectrical impedance (BIA) and dual-energy X-ray absorptiometry (DXA) [19–21].
Currently, there are no studies assessing body composition in children with CD. The scarcity of
documentation describing body composition in patients with CD, representing varied age groups (at
the time of the diagnosis, and during the nutritional therapy), provides for ambiguous evidence and
leads to a difficulty in the ability to make comparisons [22,23]. The lack of unanimity of opinion in
this regard suggests a need for further research and analyses, in particular, related to children and
adolescents. Given the above, the present study was designed to assess the effects of a GFD in the
body composition in children with CD.
2. Materials and Methods
2.1. Ethics
The study was approved by the institutional Bioethics Committee at the University of Rzeszów
(Resolution No. 5/02/2012) and by all appropriate administrative bodies. The study was conducted in
accordance with ethical standards laid down in an appropriate version of the Declaration of Helsinki
and in Polish national regulations. The study was conducted according to the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) criteria.
2.2. Subjects
The study involved 41 children and adolescents (20 girls, 48.7%) with celiac disease receiving
inpatient treatment at the Clinical Department of Pediatrics with the Pediatric Neurology Unit, at the
Clinical Regional Hospital No. 2 in Rzeszów. The study group consisted of patients with newly
diagnosed CD and subjects at different stages of treatment.
The inclusion criteria were as follows: diagnosed celiac disease, age 4 to 18 years, no other
autoimmune or chronic diseases affecting height, weight or nutritional status, as well as written
informed consent, signed by parents or legal guardians, and by the adolescents over 16 years of age.
The control group consisted of the same number of children and adolescents attending primary,
middle, and secondary schools in urban and rural areas. Inclusion criteria were the same as for the
study group with the exception for CD diagnosis. The healthy participants and those with CD were
strictly matched for age (the nearest birth date) and gender in a 1:1 case-control manner. Figure 1
presents the recruitment process for the study group and the controls, while Table 1 shows the
characteristics of the groups.
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Detailed information concerning the children with CD, namely the diagnosis, the course
and treatment of the disease, and comorbidities, was retrieved from their medical records. In
addition, laboratory tests (level of IgA class anti-tissue transglutaminase antibodies TTG, level of IgA
anti-endomysium antibodies EmA, and level of IgA class anti-deamidated gliadin-analog antibodies,
GAF-3X) and endoscopy were performed to ensure CD diagnosis and to assess the intestinal mucosa
status at the time of the diagnosis according to the Marsh scale, modified by Oberhuber [24]. These
assessments were supplemented by a medical history of eating habits, based on a questionnaire about
the frequency of usual intake of basic product groups during the week.
Figure 1. Flow chart demonstrating study participants selection.
Table 1. Anthropometric parameters of the study and control groups. Significant differences in bold.
Parameter
Celiac Disease (N = 41) Control (N = 41)
p Value
Mean SD Mean SD
Age, years 10.81 3.96 10.63 4.01 0.989
Gender, n
1.000Male 21 n/a 21 n/a
Female 20 n/a 20 n/a
Weight, kg 33.59 13.79 39.70 15.25 0.046 *
Height, cm 137.62 21.68 144.20 19.63 0.167
BMI, kg/m2 16.94 2.65 18.29 3.49 0.089
* indicate significant values (p < 0.05); BMI-body mass index; SD-standard deviation; n/a—not applicable.
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2.3. Assessments
All the adolescents were assessed for height and weight, and their body mass index (BMI) was
calculated. Subsequently, BIA was performed with AKERN BIA-101 analyser (Akern SRL, Pontassieve,
Florence, Italy) to examine their body composition and nutritional status. The measurements were
performed between 7:00 a.m. and noon, on an empty stomach, in the supine position, with abducted
upper (30◦) and lower (45◦) limbs, following at least a 5-min rest.
A tetrapolar electrode arrangement was applied with the contralateral recording mode. The
amplitude of the measured current was 800 μA, sinusoidal, 50 kHz. To ensure the results were reliable
and reproducible, two measurements were performed, one after another. Disposable electrodes were
placed on the dorsal surface of the right arm (above the wrist) and the right leg (on the ankle). All
measurements were performed according to guidelines described by other authors [25–27]. Dedicated
software (Bodygram1_31 from AKERN, Pontassieve, Florence, Italy) was used to perform analyses
of the results. The BIA took into account: fat mass (FM), fat free mass (FFM), muscle mass (MM) (kg
and %), total body water (TBW), intra- and extra-cellular water (ICW and ECW) (litres and %), body
cell mass (BCM) (kg and %) and body cell mass index (BCMI). Additionally, phase angle (PA) was
calculated, based on resistance and reactance.
2.4. Statistical Analysis
Statistical analysis was performed using the Statistical Software for the Social Sciences SPSS
Statistics 20 (IBM Software Group, San Francisco, CA, USA). For this purpose, parametric and
non-parametric tests of significance were applied. Normality of the distributions of the quantitative
variables was verified with the Kolmogorov–Smirnov test. Homogeneity of variances was then
examined with the Levene’s test, and equivalence of variables distributions was verified using the χ2
test. If the conditions for application of parametric tests were fulfilled, it was possible to use the t-test
for independent samples, one-way analysis of variance (ANOVA) or Pearson’s correlation. A p-value
below 0.05 was considered statistically significant.
3. Results
Body composition parameters were significantly different between the CD and control groups.
CD children had significantly higher mean values of the fat-free mass and total body water, and lower
mean values of the fat mass (Table 2).
Table 2. Results of BIA in the study and control groups.
Parameter
Celiac Disease (N = 41) Control (N = 41)
p Value
Mean SD Mean SD
FM, kg 6.66 4.19 9.47 5.15 0.007 *
FFM, kg 26.15 10.72 30.24 11.57 0.098
MM, kg 17.17 7.45 19.55 8.10 0.168
TBW, L 22.71 10.96 23.73 8.72 0.312
ECW, L 9.33 3.47 10.28 3.73 0.246
ICW, L 12.35 4.86 13.55 5.16 0.170
BCM, kg 13.89 6.11 15.85 6.64 0.164
FM% 19.32 7.36 23.34 7.36 0.015 *
FFM% 80.68 7.36 76.66 7.36 0.015 *
MM% 50.72 5.98 48.94 5.62 0.168
TBW% 65.22 8.94 60.47 7.66 0.012 *
ECW% 43.86 5.18 43.82 3.59 0.981
ICW% 56.14 5.18 56.18 3.59 0.981
BCM% 50.66 3.96 51.62 3.73 0.373
BCMI 6.91 1.28 7.22 1.50 0.322
PA 5.45 0.67 5.63 0.69 0.241
SD—standard deviation; FM—fat mass; FFM–fat free mass; MM—muscle mass; TBW–total body water;
ECW—extracellular water; ICW—intracellular water; BCM—body cell mass; BCMI—body cell mass index;
PA—phase angle; * Bold characters indicate significant values (p < 0.05).
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Among children with CD participants who were non-compliant to GFD presented apparently
lower mean values of FM (kg) and also FM% and FFM%, than children who did follow dietary
recommendations, but the difference did not reach the level of statistical significance (Table 3).
Table 3. Anthropometric parameters and bioelectrical impedance (BIA) results among patients
following and non-compliant to gluten free diet.
Parameter
Compliant to GFD (N = 26) Non-Compliant to GFD (N = 15) p Value
Mean SD Mean SD
Age, years 11.00 4.10 10.47 3.82 0.683
Gender, n
0.239Male 11 n/a 10 n/a




74.23 58.10 26.07 40.93 0.002 *
Marsh scale
0.584
IIIA 4 n/a 3 n/a
IIIB 9 n/a 7 n/a
IIIC 13 n/a 5 n/a
Weight, kg 35.67 14.07 29.99 12.96 0.208
Height, cm 141.02 21.73 131.73 21.00 0.190
BMI 17.22 2.55 16.45 2.84 0.272
FM 7.48 4.24 5.24 3.82 0.064
FFM 28.19 11.01 22.62 9.53 0.110
MM 17.95 7.63 15.83 7.17 0.388
TBW 22.49 8.00 23.08 15.12 0.675
ECW 9.65 3.56 8.76 3.35 0.434
ICW 12.91 4.67 11.37 5.18 0.457
BCM 14.52 6.26 12.79 5.89 0.390
FM% 20.81 6.60 16.73 8.10 0.087
FFM% 79.19 6.60 83.27 8.10 0.087
MM% 49.88 5.60 52.17 6.52 0.241
TBW% 63.89 8.69 67.52 9.19 0.214
ECW% 43.27 4.15 44.88 6.64 0.345
ICW% 56.73 4.15 55.12 6.64 0.345
BCM% 50.80 3.18 50.41 5.17 0.745
BCMI 6.91 1.16 6.90 1.50 0.978
PA 5.47 0.58 5.43 0.83 0.862
GFD—gluten-free diet; SD—standard deviation; FM—fat mass; FFM—fat free mass; MM—muscle mass; TBW—total
body water; ECW—extracellular water; ICW—intracellular water; BCM—body cell mass; BCMI—body cell mass
index; PA—phase angle; * Bold characters indicate significant values (p < 0.05); n/a—not applicable.
In a subset of 22 children and adolescents with CD, we performed a follow-up examination after a
mean of 17.2 months. In this analysis children with CD demonstrated, as could be expected, significant
weight, height and (borderline) BMI gain higher values of fat free mass, muscle mass, total body water
(extracellular and intracellular), body cell mass and body cell mass index, while fat mass in kg did not
increase significantly. None of these parameters expressed as a percentage of body composition has
changed significantly during follow-up (Table 4).
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Table 4. Anthropometric parameters and BIA results among 22 patients (14 boys) followed for mean
17.2 months.
Parameter
Baseline (N = 22) Follow-Up (N = 22)
p Value
Mean SD Mean SD
Age, years 10.05 4.08 11.41 4.08 <0.001 *
Disease duration, months 63.68 67.61 80.86 68.14 <0.001 *
Weight, kg 32.40 15.68 36.01 14.08 <0.001 *
Height, cm 134.50 24.62 142.14 23.14 <0.001 *
BMI, kg/m2 16.81 2.76 17.07 2.09 0.046 *
FM, kg 7.20 4.62 7.42 3.75 0.101
FFM, kg 25.20 12.17 28.59 11.91 0.001 *
MM, kg 16.05 8.45 18.33 8.24 <0.001 *
TBW, L 20.16 9.25 22.81 9.02 <0.001 *
ECW, L 8.63 3.89 9.83 3.95 0.003 *
ICW, L 11.63 5.61 12.98 5.28 <0.001 *
BCM, kg 12.99 6.93 14.85 6.74 <0.001 *
FM% 22.05 6.50 21.17 6.94 0.972
FFM% 77.95 6.50 78.83 6.94 0.972
MM% 48.78 5.76 49.96 5.76 0.167
TBW% 62.66 8.50 63.39 9.00 0.455
ECW% 43.79 5.03 43.56 4.40 0.788
ICW% 56.21 5.03 56.44 4.40 0.788
BCM% 50.40 3.58 51.13 3.19 0.102
BCMI 6.60 1.26 6.88 1.12 0.005 *
PA 5.40 0.64 5.54 0.61 0.121
SD—standard deviation; FM—fat mass; FFM—fat free mass; MM—muscle mass; TBW—total body water;
ECW—extracellular water; ICW—intracellular water; BCM—body cell mass; BCMI—body cell mass index;
PA—phase angle; * Bold characters indicate significant values (p < 0.05).
Children and adolescents with CD who were non-compliant to GFD presented lower weight
increase, and fall in BMI which was significantly different compared to group compliant to GFD.
In addition, fat mass decreased, but the difference with participants who followed GFD did not achieve
the level of statistical significance (Table 5).
Table 5. Differences in anthropometric parameters and body composition between 17 patients
compliant and 5 patients non-compliant to gluten-free diet during follow-up.
Parameter
Compliant to GFD (N = 17) Non-Compliant to GFD (N = 5)
p Value
Mean SD Mean SD
Weight increase, kg 4.16 6.65 1.74 0.40 0.034 *
Height increase, cm 8.12 5.47 6.00 3.37 0.426
BMI increase, kg/m2 0.47 2.13 -0.44 0.78 0.021 *
FM increase, kg 0.47 3.66 -0.64 2.06 0.078
FFM increase, kg 3.69 4.90 2.38 2.39 0.308
MM increase, kg 2.51 3.26 1.48 1.86 0.182
TBW increase, L 2.45 3.21 3.34 3.47 0.597
ECW increase, L 1.37 2.04 0.64 0.60 0.209
ICW increase, L 0.96 1.45 2.70 2.92 0.610
BCM increase, kg 2.05 2.64 1.22 1.57 0.240
BCMI increase 0.31 0.72 0.20 0.53 0.289
PA increase 0.14 0.41 0.12 0.40 0.919
GFD—gluten-free diet; SD—standard deviation; FM—fat mass; FFM—fat free mass; MM—muscle mass; TBW—total
body water; ECW—extracellular water; ICW—intracellular water; BCM—body cell mass; BCMI—body cell mass
index; PA—phase angle; * Bold characters indicate significant values (p < 0.05).
4. Discussion
In the present case-controlled study, we observed that selected body composition parameters
(fat mass, fat free mass, muscle mass, total, intracellular and extracellular body water, and body cell
mass) and nutritional indicators (body mass index and body cell mass index) in children with CD are
significantly different than in healthy controls. Reports related to changes in body composition, in
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adults and in children, both at the stage of diagnosis and during treatment, are limited and ambiguous.
They depend on a number of variables, such as the age at the time of diagnosis, the disease progression,
duration of impairments associated with malabsorption syndrome, methods of body composition
assessment, as well as the degree of compliance to dietary guidelines.
The results of the present study showed that children with CD had significantly lower mean
values of the FM expressed both in kg and as percentage of body mass (p = 0.007 and p = 0.015,
respectively), and higher mean percentage values of the FFM (p = 0.015), and TBW (p = 0.012). Our
results provide evidence that children with CD have lower energy reserves reflected as a lower total
body fat mass, which may result in reduced immunity, a potential higher risk of malnutrition and
faster dynamics of body components changes due to existing malnutrition. Furthermore, our results
show, that children who were at baseline compliant to GFD presented apparently higher, but not
statistically significant, mean values of FM and FFM (both in kg and in %), than children who did
not follow dietary recommendations. The described differences in body composition components
were close to the level of statistical significance despite the relatively low number of children in each
group. After mean 17.2 months of follow-up, children with CD, as could be expected, demonstrated a
significant increase of FFM, MM, TBW, BCM, and BCMI expressed in kg or L. However, the percentage
of body mass components did not change significantly. Within this group children who did not
follow strictly GFD presented lower weight gain and even decrease in BMI which was significantly
different compared to the children compliant to GFD (p = 0.034 and p = 0.021, respectively). In addition,
changes in fat mass tended to be different between compliant and non-compliant groups, which did
not achieve statistical significance due to a very small number of children in each group. This indicates
lower energy reserves and increased the potential risk of malnutrition in case of exacerbation of the
disease in children not following GFD. Some studies report no significant changes in the specific
components of body composition after a GFD is introduced [28], or, in fact, describe a decrease in
fat-free components coinciding with stable fat mass one year after gluten withdrawal [19]. Other
studies, including long-term research, provide evidence that after a GFD is introduced, the majority of
the components of body composition are stable [17,18], sometimes with a slightly higher increase in
FM than in FFM [29].
Our findings support suggestions made by other authors who agree that the earlier the diet is
introduced, the faster it is possible to reverse abnormalities in body composition [18]. Important and
constructive opinions regarding the necessity of the strict adherence to a GFD are voiced by studies
which show that children, who fail to follow the recommendations, are found to have a significantly
lower bone mineral density, which leads to a risk of osteoporosis in adulthood [30,31].
Another important, yet controversial issue, is the effect of a GFD in anthropometric parameters, in
particular, the value of weight and BMI. Dyspepsia and malabsorption associated with progressing CD
lead to malnutrition in quantitative and qualitative terms [32,33], which results, e.g., in both delayed
growth and puberty [34]. Due to this, until recently, these patients were identified exclusively with
low BMI. Currently, we know that over time CD may be accompanied by normal as well as excessive
body mass, or even by obesity [35–37], because a GFD may contain both a high energy and high
fat load [32]. The effects of a GFD, related to BMI vary greatly. Numerous studies show that the
strict GFD results in normalization of BMI in initially underweight children and adults [28,35,38,39],
and leads to significantly improved and faster growth and development in children, if the disease is
diagnosed and treated early [40]. Conversely, in individuals with excessive body mass, at the time
of CD diagnosis, BMI tends to decrease after the diet is introduced [39]. One should keep in mind
that CD is a very heterogeneous disease, and the occurrence of the diagnosis among obese patients is
no more surprising [37]. Our findings could be highly influenced by the duration of the disease and
adherence to the GFD.
Based on current research it should be emphasized that adherence to a GFD is of critical
importance in the treatment of CD and the further prevention of related complications. However,
in order to achieve satisfying results, it is necessary to ensure the consistent monitoring of dietary
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restrictions, in combination with a systematic assessment of the patient’s nutritional status and body
composition. Despite this, most patients with CD respond to a GFD, approximately 20% of them
have persistent or recurrent symptoms. Following a GFD can be difficult for patients with CD and
understanding the barriers/challenges experienced by patients in maintaining a GFD is essential for
compliance [41]. There is also evidence suggesting that adherence to GFD is not enough, particularly in
adolescent patients [42,43]. Our studies present 36.5% (15/41) non-compliant patients and our findings
are similar to UK cross-sectional study in a group of patients with CD recruited from two London
children’s hospitals. The high number of noncompliant participants 35.3% (36/102) indicates that
maintaining GFD is difficult for practical and social reasons [44]. There are many studies evaluating
not only the number of patients who do not follow the GFD but also analyzing the reasons for this
noncompliance and their consequences for the quality of life [45]. Furthermore, a poorly balanced GFD
may lead to deficiencies and, consequently, nutritional imbalance, which is particularly important in
the case of children as it adversely affects growth, development, and physical activity. By monitoring
the diet and by applying the simple methods to assess anthropometric parameters and indices,
as well as body composition, it is possible to quickly identify and adequately correct any effects
of nutritional errors, such as selective deficiencies of nutrients, as well as obesity, and to prevent
health-related consequences.
Our study is obviously not free from several limitations. Despite our best efforts and inclusion in
our study of as many participants as was possible, the relatively low number of study participants
is the most important limitation. It did not allow us to find other significant differences between
study and control groups as well as between participants with CD following and not-following GFD.
Because assessment of important markers of nutritional status (albumin and/or pre-albumin level)
was not done in all the children, we were not able to analyze the association of these variables with
body composition components. Searching for such relationships would be an intriguing implication
for further research. We also did not perform serology markers assessment at the follow-up visit. It
would be interesting to analyze its relationship with compliance to GFD.
Given the controversies related to changes in anthropometric indices and body composition
observed in individuals following a GFD, this problem unquestionably requires further study. It
would be of extreme importance to conduct a long-term assessment of the effects produced by a
GFD on body composition, beginning from childhood, when patients receive CD diagnosis until
they reach adulthood. It would then be easier to eliminate small fluctuations in the components
of body composition associated with age and the level of gluten cross-contamination in foods, and
consequently to obtain reliable results.
5. Conclusions
The children with celiac disease differ significantly in body composition compared to healthy
comparators. Participants adhering to a gluten-free diet presented a trend towards higher indices
of selected body composition components. To assess the predictive and prognostic value of these
findings, further prospective, longer-lasting studies, including a higher number of participants are
required in this population.
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21. Więch, P.; Dąbrowski, M.; Bazaliński, D.; Sałacińska, I.; Korczowski, B.; Binkowska-Bury, M. Bioelectrical
impedance phase angle as an indicator of malnutrition in hospitalized children with diagnosed inflammatory
bowel diseases—A case control study. Nutrients 2018, 10, 499. [CrossRef] [PubMed]
22. Bardella, M.T.; Molteni, N.; Prampolini, L.; Giunta, A.M.; Baldassarri, A.R.; Morganti, D.; Bianchi, P.A. Need
for follow up in coeliac disease. Arch. Dis. Child. 1994, 70, 211–213. [CrossRef] [PubMed]
23. Troncone, R.; Mayer, M.; Spagnuolo, F.; Maiuri, L.; Greco, L. Endomysial antibodies as unreliable markers
for slight dietary transgressions in adolescents with celiac disease. J. Pediatr. Gastroenterol. Nutr. 1995, 21,
69–72. [CrossRef] [PubMed]
24. Oberhuber, G.; Granditsch, G.; Vogelsang, H. The histopathology of coeliac disease: Time for a standardized
report scheme for pathologists. Eur. J. Gastroenterol. Hepatol. 1999, 11, 1185–1194. [CrossRef] [PubMed]
25. Yanovski, S.Z.; Hubbard, V.S.; Heymsfield, S.B.; Lukaski, H.C. Bioelectrical impedance analysis in body
composition measurement: National institutes of health technology assessment conference statement. Am. J.
Clin. Nutr. 1996, 64, 524S–532S.
26. Kyle, U.G.; Bosaeus, I.; de Lorenzo, A.D.; Deurenberg, P.; Elia, M.; Manuel Gómez, J.; Heitmann, B.L.;
Kent-Smith, L.; Melchior, J.C.; Pirlich, M.; et al. Bioelectrical impedance analysis—Part II: Utilization in
clinical practice. Clin. Nutr. 2004, 23, 1430–1453. [CrossRef] [PubMed]
27. Kushner, R.F. Bioelectrical impedance analysis: A review of principles and applications. J. Am. Coll. Nutr.
1992, 11, 199–209. [PubMed]
28. Barone, M.; Della, V.N.; Rosania, R.; Facciorusso, A.; Trotta, A.; Cantatore, F.P.; Falco, S.; Pignatiello, S.;
Viggiani, M.T.; Amoruso, A.; et al. A comparison of the nutritional status between adult celiac patients on
a long-term, strictly gluten-free diet and healthy subjects. Eur. J. Clin. Nutr. 2016, 70, 23–27. [CrossRef]
[PubMed]
29. Capristo, E.; Addolorato, G.; Mingrone, G.; De Gaetano, A.; Greco, A.V.; Tataranni, P.A.; Gasbarrini, G.
Changes in body composition, substrate oxidation, and resting metabolic rate in adult celiac disease patients
after a 1-y gluten-free diet treatment. Am. J. Clin. Nutr. 2000, 72, 76–81. [CrossRef] [PubMed]
30. Blazina, S.; Bratanic, N.; Campa, A.S.; Blagus, R.; Orel, R. Bone mineral density and importance of strict
gluten-free diet in children and adolescents with celiac disease. Bone 2010, 47, 598–603. [CrossRef] [PubMed]
31. Abenavoli, L.; Delibasic, M.; Peta, V.; Turkulov, V.; De Lorenzo, A.; Medić-Stojanoska, M. Nutritional profile
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Abstract: Screening strategies to detect celiac disease (CD) in at-risk subjects are of paramount
importance to prevent the possible long-term complications of this condition. It is therefore of
strategic relevance to understand whether patients diagnosed through screening follow a strict
gluten-free diet (GFD), as the non-compliance to this diet can make screening efforts pointless.
Currently, no studies have verified whether CD patients diagnosed in their adulthood are adhering
to the GFD years after the diagnosis. We retrospectively evaluated the medical records of 750 CD
patients diagnosed in our center during January 2004–December 2013 to verify differences between
screening detected and clinically diagnosed patients. The groups shared a similar adherence to
the GFD (91.2 versus 89.8%, p = 0.857). Moreover, the rates of non-responsive CD, GFD-induced
metabolic alterations, and persistence in controls were also similar. Instead, screening-detected
patients had a significantly lower rate of osteopenia/osteoporosis at diagnosis (31.3 versus 46%,
p < 0.001). In conclusion, screening strategies for CD in at-risk groups should be encouraged even
in the adult population. Patients diagnosed through these strategies had no additional problems
compared to those diagnosed for clinical suspicion and might benefit from a protective effect against
metabolic bone disease.
Keywords: celiac disease; gluten; gluten-free diet; screening; outcome; gluten sensitivity; osteoporosis
1. Introduction
Celiac disease (CD) is a chronic small intestinal immune-mediated enteropathy precipitated by
exposure to dietary gluten in genetically predisposed people [1]. The prevalence of CD is about
1% of the general population [1]. However, a significant underdiagnosis issue exists, and most CD
patients are still to be detected [2]. The identification of CD patients relies both on a case-finding
strategy in subjects with gluten-related manifestations and on a screening strategy in subjects at high
risk of disease. These high-risk populations include first-degree relatives of CD patients, patients
with immune deficiencies (Immunoglobulin A deficiency, common variable immunodeficiency),
autoimmune diseases (in particular, type 1 diabetes mellitus), congenital chromosomal abnormalities
(Down and Turner syndromes) [3–5]. Unlike CD patients diagnosed on the basis of the presence
of gluten-related symptoms, patients diagnosed through screening often have milder symptoms
or no symptoms at all. The gluten-free diet (GFD) has consequently a more limited impact on
Nutrients 2018, 10, 1940; doi:10.3390/nu10121940 www.mdpi.com/journal/nutrients269
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their symptoms, exposing these patients to a higher theoretical risk of incorrect GFD compliance
(and therefore to an increased risk of complications). Therefore, it is of capital importance to verify
whether screening-diagnosed patients follow the GFD, as the lack of compliance negates any benefit of
an early diagnosis. Unfortunately, until now adherence to the GFD in screening-diagnosed adults has
been verified only in two studies performed in Northern Europe cohorts [6,7]. The colleagues found
that the adherence of screening-detected subjects was similar to that of patients diagnosed on the basis
of clinical suspicion. Other hints came from a recent survey in which 236 patients completed health,
quality of life, and dietary adherence questionnaires a median of 18.5 years after childhood diagnosis.
Even in this case, the authors reported comparable long-term outcomes between screening-diagnosed
and clinically detected patients [8]. However, until now, no study has combined the strengths of a large
cohort [7] with an extended follow-up [6], leaving this topic open. Lessons from previous studies in
children, in fact, taught us that the compliance may drop after an extended follow-up [9,10], especially
in screening-diagnosed subjects [10] and that patients from different geographical regions may have a
very different adherence to the GFD [11]. At the same time, not all of the information can be translated
from the pediatric experience, as adults may have different peculiarities. For instance, the impact
deriving from a significant dietary change after decades of a gluten-containing diet and the increased
risk of complicated CD (which is virtually absent in childhood) [12] are to be considered. Moreover, it
is in adulthood that CD-related osteoporosis and GFD-induced metabolic alterations may reach their
full clinical expression [13].
The objective of our study was to verify whether CD patients diagnosed in adulthood through
screening procedures had different characteristics compared to CD patients diagnosed on the basis of
the presence of symptoms. In particular, we intended to analyze clinical data at baseline, adherence,
and responsiveness to the GFD and metabolic problems induced by the GFD. According to our
national guidelines and government policies, every CD patient has to be evaluated six months after
the beginning of the GFD and every 18–24 months after that [14]. Consequently, patients followed for
a long period can be considered as adhering to the follow-up procedures rather than attention-seeking
subjects, thus avoiding (or at least reducing) possible biases. For this reason, we also compared the
persistence in the follow-up procedures between groups.
2. Materials and Methods
2.1. Clinical Setting
We retrospectively analyzed the medical records of patients who were consecutively diagnosed
with CD in our outpatient clinic (Bologna Authority Hospital S.Orsola-Malpighi, Bologna, Italy)
between January 2004 and December 2013. The final cut-off of December 2013 was chosen to grant a
theoretical minimum five-year follow-up even for the most recently diagnosed patients.
2.2. Inclusion and Exclusion Criteria
A diagnosis of CD performed according to the North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition [4] was regarded as the key inclusion criterion. Patients
with incomplete medical records or unconfirmed diagnosis were excluded from this study. (Figure 1).
All the remaining patients were considered eligible for the following comparative analysis:
Clinical presentation (symptomatic versus asymptomatic), severity of histology lesions according to
the Marsh–Oberhuber classification (3a versus 3b versus 3c), prevalence of iron-deficiency anaemia,
prevalence of osteopenia.
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Figure 1. Patients’ flow chart. CD: celiac disease
Instead, only patients who performed at least two evaluations (one of which at least six months
after the beginning of the GFD) were considered to be eligible for the additional comparative analyses.
These further comparisons included: Compliance to the GFD, prevalence of non-responder CD defined
according to the Oslo classification [1], and prevalence of metabolic alterations (body weight increase
>10 kg, total cholesterol increase >50 mg/dL, development of overt metabolic syndrome).
2.3. Clinical Evaluations
Clinical evaluations were scheduled according to the local guidelines (six months after the
beginning of the GFD and every 18–24 months after that [14]). Each evaluation consisted of: (1) medical
history; (2) physical examination; (3) evaluation of laboratory tests.
Medical history was examined with particular attention to reported intentional or accidental
gluten ingestion, modifications of gluten-related symptoms (diarrhea, abdominal pain, bloating,
dyspepsia, constipation, skin rash, myalgia, oral aftosis, etc.), onset of any new symptom, and list of
current medications [14].
Physical examination included the evaluation of vital signs and body weight. Abdomen, thorax,
heart, and neck examinations were also performed [14].
Laboratory tests included: Complete blood count, ferritin, calcium, glycaemia, total cholesterol,
alanine and aspartate aminotransferase, thyroid-stimulating hormone, anti-thyroperoxidase and
anti-thyroglobulin antibodies, anti-tissue transglutaminase immunoglobulin A, and anti-deamidated
gliadin peptides immunoglobulin G antibodies. Additional tests were performed at diagnosis
(other anti-organ- and non-organ-specific antibodies) or on a clinical basis (second-level metabolic and
osteometabolic tests) [14].
Dual-energy X-ray absorptiometry (DXA) was performed at the diagnosis of CD.
2.4. Evaluation of Adherence to the GFD
The patients were considered to have complied to the GFD if all the following criteria were
satisfied: (1) No reported intentional or accidental gluten ingestion; (2) absence of CD-related
symptoms; (3) negative anti-transglutaminase IgA antibodies [4].
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2.5. Ethics
This study was approved by the Institutional Review Board of the Bologna Authority Hospital
S.Orsola-Malpighi (Protocol 243/2013/O/OssN) and performed according to the Declaration of
Helsinki guidelines. All patients signed an informed consent.
2.6. Sample Size Considerations
The main aim of our study was to compare the rate of patients strictly following the GFD during
the follow-up. On the basis of the previous reviews on the adult population [6,7], we estimated a
global adherence to the GFD of 90%. To detect a decrease of 10% in one of the two study groups with
an alpha error of 0.05 and a power of 90%, we estimated to enroll a minimum of 640 patients.
2.7. Statistical Analysis
Distribution of continuous variables was assessed with a Shapiro–Wilk test, which showed
non-normal distributions. Consequently, continuous variables were expressed as median and
interquartile range. Categorical variables were expressed as frequencies. Group comparisons were
subsequently performed using the Mann–Whitney test for continuous variables and the two-tailed
Fisher’s test for categorical variables. Binary logistic regression was performed to assess the relationship
between correct compliance with the GFD (dependent variable) and other clinical variables. Log-rank
test and Cox proportional hazard models were used to evaluate the relationship between the persistence
to the follow-up procedure and other clinical variables of interest. Variables for which the association
in the univariate analysis was p < 0.10 were entered into the multivariate models. A p < 0.05 was
considered to be the cut-off for statistical significance. All of the statistical analyses were performed
with SPSS version 23.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Study Population
A total of 750 CD patients were identified using the specified inclusion and exclusion criteria.
Of these patients, 115 (15.3%) had been identified through screening procedures, and 635 (84.7%)
because of clinical suspicion. The clinical motivations leading to the screening procedures are reported
in Table 1.
Table 1. Conditions which justified the screening for celiac disease in at-risk groups.
Familiar Screening (Total) 78 (67.8)
Index case: brother/sister 26 (22.6)
Index case: father/mother 18 (15.7)
Index case: son/daughter 18 (15.7)
Index case: nephew/grandchild 11 (9.6)
Index case: cousin 5 (4.3)
At-Risk Associated Conditions (Total) 37 (32.2)
Autoimmune thyroid disease 10 (8.7)
Type-1 diabetes mellitus 6 (5.2)
Primary biliary cholangitis 3 (2.6)
IgA deficiency 3 (2.6)
Down syndrome 3 (2.6)
Vitiligo 3 (2.6)
Sjogren syndrome 1 (0.9)
Turner syndrome 1 (0.9)
Other 7 (6.1)
Data are reported as absolute frequencies (percentage).
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3.2. Characteristics at Diagnosis
A comparison of the main characteristics of screening- and clinically detected patients is detailed
in Table 2.
Table 2. Characteristics of screening- and clinically detected patients.
Parameter Screening (n = 115) Clinical Suspicion (n = 635) p
Age (Years) 34 (22–46) 33 (22–44) 0.690
Sex (Female) 80 (69.6) 502 (79.1) 0.021
Time since Diagnosis (Years) 1.5 (0.0–5.0) 2.0 (0.0–6.50) 0.145
Symptoms 29 (25.2) 594 (93.5) <0.001
Iron-Deficiency Anemia 25 (21.7) 324 (51.0) <0.001
Osteopenia/Osteoporosis 36 (31.3) 292 (46.0) 0.003
Histology
-Marsh 3a 33 (28.7) 182 (28.7)
-Marsh 3b 43 (37.4) 180 (28.3) 0.100
-Marsh 3c 39 (33.9) 273 (42.3)
Categorical variables are reported as absolute number (percentage), continuous variables are described as median
(interquartile range).
Female sex was slightly preponderant in clinically detected patients, while the age at the diagnosis
did not significantly differ between groups. As expected, the prevalence of symptomatic patients
was sharply higher in clinically detected compared to screening-detected patients. In parallel,
iron-deficiency anemia and osteopenia/osteoporosis were also more prevalent in the clinically detected
group of patients. No differences in the severity of villous atrophy were noted.
3.3. Follow-Up
A total of 13 patients in the screening group (11.3%) and 74 clinically detected patients (11.7%)
dropped out after the first evaluation in our centre (p = 1.000). The remaining patients (102 and 561,
respectively) were assessed for compliance to the GFD, prevalence of non-responder CD, and metabolic
alterations (Table 3).
Table 3. Comparison of the compliance to the gluten-free diet, persisting symptoms, and metabolic
alterations at the follow-up evaluations between screening- and clinically detected patients.
Parameter Screening (n = 102) Clinical suspicion (n = 561) p
Correct Compliance 93 (91.2) 504 (89.8) 0.857
Accidental Contaminations 2 (2.0) 25 (4.5) 0.410
Voluntary Gluten Ingestion 7 (6.9) 32 (5.7) 0.647
Gerd-like Symptoms 2 (2.0) 17 (3.0) 0.753
Ibs-like Symptoms (Total) 8 (7.8) 79 (14.1) 0.110
(a) classical ibs 4 (3.9) 43 (7.7) 0.212
(b) Diarrhea-predominant IBS 1 (1.0) 6 (1.1) 1.000
(c) Constipation-predominant IBS 3 (2.9) 30 (5.3) 0.457
Metabolic Alterations (tOtal) 15 (14.7) 96 (17.1) 0.666
(a) weight increase >10% 7 (6.9) 34 (6.1) 0.823
(b) cholesterol increase >50 mg/dL 7 (6.9) 36(6.4) 0.864
(c) metabolic syndrome 1 (1.0) 26 (4.6) 0.103
IBS: irritable bowel syndrome; GERD: gastroesophageal reflux disease. Categorical variables are reported as absolute
number (percentage), continuous variables are described as median (interquartile range).
Compliance to the GFD was similar in screening- and clinically detected patients (91.2 versus
89.8%, p = 0.857). Two patients in the screening-diagnosed group and 25 patients in the clinically
detected group referred possible accidental contaminations with gluten, mainly when they ate at work
or at a restaurant. Instead, seven and 32 patients, in the screening- and clinically-detected groups
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respectively, voluntarily ingested gluten at least twice per month. At the binary logistic regression
analysis, only the presence of gluten-related symptoms at baseline was marginally associated with
better compliance (hazard ratio 2.110, 95% confidence interval 0.888–5.012, p = 0.091). On the contrary,
sex (p = 0.283), age at the diagnosis (p = 0.504), and presence of a relative with CD (p = 0.183) did not
correlate with compliance.
Overall, persistent symptoms were found in 19 (18.6%) screening-diagnosed patients and 153
(27.3%) clinically detected patients. Briefly, the aforementioned incomplete compliance to the GFD
was one of the leading causes of persistent symptoms in both groups. Co-existing irritable bowel
syndrome and gastroesophageal reflux disease were not significantly different across the study
groups. Complicated CD was confirmed to be a rare condition. Interestingly, all seven cases of
complicated CD were found in the clinically diagnosed patients and not in the screening-diagnosed
group. Complications were found at diagnosis in three cases (two small bowel adenocarcinoma, one
enteropathy-associated T cell lymphoma) and were diagnosed in the follow-up in the remaining five
cases (three patients with type-1 refractory CD, one case of a type-2 refractory CD, and one case of
hyposplenism).
Persistence in the follow-up procedures was also similar between the two groups, with a median
follow up of 6.5 years (95% confidence interval 5.1–7.9) in screening-detected and 6.3 years (95%
confidence interval 5.7–6.9) in clinically detected patients (p = 0.452) (Figure 2).
Figure 2. Persistence in the follow-up procedures in patients detected by screening and in patients
diagnosed because of clinical suspicion.
Age at diagnosis was the only factor associated with persistence, with an inverse correlation
(hazard ratio 0.988, 95% confidence interval 0.982–0.994, p < 0.001). Sex (p = 0.325), familiarity for
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CD (p = 0.696), symptoms at the diagnosis (p = 0.155), and adherence to GFD (p = 0.392) were not
associated with the length of the follow-up.
4. Discussion
In this paper, we assessed different clinical aspects of adult CD patients in which their condition
was discovered thanks to screening programs. In particular, we explored both their baseline and their
follow-up evaluations. These tasks were performed in a large cohort with a median six-year follow-up.
First, our data showed that adult CD patients diagnosed by screening had a GFD adherence
which was similar to that of clinically detected patients after a six-year median follow-up. Both groups
had an adherence as high as 90%. As previously stated, local policies may influence compliance. In the
case of this study, it should be noted that Italy has official government policies protecting CD patients
and helping them in the management of their conditions. These policies establish that diagnosed CD
patients receive vouchers to buy specially produced gluten-free foods for up to 120 euro/month and
call for strict respect of the local guidelines which recommend a clinical and laboratory follow-up
at regular intervals. It is, therefore, possible that even patients who are diagnosed in the absence
of severe symptoms are sufficiently eased in their difficult endeavors, which would favor higher
compliance. The similarity in the compliance to the GFD of screening- and clinically detected CD
patients had been already suggested in a series of studies on pediatric populations, mainly from
North-European countries [15–17]. Data in the adult screening-detected population are more limited.
Viljamaa and colleagues [6] firstly reported adherence of 82 versus 77% in 53 screening-detected and
44 clinically detected adult patients after a 14-year follow-up. In the only large study, Ukkola et al. [7]
analyzed 123 screening-detected patients versus 698 patients diagnosed because of clinical suspicion.
The self-reported adherence to the GFD after one year was similar between the study groups (91 versus
85%). Compared to Ukkola et al., the design of our study is different. While we lack the strengths of
a prospective evaluation, we benefited from a longer follow-up and a physician-assessed adherence.
Moreover, a difference in the geographical regions of enrolment should also be considered. With
all these differences in mind, our results are surprisingly similar to those of Ukkola, thus validating
them even in a different social context and in a more extended follow-up period. We also report
novel findings based on the analysis of the persistence in the follow-up procedures, the rate of the
non-responsive CD, and the metabolic alterations potentially induced by the GFD. In particular, all
these factors were consistent across the study groups. It is also interesting to note that all the patients
with complications belonged to the clinically detected group, even if our study was not designed nor
powered enough to detect significant differences in this variable. A final word on this topic, therefore,
will only come from extensive studies with decade-long follow-up.
Second, our data validated on a large scale the preliminary evidence that screening-detected
patients have peculiar features during diagnosis when compared to patients recognized because of
clinical suspicion. Approximately 25% of our screening-detected patients had mild gluten-related
symptoms which could have led to the diagnosis, suggesting that the local screening strategies were
reasonably good. This rate is, in fact, lower if compared to those previously described in adults [18]
and pediatric series [15], in which at least half of the cases diagnosed by screening had symptoms.
More interestingly, our screening-diagnosed patients were significantly less affected by iron-deficiency
anemia and osteopenia. In a series of 19 screening-detected patients, Mustalahti and colleagues [19]
firstly reported that bone mineral density (BMD) was lower than average. Following this report,
Sundar et al. [20] compared the characteristics of 24 screening-detected versus 105 clinically detected
CD patients, confirming a higher rate of BMD abnormalities in the latter group but also calling for
further evidence from larger cohorts. We, therefore, suggest that the prevention of metabolic bone
disease should strongly encourage CD screening in at-risk subjects. In fact, CD subjects are at increased
risk of fractures [21,22] and benefit from GFD, which generally leads to an improvement in BMD in
the first 12 months [23,24].
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The strengths of our study include a large cohort of patients, the systematic clinical assessment
of the compliance to the GFD, and the availability of additional information including the rate of
clinical response to the GFD and its metabolic impact. We are aware that our study also comes with
limitations, including its retrospective nature, the lack of systematic assessment of all features of
metabolic syndrome (for instance, high-density lipoprotein cholesterol), and the lack of structured
questionnaires for an even more comprehensive collection of both symptoms and dietary adherence.
Finally, because of the observational nature of our study, we did not investigate the prevalence of some
polymorphisms involved in iron absorption in children (DMT 1 IVS4 + 44C > A) [25] and lower bone
mineral density in adults (IL1B-511T) [26], as reported in previous studies in CD patients.
5. Conclusions
Our data support the use of screening procedures for CD in the adult population. In particular,
we demonstrated that an early diagnosis might protect from severe metabolic bone disease. Also,
compared to clinically diagnosed patients, screening-diagnosed patients did not show an impaired
adherence to the GFD nor an increased rate of GFD-related problems.
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Abstract: It is unclear whether patients with non-celiac gluten sensitivity (NCGS) can tolerate
gluten. We have evaluated the changes of both gastrointestinal symptoms and quality of life for
NCGS patients after the re-introduction of dietary gluten. Twenty-two NCGS patients reporting
functional gastroenterological symptoms and on gluten-free diet (GFD) for the previous three weeks
were exposed to incremental gluten-containing diets. Three groups were compared at baseline
(immediately after 3-weeks on GFD) and immediately after the return of symptomatology: (i) a group
tolerating a low-gluten diet (3.5 g gluten/day, week 1, n = 8), (ii) a group tolerating a mid-gluten diet
(8 g gluten/day, week 2, n = 6), and (iii) a group tolerating a high-gluten diet (13 g gluten/day,
week 3, n = 8). Their gastrointestinal symptoms and quality of life were assessed at baseline
and post-intervention. The most common symptoms were: constipation (46%), abdominal pain
(50%) and dyspepsia (38%). A decrease in several short form health survey (SF-36) sub-scores
(all p < 0.03) after gluten re-introduction was only observed in the group tolerating the low-gluten
diet; the same group showed a lower post-intervention role-emotional SF-36 score (p = 0.01). Most
gastrointestinal symptoms remained similar after gluten re-introduction. However, a decrease in the
general perception of well-being was only found after gluten re-introduction in the group tolerating a
low-gluten diet (p = 0.01); the same was true when comparing the post-intervention general well-being
perception among the three groups (p = 0.050). In conclusion, dissimilar responses from patients
with NCGS were observed after the re-introduction of gluten, with gluten at a low dosage affecting
the quality of life and general well-being of a group of patients, whereas others tolerate even higher
doses of dietary gluten.
Keywords: non-celiac gluten sensitivity; gluten re-introduction; gluten-free diet; gastrointestinal
symptoms
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1. Introduction
Non-celiac gluten sensitivity (NCGS) is characterized by intestinal and extra-intestinal symptoms
related to the ingestion of gluten-containing foods, in subjects that are not affected by either celiac
disease (CD) or wheat allergy [1–3]. The symptomatology commonly found in NCGS comprises:
bloating, abdominal pain, diarrhea, epigastric pain, nausea, aerophagia, lack of well-being, tiredness,
headache, foggy mind, and anxiety among other symptoms [4]. Symptoms disappear after starting
on a gluten-free diet (GFD) and appear again after a gluten challenge within a few hours or a couple
of days [5,6]. However, this latter finding can be attributed to a placebo/nocebo effect [7,8]. Several
studies have evaluated the effect of a gluten re-challenge in NCGS patients after GFD (a summary of
studies is shown in Table 1). According to a recent meta-analysis, there is a wide range of patients
relapsing after a gluten challenge (between 7% and 77%) and no effect of a gluten challenge was found
on the risk of relapse [9]. These results are in line with another review of studies on patients with
suspected NCGS, indicating that only 16% of them show clear gluten-specific symptoms [10]. These
studies highlight the fact that further methodological considerations are required in studies evaluating
the gluten challenge.
The current clinical consensus is that the diagnostic criteria on NCGS should include self-reported
gluten intolerance, negative serology for CD (including immunoglobulin A (IgA) endomysial
antibodies, IgA tissue transglutaminase antibodies, and IgG de-amidated gliadin peptide antibodies)
and the absence of villous atrophy at duodenal histology (whilst on a gluten-containing diet) [1,3,11].
Similarly to CD and wheat allergy, the cornerstone of NCGS treatment is the withdrawal of
gluten-containing foods. Although considered safe and effective, the lifelong elimination of gluten
from the diet carries psychological and social implications. Patients with CD report about concerns
related to the management of their social relationships and life routine [12]. Support and education
are important to enable patients to adapt to their new diet [13]. However, given the uncertainty
on the pathogenesis and trigger(s) of NCGS, it is not clear how strict such a new diet needs to be,
how long its implementation and how to monitor the efficacy of the treatment other than by clinical
response. Clinical experience suggests that patients affected by NCGS range from those who need to
adhere to a strict GFD to those who can tolerate potential cross-contamination without any clinical
consequences [14].
NCGS is a disorder treated with a GFD. There is currently discussion whether the symptoms
described in NCGS are exclusively due to the ingestion of gluten proteins rather than other components
included in wheat [15]. Wheat has some components that are different from gluten proteins and can
be harmful to patients suffering from NCGS, including wheat germ agglutinins (WGA), amylase
inhibitors/trypsin (ATI), and fermentable oligo/di/monosaccharides and polyols (FODMAP) [16–19].
ATIs are a family of structurally similar proteins, which serve as protective proteins in wheat and other
cereals, by inhibiting the enzymes (trypsin and trypsin-like activities) of wheat and some parasites [20]
ATIs have been described as triggers of the activation of innate immunity in intestinal cells [18].
WGAs [19], similar to ATIs, serve as protective proteins as they are resistant to heat and proteolysis.
WGAs have shown to promote the production of pro-inflammatory cytokines, which affect the integrity
of the intestinal epithelium [21]. Finally, FODMAP-containing foods include such components as
oligosaccharides, disaccharides, monosaccharides, and sugar alcohols. They are resistant to digestion
and can ferment completely or partially in the large intestine. Their efficacy in the treatment of
gastrointestinal symptoms related to IBS has been described, and their function is being evaluated in
various pathologies affecting the intestine [22,23].
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There is currently no data that can support any recommendations on the need for, or frequency of,
repeated follow-up visits in these patients. It is considered good clinical care to study these patients at
regular intervals in order to ensure they remain healthy and to involve a nutritionist to make sure they
are not at risk of nutrient deficiencies. It is also advisable that the continued need for “strict” avoidance
of all gluten-related products be regularly reviewed following recovery because some patients can
possibly follow a less restrictive diet with no recurrence of symptoms. A lifelong strict GFD (as in CD)
vs. an “on-demand” approach is the main question. Many experts recommend that patients should
undergo periodic re-evaluation with the re-introduction of gluten (e.g., every 6–12 months) [8].
A GFD leads to the complete disappearance of symptoms in most patients with NCGS but in
some cases the level of improvement after gluten withdrawal is only partial. However, it should be
mentioned that the level of tolerance varies among individuals and there are patients with NCGS
who do not tolerate even very small amounts of gluten. As it is presently unclear whether gluten
sensitivity is a permanent or transient condition, the re-introduction of gluten after 1–2 years on a
GFD is potentially advisable [33]. Thus, the aim of the present study was to evaluate the changes in
gastrointestinal symptoms and quality of life for NCGS patients after exposure to different amounts of
dietary gluten.
2. Materials and Methods
Between 2013 and 2014, patients reporting functional gastroenterological symptoms according
to the Rome III criteria [34] were invited to participate in this study. All were recruited from the
gastroenterological outpatient clinic at the Center for Prevention and Diagnosis of Celiac Disease,
Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
in Milan (Italy). The patients who agreed to participate gave their written informed consent and were
enrolled in the study. The local Ethics Committee for Human Research of the City of Milan approved
the study protocol. The trial was registered in ClinicalTrial.gov (NCT01864993).
The inclusion criteria were: adult age (>18 years old), being on a gluten-containing diet, with
negative anti-tissue transglutaminase IgA, normal IgA dosage, negative IgE-mediated wheat allergy
as verified by skin prick test and serological IgE dosage. The exclusion criteria were: diagnosis of
CD, wheat allergy, inflammatory bowel disease, psychiatric disorders, major abdominal surgery
(in particular, intestinal resections), diabetes mellitus, systemic autoimmune diseases, previous
anaphylactic episodes, any systemic disorders, patients already following or having followed a
GFD regimen in the previous six months, pregnant or breastfeeding women, and patients already
on pharmacological therapy. The patients were evaluated by a gastroenterologist and a qualified
nutritionist. The diagnosis of NCGS was made in accordance with the latest NCGS consensus [4].
After recruitment, patients were requested to follow a GFD plan for 3-weeks before the start of
the dietary intervention (i.e., the low/mid/high-gluten diet). Their overall health, gastrointestinal
symptoms, and quality of life were assessed by medical examination. Their adherence to the GFD was
evaluated according to the celiac dietary adherence test (CDAT) [35]. The CDAT is a clinically relevant,
easily administrated 7-item instrument which allows the standardized evaluation of GFD adherence.
It is a sensitive tool developed using standard psychometric techniques. Only those patients with
excellent or very good GFD adherence were included in the study. CDAT is based on a score ranging
from 7 to 35 against seven questions, each on a 5-point scale, with higher scores denoting worse GFD
adherence [35].
2.1. Intervention
Twenty-four patients were recruited (Figure 1). As mentioned above, all the recruited patients
were instructed to follow a strict GFD for 3 weeks. After that time, the intervention period started.
A qualified nutritionist designed a personalized GFD adjusted to match daily requirements for energy,
macronutrients and micronutrients. A structured 3-week dietary plan was indicated and explained
to every patient, to cover structured meals, foods/beverages and alternatives for food purchase.
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The patients were also encouraged to immediately contact the nutritionist by phone in case of any
doubt related to the diet. After the three weeks on the GFD, the intervention period started. The patients
started the study with a low-gluten diet during the first week (3.5–4 g gluten/day, week 1, n = 24).
Two patients dropped out of the study during the first week because they did not want to continue the
diet. Afterwards, the patients who did not report adverse symptoms were administered a mid-gluten
diet in the second week (6.7–8 g gluten/day, week 2, n = 14). Then, the patients who passed the second
week were started on a high-gluten diet for the following week (10–13 g gluten/day, week 3, n = 8).
Each patient had been instructed to immediately contact the research team at the end of each week
should any of the previously reported symptoms at the beginning of the study return. A clinical
evaluation was then arranged and the patient was to stop their gluten-containing diet and return to
the GFD (i.e., for patients reporting adverse symptomatology at the end of the first week) or to the
previous gluten-containing diet (i.e., for patients reporting adverse symptomatology at the end of the
second and third week). In such cases, the nutritionist would also reinforce the instructions and food
education on the practice of the GFD. A flow-chart of patients is shown in Figure 1. The patients with
symptomatic relapse at the end of week 1 returned to the GFD (as indicated in the previous three
weeks after recruitment). The patients who experienced a symptomatic relapse at the end of week
2 returned to a low-gluten diet (3.5–4 g/day) and stayed on that dietary treatment until the end of
week 3. Finally, none of the patients who had undergone the high-gluten diet (n = 8) reported any
worsening of gastrointestinal symptoms and at the end of week 3, they were instructed to return to
their regular dietary pattern.
2.2. Diets
The nutritional evaluation aimed to assess anthropometrical parameters, nutritional status, and
usual dietary patterns. At the beginning of the study, after clinical evaluation, a structured 7-day
dietary plan was generated for each patient, adjusted to his/her daily nutritional requirements for
energy, macronutrients and micronutrients. For each week, according to the low/mid/high-gluten
amount contained, meals were listed (breakfast, morning snack, lunch, afternoon snack, dinner and
other snacks during the day) with specific foods/beverages (see examples in Table 2). For week
1 the source of gluten was only wheat pasta (50 g, about 3.5–4 g of gluten) administered during
dinner. In week 2 the sources of gluten were wheat pasta (50 g, about 3.5–4 g of gluten) during
dinner and wheat bread (50 g, about 3.2–4 g gluten) during the daytime. For week 3 the sources of
gluten were wheat pasta (60 g at lunch and 60 g at dinner, ~8.4–9.6 g gluten) and wheat bread (30 g
during the day, 1.9–3 g gluten). The gluten content of each of the three diets was calculated referring
to Schalk et al. [36]. In that study, the gluten content was determined through a comprehensive
strategy to isolate gluten protein fractions and gluten protein types (GPT) from wheat, rye, barley, and
oat flours. All of the isolated GPTs were fully characterized by means of analytical reversed-phase
high-performance liquid chromatography (RP-HPLC), sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), N-terminal sequencing, electrospray-ionization quadrupole time-of-flight
mass spectrometry (LC-ESI-QTOF-MS) and untargeted LC-MS/MS of chymotryptic hydrolysates of
the single GPT. Successively, all of the GPTs were reproducibly isolated in high purity from the flours
and were made suitable to be used as a reference material, i.e., for calibration of liquid chromatography
tandem mass spectrometry methods or enzyme-linked immunosorbent assays (ELISAs) [36].
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Figure 1. Flow-chart of the patients’ activity in the study. Two patients (drop-outs) decided to abandon
the diet during the first week of intervention; GFD: gluten-free diet.
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1 small cup of coffee, 300
mL partly skimmed milk,
1 gluten-free croissant
1 small cup of coffee, 300
mL partly skimmed milk,
4 gluten-free biscuits
1 small cup of coffee, 300
mL partly skimmed milk,
4 gluten-free rusks










100 g gluten-free pasta,
90 g mixed vegetables,
1 portion of chard,
4 mandarins
100 g gluten-free pasta,
40 g cow ricotta cheese,
100 g potatoes, 2 bananas
60 g wheat pasta with
broccoli, 2 teaspoonfuls
grated Parmesan cheese,
1 portion of mixed salad,
2.5 glasses of fruit salad
Afternoon snack 1 bowl of strawberries 1 bowl of strawberries 1 pear
Dinner
50 g wheat pasta with
zucchini, 100 g turkey
thigh 200 g potatoes,
5 slices of pineapple
50 g wheat pasta with
tomato sauce, 1 spoon of
fresh peas 120 g pork,
1 portion of chard
5 mandarins
60 g wheat pasta with
tomato sauce, 100 g
halibut, 200 g potatoes,
2 glasses of fruit salad
During the day
40 g gluten-free bread,
6.5 teaspoonfuls virgin
olive oil
50 g of white wheat
bread, 3.5 teaspoonfuls
virgin olive oil
30 g white wheat bread,
8 teaspoonfuls virgin
olive oil
1 Example of a typical day per week for each of the three different diets, as calculated for an average 2000 Kcal/day
energy requirement.
2.3. Gastrointestinal Symptoms and Quality of Life
The gastrointestinal symptoms and quality of life of each patient were assessed at the beginning
of the study and soon after the return of symptoms after administering one of the gluten-containing
diets (i.e., after gluten exposure). A visual analogue scale (VAS) was used to assess the patient’s
gastrointestinal symptoms and general perception of well-being as previously described by our
group [23]. This instrument recorded the severity of specific symptoms: abdominal pain, bloating,
postprandial fullness, early satiety, epigastric pain, non-specific functional gastrointestinal symptoms,
and satisfaction with stool consistency. For each question, each patient was asked to put a mark
along a 10-cm long line with one end 0 meaning “absence of symptom” and the other end 10
“severe symptomatology”. A further VAS evaluated the satisfaction about the current level of general
well-being, with 0 meaning “completely unsatisfied” and 10 “absolutely satisfied”.
The patient’s quality of life was evaluated through the short form health survey (SF-36)
questionnaire. This instrument comprises 36 questions that conceptually refer to eight health
domains [37]. The patients were asked to answer each question and then domain-specific scores
ranging between 0 and 100 were calculated, where 100 represented the best possible perception of
quality of life.
2.4. Statistical Analysis
The data are provided as mean ± SEM or median (interquartile range) unless indicated otherwise.
Twenty-two patients were included for analysis. Comparisons were made according to the group
of patients that reported the return of symptomatology after gluten exposure, that is 3 groups:
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low-gluten (patients that reported adverse symptomatology after 1 week on a gluten-containing
diet, n = 8), mid-gluten (patients that reported adverse symptomatology after 2 weeks on a
gluten-containing diet, n = 6), and high-gluten (patients that reported adverse symptomatology after
3 weeks on a gluten-containing diet, n = 8). One-way ANOVA was used to evaluate between-group
differences as to age and body-mass index; Fisher’s exact test was used to compare categorical
variables (i.e., gender distribution and presence of gastrointestinal symptoms) between the groups.
The within-group differences of SF-36 and VAS scores before (immediately after 3-weeks on a GFD)
and after gluten exposure (i.e., baseline vs. the time when gastrointestinal symptoms returned
after the gluten-containing diets) were assessed using a non-parametric Wilcoxon’s rank sum test.
The between-group differences were evaluated after gluten exposure using the non-parametric
Kruskal-Wallis test. STATA® ver. 13.1 software (StataCorp, College Station, TX, USA) was used
for statistics and statistical significance was set at a 5% α-level.
3. Results
3.1. Patients
All patients included in the study obtained a CDAT score from 7 to 13, thus indicating very
good adherence to the GFD. As shown in Table 3, the patients were middle-aged, mainly women,
and within the normal weight range. Regarding the clinical symptomatology at baseline, symptoms
such as constipation, abdominal pain, and dyspepsia were the most frequently reported by the whole
sample (46%, 50%, and 38%, respectively). All three groups were comparable regarding both general
characteristics and present gastrointestinal symptoms at baseline (Table 3). In regards to the estimated
gluten content in the foods used in the intervention diets, the gluten content was 3.5–4 g/day in the
low-gluten diet, 6.7–8 g/day in the mid-gluten diet, and 10–13 g/day in the high-gluten diet.
Table 3. General characteristics of the group of patients at baseline 1.
Low-Gluten
(3.5–4 g/day, n = 8)
Mid-Gluten
(6.7–8 g/day, n = 6)
High-Gluten
(10–13 g/day, n = 8) p-Value
†
Age, years 44.6 ± 4.5 45.5 ± 3.1 44.6 ± 5.2 0.98
Gender, F/M 7/1 6/0 7/1 0.99
BMI, kg/m2 23.0 ± 1.7 23.8 ± 1.8 21.8 ± 0.7 0.65
Diarrhea, n (%) 1 (12.5) 0 (0) 1 (12.5) 0.99
Bloating, n (%) 0 (0) 2 (33.3) 1 (12.5) 0.24
Constipation, n (%) 3 (37.5) 5 (83.3) 3 (37.5) 0.21
Abdominal pain, n (%) 5 (62.5) 4 (66.6) 3 (37.5) 0.64
Dyspepsia, n (%) 6 (75) 1 (16.6) 2 (25) 0.08
1 Data are shown as mean ± SEM for continuous variables and frequency and/or relative number for nominal
variables. † p-value for comparison between groups using one-way ANOVA or Fisher’s exact test for categorical
variables. F: female; M: male; BMI: body mass index.
3.2. Quality of Life
The resulting SF-36 scores are shown in Table 4. There was a significant decrease in several SF-36
sub-scores (role physical, role emotional, bodily pain, mental health, vitality and social interaction,
all p < 0.03) after gluten exposure in the group of patients receiving the low-gluten diet but not in
the groups receiving mid- and high-gluten content (Table 4). However, when comparing the change
in SF-36 scores after dietary gluten exposure between the three groups, we observed a change only
in the role emotional score, which was lower in the low-gluten content group. No post-intervention
differences were found regarding the general health score among the three groups (Table 4).
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3.3. Gastrointestinal Symptoms
The within-group comparisons showed no significant changes in most of the evaluated
gastrointestinal symptoms before and after dietary intervention (Table 5). However, a decrease
in the general perception of well-being was found in the low-gluten group (but not in the mid- and
high-gluten groups) after intervention (p = 0.01). In line, when comparing the three groups after dietary
gluten exposure, a further decrease of the general well-being level was found in the low-gluten group
compared with the mid- and high-gluten groups (p = 0.050, Table 5).
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4. Discussion
This study evaluated the effects of a short-term re-introduction of gluten on individuals diagnosed
with NCGS. Our results show that a level of tolerance is present in patients without showing any
adverse signs or gastrointestinal symptoms when consuming gluten. There was a different response
among individuals with NCGS when exposed to different amounts of dietary gluten. A subgroup of
patients had an immediate response with some worsening of their quality of life and general well-being
at a low-gluten dosage, whereas other patients were able to tolerate medium and high doses of gluten,
indicating that these latter groups can be administered some gluten without adverse health effects.
At present, it is well known that a GFD is the treatment of choice for patients suffering from NGCS.
Several randomized controlled trials (RCTs) [10] have been carried out to identify gluten as the trigger
of symptoms (Table 1). Those reports have shown variable results and are not conclusive regarding
the cause-effect relationship of gluten and gastrointestinal symptoms [30,32]. We have previously
suggested that gluten can be a major trigger of gastrointestinal symptoms in line with other [5,38,39].
Although the data to date suggest a benefit from a GFD for a selected group of patients, it is possible
that the improvement in symptoms might not be due to gluten itself. Other components in wheat
may trigger the reported symptoms in these patients, suggesting the clinical feature of non-celiac
wheat sensitivity. This last entity has not completely been clarified as it is not clear whether patients
are suffering from gluten-related symptoms or another component of wheat (such as fructans) [40].
Regardless of the nomenclature, Carroccio et al. [41] provided a clinically useful approach confirming
non-celiac wheat sensitivity as a unique clinical condition. Their results suggest the existence of two
different groups of patients with this condition: one with characteristics similar to CD and the other
with characteristics resembling food allergy [41]. The current nomenclature of gluten sensitivity [1],
NCGS [5] and gluten-related disorders does not resolve this problem and may confuse clinicians as to
which component in wheat might be triggering patients’ symptomatology. Expert recommendations
have proposed a periodic evaluation with re-introduction of gluten for NCGS patients on consideration
of the economic costs and quality of life that a lifelong GFD entails [8].
Regarding the quality-of-life perception, previous data of our group from a cross-over study has
shown that patients with NCGS treated with a GFD enjoy an improvement in the majority of the SF-36
scores after 7 days [30]. In our study, we observed that the group who tolerated only a low amount of
dietary gluten was the only group showing a decrease in several SF-36 sub-scores. On the other hand,
it is important to point out that the groups on a mid- and high-gluten diet did not show any significant
change in their quality of life. This finding is intriguing because it would suggest that a greater gluten
intake by patients with NCGS would not necessarily further affect their quality of life, thus reinforcing
the idea of inter-individual variability against gluten in this group.
After the re-introduction of gluten, the gastrointestinal symptomatology showed no main changes
against our dietary intervention. Moreover, no differences were found after gluten exposure among
the three groups (i.e., at the end of the intervention period). However, we did find a change in the
perception of general well-being, which was significantly affected in the group receiving a low level
of gluten; such a result is in line with what we found on the patients’ quality of life. Overall, these
findings suggest that with regard to quality of life and general well-being the changes observed in
the group on a low-gluten diet would be related to a systemic response to gluten consumption rather
than only gastrointestinal symptomatology or, at least, a combination of both. Even if our results are
interesting per se they require further confirmation in larger samples and with different populations of
patients suffering from NCGS.
This was an exploratory study that worked on a small sample of patients to evaluate the
re-introduction of gluten through dietary modifications in a homogeneous group of patients correctly
diagnosed with NCGS. As to limitations, we would like to point out that all the patients did not receive
all their gluten doses in a balanced cross-over design. This was mainly due to ethical considerations
since, at the time the clinical picture began to worsen, the patients stopped the administered diet and
returned to their established treatment with GFD.
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To summarize, we have shown a dissimilar response after the reintroduction of gluten in patients
with NCGS who were on GFD for the last 3-weeks. We have also shown that for a group of them
the re-introduction of gluten at low dosage affected their quality of life and general well-being,
whereas other patients could tolerate higher doses of dietary gluten. Further studies are needed to
establish whether NCGS patients require a dietary regimen free of gluten or just a gluten-restricted
diet. Therefore, a controlled re-introduction of gluten potentially helps the improvement of selected
patients that are able to tolerate gluten intake by developing a personalized diet containing gluten
without the reappearance of symptoms. Further research is needed to assess the long-term clinical
response of the increase in the dietary gluten content as concerns symptomatology and quality of life
for patients with NCGS.
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Abstract: The high global demand of wheat and its subsequent consumption arise from the
physicochemical properties of bread dough and its contribution to the protein intake in the human diet.
Gluten is the main structural complex of wheat proteins and subjects affected by celiac disease (CD)
cannot tolerate gluten protein. Within gluten proteins, α-gliadins constitute the most immunogenic
fraction since they contain the main T-cell stimulating epitopes (DQ2.5-glia-α1, DQ2.5-glia-α2,
and DQ2.5-glia-α3). In this work, the celiac immunotoxic potential of α-gliadins was studied within
Triticeae: diploid, tetraploid, and hexaploid species. The abundance and immunostimulatory capacity
of CD canonical epitopes and variants (with one or two mismatches) in all α-gliadin sequences were
determined. The results showed that the canonical epitopes DQ2.5-glia-α1 and DQ2.5-glia-α3 were
more frequent than DQ2.5-glia-α2. A higher abundance of canonical DQ2.5-glia-α1 epitope was
found to be associated with genomes of the BBAADD, AA, and DD types; however, the abundance
of DQ2.5-glia-α3 epitope variants was very high in BBAADD and BBAA wheat despite their low
abundance in the canonical epitope. The most abundant substitution was that of proline to serine,
which was disposed mainly on the three canonical DQ2.5 domains on position 8. Interestingly,
our results demonstrated that the natural introduction of Q to H at any position eliminates the
toxicity of the three T-cell epitopes in the α-gliadins. The results provided a rational approach for
the introduction of natural amino acid substitutions to eliminate the toxicity of three T-cell epitopes,
while maintaining the technological properties of commercial wheats.
Keywords: celiac disease; α-gliadin; 33-mer; DQ2.5-glia-α1; DQ2.5-glia-α2; DQ2.5-glia-α3 epitopes;
wheat species
1. Introduction
Wheat is one of the most widely cultivated cereals in the world and constitutes a major source
of energy, protein, and fiber in the diet. Increasing global demand for wheat and its subsequent
consumption, with an annual production of about 750 million tons, is due to its unique viscoelastic
properties for its inclusion in food products and to industrialization and westernization [1–3].
The wheat group has evolved through allopolyploidization, that is, through hybridization between
species from the genera Aegilops and Triticum followed by genome doubling [4]. Genetic studies
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have provided valuable information regarding which wild cereal species are the relatives of modern
domesticated cereals, and which geographical wild plant produced the domesticated forms that are
used in food production today [5]. The diploid wild wheat that was first domesticated is thought to
have been Triticum monococcum (AmAm), which is still growing in some parts of the world both for
animal feed and human consumption. Wheats with more than one genome are known as polyploid
wheats. The AA genome of the tetraploid wheats is closely similar to that of T. urartu, and the BB
genome is related to Aegilops speltoides (BB). The wild tetraploid, formed after the hybridization,
was designated as Triticum turgidum ssp. dicoccoides (wild emmer; BBAA), and the first domesticated
tetraploid was T. turgidum ssp. dicoccum (cultivated emmer; BBAA), from which, the cultivated
T. turgidum ssp. durum has evolved. The hexaploid wheat, Triticum aestivum ssp. aestivum (BBAADD),
consists of three genomes designated A, B, and D. The A and B genomes of hexaploid wheats come
from the A and B genomes of tetraploid wheat. The hexaploid wheats resulted from the hybridization
of cultivated emmer and a wild grass species identified as Aegilops tauschii (DD), followed by polyploid
formation which gave rise to a new species that has three genomes designated BBAADD [6,7]. The main
wheat species grown throughout the world is the hexaploid T. aestivum, usually called “common” or
“bread” wheat. In terms of total production, the next variety in importance is the tetraploid durum
or macaroni wheat (T. turgidum L. subsp. durum Desf.). This is adapted to hot dry climates and is
widely used for the production of pasta. Common wheat species account for nearly 94% of the total
production, with durum wheat representing 5%, and other wheat forms about 1% [6,8].
Although wheat has always been recognized as a fundamental food, this cereal cannot be tolerated
by certain individuals since it is responsible for significant pathologies, called gluten-related disorders,
such as celiac disease (CD), wheat allergy, non-celiac gluten sensitivity, gluten ataxia, and dermatitis
herpetiformis [9]. CD is an immune-mediated systemic disorder elicited by the ingestion of gluten
in genetically susceptible individuals. It affects around 1% of the global population and is based
on a variable combination of intestinal and extra-intestinal signs and symptoms, celiac specific
antibodies, HLA-DQ2/8 haplotypes, and enteropathy [9–11]. Gluten proteins are rich in proline
and glutamine residues, which make them resistant to being fully digested in the gastrointestinal
track. Partial digestion of gluten generates small peptides that provoke autoimmune disorders in celiac
people. The most accepted model for explaining CD immunopathogenesis is the two-signal model [12]
characterized by a first innate immune response followed by a secondary antigen-specific adaptive
response. According to this model, certain peptides, such as the 19-mer gliadin peptide, trigger an
innate immune response [13] mainly characterized by the production of interleukin 15 (IL-15) by
epithelial cells. The result is the disruption of the epithelial barrier by increasing the permeability
and inducing enterocyte apoptosis [14]. As a consequence, the immune-adaptive peptides, like the
33-mer, can now reach the lamina propria where they are deaminated by the tissue transglutaminase
(tTG2). Such deamidation provides a negative charge to gliadin peptides and hence enhances their
affinity to bind within the HLA-DQ2/8 bound, which is also the ‘susceptibility gene’ in CD, expressed
on the surface of dendritic cells (DCs) [15–17]. DCs are therefore central in CD pathogenesis since
they present a gluten antigen to T cells, [18] thereby driving progression of the pro-inflammatory
antigen-specific adaptive immune response, which will turn into the symptomatology of the disease.
Gluten is a complex mixture of storage proteins of cereals such as wheat, rye, barley, oats,
and their hybrid derivatives. Gluten proteins have been classified according to their solubility [19].
In wheat, these proteins are defined as gliadins (soluble in 60–70% ethanol) and glutenins (only soluble
under stronger conditions, i.e. acids, reducing agents and detergents, urea, etc.) [20]. According to
their electrophoretic mobilities, gliadins are divided into three groups: α- and β-gliadins, γ-gliadins,
and ω-gliadins [19], while the glutenins are divided into the high molecular weight (HMW) and the
low molecular weight (LMW) glutenin subunits (GSs) [21,22]. Among the gliadins, the α-gliadins
have the strongest immunogenicity [23], and four T-cell stimulatory epitopes have been identified as
being responsible for eliciting the immunogenicity of α-gliadin. Two of these are the major epitopes
and they are present in the 33-mer peptide, which is the main contributor to the immunogenicity
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of the gluten [24] and contains six copies of these two overlapping T-cell epitopes: three copies of
the DQ2.5-glia-α1 and three copies of the DQ2.5-glia-α2. The other two T-cell stimulatory epitopes
are minor epitopes: DQ2.5-glia-α3 and DQ8-glia-α1 [24–27]. However, natural substitutions of these
canonical epitopes could also contribute to the toxicity of wheat [28], and it could suggest that the
total CD immunogenicity of gluten protein is a result of the canonical epitopes and their variants,
some of which are more abundant than the canonical epitopes themselves. Gluten can have different
immunogenic potential sequences whose proportions in each species are also variable. For this reason,
it is important to study the amino acid substitutions in the variants of these epitopes; interestingly,
these variants could increase, reduce, or suppress the CD response.
In earlier work, next-generation sequencing and Sanger sequencing of α-gliadins from diploid
and polyploid wheats provided six types of α-gliadins with major differences in their frequencies.
The canonical CD epitopes and their variants were identified in the different types of α-gliadins [29].
In the present study, we used the sequence data with one or two mismatches and canonical epitopes
obtained in Ozuna et al. [29], and we have built upon the previous research by exploring the abundance
of different DQ2.5-glia-α1, DQ2.5-glia-α2, and DQ2.5-glia-α3 epitope variants per species in diploid
and polyploid wheats. Moreover, the immunogenic potential of these epitope variants in wheat species
was studied by testing their binding capacity to anti-33-mer monoclonal antibodies (moAbs) [30,31]
and to induce T-cell proliferation. The anti-33-mer antibodies were able to detect the presence of gliadin
33-mer related epitopes in prolamins from wheat, barley, rye, and various oats varieties as well as in
food samples and human samples to monitor gluten free diet (GFD) compliance and transgressions [32].
Our study showed that the canonical epitopes DQ2.5-glia-α1 and DQ2.5-glia-α3 were more frequent
than DQ2.5-glia-α2. The most abundant natural modification was found in the DQ2.5-glia-α3 domain
in all the sequences studied. However, this variant decreased its immunogenicity with respect to
the canonical epitope. On the other hand, one of the most representative variants of DQ2.5-glia-α2
(40%) showed an immunogenicity equivalent to the canonical epitope. Our results provide a rational
approach for the introduction or selection of natural amino acid substitutions to eliminate the toxicity
of three α-gliadin T-cell epitopes, while keeping the technological properties of the commercial wheats.
2. Materials and Methods
2.1. Catalogue and Abundance of CD Epitopes from Diploid, Tetraploid, and Hexaploid Wheat Varieties
Canonical epitopes DQ2.5-glia-α1 (PF/YPQPQLPY), DQ2.5-glia-α2 (PQPQLPYPQ), and
DQ2.5-glia-α3 (FRPQQPYPQ) and variants with one or two mismatches provided by Ozuna et al. [29]
were obtained from diploid, tetraploid, and hexaploid wheats (Figure 1).
The frequency/abundance of each peptide in the sequences of the different wheats was studied
in silico. The abundance of each epitope was calculated by multiplying the total number of epitopes
found in a given gene by the frequency of that gene in the genome.
These canonical CD epitopes and their most representative variants with one or two mismatches
were synthesized as deaminated and non-deaminated 9-mer peptides. The peptides were supplied by
Biomedal S.L. (Seville, Spain).
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Figure 1. Schematic representation of 96 accessions from Triticum and Aegilops sp. showing their
origin and breeding status. In total, there are thirty-five accessions of hexaploid wheats, thirty-seven
accessions of tetraploid wheats, and twenty-four accessions of diploid wheats. AA, BB, and DD:
diploids; BBAA: tetraploids; BBAADD: hexaploids (partially adapted from Ozuna and Barro) [3].
2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
Maxisorp microtitre plates (Nunc, Roskilde, Denmark) were coated with gliadin solution (Sigma,
St Louis, MO, USA) and incubated overnight at 4 ◦C. The plates were washed with phosphate-buffered
saline (PBS) containing 0.05% Tween 20 and blocked with PBS-bovine serum albumin (BSA) 3% for
1 h at room temperature (RT), and 33-mer peptide was used as standard. Serial dilutions of peptides
were made, to each of which horseradish peroxidase (HRP)-conjugate with anti-33-mer antibody
(moAb) was added [32]. The samples were pre-incubated at RT for 1 h and then added to the wells.
After 1 h of incubation at RT, the plates were washed and substrate solution (TMB, Sigma) was added.
The reaction was stopped at 15 min with 1 M sulfuric acid and the absorbance at 450 nm was measured
(microplate reader UVM340; Asys Hitech GmbH, Eugendorf, Austria). Two separate assays were
performed, each with two repetitions.
2.3. Peripheral Blood Mononuclear Cells (PBMCs) and Cell Cultures
Peripheral blood mononuclear cells from 18 child patients with active CD on a gluten-containing
diet were isolated from 6 mL of heparinized blood by Histopaque gradient centrifugation and
cultured at a density of 1 × 106 cells per milliliter in 96-multiwell culture plates in RPMI-1640 culture
medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (GIBCO-Invitrogen Ltd), 1%
penicillin-streptomycin, and 0.1% gentamicin (Sigma-Aldrich). After 48 h, PBMCs were incubated
with different peptides (50 μg/mL). After 48 h of stimulation, the free supernatants were collected and
stored at −80 ◦C until the interferon gamma (IFN-γ) analyses were carried out.
2.4. Cell Proliferation Analysis
T-cell proliferation was determined after 48 h of incubation using the ELISA
5-bromo-2-deoxyuridine (BrdU) cell proliferation test (Millipore Chemicon, Temecula, California, USA).
The stimulation index (SI) value was calculated by dividing the mean absorbance at 450 nm after
stimulation by the mean absorbance of T cells exposed to the culture medium alone (negative control).
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2.5. IFN-γ Production
Supernatants from the PBMC culture were collected after 48 h and stored at 80 ◦C for IFN- γ
determination using a commercial ELISA kit in accordance with the manufacturer’s instructions
(Thermo Scientific, Madrid, Spain). Standards were run on each plate. The sensitivity of the assay was
<2 pg/mL.
2.6. Statistical Analysis of T Cells and IFN-γ Assays
Each experiment was carried out in duplicate on separate days. The data is expressed as mean
and SD. All statistical analyses were performed with the STATGRAPHICS Centurion XVI program.
The analysis of variance (ANOVA), followed by the Tukey test for mean multiple comparison, was used.
In this study, p values lower than 0.05 (p < 0.05) were considered significant.
3. Results and Discussion
3.1. Relative Abundance of DQ2.5-Glia-α1, DQ2.5-Glia-α2, and DQ2.5-Glia-α3 Domains and Their Variants
in Triticum and Aegilops Species
The complete repertoire of peptides involved in the pathogenesis of CD remains a daunting
task due to the great heterogeneity of gluten proteins [23,26]. Several studies have demonstrated
that peptides derived from α-gliadins induce the strongest T-cell responses in the vast majority of
patients [23,33–35]. The α-gliadins can have different sequences and their proportions in each species
are also variable. In the present study, we have explored the abundance of different DQ2.5-glia-α1,
DQ2.5-glia-α2, and DQ2.5-glia-α3 variants in 96 genotypes from diploid and polyploid wheats. Among
these genotypes, 27 accessions were commercial lines and 69 were non-commercial lines (Figure 1).
The DQ2.5-glia-α epitopes are located in the 33-mer region of α-gliadins (Figure 2a). Although
seventy-eight variants were found for these three canonical epitopes across the Triticeae species [29],
only the most representative variants (covered by >80 reads), encompassing one or two mismatches,
were used for this study; of which 9 variants were from DQ2.5-glia-α1, 10 from DQ2.5-glia-α2, and 14
from DQ2.5-glia-α3 (Figure 2b).
Figure 2. Celiac disease (CD) epitopes and variants derived from α-gliadin. (a) Location of canonical
epitopes DQ-2.5-glia-α1, DQ-2.5-glia-α2, and DQ-2.5-glia-α3 into α-gliadin protein. (b) Variants of the
canonical CD epitopes with one or two mismatches selected with more than 80 reads found in Triticum
and Aegilops ssp. The mismatches are indicated in red.
In view of the total abundance of the different canonical epitopes, DQ2.5-glia-α1 and
DQ2.5-glia-α3 were more abundant than DQ2.5-glia-α2 (p < 0.05, Figure 3). There were no significant
differences between the abundance of DQ2.5-glia-α1 and DQ2.5-glia-α3, however, we found higher
variability of the DQ2.5-glia-α1 canonical epitope in hexaploid wheats, since its abundance fluctuated
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widely depending on the different hexaploid species, while it remained evenly distributed in the
DQ2.5-glia-α3 canonical epitope (p = 0.02, Figure 3).
Figure 3. Abundance of CD canonical epitope and variants per wheat genome type. (a) Abundance
of the canonical epitope DQ2.5-glia-α1 and variants, (b) abundance of the canonical DQ2.5-glia-α2
epitope and variants, and (c) abundance of the canonical DQ2.5-glia-α3 epitope and variants. BBAADD:
hexaploid genome; BBAA: tetraploid genome; AA, DD, and BB: diploid genomes.
Figure 4 shows the abundance of CD canonical epitopes and variants per species. The percentage
of DQ2.5-glia-α1 canonical epitope with respect to variants was 80%. This epitope was present
in all wheat genomes with the exception of BB diploids. The highest abundance was found in
T. compactum, T. monococcum, and Ae. tauschii. The most abundant variant (range from 0.1% to 20%) was
P1Y2P3Q4P5Q6L7F8P9 with two mismatches (P to F at p8 and Y to P at p9). This variant was present in
all wheat genomes with the exception of BB and DD diploids. The next most abundant variant was the
substitution of P to L at p5, but this variant was present in only BBAA and BB genomes (Figure 5).
The percentage of DQ2.5-glia-α2 canonical epitope with respect to the different variants of
this epitope was 14%, and this epitope was only present in hexaploids BBAADD and DD diploids.
This finding may indicate that this epitope came from Ae. tauschii, the donor of the D genome to
bread wheat. The DQ2.5-glia-α2 variants P1Q2P3Q4L5P6Y7S8Q9 and P1Q2P3Q4P5Q6Y7P8Q9 were the
most frequent (80%). The highest abundance score (range from 46% to 74%) of P1Q2P3Q4L5P6Y7S8Q9
(P to S substitution at p8) occurred in AA diploids and was absent from DD and BB diploid genomes.
In contrast, P1Q2P3Q4P5Q6Y7P8Q9 (L to P at p5 and P to Q at p6), with two mismatches, presented
high abundance in all genomes, with the exception of T. monococcum (AmAm diploid) (Figures 4 and 5).
Regarding the DQ2.5-glia-α3, the epitope variant F1P2P3Q4Q5P6Y7P8Q9 (with R to P substitution
at p2) was the most frequent, with an abundance greater than 75% across all species, except in Triticum
polonicum (BBAA) and Triticum urartu (AuAu), with abundances of 67.9% and 42.2%, respectively.
The second and third most frequent variants, F1L2P3Q4L5P6Y7P8Q9 (R to L at p2 and Q to L at p5) and
F1P2P3Q4Q5S6Y7P8Q9 (R to P at p2 and P to S at p6), had two mismatches and were absent in AA
and DD diploid genomes, which could indicate that the BB genome is the origin of this variant in the
polyploid varieties; in fact, the abundance of this epitope variant in the remaining genomes was very
similar (≈20%) (Figures 4 and 5).
The process of hybridization between Ae. tauschii and T. dicoccum provided the DD genome,
and new gluten gene combinations, to hexaploid wheats, thereby considerably improving their bread
baking properties compared to that of tetraploid wheats, particularly the HMW-glutenin subunits [36].
However, the DD genome also encodes for gliadins that have been reported as highly immunogenic,
as the DD genome has the highest number of potential immunogenic α-gliadin peptides [37], while
those from the BB genome contribute the least [38,39]. We found that the three canonical epitopes are
present in the DD genome, with a representation ranging from 43% to 65%. In hexaploids (BBAADD),
all canonical epitopes are also present, but in a smaller proportion (<40%) than the DD genome.
In contrast, in the AA genome, only DQ2.5-glia-α1 and DQ2.5-glia-α3 are present, and the BB genome
is not represented by any of the canonical epitopes.
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Figure 4. Abundance of CD canonical epitopes and variants per wheat species. (a) Abundance
in the DQ2.5-glia-α1 epitope variants, (b) abundance in DQ2.5-glia-α1 epitope variants by species,
(c) abundance in DQ2.5-glia-α2 epitope variants, (d) abundance in DQ2.5-glia-α2 epitope variants by
species, (e) abundance in DQ2.5-glia-α3 epitope variants, and (f) abundance in DQ2.5-glia-α2 epitope
variants by species.
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Figure 5. Abundance of epitope variants according to wheat genome type. The epitopes represented
showed more than 1% of abundance in each gliadin domain. (a) AA genome, (b) BB genome, (c) DD
genome, (d) BBAA genome, and (e) BBAADD genome. DQ2.5-glia-α1 epitope: green; DQ2.5-glia-α2
epitope: red; DQ2.5-glia-α3 epitope: blue.
3.2. Anti-33-mer MoAb Binding Capacity and T-cell Stimulatory of DQ2.5-α-Gliadin-Derived Peptides
Several of the amino acid variants that we found in the α-gliadin epitope sequences had never
been described previously, while a number had been described but had never been tested for their
immunogenic and stimulatory capacities. In order to determine which variants are capable of inducing
a CD stimulatory response, the variants from DQ2.5-glia-α epitopes were synthesized as native and
deaminated peptides and tested for their capacity to bind to anti-33-mer monoclonal antibodies
(moAbs) and to induce T-cell proliferation, respectively (Figure 6). The latter was confirmed with
gamma interferon assays (IFN-γ). The positioning of deamidated glutamine residues is strongly related
to the positioning of proline residues, which is particularly strict in the case of DQ2.5 epitopes (but not
DQ8 epitopes), as DQ2.5 only accepts proline at a certain position in the peptide binding groove [26,40].
The capacity of DQ2.5-glia-α epitopes to trigger proliferation of T cells was tested in deaminated
peptides, deamidation of glutamine (Q) at p6 in DQ2.5-glia-α1 domain, p4 in DQ2.5-glia-α2 domain,
and p4 in DQ2.5-glia-α3 domain.
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The DQ2.5-glia-α1 and DQ2.5-glia-α2 epitopes were regarded as major CD epitopes, as they
are recognized by most of CD patients [41]. The anti-33-mer moAbs reacted strongly with the
canonical DQ2.5-glia-α1 epitope P1{F/Y}2P3Q4P5Q6L7P8Y9. In comparison with the canonical
CD epitope, the variants P1F2L3Q4P5Q6L7P8Y9 (proline (P) to leucine (L) substitution at p3) and
P1F2S3Q4P5Q6L7P8Y9 (P to serine (S) substitution at p3) showed a cross-reactivity (CR) of 37.7% and
55.4%, respectively. With regard to studies of PBMCs in DQ2.5-glia-α1 variants, the single substitution
P to S at p3 maintained similar stimulation capacity to that of the canonical epitope, although it was not
abundant (0.2% to 0.8%) in wheat species. Similarly, the variant with P to L substitution at p3 was very
low in abundance (0.1% to 1.6%) and was found in all the polyploid species except for T. spelta, while
in diploids it was only found in species with the AA genome. However, substitutions of Q to histidine
(H) at p4 and p6, respectively, abolished the stimulatory capacity of this epitope, probably because
it provides a positive charge or via its influence in the deamidation at p6, as previously observed
by Schumann et al. [42]. Moreover, P to L at p8, or two substitutions, also abolished the stimulatory
capacity and showed no affinity for the moAbs (Figure 6a).
As indicated in Figure 6b, the variant P1Q2P3Q4L5P6Y7S8Q9 (P to S substitution at p8)
showed an anti-33-mer binding capacity and PBMC stimulation similar to that of the DQ2.5-glia-α2
canonical CD epitope. This common variant was found in polyploid and diploid species with
AA genome, but was not found in BB and DD genomes. Those peptides with two mismatches,
such as P1Q2P3Q4P5Q6Y7P8Q9 (substitutions L to P at p5 and P to Q at p6), L1Q2P3Q4L5P6Y7S8Q9
(substitutions P to L at p1 and P to S at p8), S1Q2P3Q4L5P6Y7S8Q9 (substitutions P to S at p1 and p8),
and P1Q2P3Q4L5P6H7S8Q9 (substitutions tyrosine (Y) to H at p7, and P to S at p8) showed a CR of
30–40% with respect to the canonical CD epitope and a stimulation index (SI) from 13 to 23 for PBMC
stimulation. In contrast, the replacement of P to L at p3, p6, or p8 showed no reactivity with the
moAbs. Among all of these variants, P1Q2P3Q4L5P6Y7S8Q9 and P1Q2P3Q4P5Q6Y7P8Q9 were the most
frequent variants of the DQ2.5-glia-α2. The modification of P to S at p8 showed high stimulation
with the moAbs and PBMCs, however, two mismatches of L to P at p5 and P to Q at p6 in the same
sequence caused a threefold decrease in the immunogenicity of the DQ2.5-glia-α2 canonical epitope.
This change is abundant in the BBAA genome, especially in the T. turgidum species.
Proliferation assays for PBMC with the canonical DQ2.5-glia-α3 epitope F1R2P3E4Q5P6Y7P8Q9
were tested with E on p4 by tTG2-deamidation of the original Q. Several peptides released an increased
stimulatory effect on T cells, such as the DQ2.5-glia-α3 variant F1L2P3Q4L5P6Y7P8Q9 with two
mismatches. However, other variants for this epitope, with several amino acid substitutions, had no
stimulatory effect on T cells, including P to S substitution at p6, Y to Q at p7, P to Q at p3, and two
substitutions of arginine (R) to P at p2 and Q to H at p9 and R to P at p2 and P to A at p3 (Figure 6c).
The replacement of R to L at p2 and Q to L at p5 in the variant F1L2P3Q4L5P6Y7P8Q9 gave it greater
stimulation capacity, given that this variant was highly abundant for the DQ2.5-glia-α3 epitope, it was
found in all the polyploid species and in the BB diploid genome. However, the non-abundant variant
F1P2P3Q4L5P6Y7P8Q9 with the change of R to P at p2 and Q to L at p5 increased both the binding of
the moAbs and stimulation with T cells. The variant F1R2P3Q4L5P6Y7L8Q9 with one mismatch (P to L
at p8) showed T-cell stimulatory capacity and moAb binding, but was low in abundance (0.6% to 2.5%).
Nevertheless, one of the most abundant variants, F1S2P3Q4Q5P6Y7P8Q9, showed no T-cell stimulatory
capacity and binding of the moAb and was found in the BB diploid genome.
According to the model of HLA-DQ2, the key amino acid residues for DQ2 binding lie at positions
1, 7, and 9, with preferential residues at positions 4 and 6 [43,44]. On the other hand, Elli et al. [45]
found that substitutions at positions 2, 3, 5, and 8 also profoundly affected T-cell stimulation, indicating
that these residues may all interact with the T-cell receptor (TCR). Our findings showed that the change
at position 2 affected T-cell stimulation in the domain DQ2.5-glia-α1, at p8 in the DQ2.5-glia-α2
domain. In addition, the changes at positions 2, 5, and 8 in the DQ2.5-glia-α3 domain profoundly
affected T-cell stimulation. Our results now provide new insights into an alternative approach, since
we have showed that, by introducing specific amino acid substitutions, such as Q to H, at any position,
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the toxicity of the three T-cell α-gliadin epitopes could be eliminated. As such, the high level of
variation influencing the immunogenicity of the major CD epitopes may offer possibilities to generate
new wheat lines with reduced CD-immunogenicity, which may be potentially used as starting points
for the breeding of safe wheats.
 
Figure 6. T-cell proliferation and anti-33-mer binding capacity of DQ2.5-glia-α1, DQ2.5-glia-α2,
and DQ2.5-glia-α3 epitope variants and canonical epitope. (a) DQ-2.5-glia-α1 epitope and variants,
(b) DQ-2.5-glia-α2 epitope and variants, and (c) DQ-2.5-glia-α3 epitope and variants. Variants and the
canonical epitope were synthesized as deaminated 9-mer peptides to peripheral blood mononuclear
cell (PBMC) assay. Proliferative responses of T cells were defined as a stimulation index (SI), which
means the specific proliferation of a sample divided by the background proliferation ([PBMC +
peptide]/[PBMC]). Glutamate residues (E) that would be formed by TG2-mediated deamination,
which are important for recognition by T cells, are shown in italics. For the T-cell assay, the responses
are represented relative to the maximum response given by the CD canonical epitope indicated
by ++++. Therefore, - corresponds with 15%; + corresponds with 15–25%; ++ corresponds with
25–50%; +++ corresponds with 50–75%; ++++ corresponds with 75–100%; and +++++ corresponds
with >100%. For the monoclonal antibody (moAb) assay, the amount of antigen detected is represented
relative to the maximum amount (mol/L) detected in a given assay by the CD canonical epitope
indicated by ++++. Therefore, - corresponds with 0%; +/- corresponds with < 5%; + corresponds with
5–10%; ++ corresponds with 10–30%; +++ corresponds to 30–60%; ++++ corresponds to 60–100%; and
+++++corresponds to > 100%. CR; cross-reactivity, was calculated as follows: (IC50 of the antigen
for which the moAb was raised/IC50 of each antigen assayed) × 100. The IC50 is defined as the
concentration of the line that reduces the peak absorbance by 50% in the assay. Each of the letters
represents the amino acid substitution of the variants.
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4. Conclusions
The results presented here about CD DQ2.5 epitopes provide the basis for the introduction
and/or selection of natural amino acid substitutions to eliminate the toxicity of the α-gliadin T-cell
epitopes. Our findings show that the most abundant epitope in the DQ2.5-glia-α1 domain is the CD
canonical epitope. Considering the DQ2.5-glia-α2 domain, the variants P1Q2P3Q4L5P6Y7S8Q9 and
P1Q2P3Q4P5Q6Y7P8Q9 are the most abundant in this domain, while F1P2P3Q4Q5P6Y7P8Q9 is the most
abundant in the DQ2.5-glia-α3 domain. Moreover, the F1P2P3Q4Q5P6Y7P8Q9 variant was also the
most frequent of all the sequences studied. Our data indicate that the changes of P to S and R to P may
be the most representative changes and the natural introduction of Q to H at any position eliminates
the toxicity of the three T-cell epitopes. These results may offer possibilities to generate wheat varieties
with a reduced CD-immunogenicity. Such varieties would help to reduce the presence of immunogenic
CD epitopes in wheat flour and, while not safe for consumption by patients, might help to prevent the
onset of CD in people that carry genetic risk factors. Overall, the more the scientific community knows
about immunogenicity of the gliadins, the closer an alternative therapy besides GFDwill be achieved.
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